AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 22, 1997
REGISTRATION NO. 333-
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------
HENRY SCHEIN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 5047 11-3136595
(STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) CLASSIFICATION CODE NUMBER) IDENTIFICATION NUMBER)
------------------------
STANLEY M. BERGMAN ROBERT J. SULLIVAN
CHAIRMAN, CHIEF EXECUTIVE OFFICER AND PRESIDENT CHAIRMAN OF THE BOARD
HENRY SCHEIN, INC. SULLIVAN DENTAL PRODUCTS, INC.
135 DURYEA ROAD 10920 WEST LINCOLN AVENUE
MELVILLE, NEW YORK 11747 WEST ALLIS, WISCONSIN 53227
(516) 843-5500 (414) 321-8881
(ADDRESS, INCLUDING ZIP CODE, AND (NAME, ADDRESS, INCLUDING ZIP CODE, AND
TELEPHONE NUMBER, INCLUDING AREA CODE, OF TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) AGENT FOR SERVICE)
------------------------
Copies to:
ROBERT A. CANTONE, ESQ. MARK E. MLOTEK, ESQ. KERRY B. WOLFE, ESQ.
PROSKAUER ROSE LLP VICE PRESIDENT, GENERAL COUNSEL AND WOLFE, WOLFE & RYD
1585 BROADWAY SECRETARY 20 N. WACKER DRIVE
NEW YORK, NEW YORK 10036 HENRY SCHEIN, INC. SUITE 3550
(212) 969-3000 135 DURYEA ROAD CHICAGO, ILLINOIS 60606
MELVILLE, NEW YORK 11747 (312) 372-6400
(516) 843-5500
------------------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE OF THE SECURITIES TO THE
PUBLIC: As soon as practicable after the effective date of this Registration
Statement.
If the securities being registered on this Form are being offered in
connection with the formation of a holding company and there is compliance with
General Instruction G, check the following box. / /
The registrant hereby amends this registration statement on such date or
dates as may be necessary to delay its effective date until the registrant shall
file a further amendment which specifically states that this registration
statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the registration statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
------------------------
CALCULATION OF REGISTRATION FEE
PROPOSED
MAXIMUM OFFERING PROPOSED
TITLE OF EACH CLASS AMOUNT TO BE PRICE PER MAXIMUM AGGREGATE AMOUNT OF
OF SECURITIES TO BE REGISTERED REGISTERED(1) SHARES(2) OFFERING PRICE(2) REGISTRATION FEE
Common Stock, par value $.01 per
share............................. 8,029,000 shares $35.81 $287,518,490 $87,126.82(3)
(1) The number of shares of Common Stock, par value $.01 (the 'Schein Common
Stock'), of Henry Schein, Inc. ('Schein') being registered is based on the
approximate maximum number of shares issuable to the shareholders of
Sullivan Dental Products, Inc. ('Sullivan') in connection with the merger of
a wholly-owned subsidiary of Schein with and into Sullivan.
(2) Estimated solely for purposes of calculating the registration fee and based,
pursuant to Rule 457(f)(1) of the Securities Act of 1933, upon the average
of the high and low prices of the Schein Common Stock on the Nasdaq National
Market on September 18, 1997, which was $35.81.
(3) A fee of $52,792 was paid by Schein, pursuant to Rule 14a-6 under the
Securities Exchange Act of 1934, in connection with the filing with the
Commission on September 9, 1997 of preliminary proxy material relating to
this transaction. Pursuant to Rule 457(b) under the Securities Act of 1933,
such fee is being credited against the registration fee and, accordingly, an
additional $34,334.82 is being paid with the filing of this Registration
Statement.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
[SCHEIN LOGO]
HENRY SCHEIN, INC.
135 DURYEA ROAD
MELVILLE, NEW YORK 11747
Dear Stockholder:
You are cordially invited to attend a Special Meeting of Stockholders of
Henry Schein, Inc. ('Schein'), which will be held at 10:00 a.m., local time, on
Wednesday, November 12, 1997, at the Huntington Hilton, 598 Broadhollow Road,
Melville, New York.
At the Special Meeting, holders of Schein common stock will be asked to
approve a proposal to issue up to 8,029,000 shares of Schein common stock in
connection with the proposed merger of a wholly-owned subsidiary of Schein with
and into Sullivan Dental Products, Inc. ('Sullivan'), pursuant to which Sullivan
would become a wholly-owned subsidiary of Henry Schein, Inc. ('Schein') and each
outstanding share of Sullivan's common stock would be converted into the right
to receive 0.735 (the 'Exchange Ratio') shares of common stock of Schein.
If the share issuance is not approved, the merger will not be consummated.
The proposed merger is more fully described in the accompanying Notice of
Meeting and Joint Proxy Statement/Prospectus. For the reasons set forth in the
Joint Proxy Statement/Prospectus, your Board of Directors has unanimously
approved the merger and unanimously recommends that the holders of Schein common
stock vote in favor of the issuance of the shares of Schein common stock in
connection with the merger. Smith Barney Inc., Schein's financial advisor, has
delivered to the Board of Directors a written opinion dated August 3, 1997 to
the effect that, as of such date and based upon and subject to certain matters
stated in such opinion, the Exchange Ratio was fair, from a financial point of
view, to Schein.
In addition, holders of Schein common stock will be asked at the Special
Meeting to approve proposals to amend Schein's Amended and Restated Certificate
of Incorporation (i) to authorize the Board to establish from time to time the
number of directors constituting the entire Board and enable the Board to amend
or repeal certain By-laws, and (ii) to reduce certain supermajority voting
requirements. If the first proposed amendment is adopted, the Board intends to
expand the Board to add Sullivan's Chairman of the Board (if the merger is
consummated) and the President of Schein's Micro Bio-Medics subsidiary, who
became an Executive Vice President of Schein in connection with Schein's
acquisition of Micro Bio-Medics in August 1997, as directors. Additional
information with respect to the proposed amendment and these individuals is set
forth in the Joint Proxy Statement/Prospectus.
THE BOARD OF DIRECTORS OF SCHEIN UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS
VOTE FOR APPROVAL OF THE ISSUANCE OF SHARES OF SCHEIN COMMON STOCK IN CONNECTION
WITH THE MERGER AND FOR APPROVAL OF THE AMENDMENTS TO SCHEIN'S AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION.
It is extremely important that your shares be represented at the Special
Meeting whether or not you are able to attend personally. Accordingly, please
complete, sign and date the accompanying proxy card promptly and return it in
the enclosed prepaid envelope. If you are present at the Special Meeting you
may, if you wish, withdraw your proxy and vote in person.
STANLEY M. BERGMAN
Chairman, Chief Executive
Officer and President
Melville, New York
September 22, 1997
HENRY SCHEIN, INC.
135 DURYEA ROAD
MELVILLE, NEW YORK 11747
------------------------------------
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
NOVEMBER 12, 1997
------------------------------------
To the Stockholders of
Henry Schein, Inc.:
NOTICE IS HEREBY GIVEN that a Special Meeting of Stockholders (the 'Special
Meeting') of Henry Schein, Inc., a Delaware corporation ('Schein'), will be held
on Wednesday, November 12, 1997, at the Huntington Hilton, 598 Broadhollow Road,
Melville, New York, commencing at 10:00 a.m., local time, for the following
purposes:
1. To consider and vote upon a proposal to issue (the 'Share
Issuance') up to 8,029,000 shares of the common stock, par value $.01, of
Schein ('Schein Common Stock') pursuant to the merger of a wholly-owned
subsidiary of Schein with and into Sullivan Dental Products, Inc.
('Sullivan'), a Wisconsin corporation. Pursuant to the merger, Sullivan
will become a wholly-owned subsidiary of Schein, and each outstanding share
of the common stock, par value $.01, of Sullivan ('Sullivan Common Stock')
will be converted into the right to receive 0.735 shares of Schein Common
Stock.
2. To consider and vote upon proposed amendments to Schein's Amended
and Restated Certificate of Incorporation (i) to authorize the Board of
Directors to establish from time to time the number of directors
constituting the entire Board of Directors and enable the Board of
Directors to amend or repeal certain By-laws, and (ii) to reduce certain
supermajority voting requirements.
3. To transact such other business as may properly come before the
Special Meeting or any adjournment or postponement thereof.
Only stockholders of record at the close of business on September 17, 1997
are entitled to notice of, and to vote at, the Special Meeting and any
adjournment or postponement thereof.
Whether or not you plan to attend the Special Meeting, please fill in,
sign, date and return the enclosed form of proxy card promptly. A return
envelope is enclosed for your convenience and requires no postage for mailing in
the United States.
By Order of the Board of Directors
MARK E. MLOTEK
Secretary
Melville, New York
September 22, 1997
[SULLIVAN LOGO]
SULLIVAN DENTAL PRODUCTS, INC.
10920 WEST LINCOLN AVENUE
WEST ALLIS, WISCONSIN 53227
Dear Shareholder:
You are cordially invited to attend a Special Meeting of the Shareholders
of Sullivan Dental Products, Inc., a Wisconsin corporation ('Sullivan'), to be
held on Wednesday, November 12, 1997 at 9:00 a.m., local time, at The Wyndham
Hotel, 139 East Kilbourn Avenue, Milwaukee, Wisconsin 53202.
At the Special Meeting, you will be asked to consider and vote upon a
proposal to approve the Agreement and Plan of Merger, dated August 3, 1997 (the
'Merger Agreement'), by and among Sullivan, Henry Schein, Inc., a Delaware
corporation ('Schein'), and HSI Acquisition Corp., a Wisconsin corporation and a
wholly-owned subsidiary of Schein ('Merger Sub'), and the transactions
contemplated thereby, pursuant to which Merger Sub will be merged with and into
Sullivan (the 'Merger'). A copy of the Merger Agreement is attached as Annex I
to this Joint Proxy Statement/Prospectus. At the effective time of the Merger,
each share of Sullivan common stock will be converted into the right to receive
0.735 shares of Schein's common stock.
I strongly support the Merger of Sullivan with Schein and join with all the
other members of the Board in enthusiastically recommending the Merger to you.
We urge you to vote in favor of approval of the Merger Agreement and the
transactions contemplated thereby.
Cleary Gull Reiland & McDevitt Inc., Sullivan's financial advisor in
connection with the Merger, has delivered to the Board of Directors its written
opinion that the consideration to be received by Sullivan's shareholders
pursuant to the Merger Agreement is fair, from a financial point of view, to
Sullivan's shareholders.
Enclosed are a Notice of Special Meeting of Shareholders and a Joint Proxy
Statement/Prospectus, which describes the Merger and the background of the
Merger. You are urged to read all of these materials carefully. The Board of
Directors has fixed the close of business on September 17, 1997 as the record
date for the Special Meeting. Accordingly, only shareholders of record on that
date are entitled to notice of, and to vote at, the Special Meeting or any
adjournment or postponement thereof.
THE BOARD OF DIRECTORS OF SULLIVAN HAS DETERMINED THAT THE MERGER IS IN THE
BEST INTERESTS OF SULLIVAN AND ITS SHAREHOLDERS. ACCORDINGLY, THE BOARD HAS
UNANIMOUSLY ADOPTED AND APPROVED THE MERGER AGREEMENT AND UNANIMOUSLY RECOMMENDS
THAT SHAREHOLDERS VOTE IN FAVOR OF APPROVING THE MERGER AGREEMENT AND THE
CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED THEREBY, INCLUDING THE MERGER.
It is extremely important that your shares be represented at the Special
Meeting, whether or not you plan to attend personally. Accordingly, please
complete, date, sign and return the enclosed proxy card promptly and return it
in the enclosed prepaid envelope. If you are present at the Special Meeting you
may, if you wish, withdraw your proxy and vote in person.
Very truly yours,
ROBERT J. SULLIVAN
Chairman
SULLIVAN DENTAL PRODUCTS
10920 WEST LINCOLN AVENUE
WEST ALLIS, WISCONSIN 53227
------------------------------------
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 12, 1997
------------------------------------
NOTICE IS HEREBY GIVEN that a Special Meeting of Shareholders of Sullivan
Dental Products, Inc., a Wisconsin corporation ('Sullivan'), will be held on
Wednesday, November 12, 1997 at 9:00 a.m., local time, at The Wyndham Hotel, 139
East Kilbourn Avenue, Milwaukee, Wisconsin 53202, for the following purposes:
1. To consider and vote upon a proposal to approve the Agreement and
Plan of Merger, dated August 3, 1997 (the 'Merger Agreement'), by and among
Sullivan, Henry Schein, Inc., a Delaware corporation ('Schein'), and HSI
Acquisition Corp., a Wisconsin corporation and a wholly-owned subsidiary of
Schein ('Merger Sub'), and the consummation of the transactions
contemplated thereby, pursuant to which Merger Sub will be merged with and
into Sullivan (the 'Merger') upon the terms and subject to the conditions
set forth in the Merger Agreement, as more fully described in the enclosed
Joint Proxy Statement/Prospectus. A copy of the Merger Agreement is set
forth as Annex I to the attached Joint Proxy Statement/Prospectus.
2. To transact such other business as may properly be brought before
the Special Meeting, or any adjournments or postponements thereof.
Only shareholders of record at the close of business on September 17, 1997
are entitled to notice of, and to vote at, the Special Meeting and any
adjournment or postponement thereof.
Whether or not you plan to attend the Special Meeting, please fill in,
sign, date and return the enclosed form of proxy card promptly. A return
envelope is enclosed for your convenience and requires no postage for mailing in
the United States.
By Order of the Board of Directors
TIMOTHY J. SULLIVAN
Secretary
West Allis, Wisconsin
September 22, 1997
JOINT PROXY STATEMENT
HENRY SCHEIN, INC. SULLIVAN DENTAL PRODUCTS, INC.
SPECIAL MEETING OF SPECIAL MEETING OF
STOCKHOLDERS TO BE HELD SHAREHOLDERS TO BE HELD
ON NOVEMBER 12, 1997 ON NOVEMBER 12, 1997
HENRY SCHEIN, INC.
PROSPECTUS
FOR UP TO
8,029,000 SHARES OF COMMON STOCK, $0.01 PAR VALUE
This Joint Proxy Statement/Prospectus relates to up to 8,029,000 shares of
common stock, par value $ .01 per share ('Schein Common Stock'), of Henry
Schein, Inc., a Delaware corporation ('Schein'), offered hereby to the
shareholders of Sullivan Dental Products, Inc., a Wisconsin corporation
('Sullivan'), upon consummation of a proposed merger (the 'Merger') of HSI
Acquisition Corp., a Wisconsin corporation and a wholly-owned subsidiary of
Schein ('Merger Sub'), with and into Sullivan (the 'Merger') pursuant to an
Agreement and Plan of Merger, dated August 3, 1997, by and among Schein, Merger
Sub and Sullivan (the 'Merger Agreement'). This Joint Proxy Statement/Prospectus
also serves as the Joint Proxy Statement of Schein and Sullivan for use in
connection with the solicitation of proxies by the Board of Directors of Schein
(the 'Schein Board') at the Special Meeting of Stockholders of Schein (the
'Schein Special Meeting') to approve the issuance of shares of Schein Common
Stock in the Merger (the 'Share Issuance') and to approve certain amendments to
Schein's Amended and Restated Certificate of Incorporation (the 'Schein
Certificate of Incorporation') described herein (the 'Schein Certificate of
Incorporation Amendments'), and by the Board of Directors of Sullivan (the
'Sullivan Board') at the Special Meeting of Shareholders of Sullivan (the
'Sullivan Special Meeting') to approve the Merger Agreement and the transactions
contemplated thereby, in each case among other matters. The Merger Agreement is
attached as Annex I to this Joint Proxy Statement/Prospectus.
Upon consummation of the Merger, each outstanding share of the common
stock, par value $.01, of Sullivan (the 'Sullivan Common Stock'), will be
converted into the right to receive 0.735 (the 'Exchange Ratio') of a share of
Schein Common Stock (with cash in lieu of fractional shares). Each option to
acquire Sullivan Common Stock that is outstanding and unexercised at the
effective time of the Merger will be converted automatically in the Merger into
an option to purchase Schein Common Stock for a number of shares, and at an
exercise price, determined by adjusting the original terms of the option to
reflect the Exchange Ratio. The Merger is expected to be consummated immediately
after the approval of the Merger and the Share Issuance by the stockholders of
Sullivan and Schein, respectively.
The Merger is subject to the approval of the holders of a majority of the
outstanding shares of the Sullivan Common Stock and the holders of a majority of
the shares of Schein Common Stock voted on the Share Issuance, as well as the
satisfaction of certain other conditions, including obtaining certain regulatory
approvals. Under the Schein Certificate of Incorporation, the Schein Certificate
of Incorporation Amendments will require the affirmative vote of at least 80% of
the outstanding shares of Schein Common Stock.
The Schein Common Stock is listed on the Nasdaq National Market under the
symbol 'HSIC.' The last sale price of Schein Common Stock reported on the Nasdaq
National Market on August 1, 1997, the last trading day preceding public
announcement of the proposed Merger, was $39.00 per share. The Sullivan Common
Stock is listed on the Nasdaq National Market under the symbol 'SULL.' The last
reported sale price of Sullivan Common Stock reported on the Nasdaq National
Market on August 1, 1997 was $22.25 per share. As of August 1, 1997, there were
27,350,241 shares of Schein Common Stock and 10,027,951 shares of Sullivan
Common Stock outstanding.
SEE 'RISK FACTORS' ON PAGE 15 FOR A DESCRIPTION OF CERTAIN FACTORS
CONCERNING SCHEIN AND ITS OPERATIONS FOLLOWING THE MERGER.
This Joint Proxy Statement/Prospectus and forms of proxy are first being
mailed to Stockholders on or about September 23, 1997.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION (THE 'COMMISSION') OR ANY STATE SECURITIES COMMISSION,
NOR HAS THE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON
THE ACCURACY OR ADEQUACY OF THIS JOINT PROXY STATEMENT/PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this Joint Proxy Statement/Prospectus is September 22, 1997.
------------------------
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATION, OTHER THAN THOSE CONTAINED IN THIS JOINT PROXY
STATEMENT/PROSPECTUS, IN CONNECTION WITH THE SOLICITATION AND THE OFFERING MADE
BY THIS JOINT PROXY STATEMENT/PROSPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION
OR REPRESENTATION SHOULD NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED. THIS
JOINT PROXY STATEMENT/PROSPECTUS DOES NOT CONSTITUTE THE SOLICITATION OF A PROXY
OR AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO PURCHASE, ANY SECURITIES
IN ANY JURISDICTION IN WHICH SUCH SOLICITATION OR OFFERING MAY NOT LAWFULLY BE
MADE.
NEITHER THE DELIVERY OF THIS JOINT PROXY STATEMENT/PROSPECTUS NOR ANY
DISTRIBUTION OF SECURITIES MADE HEREUNDER SHALL IMPLY THAT THERE HAS BEEN NO
CHANGE IN THE INFORMATION SET FORTH HEREIN OR IN THE AFFAIRS OF SCHEIN OR
SULLIVAN SINCE THE DATE HEREOF OR THAT THE INFORMATION HEREIN IS CORRECT AS OF
ANY TIME SUBSEQUENT TO ITS DATE.
------------------------
AVAILABLE INFORMATION
Schein and Sullivan are subject to the informational requirements of the
Securities Exchange Act of 1934 (the 'Exchange Act'). In accordance with the
Exchange Act, Schein and Sullivan file reports, proxy statements and other
information with the Securities and Exchange Commission (the 'SEC').
Schein has filed, through the Electronic Data Gathering, Analysis and
Retrieval System ('EDGAR'), a Registration Statement on Form S-4 (the
'Registration Statement') with the SEC under the Securities Act of 1933 (the
'Securities Act') with respect to the shares of Schein Common Stock to be issued
upon consummation of the Merger. This Joint Proxy Statement/Prospectus does not
contain all the information set forth in the Registration Statement and the
exhibits thereto, certain portions of which have been omitted as permitted by
the rules and regulations of the SEC. Copies of the Registration Statement
(including such omitted portions) are available from the SEC upon payment of
prescribed rates. For further information, reference is made to the Registration
Statement and the exhibits filed therewith. Statements contained in this Joint
Proxy Statement/Prospectus relating to the contents of any contract or other
document referred to herein or therein are not necessarily complete, and in each
instance reference is made to the copy of such contract or other document filed
as an exhibit to the Registration Statement or such other document, each such
statement being qualified in all respects by such reference.
This filed material can be inspected and copied at the public reference
facilities maintained by the SEC at Room 1024, 450 Fifth Street, N.W.,
Washington, D.C. 20549, and at the following Regional Offices of the SEC:
Chicago Regional Office (Suite 1400, Citicorp Center, 500 West Madison Street,
Chicago, Illinois 60661) and New York Regional Office (Seven World Trade Center,
New York, New York 10048). Copies of such material may be obtained by mail from
the Public Reference Section of the SEC, 450 Fifth Street, N.W., Washington,
D.C. 20549, at prescribed rates. In addition, such material can be inspected at
the offices of the National Association of Securities Dealers, Inc. (the
'NASD'), 1735 K Street, N.W., Washington, DC 20006. Material filed
electronically through EDGAR may also be accessed through the SEC's home page on
the World Wide Web at http://www.sec.gov.
2
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents are incorporated by reference in this Joint Proxy
Statement/Prospectus:
(a) Schein's Annual Report on Form 10-K for the year ended December 28,
1996 (File No. 0-27028);
(b) Schein's Amended Annual Report on Form 10-K/A for the year ended
December 28, 1996;
(c) Schein's Current Report on Form 8-K dated June 24, 1997;
(d) Schein's Quarterly Report on Form 10-Q for the period ended March 29,
1997;
(e) Schein's Current Report on Form 8-K dated August 1, 1997;
(f) Schein's Quarterly Report on Form 10-Q for the period ended June 28,
1997;
(g) Schein's Registration Statement on Form 8-A dated October 27, 1995;
(h) Sullivan's Annual Report on Form 10-K for the year ended December 31,
1996 (File No. 0-18347);
(i) Sullivan's Quarterly Report on Form 10-Q for the period ended March
31, 1997; and
(j) Sullivan's Quarterly Report on Form 10-Q for the period ended June 30,
1997.
All reports and definitive proxy or information statements filed by Schein
or Sullivan pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act
subsequent to the date of this Joint Proxy Statement/Prospectus and prior to the
date of the their respective Special Meetings shall be deemed to be incorporated
by reference into this Joint Proxy Statement/Prospectus from the dates of filing
of such documents. Any statement contained in a document incorporated or deemed
to be incorporated in this Joint Proxy Statement/Prospectus, to the extent that
a statement contained herein or in any other subsequently filed document that
also is or is deemed to be incorporated herein by reference modifies or
supersedes such statement, shall be deemed so modified or superseded. Any such
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Joint Proxy Statement/Prospectus.
All information appearing in this Joint Proxy Statement/Prospectus or in any
document incorporated herein by reference is not necessarily complete and is
qualified in its entirety by the information and financial statements (including
notes thereto) appearing in the documents incorporated by reference herein and
should be read together with such information and documents.
All information contained in this Joint Proxy Statement/Prospectus relating
to Schein or Merger Sub has been supplied by Schein, and all information
relating to Sullivan has been supplied by Sullivan.
THIS JOINT PROXY STATEMENT/PROSPECTUS INCORPORATES DOCUMENTS BY REFERENCE
WHICH ARE NOT PRESENTED HEREIN OR DELIVERED HEREWITH. COPIES OF ANY SUCH
DOCUMENTS (EXCLUDING EXHIBITS TO SUCH DOCUMENTS UNLESS SUCH EXHIBITS ARE
SPECIFICALLY INCORPORATED BY REFERENCE INTO THE INFORMATION INCORPORATED HEREIN)
ARE AVAILABLE WITHOUT CHARGE TO ANY PERSON, INCLUDING ANY BENEFICIAL OWNER OF
SULLIVAN COMMON STOCK AND ANY BENEFICIAL OWNER OF SCHEIN COMMON STOCK, TO WHOM
THIS JOINT PROXY STATEMENT/PROSPECTUS IS DELIVERED UPON REQUEST. WITH RESPECT TO
SCHEIN'S DOCUMENTS, REQUESTS SHOULD BE DIRECTED TO SCHEIN AT 135 DURYEA ROAD,
MELVILLE, NEW YORK 11747, ATTN: MARK E. MLOTEK (TELEPHONE: (516) 843-5500). WITH
RESPECT TO SULLIVAN'S DOCUMENTS, REQUESTS SHOULD BE DIRECTED TO SULLIVAN AT
10920 WEST LINCOLN AVENUE, WEST ALLIS, WISCONSIN 53227, ATTN: TIMOTHY J.
SULLIVAN (TELEPHONE: (414) 321-8881). IN ORDER TO ENSURE TIMELY DELIVERY OF SUCH
DOCUMENTS, ANY REQUEST SHOULD BE MADE BY NOVEMBER 4, 1997.
3
TABLE OF CONTENTS
PAGE
----
SUMMARY.................................................................................................... 1
Special Meetings......................................................................................... 1
Required Vote............................................................................................ 2
Proxies.................................................................................................. 2
Certain Significant Considerations....................................................................... 2
The Merger............................................................................................... 3
Irrevocable Proxy and Termination Rights Agreement....................................................... 7
Regulatory Matters....................................................................................... 7
Certain Tax Consequences of the Merger................................................................... 8
Anticipated Accounting Treatment......................................................................... 8
Comparison of Stockholder Rights......................................................................... 8
Market Price Data........................................................................................ 8
Summary Consolidated Historical Financial Information and Operating Data................................. 9
Schein Summary Consolidated Historical Financial Information and Operating Data.......................... 10
Sullivan Summary Historical Financial Information........................................................ 12
Summary Unaudited Pro Forma Combined Financial Information............................................... 13
Comparative Unaudited Per Share Data..................................................................... 14
RISK FACTORS............................................................................................... 15
Fixed Exchange Ratio..................................................................................... 15
Difficulty of Integration of Operations Following the Merger; Loss of Sales Representatives and
Suppliers............................................................................................. 15
Interests of Certain Persons in the Merger............................................................... 15
Irrevocable Proxy and Termination Rights Agreement....................................................... 16
Competition.............................................................................................. 16
Expansion of Schein Through Acquisitions and Joint Ventures.............................................. 16
Minority Status of Former Sullivan Shareholders; Control by Insiders..................................... 17
Fluctuations in Quarterly Earnings....................................................................... 17
Practice Management Software and Other Value Added Products.............................................. 18
Foreign Operations....................................................................................... 18
Dependence on Senior Management.......................................................................... 18
Changes in Healthcare Industry........................................................................... 18
Government Regulation.................................................................................... 19
Risk of Product Liability Claims and Insurance........................................................... 19
Cost of Shipping......................................................................................... 19
Reliance on Telephone and Computer Systems............................................................... 19
State Sales Tax Collection............................................................................... 19
Potential Volatility of Schein Common Stock Prices....................................................... 20
Anti-takeover Provisions; Possible Issuance of Preferred Stock........................................... 20
Shares Eligible for Future Sale.......................................................................... 20
Reorganization........................................................................................... 21
SULLIVAN SPECIAL MEETING................................................................................... 21
General.................................................................................................. 21
Approval of the Merger................................................................................... 21
Record Date; Shares Entitled to Vote..................................................................... 22
Required Vote............................................................................................ 22
Proxies; Proxy Solicitation.............................................................................. 22
SCHEIN SPECIAL MEETING..................................................................................... 23
General.................................................................................................. 23
Approval of the Share Issuance........................................................................... 23
Approval of the Schein Certificate of Incorporation Amendments........................................... 23
Intended Appointees to the Schein Board.................................................................. 25
Record Date; Shares Entitled to Vote..................................................................... 26
Required Vote............................................................................................ 26
Proxies; Proxy Solicitation.............................................................................. 26
i
PAGE
----
THE MERGER................................................................................................. 27
Background of the Merger................................................................................. 27
Consideration and Recommendation of the Merger by the Sullivan Board..................................... 28
Schein's Reasons for the Merger.......................................................................... 30
Opinion of Cleary Gull................................................................................... 31
Opinion of Smith Barney Inc.............................................................................. 35
Effective Time........................................................................................... 39
Exchange Ratio........................................................................................... 39
Exchange Agent; Exchange Procedures; Distributions with Respect to Unexchanged Shares; No Further
Ownership Rights in Sullivan Common Stock; No Fractional Shares of Schein Common Stock................ 39
Admission for Trading on Nasdaq National Market.......................................................... 41
Cessation of Nasdaq National Market Trading and Deregistration of Sullivan Common Stock After the
Merger................................................................................................ 41
Certain Significant Considerations....................................................................... 41
Certain Tax Consequences of the Merger................................................................... 41
Anticipated Accounting Treatment......................................................................... 42
Irrevocable Proxy and Termination Rights Agreement....................................................... 42
Interests of Certain Persons in the Merger............................................................... 43
Operations After the Merger.............................................................................. 45
Dividends................................................................................................ 45
Treatment of Sullivan Stock Options...................................................................... 46
Right of the Sullivan Board to Withdraw Recommendation................................................... 46
Regulatory Filings and Approvals......................................................................... 46
Resale of Schein Common Stock Received in the Merger..................................................... 46
DESCRIPTION OF SCHEIN...................................................................................... 47
General.................................................................................................. 47
Reorganization........................................................................................... 48
MANAGEMENT OF SCHEIN....................................................................................... 50
Directors and Executive Officers......................................................................... 50
Background of Directors and Executive Officers........................................................... 50
DESCRIPTION OF SULLIVAN.................................................................................... 53
Sales and Service........................................................................................ 53
Sources of Supply........................................................................................ 53
COMPARATIVE STOCK PRICES AND DIVIDENDS..................................................................... 54
Schein Common Stock...................................................................................... 54
Sullivan Common Stock.................................................................................... 55
UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL STATEMENTS................................................ 56
SCHEIN CONSOLIDATED SELECTED HISTORICAL FINANCIAL INFORMATION AND OPERATING DATA........................... 63
SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS............... 66
Overview................................................................................................. 66
Recent Developments...................................................................................... 66
Results of Operations.................................................................................... 68
Six Months Ended June 28, 1997 Compared to Six Months Ended June 29, 1996................................ 68
1996 Compared to 1995.................................................................................... 69
1995 Compared to 1994.................................................................................... 70
Inflation................................................................................................ 71
Risk Management.......................................................................................... 71
Liquidity and Capital Resources.......................................................................... 72
Effect of Recently Issued Accounting Standards........................................................... 73
SULLIVAN SELECTED HISTORICAL FINANCIAL INFORMATION......................................................... 74
ii
PAGE
----
SULLIVAN MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS............. 76
Results of Operations.................................................................................... 76
Six Months Ended June 30, 1997 Compared to Six Months Ended June 30, 1996................................ 76
Fiscal 1996 Compared to Fiscal 1995...................................................................... 76
Fiscal 1995 Compared to Fiscal 1994...................................................................... 77
Liquidity and Capital Resources.......................................................................... 77
New Accounting Pronouncements............................................................................ 78
TERMS OF THE MERGER AGREEMENT.............................................................................. 79
The Merger; Exchange and Conversion of Shares............................................................ 79
Exchange of Share Certificates........................................................................... 79
Treatment of Sullivan Stock Options...................................................................... 80
Effective Time........................................................................................... 80
Termination Rights....................................................................................... 81
Certain Fees and Expenses................................................................................ 82
Condition to the Merger.................................................................................. 82
Representations and Warranties........................................................................... 83
Indemnification; Officers' and Directors' Liability Insurance............................................ 83
Certain Covenants of Sullivan............................................................................ 84
Certain Covenants of Schein.............................................................................. 84
Certain Covenants of Sullivan and Schein................................................................. 85
No Solicitation of Other Offers.......................................................................... 85
Solicitation of Employees................................................................................ 86
Amendments............................................................................................... 86
COMPARISON OF RIGHTS OF STOCKHOLDERS OF SULLIVAN AND SCHEIN................................................ 87
Certain Provisions of Delaware and Wisconsin Law......................................................... 87
Authorized Capital Stock................................................................................. 87
Directors................................................................................................ 88
Number of Directors; Cumulative Voting................................................................... 88
Removal of Directors; Filling Vacancies on the Board of Directors........................................ 88
Transactions with Interested Directors................................................................... 89
Limitation on Directors' Liability; Indemnification...................................................... 89
Meetings of Stockholders................................................................................. 90
Quorum For Stockholder Meetings.......................................................................... 91
Stockholder Voting Requirements Generally................................................................ 91
Stockholder Action By Written Consent.................................................................... 91
Supermajority Provisions................................................................................. 91
Stockholder Voting In Certain Significant Transactions; Takeover Legislation............................. 92
Statutory Stockholder Liability.......................................................................... 93
Derivative Actions....................................................................................... 93
Dissenters' Rights and Appraisal Rights.................................................................. 93
Stockholder Inspection of Books and Records.............................................................. 94
Loans to Directors....................................................................................... 94
Amendment or Repeal of the Certificates and By-laws...................................................... 94
Dividend Declarations.................................................................................... 95
EXPERTS.................................................................................................... 95
LEGAL MATTERS.............................................................................................. 95
ANNEX I--Agreement and Plan of Merger
ANNEX II--Opinion of Cleary Gull Reiland & McDevitt Inc.
ANNEX III--Opinion of Smith Barney Inc.
ANNEX IV--Current Article FIFTH of the Schein Certificate of Incorporation
iii
SUMMARY
The following is a summary of certain information contained elsewhere in
this Joint Proxy Statement/Prospectus. Reference is made to, and this summary is
qualified in its entirety by, the more detailed information contained elsewhere
in this Joint Proxy Statement/Prospectus, in the attached Annexes and in the
documents incorporated herein by reference. Stockholders are urged to read
carefully this Joint Proxy Statement/Prospectus and the attached Annexes in
their entirety.
This Joint Proxy Statement/Prospectus relates to the proposed issuance (the
'Share Issuance') of up to 8,029,000 shares of the common stock, par value $.01
(the 'Schein Common Stock'), of Henry Schein, Inc., a Delaware corporation
('Schein'), in connection with the proposed merger (the 'Merger') of HSI
Acquisition Corp., a Wisconsin corporation and a wholly-owned subsidiary of
Schein ('Merger Sub'), with and into Sullivan Dental Products, Inc., a Wisconsin
corporation ('Sullivan'), pursuant to an Agreement and Plan of Merger dated
August 3, 1997 (the 'Merger Agreement'). As a result of the Merger, Sullivan
will become a wholly-owned subsidiary of Schein. At the effective time of the
Merger (the 'Effective Time'), each outstanding share of common stock, par value
$.01, of Sullivan (the 'Sullivan Common Stock'), will be converted into the
right to receive 0.735 shares of Schein Common Stock. The exchange ratio of
0.735 shares of Schein Common Stock for each share of Sullivan Common Stock is
hereinafter referred to as the 'Exchange Ratio'.
Based upon the Exchange Ratio and the closing sales price of a share of
Schein Common Stock on September 18, 1997, as reported on the Nasdaq National
Market, each outstanding share of Sullivan Common Stock would have been
converted into Schein Common Stock with a then current market value of $26.46
had the Merger been consummated on that date, and the aggregate then current
market value of the shares of Schein Common Stock issued in the Merger
(7,560,738 shares assuming no change in the number of shares of Sullivan Common
Stock outstanding as of the Record Date as a result of the exercise of
outstanding options to purchase Sullivan Common Stock) would have been
$272,186,568.
SPECIAL MEETINGS
A Special Meeting of the shareholders of Sullivan will be held at 9:00
a.m., local time, on Wednesday, November 12, 1997 (the 'Sullivan Special
Meeting'), at The Wyndham Hotel, 139 East Kilbourn Avenue, Milwaukee, Wisconsin
53202. Only holders of record of Sullivan Common Stock at the close of business
on September 17, 1997 (the 'Sullivan Record Date') will be entitled to notice
of, and to vote at, the Sullivan Special Meeting. At the Sullivan Special
Meeting, the holders of Sullivan Common Stock will be asked to consider and vote
upon the approval of the Merger Agreement, a copy of which is attached as Annex
I to this Joint Proxy Statement/Prospectus. The holders of Sullivan Common Stock
will also transact such other business as may properly come before the Sullivan
Special Meeting. See 'SULLIVAN SPECIAL MEETING--Approval of the Merger.'
A Special Meeting of the stockholders of Schein will be held at 10:00 a.m.,
local time, on Wednesday, November 12, 1997 (the 'Schein Special Meeting' and,
together with the Sullivan Special Meeting, the 'Special Meetings'), at the
Huntington Hilton, 598 Broadhollow Road, Melville, New York. Only holders of
record of Schein Common Stock at the close of business on September 17, 1997
(the 'Schein Record Date' and together with the Sullivan Record Date, the
'Record Dates'), will be entitled to notice of, and to vote at, the Schein
Special Meeting. At the Schein Special Meeting, the holders of Schein Common
Stock will be asked to consider and vote upon the approval of the issuance of up
to 8,029,000 shares of Schein Common Stock pursuant to the Merger (the 'Share
Issuance') and proposed amendments to Schein's Certificate of Incorporation (the
'Schein Certificate of Incorporation Amendments') that would (i) authorize
Schein's Board of Directors (the 'Schein Board') to establish from time to time
the number of directors constituting the entire Schein Board and enable the
Schein Board to amend or repeal certain By-laws, and (ii) reduce certain
supermajority voting requirements. The holders of Schein Common Stock will also
transact such other business as may properly come before the Schein Special
Meeting. If the proposed amendment relating to the Schein Board is adopted, the
Schein Board intends to appoint Robert J. Sullivan, Sullivan's Chairman of the
Board, and Bruce J. Haber, an Executive Vice President of Schein and President
of Schein's Micro Bio-Medics, Inc. subsidiary, to the Schein
Board. See 'SCHEIN SPECIAL MEETING--Approval of the Share Issuance',
'--Approval of the Schein Certificate of Incorporation Amendments' and 'Intended
Appointees to the Schein Board.'
REQUIRED VOTE
The affirmative vote of the holders of a majority of the outstanding shares
of Sullivan Common Stock is required for the approval of the Merger Agreement.
As an inducement for Schein to enter into the Merger Agreement, certain
shareholders of Sullivan, including Sullivan's Chairman of the Board and certain
of his family members, its Chief Executive Officer, its President and certain of
its other executive officers (the 'Granting Holders'), entered into an
Irrevocable Proxy and Termination Rights Agreement with Schein (the 'Irrevocable
Proxy and Termination Rights Agreement') pursuant to which such individuals,
among other things, irrevocably appointed Schein their lawful agent, attorney
and proxy to vote substantially all of the shares of Sullivan Common Stock that
they beneficially own as a group (approximately 19.6% of the outstanding shares)
in favor of the Merger Agreement and the Merger. See 'THE MERGER--Irrevocable
Proxy and Termination Rights Agreement' and 'SULLIVAN SPECIAL MEETING--Required
Vote'.
The affirmative vote of the holders of a majority of the shares of Schein
Common Stock voted on the proposed Share Issuance will be required to approve
the Share Issuance. The affirmative vote of the holders of eighty percent (80%)
of the outstanding shares of Schein Common Stock will be required for the
approval of the Schein Certificate of Incorporation Amendments. See 'THE SCHEIN
SPECIAL MEETING--Required Votes'. Certain of Schein's current principal
stockholders have executed a Voting Trust Agreement (which expires December 31,
1998 unless terminated earlier) with Stanley M. Bergman, Chairman of the Board,
Chief Executive Officer and President of Schein, as voting trustee. Mr. Bergman
will own, immediately prior to the Merger, directly or indirectly, approximately
5.0% of the outstanding shares of Schein Common Stock and will have the right to
vote up to an aggregate of approximately 15.6% of the outstanding shares of
Schein Common Stock.
PROXIES
Sullivan shareholders are requested to complete, sign, date and return
promptly the enclosed proxy card in the postage-paid envelope provided for this
purpose to ensure that their shares are voted. A holder of shares of Sullivan
Common Stock may revoke a proxy by submitting a later dated proxy with respect
to the same shares at any time prior to the vote on the approval of the Merger
Agreement, by delivering written notice of revocation to the Secretary of
Sullivan at any time prior to such vote, or by attending the Sullivan Special
Meeting and voting in person. Mere attendance at the Sullivan Special Meeting
will not in and of itself revoke a proxy.
Schein stockholders are requested to complete, sign, date and return
promptly the enclosed proxy card in the postage-paid envelope provided for this
purpose to ensure that their shares are voted. A holder of shares of Schein
Common Stock may revoke a proxy with respect to the Share Issuance or the Schein
Certificate of Incorporation Amendments by submitting a later dated proxy with
respect to the same shares at any time prior to the vote thereon, by delivering
written notice of revocation to the Secretary of Schein at any time prior to
such vote, or by attending the Schein Special Meeting and voting in person. Mere
attendance at the Schein Special Meeting will not in and of itself revoke a
proxy.
CERTAIN SIGNIFICANT CONSIDERATIONS
In considering whether to approve the Merger and the Share Issuance,
respectively, the stockholders of Sullivan and Schein should carefully consider
the factors described under 'RISK FACTORS' as well as the fact that the Exchange
Ratio is fixed and will not be adjusted based upon changes in the market price
of the shares of Schein Common Stock, which at the Effective Time may vary
significantly from the most recent market price set forth in this Joint Proxy
Statement/Prospectus or the market price on the date of the fairness opinion of
Cleary Gull Reiland & McDevitt Inc. ('Cleary Gull'), which has acted as
Sullivan's financial advisor in connection with the Merger, or on the date of
the Special Meetings. Shareholders of Sullivan should also consider that certain
members of Sullivan's management have interests in the Merger in addition to
their interests as shareholders of Sullivan, which interests may be viewed as
giving rise to potential conflicts of interest. For certain information about
these factors and the consideration given to them by the Board of Directors of
Sullivan (the 'Sullivan Board'), see '--Review and Recommendation of the Merger
by the Sullivan Board' and
2
'--Interests of Certain Persons in the Merger' in this Summary, 'RISK
FACTORS--Potential Volatility of Schein Common Stock Prices' and 'THE
MERGER--Background of the Merger,' '--Consideration and Recommendation of the
Merger by the Sullivan Board' and '--Interests of Certain Persons in Merger.'
For information about certain factors and the consideration given them by
the Schein Board see '--Review and Recommendation of the Merger by the Schein
Board,' '--Interests of Certain Persons in the Merger' in this Summary, 'RISK
FACTORS--Potential Volatility of Schein Common Stock Prices,' 'THE MERGER--
Background of the Merger' and '--Consideration and Recommendation of the Merger
by the Schein Board.'
THE MERGER
The Parties. Schein is the largest direct marketer of healthcare products
and services to office-based healthcare practitioners in the combined North
American and European markets. Schein has operations in the United States,
Canada, the United Kingdom, The Netherlands, Belgium, Germany, France, the
Republic of Ireland and Spain. Schein sells products and services to over
230,000 customers, primarily dental practices and dental laboratories, as well
as physician practices, veterinary clinics and institutions. In 1996, Schein
sold products to over 65% of the estimated offices are located at 135 Duryea
Road, Melville, New York 11747, telephone number (516) 843-5500. As used in this
Joint Proxy Statement/Prospectus, 'Schein' refers to Henry Schein, Inc., its
subsidiaries and 50% owned companies, and its predecessor, unless otherwise
indicated.
Merger Sub, a Wisconsin corporation, is a wholly-owned subsidiary of Schein
that was formed solely for the purpose of effecting the Merger.
Sullivan distributes consumable dental supplies to dentists using a
marketing strategy which combines personal visits by sales representatives with
a catalog of approximately 12,000 competitively priced items. The catalog is
updated semi-annually, mailed directly to customers, and used by Sullivan's
sales representatives to obtain additional business from existing customers and
to develop new accounts. Sullivan believes that its catalog includes
substantially all of the product categories used in general dentistry. Sullivan
also sells, installs and services dental equipment through 52 sales and service
centers located throughout the United States. Sullivan's principal executive
offices are located at 10920 West Lincoln Avenue, West Allis, Wisconsin 53227,
telephone number (414) 321-8881.
Exchange Ratio. At the Effective Time, each outstanding share of Sullivan
Common Stock will be converted into the right to receive 0.735 shares of Schein
Common Stock and each option to acquire Sullivan Common Stock that is
outstanding and unexercised will be converted automatically into a stock option
to purchase Schein Common Stock for a number of shares and at an exercise price
determined by adjusting the original terms of the option to reflect the Exchange
Ratio. No fractional shares of Schein Common Stock will be issued in the Merger
and the holders of shares of Sullivan Common Stock will be entitled to a cash
payment in lieu of any such fractional shares of Schein Common Stock that would
otherwise be issued in the Merger.
Consideration and Recommendation of the Merger by the Board of Directors of
Sullivan. THE SULLIVAN BOARD HAS UNANIMOUSLY ADOPTED THE MERGER AGREEMENT,
DETERMINED THAT THE MERGER IS IN THE BEST INTERESTS OF SULLIVAN AND ITS
SHAREHOLDERS, AND RECOMMENDS THAT THE SHAREHOLDERS OF SULLIVAN VOTE FOR THE
APPROVAL OF THE MERGER AGREEMENT. IN REACHING ITS DECISION TO ADOPT THE MERGER
AGREEMENT AND RECOMMEND THE MERGER, THE SULLIVAN BOARD CONSIDERED A NUMBER OF
FACTORS, INCLUDING THE SUBSTANTIAL PREMIUM REPRESENTED BY THE EXCHANGE RATIO,
THE INCREASED LIQUIDITY FOR SULLIVAN'S SHAREHOLDERS, AND THE STRATEGIC BUSINESS
ADVANTAGES THAT THE COMBINED COMPANIES ARE EXPECTED TO ENJOY.
Schein's Reasons for the Merger. The Schein Board has unanimously approved
the Merger Agreement, determined that the Merger is in the best interests of
Schein and its stockholders, and recommends that the stockholders of Schein vote
FOR the Share Issuance and FOR the adoption of the proposed Schein Certificate
of Incorporation Amendments.
In reaching its decision, the Schein Board considered that the Merger will
increase its market share and complement its strategic business goal of becoming
a full-service supplier of dental products, equipment and services throughout
the United States through a single transaction rather than through a series of
smaller regional acquisitions, thereby permitting Schein and its stockholders to
realize the potential benefits of such business strategy more quickly and to a
greater extent than would otherwise be possible. The combined entity, Schein
3
believes, will be able to compete effectively in establishing prime vendor
relationships with customers and increase the range of goods and services that
may be sold to Schein's and Sullivan's existing customers.
Opinion of Cleary Gull. Cleary Gull Reiland & McDevitt Inc. ('Cleary
Gull'), which has acted as Sullivan's financial advisor in connection with the
Merger, delivered an oral opinion to the Sullivan Board on August 1, 1997, the
date on which the Sullivan Board considered and approved the Merger Agreement,
that the consideration to be received pursuant to the Merger Agreement by the
holders of Sullivan Common Stock was fair, from a financial point of view, to
such holders as of such date. Such opinion was subsequently confirmed in a
written fairness opinion dated August 3, 1997. The full text of Cleary Gull's
opinion, which sets forth the assumptions made, matters considered and
limitations on the review undertaken in connection with such opinion, is
attached as Annex II to this Joint Proxy Statement/Prospectus and is
incorporated herein by reference. The opinion of Cleary Gull is directed to the
Sullivan Board and relates only to the fairness, from a financial point of view,
of the consideration to be received pursuant to the Merger Agreement by the
Sullivan shareholders, does not address any other aspect of the Merger or
related transactions, and does not constitute a recommendation to any
shareholder as to how such shareholder should vote at the Sullivan Special
Meeting. HOLDERS OF SULLIVAN COMMON STOCK ARE STRONGLY URGED TO READ SUCH
OPINION IN ITS ENTIRETY. See 'THE MERGER--Opinion of Cleary Gull.'
Opinion of Smith Barney Inc. Smith Barney Inc. ('Smith Barney') has acted
as financial advisor to Schein in connection with the Merger and has delivered
to the Schein Board a written opinion dated August 3, 1997 to the effect that,
as of the date of such opinion and based upon and subject to certain matters
stated therein, the Exchange Ratio was fair, from a financial point of view, to
Schein. The full text of the written opinion of Smith Barney dated August 3,
1997, which sets forth the assumptions made, matters considered and limitations
on the review undertaken, is attached as Annex III to this Joint Proxy
Statement/ Prospectus and should be read carefully in its entirety. The opinion
of Smith Barney is directed to the Schein Board and relates only to the fairness
of the Exchange Ratio from a financial point of view to Schein, does not address
any other aspect of the Merger or related transactions and does not constitute a
recommendation to any stockholder as to how such stockholder should vote at the
Schein Special Meeting. See 'THE MERGER--Opinion of Smith Barney Inc.'
Interests of Certain Persons in the Merger. As is noted in 'THE
MERGER--Schein's Reasons for the Merger,' Schein views the retention of
Sullivan's management team as a key benefit of the Merger. Consequently, Schein
has agreed to enter into employment agreements with each of the following
executive officers of Sullivan: Robert J. Sullivan, Chairman of the Board,
Robert E. Doering, Chief Executive Officer, Timothy J. Sullivan, President,
Kevin J. Ackeret, Executive Vice President, Geoffrey A. Reichardt, Senior Vice
President, David A. Steck, Vice President--Product Division, and Kenneth A.
Schwing, Vice President-- Equipment Division. Robert J. Sullivan will provide
executive services as directed by the Schein Board and Chairman of Schein and,
if the Schein Certificate of Incorporation Amendment relating to the maximum
size of the Schein Board, the fixing of the number of directors, and the
authority of the Board of Directors to amend certain By-laws is approved and
adopted, he is expected to be appointed as a director of Schein and Vice
Chairman of the Schein Board. Robert E. Doering will also provide executive
services as directed by the Schein Board and the Board of Directors of Schein's
U.S. Dental Division. Each of the others will have offices and responsibilities
with the U.S. Dental Division that are comparable to their existing offices and
responsibilities with Sullivan. As of the Effective Time, Schein's U.S. Dental
Division will consist of Sullivan's business and Schein's existing U.S. dental
distribution business. The employment agreements of Robert J. Sullivan and
Robert E. Doering will have terms of three years from the Effective Time, and
the other employment agreements will have terms of five years from the Effective
Time. Among other things, the employment agreements provide for salaries ranging
from $150,000 to $250,000 per annum, signing bonuses ranging from $160,000 to
$550,000, annual incentive compensation (excluding Robert J. Sullivan and Robert
E. Doering) in accordance with Schein's practices, options to purchase from
10,000 to 60,000 shares of Schein Common Stock, and restricted stock (excluding
Robert J. Sullivan and Robert E. Doering) with a value (at the Effective Time)
ranging from $75,000 to $200,000. Timothy J. Sullivan, Robert J. Sullivan,
Robert E. Doering and Kevin J. Ackeret will also receive $950,000, $550,000,
$550,000 and $255,000, respectively, in exchange for their covenants not to
compete (subject to certain exceptions and limitations) for a period of five
years commencing upon the expiration of their respective employment terms. See
'THE MERGER--Interests of Certain Persons in the Merger' and 'DESCRIPTION OF
SCHEIN--Proposed Appointees to the Schein Board.' In addition, Howard O. Wolfe,
a
4
director and shareholder of Sullivan, and Kerry B. Wolfe, a director and
shareholder of Sullivan, are members of the law firm of Wolfe, Wolfe & Ryd,
which is Sullivan's general counsel. A portion of the legal fees of Wolfe, Wolfe
& Ryd for services provided in connection with the Merger will only be paid upon
consummation of the Merger.
Security Ownership of Certain Persons. As of the Sullivan Record Date,
there were 10,286,719 shares of Sullivan Common Stock outstanding, of which
2,146,700 shares (approximately 20.8% of the outstanding shares of Sullivan
Common Stock) were beneficially owned or voted by directors and executive
officers of Sullivan. All such directors and executive officers and their
affiliates have indicated to Sullivan that they intend to vote or direct the
vote of all such shares in favor of the approval of the Merger Agreement. In
addition, certain shareholders of Sullivan have entered into the Irrevocable
Proxy and Termination Rights Agreement. See '--Irrevocable Proxy and Termination
Rights Agreement.'
Treatment of Sullivan Stock Options. At the Effective Time, each
outstanding option to purchase Sullivan Common Stock will be automatically
assumed by Schein and converted into an option (the 'Converted Options') to
purchase shares of Schein Common Stock in an amount and at an exercise price
determined by adjusting the original terms of the option to reflect the Exchange
Ratio.
As of the Sullivan Record Date, there were outstanding options to purchase
an aggregate of approximately 1,674,825 shares of Sullivan Common Stock.
Assuming all such options remain outstanding at the Effective Time, an aggregate
of approximately 1,230,996 shares of Schein Common Stock would thereafter be
issuable upon the exercise of such Converted Options.
Conditions to the Merger. The obligations of Schein, Merger Sub and
Sullivan to consummate the Merger are subject to the satisfaction or waiver of
various conditions, including, without limitation, Sullivan shareholder approval
of the Merger Agreement, Schein stockholder approval of the Share Issuance and
antitrust regulatory approval. See '--Regulatory Matters' and 'TERMS OF THE
MERGER AGREEMENT--Conditions to the Merger.'
No Solicitation. The Merger Agreement provides that neither Sullivan, its
subsidiaries or affiliates, nor any of their respective directors, officers,
employees, agents or representatives shall, among other things, directly or
indirectly, solicit, initiate, facilitate or encourage (including by way of
furnishing or disclosing non-public information) any inquiries or the making of
any proposals with respect to, or which may reasonably be expected to lead to,
an Acquisition Transaction (as defined in the Merger Agreement), or negotiate,
explore or otherwise engage in discussions with any person with respect to any
Acquisition Transaction, or endorse any Acquisition Transaction; provided,
however, that Sullivan may, in response to an unsolicited written proposal from
a third party with respect to an Acquisition Transaction, furnish information to
and engage in discussions with such third party if (i) the Sullivan Board
determines in good faith by a majority vote, after consultation with Sullivan's
financial advisor and based upon advice of outside counsel, that failing to take
such action would result in a breach of the fiduciary duties of the Sullivan
Board and (ii) prior to taking such action, Sullivan (x) provides reasonable
notice to Schein to the effect that it is taking such action and (y) receives
from such person (and delivers to Schein) an executed confidentiality agreement
in reasonably customary form. Sullivan is required to immediately advise Schein
in writing of any inquiries or proposals with respect to an Acquisition
Transaction and the terms thereof, including the identity of such third party,
and to update the status thereof on an ongoing basis or upon Schein's request.
See 'TERMS OF THE MERGER AGREEMENT--No Solicitation of Other Offers.'
Right of the Sullivan Board to Withdraw Recommendation. Under the Merger
Agreement, the Sullivan Board may not, among other things, (i) withdraw or
modify, in a manner adverse to Schein or Merger Sub, the Sullivan Board's
approval or recommendation of the Merger Agreement or the Merger, (ii) approve
or recommend any Acquisition Transaction, or (iii) cause Sullivan to enter into
any agreement with respect to any Acquisition Transaction. Notwithstanding the
foregoing, if the Sullivan Board determines in its good faith reasonable
judgment, by majority vote, after consultation with Sullivan's financial
advisor, that such Acquisition Transaction is more favorable to the holders of
Sullivan Common Stock than the Merger and, based upon the advice of outside
counsel, that such action is required by its fiduciary duties, the Sullivan
Board may withdraw or modify its approval or recommendation of the Merger
Agreement and the Merger, approve or recommend an Acquisition Transaction, or
cause Sullivan to enter into an agreement with respect to an Acquisition
Transaction; provided, in each case, that the Sullivan Board gives Schein at
least five business days' prior written notice
5
thereof, during which period Schein may make a counter proposal to such
Acquisition Transaction. If Schein makes a counter proposal, Sullivan is
obligated to consider such proposal in good faith. See 'THE MERGER-- Right of
the Sullivan Board to Withdraw Recommendation.'
Termination. The Merger Agreement may be terminated and the Merger
abandoned at any time prior to the Effective Time and regardless of whether the
shareholders of Sullivan shall have approved the Merger Agreement and the
Merger: (i) by mutual written consent of Schein and Sullivan, (ii) by either
Schein or Sullivan, except in certain circumstances, if the Merger shall not
have been consummated before January 31, 1998 or if any permanent injunction or
action by any Governmental Entity (as defined in the Merger Agreement) shall
have become final and nonappealable; provided, however, that, except under
certain circumstances, either Schein or Sullivan may extend the date upon which
the Merger Agreement may be so terminated for up to 90 additional days in the
absence of any such permanent injunction or other action by any Governmental
Entity, (iii) by Schein, if (a) the Sullivan Special Meeting is canceled or
otherwise not held (except in certain circumstances) prior to January 31, 1998
(or such later date to which the Merger Agreement may be extended as described
above), (b) there has been a breach of any representation or warranty of
Sullivan set forth in the Merger Agreement which, individually or together with
all other such breaches, has or will have a material adverse effect on the
financial condition, results of operations, assets or liabilities of Sullivan
and its subsidiaries, taken as a whole, or the ability of Sullivan to consummate
the Merger and the other transactions contemplated by the Merger Agreement, (c)
there has been a breach in any material respect of any of the covenants or
agreements set forth in the Merger Agreement on the part of Sullivan, which
breach is not cured within 30 days after written notice of such breach is given
by Schein to Sullivan, (d) the Sullivan Board (1) withdraws or amends or
modifies in a manner materially adverse to Schein or Merger Sub its
recommendation of approval to shareholders in respect of the Merger Agreement or
the Merger, (2) makes any recommendation with respect to an Acquisition
Transaction (including making no recommendation or stating an inability to make
a recommendation), other than a recommendation to reject such Acquisition
Transaction, or (3) takes any action that violates the non-solicitation
provisions of the Merger Agreement, (e) subject to certain exceptions, any
corporation, partnership, person or other entity or group ('Acquiring Person')
other than Schein, or any affiliate or subsidiary of Schein, shall have become
the beneficial owner of more than 20% of the outstanding voting equity of
Sullivan (either on a primary or a fully diluted basis), or (f) any other
Acquisition Transaction shall have occurred with any Acquiring Person other than
Schein, or any affiliate or subsidiary of Schein, or (iv) by Sullivan, if (a)
the Schein Special Meeting is canceled or otherwise not held (except in certain
circumstances) prior to January 31, 1998 (or such later date to which the Merger
Agreement may be extended as described above), (b) there has been a breach of
any representation or warranty of Schein set forth in the Merger Agreement
which, individually or together with all other such breaches, has or will have a
material adverse effect on the financial condition, results of operations,
assets, liabilities or prospects of Schein and its subsidiaries, taken as a
whole, or the ability of Schein to consummate the Merger and the other
transactions contemplated by the Merger Agreement, (c) there has been a breach
in any material respect of any of the covenants or agreements set forth in the
Merger Agreement on the part of Schein, which breach is not cured within 30 days
after written notice of such breach is given by Sullivan to Schein or (d) such
termination is necessary to allow Sullivan to enter into an Acquisition
Transaction permitted under the Merger Agreement. See 'TERMS OF THE MERGER
AGREEMENT--Termination Rights.'
Certain Fees and Liquidated Damages. If the Merger Agreement is terminated
as provided above: (i) by Schein due to the Sullivan Board having withdrawn or
modified its recommendation or approval with respect to the Merger Agreement or
the Merger or having made a recommendation to shareholders with respect to an
Acquisition Transaction, or an Acquiring Person having become the owner of 20%
or more of Sullivan's outstanding voting equity, or any other Acquisition
Transaction having occurred, (ii) by Sullivan, in order to enter into an
Acquisition Transaction permitted by the Merger Agreement, (iii) by either
Schein or Sullivan due to the Merger not being consummated before January 31,
1998 (or such later date to which the Merger Agreement may be extended as
described above under '--Termination'), (iv) by Schein due to the Sullivan
Special Meeting not occurring prior to January 31, 1998 (or such later date to
which the Merger Agreement may be extended as described above under
'--Termination'), or (v) by Schein due to a material breach of any
representation, warranty, covenant or agreement and, in the case of a
termination described in clauses (iii) through (v), within six months of such
termination Sullivan or any of its subsidiaries consummates an Acquisition
Transaction or enters into a definitive agreement with respect thereto; then
Sullivan shall pay to Schein a termination fee of $12,000,000 (the 'Termination
Fee'). If the Merger Agreement terminates under the
6
circumstances described in clauses (iv) and (v) and an Acquisition Transaction
does not occur within six months of such termination, Sullivan is required to
pay to Schein the amount of $7,000,000 as liquidated damages. If Sullivan
terminates the Merger Agreement due to a material breach of any representation,
warranty, covenant or agreement by Schein or due to the Schein Special Meeting
not occurring prior to January 31, 1998 (or such later date to which the Merger
Agreement may be extended as described above under '--Termination'), then Schein
is required to pay to Sullivan the amount of $7,000,000 as liquidated damages.
Absence of Appraisal Rights. Under the WBCL, holders of shares of Sullivan
Common Stock will not have appraisal rights in connection with the Merger.
IRREVOCABLE PROXY AND TERMINATION RIGHTS AGREEMENT
Schein and the Granting Holders, including Sullivan's Chairman of the
Board, its Chief Executive Officer and its President, have entered into the
Irrevocable Proxy and Termination Rights Agreement, pursuant to which the
Granting Holders have granted to Schein an irrevocable proxy to vote
substantially all of the shares of Sullivan Common Stock that they beneficially
own as a group to vote in favor of the Merger Agreement and against any other
Acquisition Transaction and certain other proposals inconsistent with the
Merger. An aggregate number of 2,015,565 shares of Sullivan Common Stock are
subject to the Irrevocable Proxy and Termination Rights Agreement.
In addition, under the terms of the Irrevocable Proxy and Termination
Rights Agreement, if any Granting Holder shall sell, exchange or otherwise
dispose of any of his, her or its shares of Sullivan Common Stock pursuant to an
Acquisition Transaction after the Merger Agreement has been terminated: (A) by
Schein due to (i) a breach of any representation or warranty of Sullivan which
individually or together with all other such breaches has or will have a
materially adverse effect on Sullivan, (ii) a material breach of any covenant or
agreement set forth in the Merger Agreement which remains uncured 30 days after
notice of the breach is given by Schein to Sullivan, (iii) the Sullivan Board
(x) withdrawing, amending or modifying in a manner adverse to Schein or the
Merger Sub its recommendation or approval in respect of the Merger Agreement or
the Merger, (y) making a recommendation with respect to an Acquisition
Transaction, other than a recommendation to reject such Acquisition Transaction,
or (z) taking any action that would constitute a violation of the Merger
Agreement's prohibition on solicitation of proposals or inquiries regarding an
Acquisition Transaction; (iv) subject to certain exceptions, any Acquiring
Person, other than Schein or any affiliate or subsidiary of Schein, becoming the
beneficial owner of more than 20% of the outstanding voting equity of Sullivan
(either on a primary or fully diluted basis); (v) an Acquisition Transaction
occurring with any Acquiring Person other than Schein or any affiliate or
subsidiary of Schein; (vi) the Sullivan Special Meeting having been canceled or
otherwise not held (except in certain circumstances) prior to January 31, 1998
(or such later date to which the Merger Agreement may be extended as described
above under '--Termination'), or (B) by Sullivan (i) in order to permit Sullivan
to enter into an Acquisition Transaction, (ii) due to the failure of Sullivan or
Schein to obtain the required stockholder consents or (iii) as a result of the
failure of the Merger to be consummated prior to January 31, 1998 (or such later
date to which the Merger Agreement may be extended as described above under
'--Termination'), then such Granting Holder shall pay or cause to be paid to
Schein upon demand an amount equal to the product of (x) 35% of the amount by
which the total consideration of all kinds and from all sources received by such
Granting Holder for each share of Sullivan Common Stock disposed of by such
Granting Holder exceeds the fair market value of 0.735 shares of Schein Common
Stock on the date of termination of the Merger Agreement and (y) the aggregate
number of shares of Sullivan Common Stock sold by such Granting Holder. See 'THE
SULLIVAN SPECIAL MEETING--Required Vote' and 'THE MERGER--Irrevocable Proxy and
Termination Rights Agreement.'
REGULATORY MATTERS
Antitrust. The Merger is subject to the requirements of the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the 'HSR
Act'), and the rules and regulations thereunder, which provide that certain
transactions may not be consummated until required information and material have
been furnished to the Antitrust Division of the Department of Justice (the
'Antitrust Division') and the Federal Trade Commission (the 'FTC') and certain
waiting periods have expired or been terminated. Sullivan and Schein filed the
required information and material with the Antitrust Division and the FTC on
August 19, 1997. Early termination of the
7
statutory waiting period under the HSR Act was granted on September 16, 1997.
See 'THE MERGER--Regulatory Filings and Approvals--Antitrust.'
CERTAIN TAX CONSEQUENCES OF THE MERGER
Schein has obtained the opinion of Proskauer Rose LLP, counsel to Schein,
to the effect that the Merger will qualify as a 'tax-free reorganization' for
United States Federal income tax purposes. Accordingly, no gain or loss will be
recognized for United States Federal income tax purposes by the Sullivan
shareholders as a result of the exchange of shares of Sullivan Common Stock for
shares of Schein Common Stock. However, cash received by Sullivan shareholders
in lieu of fractional shares of Schein Common Stock may give rise to taxable
gain or loss. Each shareholder of Sullivan is urged to consult his or her tax
advisor to determine the specific tax consequences of the Merger to such
shareholder. The obligations of both Sullivan and Schein to consummate the
Merger are subject to Proskauer Rose LLP's opinion not being withdrawn or
modified in any material respects. For a further discussion of the tax
consequences of the Merger, See 'THE MERGER--Certain Tax Consequences of the
Merger.'
ANTICIPATED ACCOUNTING TREATMENT
Schein and Sullivan believe that the Merger will qualify as a 'pooling of
interests' for accounting and financial reporting purposes. It is a condition to
Schein's obligation to consummate the Merger that BDO Seidman, LLP, the
independent auditors for Schein, and Deloitte & Touche LLP, the independent
auditors for Sullivan, issue their respective opinions that, subject to
customary qualifications, the Merger qualifies as a pooling of interests for
financial reporting purposes in accordance with generally accepted accounting
principles. See 'THE MERGER--Anticipated Accounting Treatment.'
Although either Schein or Sullivan may waive this condition to the
consummation of the Merger and the tax opinion condition to the consummation of
the Merger described in '--Certain Tax Consequences of the Merger,' neither
Schein nor Sullivan anticipates waiving these conditions, and will not do so
without resoliciting the holders of Sullivan Common Stock and Schein Common
Stock for their approval of the Merger and the Share Issuance, respectively, on
the basis of such waiver or waivers.
COMPARISON OF STOCKHOLDER RIGHTS
If the Merger is consummated, shareholders of Sullivan will become
stockholders of Schein, a Delaware corporation, which will result in their
rights as stockholders being governed by Delaware law and Schein's Certificate
of Incorporation and Amended and Restated By-laws, rather than Wisconsin law
(Sullivan is a Wisconsin corporation) and Sullivan's Articles of Incorporation,
as amended, and By-laws, as amended. It is not practical to describe all the
differences between Delaware law and Wisconsin law and between Schein's
governing documents and Sullivan's governing documents. A summary of certain of
such differences is set forth in 'COMPARISON OF STOCKHOLDER RIGHTS,' including,
without limitation, differences with respect to the size of the board of
directors, the calling of special meetings of stockholders, and the required
stockholder vote for the approval of certain transactions or the amendment of
the governing documents.
MARKET PRICE DATA
Both the Schein Common Stock (symbol: HSIC) and the Sullivan Common Stock
(symbol: SULL) are admitted for trading on the Nasdaq National Market.
The following table sets forth the high and low sales prices per share of
the Schein Common Stock and the Sullivan Common Stock (on a historical and
equivalent per share basis) on the Nasdaq National Market on August 1, 1997, the
last trading day prior to public announcement of the signing of the Merger
Agreement:
HIGH LOW
---- ---
Schein Common Stock.......................................... $39 $37
Sullivan Common Stock........................................ 22 1/2 21 1/2
Equivalent share basis(1).................................... 28 5/8 27 3/16
(Footnotes on next page)
8
(Footnotes from previous page)
- ------------------
(1) Equivalent share basis is determined by multiplying the applicable Schein
Common Stock price by 0.735 (the Exchange Ratio) to reflect the terms of the
Merger Agreement.
SUMMARY CONSOLIDATED HISTORICAL FINANCIAL INFORMATION AND OPERATING DATA
The following tables present summary consolidated selected historical
financial information of Schein and summary selected financial information of
Sullivan. Schein and Sullivan's historical financial information and operating
data for each of the annual periods presented have been derived from their
respective audited financial statements previously filed with the SEC. Schein's
historical consolidated financial information for the six months ended June 28,
1997 and June 29, 1996, and Sullivan's historical financial statements for the
six months ended June 30, 1997 and 1996 have been derived from Schein's and
Sullivan's respective unaudited financial statements for such periods previously
filed with the SEC. In the opinions of the management of Schein and Sullivan,
respectively, with respect to such companies' respective six-month financial
statements, all adjustments considered necessary for a fair presentation have
been made. Such adjustments consist of only those of a recurring nature.
Operating results for the six month periods are not necessarily indicative of
the results that may be expected for the year. The summary selected historical
financial information and operating data should be read in conjunction with the
selected historical financial information and operating data presented elsewhere
in this Joint Proxy Statement/Prospectus. Neither Schein's nor Sullivan's
Selected Operating Data has been audited. See 'SCHEIN CONSOLIDATED SELECTED
HISTORICAL FINANCIAL INFORMATION AND OPERATING DATA' and 'SULLIVAN SELECTED
HISTORICAL FINANCIAL INFORMATION.'
9
SCHEIN SUMMARY CONSOLIDATED HISTORICAL FINANCIAL INFORMATION AND OPERATING DATA
(IN THOUSANDS, EXCEPT PER SHARE AND SELECTED OPERATING DATA)
YEARS ENDED
----------------------------------------------------------------------------
DECEMBER 28, DECEMBER 30, DECEMBER 31, DECEMBER 25, DECEMBER 26,
1996 1995 1994 1993 1992
------------ ------------ ------------ ------------ ------------
STATEMENT OF OPERATIONS DATA:
Net sales............................... $ 840,122 $ 623,302 $ 490,834 $ 417,838 $ 363,477
Gross profit............................ 253,109 195,854 145,966 122,884 106,215
Selling, general and
administrative expenses............... 220,500 174,867 131,009 111,214 96,853
Special charges(1)...................... -- 20,797 23,603 6,057 7,510
Operating income (loss)................. 32,609 190 (8,646) 5,613 1,852
Net income (loss)....................... $ 22,523 $ (8,801) $ (10,065) $ 4,125 $ 487
PRO FORMA INCOME DATA(2):
Pro forma operating income.............. $ 32,609 $ 20,987 $ 14,957
Pro forma net income.................... $ 21,326 $ 10,289 $ 7,483
Pro forma net income per common share... $ 0.98 $ 0.71 $ 0.57
Pro forma average shares outstanding.... 21,794 14,517 13,197
SELECTED OPERATING DATA:
Number of orders shipped................ 3,079,000 2,630,000 2,275,000 2,044,000 1,824,000
Average order size...................... $ 273 $ 237 $ 216 $ 204 $ 199
BALANCE SHEET DATA (AT PERIOD END):
Working capital......................... $ 204,575 $ 104,455 $ 76,814 $ 74,167 $ 28,066
Total assets............................ 467,450 299,364 191,373 161,437 138,043
Total debt.............................. 39,746 43,049 61,138 56,712 41,526
Redeemable stock(3)..................... -- -- 14,745 -- --
Minority interest....................... 5,289 4,547 1,823 1,051 411
Stockholders' equity.................... 292,016 143,865 40,266 43,896 39,927
SIX MONTHS ENDED
------------------------------
JUNE 28, 1997 JUNE 29, 1996
------------- -------------
STATEMENT OF OPERATIONS DATA:
Net sales........................................................................... $ 503,605 $ 384,595
Gross profit........................................................................ 150,764 116,426
Selling, general and administrative expenses........................................ 133,175 104,140
Merger and integration costs(4)..................................................... 4,353 --
Operating income.................................................................... 13,236 12,286
Net income.......................................................................... $ 6,803 $ 7,820
Net income per common share......................................................... $ 0.28
Average shares outstanding.......................................................... 23,977
PRO FORMA INCOME DATA(5):
Pro forma net income................................................................ $ 7,390
Pro forma net income per common share............................................... $ 0.37
Pro forma average shares outstanding................................................ 19,957
BALANCE SHEET DATA (AT PERIOD END):
Working capital..................................................................... $ 209,772
Total assets........................................................................ 484,753
Total debt.......................................................................... 61,220
Minority interest................................................................... 2,448
Stockholders' equity................................................................ 304,579
(Footnotes on next page)
10
(Footnotes from previous page)
- ------------------
(1) Includes: (a) for 1995, non-cash special management compensation charges of
$17.5 million arising from final mark-to-market adjustments (reflecting an
increase in estimated market value from 1994 to the initial public offering
price of $16.00 per share of Schein Common Stock) for stock grants made to
an executive officer of Schein in 1992 and other stock issuances made to
certain other senior management of Schein (because of certain repurchase
features which expired with the initial public offering), an approximate
$2.8 million non-cash special management compensation charge (also based on
the initial public offering price of $16.00 per share) relating to
compensatory options granted in 1995, and a cash payment of $0.5 million for
additional income taxes resulting from such stock issuances; (b) for 1994
special professional fees of $2.0 million incurred by Schein in connection
with the reorganization of Schein's ownership, including various agreements
entered into in connection therewith, between 1992 and 1994, non-cash
special management compensation arising from accelerated amortization of
deferred compensation arising from the 1992 stock grants to an executive
officer of Schein of $17.3 million, which included a 1994 mark-to-market
adjustment (because of the repurchase features referred to above) of $9.1
million, due to the resolution, with the closing of such reorganization, of
certain contingencies surrounding the issuance of the stock grants, non-cash
special management compensation charges of $1.6 million (net of prior
accruals of approximately $1.9 million under an executive incentive plan)
arising from stock issuances to certain other senior management of Schein,
valued at $3.5 million, and cash payments for income taxes of approximately
$2.4 million resulting from these stock issuances and $0.3 million for
additional income taxes resulting from the 1992 stock grants; (c) for 1993,
special professional fees of $2.2 million relating to such reorganization,
special contingent consideration of $0.7 million paid in connection with an
acquisition and $2.5 million resulting from the buyout of employees' rights
to future income contained in their employment agreements, and non-cash
special management compensation charges of $0.6 million in amortization of
deferred compensation arising from the 1992 stock grants; and (d) for 1992,
special professional fees of $2.2 million relating to such reorganization,
and cash payments of $5.3 million for income taxes resulting from stock
grants made to an executive officer of Schein. See 'Description of Schein'
and 'Schein Management's Discussion and Analysis of Financial Condition and
Results of Operations--Overview.'
(2) Reflects the pro forma elimination of special charges incurred in 1995 and
1994 for special management compensation of $20.8 million and $21.6 million,
respectively, and special professional fees incurred in 1994 of $2.0
million, arising from the reorganization referred to in note (1) above, and
the related tax effects of $1.2 million and $5.8 million for 1995 and 1994,
respectively, and provision for income taxes on previously untaxed earnings
of Dentrix Dental Systems, Inc. as an S Corporation, of $1.2 million, $0.5
million and $0.3 million for 1996, 1995 and 1994, respectively. See
'Description of Schein' and 'Schein Management's Discussion and Analysis of
Financial Condition and Results of Operations--Overview.'
(3) Redeemable stock includes stock issued for compensation which was subject to
repurchase by Schein at fair market value in the event of termination of
employment of the holder of such shares, as well as shares purchased by the
trust for Schein's ESOP and allocable to the ESOP participants. With the
completion of Schein's initial public offering, the stock issued for
compensation and the ESOP Common Stock were no longer subject to repurchase.
See 'Description of Schein' and 'Schein Management's Discussion and Analysis
of Financial Condition and Results of Operations--Overview.'
(4) During the six months ended June 28, 1997, Schein issued 1,916,866 shares of
Common Stock in connection with four acquisitions accounted for under the
pooling of interests method of accounting. In connection with these
acquisitions Schein incurred certain merger and integration costs of
approximately $4.4 million. Net of taxes, merger and integration costs were
approximately $0.17 per share. Merger and integration costs consist
primarily of investment banking, legal, accounting and advisory fees, as
well as certain other integration costs associated with these mergers.
(5) Reflects the pro forma provision for income taxes of $0.4 million on
previously untaxed earnings of an acquisition.
11
SULLIVAN SUMMARY HISTORICAL FINANCIAL INFORMATION
(IN THOUSANDS, EXCEPT PER SHARE DATA)
YEARS ENDED DECEMBER 31,
--------------------------------------------------------
1996 1995 1994 1993 1992
-------- -------- -------- -------- --------
STATEMENT OF OPERATIONS DATA:
Net sales............................................ $241,583 $215,568 $203,602 $169,000 $118,022
Gross profit......................................... 82,646 73,815 69,617 57,470 40,342
Total expenses....................................... 73,981 66,575 61,940 51,294 34,897
Net income........................................... $ 8,665 $ 7,240 $ 7,677 $ 6,176 $ 5,445
Net income per common share.......................... 0.91 0.77 0.82 0.66 0.60
Average shares outstanding........................... 9,523 9,405 9,409 9,415 9,049
Cash dividends per share............................. $ 0.20 $ 0.20 -- -- --
BALANCE SHEET DATA (AT PERIOD END):
Working capital...................................... $ 54,201 $ 47,028 $ 45,536 $ 37,577 $ 32,217
Long-term debt (net of current maturities)........... -- -- -- -- --
Total assets......................................... 101,050 96,915 81,105 68,604 54,448
Stockholders' equity................................. 76,459 62,453 57,617 49,274 42,319
SIX MONTHS ENDED JUNE 30,
-------------------------
1997 1996
---- ----
STATEMENT OF OPERATIONS DATA:
Net sales........................................................................... $ 128,392 $ 112,957
Gross profit........................................................................ 44,242 38,518
Operating expenses.................................................................. 36,960 33,349
Net income.......................................................................... $ 4,610 $ 3,229
Net income per common share......................................................... $ 0.44 $ 0.35
Average shares outstanding.......................................................... 10,521 9,351
Cash dividends per share............................................................ $ 0.10 $ 0.05
BALANCE SHEET DATA (AT PERIOD END):
Working capital..................................................................... $ 58,674 49,002
Short-term bank debt................................................................ -- --
Total assets........................................................................ 108,406 89,368
Stockholders' equity................................................................ 84,417 64,300
12
SUMMARY UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
The following tables present summary unaudited pro forma combined financial
information after giving effect to the Merger under the pooling of interests
method of accounting as if the Merger had been consummated as of the beginning
of the periods presented. The tables have been derived from, or prepared on a
basis consistent with, the unaudited pro forma combined information included in
this Joint Proxy Statement/Prospectus. The selected pro forma combined financial
information should be read in conjunction with, and is qualified in its entirety
by reference to, the unaudited pro forma combined condensed financial statements
and the notes thereto. See 'UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL
STATEMENTS.' The following data are presented for illustrative purposes only and
are not necessarily indicative of the operating results or financial position
that would have occurred or that will occur after consummation of the Merger.
JUNE 28, 1997
--------------
(IN THOUSANDS)
BALANCE SHEET DATA:
Working capital................................................................ $255,246
Total assets................................................................... 593,159
Total debt..................................................................... 61,220
Stockholders' equity........................................................... 375,796
SIX MONTHS YEARS ENDED
ENDED --------------------------------------------
JUNE 28, DECEMBER 28, DECEMBER 30, DECEMBER 31,
1997 1996 1995 1994
---------- ------------ ------------ ------------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
STATEMENT OF OPERATIONS DATA:
Net sales................................................ $631,997 $1,081,705 $838,870 $694,436
Operating income(1)...................................... 20,518 46,354 11,540 3,724
Net income (loss)........................................ $ 11,413 $ 31,188 $ (1,561) $ (2,388)
Net income per common share.............................. $ 0.36
Weighted average common and common equivalent shares
outstanding............................................ 31,730
Pro forma operating income(2)............................ $ 32,337 $ 27,327
Pro forma net income(3).................................. $ 29,991 17,529 15,160
Pro forma net income per common share.................... $ 1.04 $ 0.82 $ 0.75
Pro forma weighted average common and common equivalent
shares outstanding..................................... 28,793 21,430 20,113
- ------------------
(1) Includes merger costs of $4,353 in 1997 and special charges of $20,797 in
1995 and $23,603 in 1994.
(2) Reflects the pro forma elimination of the special charges.
(3) Reflects the pro forma elimination of the special charges and relative tax
benefit and the provision for income taxes on previously untaxed earnings of
Dentrix as an S Corporation.
13
COMPARATIVE UNAUDITED PER SHARE DATA
The following table summarizes certain unaudited comparative per share data
for Schein and Sullivan on a pro forma combined basis, on a pro forma share
equivalent basis and on a historical basis giving effect to the Merger as a
pooling of interests for accounting purposes. Such information is derived from,
and should be read in conjunction with, the Unaudited Pro Forma Combined
Condensed Financial Information, including the notes thereto, contained
elsewhere in this Joint Proxy Statement/Prospectus. The unaudited pro forma
statements presented are for comparative purposes only and are not necessarily
indicative of future combined earnings or financial position or combined
earnings or financial position that would have been reported had the Merger been
completed at the beginning of the respective periods or as of the dates for
which such unaudited pro forma information is presented. The Sullivan Per Share
Equivalents are calculated by multiplying the Pro Forma Combined per share
amounts by the Exchange Ratio of 0.735.
AT OR FOR THE PERIODS ENDED(1)
SIX MONTHS --------------------------------------------
ENDED DECEMBER 28, DECEMBER 30, DECEMBER 31,
JUNE 28, 1997 1996 1995 1994
------------- ------------ ------------ ------------
PRO FORMA COMBINED
Net income per common share.......................... $ 0.36 $ 1.04 $ 0.82 $ 0.75
Book value per common share.......................... 11.94
SULLIVAN PER SHARE EQUIVALENTS
Net income per common share.......................... 0.26 0.76 0.60 0.55
Book value per common share.......................... 8.78
SULLIVAN--HISTORICAL
Net income per common share.......................... 0.44 0.91 0.77 0.82
Book value per common share.......................... 8.02
SCHEIN
Net income per common share--Historical.............. 0.28
Pro forma net income per common share(2)............. 0.98 0.71 0.57
Book value per common share--Historical.............. 12.62
- ------------------
(1) Combines Schein's amounts at and for the six fiscal months ended in June and
each of the fiscal years ended in December with Sullivan's amounts at and
for its corresponding fiscal periods.
(2) For Schein, excludes special management compensation and related tax effects
for 1995 and 1994, and special professional fees and related tax effects for
1994. See note (1) to '--Schein Summary Consolidated Historical Financial
Information and Operating Data' on page 11.
Except for a dividend paid by Schein in 1992 and distributions made by Dentrix
prior to its business combination with Schein, Schein has never paid a cash
dividend and does not anticipate doing so in the foreseeable future. Schein's
revolving credit facility and a note issued in connection with an acquisition in
the Netherlands limit Schein's ability to pay dividends without the prior
written consent of the lenders. Sullivan declared (and subsequently paid) cash
dividends of $.20 per share in 1995, four quarterly dividends of $.05 per share
in 1996 and dividends of $.05 per share for each of the first two quarters of
1997. The Merger Agreement prohibits Sullivan from paying dividends without
Schein's consent and it is not anticipated that any dividends will be paid on
the Sullivan Common Stock.
14
RISK FACTORS
In addition to other information in this Joint Proxy Statement/Prospectus,
the following factors should be considered carefully by the holders of shares of
Schein and Sullivan Common Stock in evaluating whether to approve and adopt the
Merger Agreement. The Private Securities Litigation Reform Act of 1995 provides
a 'safe harbor' for forward looking statements. Any forward looking statements
contained in this Joint Proxy Statement/Prospectus, including, without
limitation, those relating to the combined operations of Schein and Sullivan
after the Merger, are subject to, among other things, the following factors.
FIXED EXCHANGE RATIO
In considering whether to approve and adopt the Merger Agreement providing
for the Merger and the Share Issuance, respectively, holders of shares of
Sullivan Common Stock and Schein Common Stock should carefully consider that the
Exchange Ratio is fixed and will not be adjusted based on changes in the market
price of the Schein Common Stock, and that the market price of the Schein Common
Stock at the Effective Time may vary from the price as of the date of this Joint
Proxy Statement/Prospectus or the date on which holders of shares of Schein
Common Stock or Sullivan Common Stock vote on the Merger due to changes in the
business, operations or prospects of Schein, market assessments of the
likelihood that the Merger will be consummated and the timing thereof, general
market and economic conditions, and other factors.
DIFFICULTY OF INTEGRATION OF OPERATIONS FOLLOWING THE MERGER; LOSS OF SALES
REPRESENTATIVES AND SUPPLIERS
The Schein Board and the Sullivan Board have each given careful
consideration to the Merger and believe it to be in the best interests of their
respective stockholders. However, the Merger involves the combination of two
companies that have operated independently. Accordingly, there can be no
assurance that Sullivan can be successfully integrated into Schein or that
Schein and its stockholders (including the shareholders of Sullivan who become
stockholders of Schein) will ultimately realize any benefits from the Merger.
The success of the combined company following the Merger will require the
dedication of management resources which may temporarily detract from attention
to the day to day business of Schein and Sullivan. There can be no assurance
that such diversion of management resources will not adversely affect revenues
or that other material adverse effects will not result from such activities.
In addition, the combined company may be adversely affected if it suffers
material defections in its combined sales force or the loss of major suppliers
of either Schein or Sullivan prior to the Merger. Schein intends to pay
significant signing bonuses to retain the members of the combined sales force.
See 'UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL STATEMENTS'. A leading
manufacturer of chairs and other large dental equipment which is a Sullivan
supplier has advised Sullivan and Schein that it intends not to sell its
products to the combined company for distribution.
INTERESTS OF CERTAIN PERSONS IN THE MERGER
Robert J. Sullivan, Robert E. Doering, Timothy J. Sullivan, Kevin J.
Ackeret, Geoffrey A. Reichardt, David A. Steck and Kenneth A. Schwing,
Sullivan's Chairman, Chief Executive Officer, President, Executive Vice
President, Senior Vice President, Vice President--Products Division and Vice
President--Equipment Division, respectively, of Sullivan (each, an 'Executive'
and, collectively, the 'Executives'), have entered into new employment
agreements with Schein which contain provisions, among other things, for salary,
signing bonuses, incentive compensation (except for Robert Sullivan and Robert
Doering), grants of restricted shares of Schein Common Stock (except for Robert
Sullivan and Robert Doering), grants of Schein Common Stock purchase options and
noncompetition covenants. These agreements all take effect at the Effective
Time. The consideration to the Executives is for services rendered or to be
rendered to Sullivan or to the surviving corporation in the Merger (the
'Surviving Corporation') and, accordingly, the holders of shares of Sullivan
Common Stock will not receive any part of this consideration. The additional
consideration to be received by the Executives may be deemed to give rise to
potential conflicts of interest for those Executives who serve as directors of
Sullivan in their performance of their duties as directors of Sullivan. The
Executives will receive, as holders of shares of Sullivan Common Stock, the same
merger consideration as all other holders of shares of Sullivan Common Stock.
See 'THE MERGER--Interests of Certain Persons in the Merger.'
15
IRREVOCABLE PROXY AND TERMINATION RIGHTS AGREEMENT
Schein and the Granting Holders have entered into the Irrevocable Proxy and
Termination Rights Agreement pursuant to which such Granting Holders have
granted to Schein an irrevocable proxy to vote substantially all of the shares
of Sullivan Common Stock that they beneficially own as a group in favor of the
Merger Agreement and against any other Acquisition Transaction. In addition,
under the terms of the Irrevocable Proxy and Termination Rights Agreement, if
any Granting Holder shall sell, exchange or otherwise dispose of any of his, her
or its shares of Sullivan Common Stock pursuant to an Acquisition Transaction
after the Merger Agreement has terminated under the circumstances described in
'THE MERGER--Irrevocable Proxy and Termination Rights Agreements', then such
Granting Holder shall pay or cause to be paid to Schein upon demand an amount
equal to the product of (x) 35% of the amount by which the total consideration
of all kinds and from all sources received by such Granting Holder for each
share of Sullivan Common Stock disposed of by such Granting Holder exceeds the
fair market value on the date of termination of the Merger Agreement of 0.735
shares of Schein Common Stock and (y) the aggregate number of shares of Sullivan
Common Stock sold by such Granting Holder.
The arrangements under the Irrevocable Proxy and Termination Rights
Agreement may be deemed to give rise to additional and different interests of
the members of the Sullivan Board in the Merger than those of other shareholders
of Sullivan. In particular, the Irrevocable Proxy and Termination Rights
Agreement may be deemed to diminish any economic interest that the members of
the Sullivan Board would otherwise have, in their individual capacities as
shareholders of Sullivan, in an Acquisition Transaction that was more favorable
to the Sullivan shareholders than the Merger. Under the terms of the Merger
Agreement, the Sullivan Board may terminate the Merger Agreement in order to
permit Sullivan to enter into an Acquisition Transaction with a third party if
it determines in its good faith reasonable judgment by majority vote, after
consultation with its financial advisor, that such Acquisition Transaction is
more favorable to the shareholders of Sullivan than the Merger and, after
reviewing the advice of outside counsel to Sullivan, that such action is
required by its fiduciary duties. See 'TERMS OF THE MERGER
AGREEMENT--Termination Rights.'
COMPETITION
The healthcare products distribution business is intensely competitive.
Schein and Sullivan compete with numerous other companies, including several
major manufacturers and distributors. Some of these competitors have greater
financial and other resources than either Schein, Sullivan or the combined
companies. Most of Schein's and Sullivan's products are available from several
sources, and their customers tend to have relationships with several
distributors. In addition, such competitors could obtain rights to market
particular products to the exclusion of Schein or Sullivan. Manufacturers also
could increase their efforts to sell directly to end-users, thereby by-passing
distributors such as Schein or Sullivan. Consolidation among healthcare products
distributors could result in existing competitors increasing their market
position through acquisitions or joint ventures, which may materially adversely
affect operating results. In addition, new competitors may emerge which could
materially adversely affect Schein or Sullivan's operating results. There can be
no assurance the combined companies will not face increased competition in the
future.
EXPANSION OF SCHEIN THROUGH ACQUISITIONS AND JOINT VENTURES
Schein intends to expand in its domestic and international markets, in part
through acquisitions and joint ventures. However, Schein's ability to
successfully expand through acquisitions and joint ventures will depend upon the
availability of suitable acquisition or joint venture candidates at prices
acceptable to Schein, Schein's ability to consummate such transactions, and the
availability of financing (in the case of non-stock transactions) on terms
acceptable to Schein. There can be no assurance that Schein will be effective in
making acquisitions or forming joint ventures. Such transactions involve
numerous risks, including possible adverse short-term effects on Schein's
operating results or the market price of Schein Common Stock. Certain of
Schein's acquisitions and future acquisitions may also give rise to an
obligation by Schein to make contingent payments or to satisfy certain
repurchase obligations, which payments could have an adverse financial effect on
Schein. In addition, integrating acquired businesses and joint ventures may
result in a loss of customers or product lines of the acquired businesses or
joint ventures, and also requires significant management attention and may place
significant demands on Schein's operations, information systems and financial
resources. In 1996, Schein
16
completed the acquisition of (or entered into definitive agreements to acquire)
seventeen other companies and has acquired or entered into definitive agreements
to acquire 16 companies (including Sullivan) so far in 1997. The failure to
effectively integrate future acquired businesses and joint ventures with the
combined companies' operations could adversely affect the combined companies.
MINORITY STATUS OF FORMER SULLIVAN SHAREHOLDERS; CONTROL BY INSIDERS
Immediately after the Merger, the former holders of Sullivan Common Stock
will hold an aggregate of approximately 22% of the then outstanding shares of
Schein Common Stock and will not be able to control, as a group, the management
of Schein. After the consummation of the Merger, Stanley M. Bergman, Chairman of
the Board, Chief Executive Officer and President of Schein, will own, directly
or indirectly, approximately 5.0% of the outstanding shares of Schein Common
Stock and, by virtue of a Voting Trust Agreement (which expires December 31,
1998 unless terminated earlier) with certain of Schein's current principal
stockholders, will have the right to vote up to an aggregate of approximately
15.6% of the outstanding shares of Schein Common Stock. In addition, until
December 31, 1998, under certain circumstances, Mr. Bergman has the right to
direct the nomination of a majority of the nominees to Schein's Board and, from
January 1, 1999 until December 31, 2003, Mr. Bergman has the right to direct the
nomination of all, or, under certain circumstances, four (out of nine), of the
nominees to the Schein Board, and in all such events certain of the current
principal stockholders are required to vote for such nominees. Because of these
voting arrangements, Mr. Bergman has significant influence over matters
requiring the approval of the Schein Board or stockholders of Schein. Under
certain circumstances, these voting arrangements may terminate prior to December
31, 1998. In that event, certain of Schein's current principal Stockholders may
be able to significantly influence all matters requiring stockholder approval,
including the election of directors. See 'DESCRIPTION OF
SCHEIN--Reorganization.'
FLUCTUATIONS IN QUARTERLY EARNINGS
Schein's business has been subject to seasonal and other quarterly
influences. Net sales and operating profits have been generally higher in the
fourth quarter due to the timing of sales of software, year-end promotions, and
purchasing patterns of office-based healthcare practitioners, and have been
generally lower in the first quarter due primarily to increased purchases in the
prior quarter. Quarterly results may also be adversely affected by a variety of
other factors, including the timing of acquisitions and related costs, the
release of software enhancements, promotions, adverse weather, and fluctuations
in exchange rates associated with international operations. Similarly, strikes
(such as the recent United Parcel Service of America, Inc. ('UPS') strike) or
other service interruptions could adversely affect Schein's and Sullivan's
ability to deliver products on a timely basis and result in incremental shipping
and payroll costs, thereby adversely impacting quarterly results. Both Schein
and Sullivan use UPS for delivery of substantially all of their domestic orders
(Sullivan does not have international orders).
In August 1997, the Teamsters' Union went on strike against UPS, thereby
substantially reducing UPS's ability to fulfill shipments of its customers'
orders. In order to maintain customer service levels, Schein and Sullivan had to
make alternative arrangements for its deliveries. Schein's transportation costs
associated with the alternative arrangements for delivery were substantially
higher than that which would have been incurred if UPS had been able to fulfill
substantially all of Schein's domestic orders. In addition, Schein experienced
increases in other operating costs, primarily payroll, as a result of having to
sort customer orders for distribution to various regional couriers.
Additionally, after the strike payroll costs continued to run at rates higher
than would otherwise be expected for several days in order to handle inbound
freight that was backlogged as a result of the UPS strike. None of these
incremental costs incurred by Schein were passed along to its customers.
Schein currently estimates that it incurred approximately $1.0 million to
$2.0 million of additional one-time operating expenses during the third quarter
of 1997 as a result of the strike, which consisted primarily of incremental
freight and payroll costs. The UPS strike did not significantly impact Schein's
sales. Subsequently, freight and payroll costs returned to normal pre-strike
levels. Sullivan's third quarter sales also were not significantly impacted by
the UPS strike. Because a significant portion of Sullivan's orders were shipped
in bulk to its various sales and service centers and then delivered to customers
by the local sales representatives, the overall effect of the UPS strike on
Sullivan was not material.
17
PRACTICE MANAGEMENT SOFTWARE AND OTHER VALUE ADDED PRODUCTS
During 1996, approximately $31.0 million, or 3.7%, and $21.4 million, or
8.5%, of Schein's net sales and gross profit, respectively, were derived from
sales of Schein's Easy Dental(Registered) Plus, Dentrix Dental System, and
AVImark(Registered) practice management software and other value added products
to United States dental and veterinary office-based healthcare practitioners.
Competition among companies supplying practice management software is intense
and increasing. Schein's future sales of practice management software will
depend, among other factors, upon the effectiveness of Schein's sales and
marketing programs, Schein's ability to enhance its products and the ability to
provide ongoing technical support. There can be no assurance that Schein will be
successful in introducing and marketing software enhancements or new software,
or that such software will be released on time or accepted by the market.
Schein's software products, like software products generally, may contain
undetected errors or bugs when introduced or as new versions are released. There
can be no assurance that problems with post-release software errors or bugs will
not occur in the future. Any such defective software may result in increased
expenses related to the software and could adversely affect Schein's
relationship with the customers using such software. Schein does not have any
patents on its software and relies upon copyright, trademark and trade secret
laws; there can be no assurance that such legal protections will be available or
enforceable to protect its software products. Schein's Easy Dental(Registered)
Plus software products are generally distributed under 'shrink-wrap' licenses
that are not signed by the customer and therefore may be unenforceable in
certain jurisdictions.
FOREIGN OPERATIONS
During 1996, approximately 17.5% and 18.1% of Schein's net sales and gross
profit, respectively, were derived from sales to customers located outside the
United States and Canada. Schein's international businesses are subject to a
number of inherent risks, including difficulties in opening and managing foreign
offices and distribution centers; establishing channels of distribution;
fluctuations in the value of foreign currencies; import/export duties and
quotas; and unexpected regulatory, economic and political changes in foreign
markets. There can be no assurance that these factors will not adversely affect
the combined companies' operating results.
DEPENDENCE ON SENIOR MANAGEMENT
Schein's future performance will depend, in part, upon the efforts and
abilities of certain members of its existing senior management, particularly
Stanley M. Bergman, Chairman, Chief Executive Officer and President, James P.
Breslawski and Bruce J. Haber, Executive Vice Presidents, and Steven Paladino,
Senior Vice President and Chief Financial Officer, as well as (if the Merger is
consummated) certain members of Sullivan's existing senior management,
particularly Robert J. Sullivan, who is expected to serve as Vice Chairman of
Schein, and Robert E. Doering, Timothy J. Sullivan and Kevin J. Ackeret, who
will serve as President Emeritus, President and Executive Vice President,
respectively, of Schein's US Dental Division. The loss of service of one or more
of these persons could have an adverse effect on Schein's business. Schein has
entered into employment agreements with Mr. Bergman, Mr. Haber and, as of the
Effective Time, Messrs. Robert J. Sullivan, Robert E. Doering, Timothy J.
Sullivan and Kevin J. Ackeret, as well as certain other members of Sullivan's
senior management. The success of certain acquisitions and joint ventures
effected by Schein may depend, in part, on Schein's ability to retain key
management of the acquired business or joint venture. Sullivan's future
performance will depend, in part, upon the efforts and abilities of certain
members of its existing senior management.
CHANGES IN HEALTHCARE INDUSTRY
In recent years, the healthcare industry has undergone significant change
driven by various efforts to reduce costs, including potential national
healthcare reform, trends toward managed care, cuts in Medicare, consolidation
of healthcare distribution companies and collective purchasing arrangements by
office-based healthcare practitioners. Schein's or Sullivan's inability to react
effectively to these and other changes in the healthcare industry could
adversely affect its operating results. Schein and Sullivan cannot predict
whether any healthcare reform efforts will be enacted and what effect any such
reforms might have on them or their respective customers and suppliers.
18
GOVERNMENT REGULATION
Both Schein and Sullivan and their respective customers and suppliers are
subject to extensive Federal and state regulation in the United States, as well
as regulation by foreign governments, and neither Schein nor Sullivan can
predict the extent to which future legislative and regulatory developments
concerning their practices and products or the healthcare industry may affect
them. In addition, both Schein and Sullivan, as marketers, distributors and (in
the case of Schein) manufacturers of healthcare products (including Schein
through, among other entities, its 50%-owned company, HS Pharmaceutical, Inc.,
which distributes and manufactures generic pharmaceuticals), are required to
obtain the approval of Federal and foreign governmental agencies, including the
Food and Drug Administration, prior to marketing, distributing and manufacturing
certain of those products, and it is possible that both Schein and Sullivan may
be prevented from selling new manufactured products should a competitor receive
prior approval. Further, Schein's and Sullivan's plants and operations are
subject to review and inspection by local, state, Federal and (in the case of
Schein) foreign governmental entities. The companies' suppliers are also subject
to similar governmental requirements.
RISK OF PRODUCT LIABILITY CLAIMS AND INSURANCE
The sale, manufacture and distribution of healthcare products involves a
risk of product liability claims and adverse publicity. Although neither Schein
nor Sullivan has been subject to a significant number of such claims or incurred
significant liabilities due to such claims, there can be no assurance that this
will continue to be the case. In addition, Schein and Sullivan maintain product
liability insurance coverage and have certain rights to indemnification from
third parties, but there can be no assurance that claims outside of or exceeding
such coverage will not be made, that the combined companies will be able to
continue to obtain insurance coverage or that they will be successful in
obtaining indemnification from such third parties. The combined companies also
may not be able to maintain existing coverage or obtain, if they determine to do
so, insurance providing additional coverage at reasonable rates.
COST OF SHIPPING
Shipping is a significant expense in the operation of both Schein's and
Sullivan's business. Schein and Sullivan ship almost all of their orders by UPS
and other delivery services, and typically bear the cost of shipment.
Accordingly, any significant increase in shipping rates could have an adverse
effect on Schein's and Sullivan's operating results. Similarly, strikes or other
service interruptions by such shippers could cause Schein's and Sullivan's
operating expenses to rise and adversely affect Schein's and Sullivan's ability
to deliver products on a timely basis. See '--Fluctuations in Quarterly
Earnings' with respect to the recent UPS strike.
RELIANCE ON TELEPHONE AND COMPUTER SYSTEMS
Both Schein and Sullivan believe that their success depends, in part, upon
their telesales and direct marketing efforts and their ability to provide
prompt, accurate and complete service to their customers on a price-competitive
basis. Any continuing disruption in either their computer system or their
telephone system could adversely affect their ability to receive and process
customer orders and ship products on a timely basis. Any such disruption could
adversely affect their relations with their customers.
STATE SALES TAX COLLECTION
As of September 8, 1997, Schein collected sales tax and other similar taxes
only on sales of products to residents of 31 states, and Sullivan collected such
taxes on sales of products to residents of 44 states. Various other states have
sought to impose on direct marketers the burden of collecting state sales taxes
on the sale of products shipped to those states' residents. A successful
assertion by a state or states that either Schein or Sullivan should have
collected or be collecting state sales taxes on the sale of products shipped to
that state's residents could have an adverse effect on the combined companies.
19
POTENTIAL VOLATILITY OF SCHEIN COMMON STOCK PRICES
As with the Sullivan Common Stock, the market price of the Schein Common
Stock may be subject to fluctuations in response to quarter-to-quarter
variations in operating results, changes in earnings estimates by investment
analysts or changes in business or regulatory conditions affecting Schein, its
customers, its suppliers or its competitors. The stock market historically has
experienced volatility which has particularly affected the market prices of
securities of many companies in the healthcare industry and which sometimes has
been unrelated to the operating performances of such companies. These market
fluctuations may adversely affect the market price of the Schein Common Stock.
From December 31, 1996 through September 18, 1997, the closing market price
of the Schein Common Stock as reported on the Nasdaq National Market has ranged
from a high of $40.50 to a low of $24.50.
ANTI-TAKEOVER PROVISIONS; POSSIBLE ISSUANCE OF PREFERRED STOCK
Certain provisions of the Schein Certificate of Incorporation and By-laws
as currently in effect may make it more difficult for a third party to acquire,
or may discourage acquisition bids for, Schein and could limit the price that
certain investors might be willing to pay in the future for shares of the Schein
Common Stock. These provisions, among other things: (i) require the affirmative
vote of the holders of at least 60% of the shares entitled to vote to approve a
merger or a sale, lease, transfer or exchange of all or substantially all of the
assets of Schein, (ii) require the affirmative vote of the holders of at least
66 2/3% of the shares entitled to vote to remove a director or to fill a vacancy
on the Schein Board, (iii) require the affirmative vote of the holders of at
least 80% of the shares entitled to vote to amend or repeal certain provisions
of the Schein Certificate of Incorporation and (iv) require the affirmative vote
of at least 66 2/3% of the Schein Board to amend or repeal the By-laws of
Schein. In addition, the rights of holders of Schein Common Stock will be
subject to, and may be adversely affected by, the rights of any holders of
preferred stock that may be issued in the future and that may be senior to the
rights of the holders of Schein Common Stock. Under certain conditions, Section
203 of the Delaware General Corporation Law would prohibit Schein from engaging
in a 'business combination' with an 'interested stockholder' (in general, a
stockholder owning 15% or more of Schein's outstanding voting stock) for a
period of three years. In addition, Schein's 1994 Stock Option Plan and 1996
Non-Employee Director Stock Option Plan provide for accelerated vesting of stock
options upon a change in control of Schein, and in certain instances, agreements
between Schein and its executive officers provide for increased severance
payments if such executive officers are terminated without cause within two
years after a change in control of Schein. At the Schein Special Meeting the
holders of Schein Common Stock will be asked to vote on the Schein Certificate
of Incorporation Amendments. See 'SCHEIN SPECIAL MEETING--Approval of Schein
Certificate of Incorporation Amendments' and 'COMPARISON OF STOCKHOLDER'S
RIGHTS.' These provisions may make it more difficult for a third party to
acquire, or may discourage acquisition bids for, Schein and could limit the
price that certain investors might be willing to pay in the future for shares of
Schein Common Stock.
SHARES ELIGIBLE FOR FUTURE SALE
Future sales of substantial amounts of Schein Common Stock (including
shares issued upon the exercise of stock options) by Schein's current
stockholders (including certain executive officers, employees and affiliates of
Schein) after the Merger, or the perception that such sales could occur, could
adversely affect the market price for the Schein Common Stock. Approximately
7,917,301 shares of Schein Common Stock that are owned by certain executive
officers, employees and affiliates of Schein, constituting approximately 28.9%
of the shares of Schein Common Stock outstanding immediately prior to the
Merger, may be eligible for immediate resale in the public market pursuant to
Rule 144 under the Securities Act of 1933, as amended (the 'Securities Act'). In
connection with the reorganization described under '--Reorganization' below,
Schein entered into a registration rights agreement with certain of its
stockholders. Schein has granted certain registration rights in connection with
certain acquisitions, and may grant additional registration rights in connection
with future acquisitions.
In addition, all of the shares of Schein Common Stock received by holders
of Sullivan Common Stock in the Merger will have been registered under the
Securities Act and will be freely transferable, except that persons who are
deemed to be affiliates of Sullivan prior to the Effective Time will enter into
agreements with Schein prohibiting such persons from disposing of any of the
shares of Schein Common Stock until after the publication
20
of operating results including the combined operations of Schein and Sullivan
for a period of at least 30 days subsequent to the consummation of the Merger,
at which time such shares may be resold by such persons in transactions
permitted by the resale provisions of Rule 145 promulgated under the Securities
Act (or Rule 144 in the case of such persons who become affiliates of Schein) or
as otherwise permitted by the Securities Act. Persons who may be deemed to be
affiliates of Sullivan or Schein generally include individuals or entities that
control, are controlled by, or are under common control with, such company and
may include certain officers and directors of such company as well as principal
stockholders of such company. In addition, up to approximately 1,230,996 shares
of Schein Common Stock will be issuable upon the exercise of outstanding options
to purchase Sullivan Common Stock that will be assumed by Schein. Schein intends
to file a registration statement under the Securities Act covering shares
issuable upon the exercise of these options. See 'THE MERGER--Treatment of
Sullivan Stock Options.'
REORGANIZATION
In connection with the reorganization of Schein's ownership and the various
agreements entered into in connection therewith between 1992 and 1994 (the
'Reorganization'), certain stockholders of Schein made customary
representations, warranties and covenants and provided for indemnification with
respect to the structure of the transaction and for breaches of such
representations, warranties and covenants. No claims for such indemnification
have arisen to date. Applicable accounting rules provide that certain amounts
paid or assumed by such stockholders on behalf of Schein in satisfaction of
indemnity obligations may be required to be recorded by Schein for financial
reporting purposes as an expense. Accordingly, although any such payment or
assumption may not materially impact Schein's cash flow, Schein's results of
operations would be negatively impacted in the period incurred. In addition,
there can be no assurance that such stockholders will have the resources in the
future to meet their respective indemnification obligations, if any, under such
agreements.
SULLIVAN SPECIAL MEETING
GENERAL
This Joint Proxy Statement/Prospectus is being furnished to holders of
shares of Sullivan Common Stock in connection with the solicitation by the
Sullivan Board of proxies for use at the Sullivan Special Meeting to be held on
Wednesday, November 12, 1997, at 9:00 a.m., local time, at The Wyndham Hotel,
139 East Kilbourn Avenue, Milwaukee, Wisconsin 53202 and at any adjournments or
postponements thereof.
APPROVAL OF THE MERGER
At the Sullivan Special Meeting, holders of Sullivan Common Stock will
consider and vote upon a proposal to approve the Merger Agreement and upon such
other matters as may properly be submitted to a vote at the Sullivan Special
Meeting. The Merger Agreement provides that, upon the terms and subject to the
conditions thereof, Merger Sub will be merged with and into Sullivan and
Sullivan will become a wholly owned subsidiary of Schein. Each share of Sullivan
Common Stock issued and outstanding immediately prior to the Merger will be
converted into the right to receive 0.735 shares of Schein Common Stock.
No certificates representing fractional shares of Schein Common Stock shall
be issued upon the surrender for exchange of certificates representing shares of
Sullivan Common Stock ('Sullivan Certificates'). Each holder of shares of
Sullivan Common Stock exchanged pursuant to the Merger who would otherwise have
been entitled to receive a fraction of a share of Schein Common Stock (after
taking into account all Sullivan Certificates delivered by such holder) will
receive, in lieu thereof, cash (without interest) in an amount determined by
multiplying (i) the fractional interest to which such holder would otherwise be
entitled and (ii) the average of the per share closing prices for Schein Common
Stock on the Nasdaq National Market for the five trading days immediately
preceding the Effective Time. In no event shall a holder of Sullivan Common
Stock receive cash in lieu of fractional shares of Schein Common Stock in an
amount greater than the value of one full share of Schein Common Stock.
THE SULLIVAN BOARD HAS UNANIMOUSLY ADOPTED THE MERGER AGREEMENT, DETERMINED
THAT THE MERGER IS IN THE BEST INTERESTS OF SULLIVAN AND ITS SHAREHOLDERS AND
RECOMMENDS THAT THE HOLDERS OF SULLIVAN COMMON
21
STOCK VOTE FOR THE APPROVAL OF THE MERGER AGREEMENT. SEE 'THE MERGER--BACKGROUND
OF THE MERGER' AND '--CONSIDERATION AND RECOMMENDATION OF THE SULLIVAN BOARD'.
RECORD DATE; SHARES ENTITLED TO VOTE
The close of business on September 17, 1997 has been fixed as the Sullivan
Record Date for determining the holders of Sullivan Common Stock who are
entitled to notice of and to vote at the Sullivan Special Meeting. As of the
Sullivan Record Date, there were 10,286,719 shares of Sullivan Common Stock
outstanding and entitled to vote, and such shares were held by approximately 364
holders of record. The holders of record on the Sullivan Record Date of Sullivan
Common Stock are entitled to one vote per share of Sullivan Common Stock on each
matter submitted to a vote at the Sullivan Special Meeting. The presence in
person or by proxy of the holders of a majority of the outstanding Sullivan
Common Stock entitled to vote is necessary to constitute a quorum for the
transaction of business at the Sullivan Special Meeting.
Proxies relating to 'street name' shares that are properly executed and
returned by brokers will be counted as shares present for purposes of
determining the presence of a quorum, but will not be treated as shares having
voted at the Sullivan Special Meeting as to the Merger Agreement if authority to
vote has been withheld by the broker (a 'broker non-vote'). Abstentions will be
recorded as such by the inspectors of election for the Sullivan Special Meeting.
As the affirmative vote of a majority of the total number of outstanding shares
of Sullivan Common Stock on the Sullivan Record Date is required to approve the
Merger Agreement, broker non-votes and abstentions will have the same effect as
votes against approval of the Merger Agreement.
REQUIRED VOTE
The affirmative vote of the holders of a majority of the outstanding shares
of the Sullivan Common Stock is required for approval of the Merger Agreement.
As of the Sullivan Record Date, the Sullivan directors and executive officers as
a group beneficially owned or voted shares representing approximately 20.8% of
the outstanding shares of Sullivan Common Stock. Each of the directors and
executive officers of Sullivan has advised Sullivan that he intends to vote or
direct the vote of all such shares over which he has voting control, subject to,
and consistent with, any fiduciary obligations in the case of shares held as a
fiduciary, for approval of the Merger Agreement. In addition, as an inducement
for Schein to enter into the Merger Agreement, the Granting Holders have entered
into the Irrevocable Proxy and Termination Rights Agreement with Schein pursuant
to which, among other things, the Granting Holders have granted to Schein an
irrevocable proxy to vote substantially all of the shares of Sullivan Common
Stock that they have beneficial ownership of in favor of the Merger Agreement
and against any other Acquisition Transaction. Approximately 2,015,565 shares of
Sullivan Common Stock (approximately 19.6% of the outstanding shares) are
subject to the Irrevocable Proxy Statement and Termination Rights Agreement. See
'THE MERGER--Irrevocable Proxy and Termination Rights Agreement.'
PROXIES; PROXY SOLICITATION
Shares of Sullivan Common Stock represented by properly executed, unrevoked
proxies received at or prior to the Sullivan Special Meeting will be voted at
the Sullivan Special Meeting in accordance with the instructions contained
therein. Shares of Sullivan Common Stock represented by properly executed,
unrevoked proxies for which no instruction is given will be voted FOR approval
of the Merger Agreement. Sullivan shareholders are requested to complete, sign,
date and return promptly the enclosed proxy card in the postage-paid envelope
provided for this purpose to ensure that their shares are voted. A holder of
shares of Sullivan Common Stock may revoke a proxy by submitting a later dated
proxy with respect to the same shares at any time prior to the vote on the
approval of the Merger Agreement, by delivering written notice of revocation to
the Secretary of Sullivan at any time prior to such vote, or by attending the
Sullivan Special Meeting and voting in person. Mere attendance at the Sullivan
Special Meeting will not in and of itself revoke a proxy.
If the Sullivan Special Meeting is postponed or adjourned for any reason,
when the Sullivan Special Meeting is convened or reconvened, all proxies will be
voted in the same manner as such proxies would have been voted at the original
convening of the meeting (except for any proxies which have theretofore
effectively been revoked
22
or withdrawn), notwithstanding that they may have been effectively voted on the
same or any other matter at a previous meeting.
The cost of the solicitation of proxies by the Sullivan Board for use at
the Sullivan Special Meeting will be borne by Sullivan. In addition to
solicitation by mail, directors, officers and employees of Sullivan may solicit
proxies by telephone, telegram or otherwise. Such directors, officers and
employees of Sullivan will not be additionally compensated for such solicitation
but may be reimbursed by Sullivan for out-of-pocket expenses incurred in
connection therewith. Brokerage firms, fiduciaries and other custodians who
forward soliciting material to the beneficial owners of shares of Sullivan
Common Stock held of record by them will be reimbursed for their reasonable
expenses incurred in forwarding such material. In addition, Sullivan has
retained Georgeson & Company Inc., a proxy solicitation organization, to assist
in the solicitation of proxies for the Sullivan Special Meeting for a fee of
approximately $1,000, plus reasonable out-of-pocket expenses.
SCHEIN SPECIAL MEETING
GENERAL
This Joint Proxy Statement/Prospectus is being furnished to holders of
shares of Schein Common Stock in connection with the solicitation by the Schein
Board of proxies for use at the Schein Special Meeting to be held on Wednesday,
November 12, 1997, at 10:00 a.m., local time, at the Huntington Hilton, 598
Broadhollow Road, Melville, New York.
APPROVAL OF THE SHARE ISSUANCE
At the Schein Special Meeting, holders of Schein Common Stock will consider
and vote upon a proposal to approve the Share Issuance. The Merger Agreement
provides that, upon the terms and subject to the conditions thereof, Merger Sub
will be merged with and into Sullivan and Sullivan will become a wholly owned
subsidiary of Schein. Each share of Sullivan Common Stock issued and outstanding
immediately prior to the Merger will be converted into the right to receive
0.735 shares of Schein Common Stock.
If the Merger is consummated, each option to purchase shares of Sullivan
Common Stock outstanding at the Effective Time will be automatically converted
into options to purchase shares of Schein Common Stock, with the number of
shares purchasable upon exercise and the exercise prices being appropriately
adjusted to reflect the Exchange Ratio. See 'Treatment of Sullivan Stock
Options'. Assuming all of the options to purchase Sullivan Common Stock
outstanding as of the Sullivan Record Date were to remain outstanding as of the
Effective Time, options to purchase approximately 1,230,996 shares of Schein
Common Stock would be issued upon the conversion of the options to purchase
shares of Sullivan Common Stock. A vote in favor of the Share Issuance will be
deemed to be a vote in favor of the issuance of such options and no separate
stockholders vote will be taken in connection therewith. The shares of Schein
Common Stock issuable upon the exercise of such options will not count against
the aggregate number of shares of Schein Common Stock that may be issued
pursuant to Schein's 1994 Stock Option Plan.
THE SCHEIN BOARD HAS UNANIMOUSLY ADOPTED THE MERGER AGREEMENT AND APPROVED
THE SHARE ISSUANCE, DETERMINED THAT THE MERGER IS IN THE BEST INTERESTS OF
SCHEIN AND ITS STOCKHOLDERS, AND RECOMMENDS THAT THE HOLDERS OF SCHEIN COMMON
STOCK VOTE FOR THE APPROVAL OF THE MERGER AGREEMENT. SEE 'THE MERGER--BACKGROUND
OF THE MERGER' AND '--RECOMMENDATION OF THE SCHEIN BOARD AND SCHEIN REASONS FOR
THE MERGER.'
APPROVAL OF THE SCHEIN CERTIFICATE OF INCORPORATION AMENDMENTS
Background. At Schein's 1997 Annual Meeting of Stockholders convened on
May 22, 1997 (the 'Schein Annual Meeting'), the Schein Board proposed (the
'Original Proposal') to amend Article 'Fifth' of the Schein Certificate of
Incorporation to: (i) eliminate the limit on the maximum number of directors of
the Company, while specifying only that the number of directors shall be as
specified in the By-Laws or as fixed from time to time by resolution of the
Board of Directors, and that there should not be fewer than five directors, (ii)
eliminate the provision preventing the Board of Directors from amending or
repealing By-Laws adopted by
23
the stockholders and (iii) eliminate the 80% voting requirement with respect to
amendments of Article 'Fifth'. As of the date the Schein Annual Meeting was
convened, a significant minority of shares had not been represented by proxies
with respect to the Original Proposal. Given the importance of the Original
Proposal and the unusually high 80% supermajority requirement under the Schein
Certificate of Incorporation for approval of such proposal, the Schein Annual
Meeting was adjourned to give stockholders a full opportunity to have their
votes counted regarding the Original Proposal. The adjournment date was set for
June 10, 1997. At the reconvened Schein Annual Meeting on June 10, 1997, a vote
was taken regarding the Original Proposal and, despite a significant majority
vote in favor of the Original Proposal, the necessary affirmative 80% vote was
not achieved. However, as a result of discussions with certain stockholders
concerning their views with respect to the Original Proposal, the Schein Board
reformulated the Original Proposal, and on June 10, 1997, further adjourned the
Schein Annual Meeting in order to propose to stockholders a revised proposal. No
vote was ever taken on the revised proposal, however, and the Schein Annual
Meeting was formally adjourned. The Schein Board has further reformulated the
Original Proposal into the two Schein Certificate of Incorporation Amendments
described herein.
The Proposed Amendments. Article 'Fifth' of the Schein Certificate of
Incorporation, the complete text of which, prior to amendment as proposed
hereby, is included as Annex IV to this Joint Proxy Statement/Prospectus,
contains various provisions relating to the governance of Schein. Specifically:
(a) Section 'A' provides that the number of directors of Schein shall
be no less than five and no more than 11 through December 31, 1998, and
thereafter the number of directors shall be nine;
(b) Section 'B1' provides that stockholders may adopt any By-Law and
may amend or repeal any By-Law adopted by the Schein Board and that the
Schein Board may not amend or repeal any By-Law adopted by the
stockholders; and
(c) Section 'C' requires the affirmative vote of 80% of the
outstanding shares to amend or repeal, or to adopt any provisions
inconsistent with, Article 'Fifth'.
The first of the proposed Schein Certificate of Incorporation Amendments
would amend Sections A and B1 to increase the maximum number of directors of
Schein, provide that the number of directors shall be as fixed from time to time
by resolution of the Schein Board, and allow the Schein Board to amend or repeal
any By-law except By-laws adopted by Schein's stockholders from and after the
1997 Annual Meeting of Stockholders. The second proposed Schein Certificate of
Incorporation Amendment would amend Section C and reduce to 66 2/3 the voting
requirement with respect to amendments to Article 'Fifth'. The two Schein
Certificate of Incorporation Amendments will be voted upon separately at the
Schein Special Meeting.
Sections 'A' and 'B1' and 'C' of Article 'Fifth', as proposed to be
amended, would read in their entirety as follows:
FIFTH:
A. The number of directors which shall constitute the entire Board of
Directors shall be as fixed from time to time by resolution of the Board of
Directors, but shall not be fewer than five nor more than nineteen.
B. In furtherance and not in limitation of the powers conferred by statute,
the Board of Directors is expressly authorized:
1. To adopt, amend or repeal any By-Law (provided, however, that (a) any
By-Law made, amended or repealed by the Board of Directors may be amended or
repealed, and that any By-Laws may be adopted, by the stockholders of the
Corporation and (b) the Board of Directors may not amend or repeal any By-Law
adopted by the stockholders of the Corporation from and after the 1997 Annual
Meeting of Stockholders of the Corporation).
[Sections B2, B3 and B4 intentionally omitted]
C. The affirmative vote of the holders of 66 2/3% or more of the shares
entitled to vote in the election of directors shall be required to amend or
repeal, or adopt any provisions inconsistent with, this Article FIFTH.
The current version of section 'A' of Article 'Fifth' provides that the
maximum number of directors shall be 11 through December 31, 1998, which is the
number of individuals presently serving as directors, and shall thereafter by
nine. The Schein Board believes that it would be desirable to give Schein the
ability to obtain the services of additional individuals as directors, by
increasing the maximum number of directors. The first of the proposed Schein
Certificate of Incorporation Amendments permitted under the Schein Certificate
of
24
Incorporation would permit one or more additional directors to be added to the
Schein Board (up to a maximum of 19) without the need for Board vacancies to
exist as a result of the death, disability, removal or resignation of a current
director. In contrast, Section A, as currently in effect, would require Schein
to reduce the size of the Schein Board by the end of 1998. If such amendment is
adopted, the Schein Board proposes to expand the number of Schein directors to
13, and to appoint Robert J. Sullivan, Sullivan's Chairman of the Board, and
Bruce J. Haber, an Executive Vice President of Schein and President of Schein's
Micro Bio-Medics, Inc. subsidiary, to fill the resulting vacancies. In the
Merger Agreement (as to Mr. Sullivan) and in Mr. Haber's employment agreement
(as to him), Schein has covenanted to use its reasonable best efforts to
nominate these individuals to the Schein Board.
With regard to the amendment to Section 'B1' of Article 'Fifth' that also
would be affected by the first of the proposed Schein Certificate of
Incorporation Amendments, Section 109 of the Delaware General Corporation Law
(the 'DGCL') allows a Delaware corporation to confer on its directors the power
to adopt, amend or repeal any By-Law, provided that such right of the directors
shall not divest the stockholders of the power to adopt, amend or repeal any
By-Law. Section B1 currently allows the Schein Board to adopt, amend or repeal
any By-Law other than any By-Law adopted by the stockholders of Schein. Since
all of the current By-Laws of Schein were adopted by the stockholders in
September 1994, Section B1 effectively prevents the directors from amending or
repealing any of Schein's By-Laws. The Schein Board believes that it would be
desirable to increase Schein's flexibility and its ability to respond to
changing conditions by permitting the directors to adopt, amend or repeal any of
Schein's By-Laws previously adopted, regardless of the manner in which such
By-Laws were originally adopted. The proposed amendment to Section B1 of Article
'Fifth' would limit the restriction on the power of the directors to adopt,
amend or repeal any By-Laws of Schein to By-Laws adopted on or after the Schein
Annual Meeting, and would continue to expressly incorporate the retained power
of the stockholders under Section 109 of the DGCL to adopt, amend or repeal any
By-Law, including any By-Law adopted, amended or repealed by the directors. (At
the Schein Annual Meeting the stockholders of Schein approved an amendment to
Schein's By-Laws that would permit the Schein Board to fill vacancies if the
proposed amendment is adopted.)
Absent a provision in the certificate of incorporation requiring a higher
percentage vote, under Section 242 of the DGCL, a simple majority of the
outstanding shares of capital stock is sufficient to authorize any amendment to
a corporation's certificate of incorporation. Section 'C' of Article 'Fifth'
currently requires the affirmative vote of 80% of the outstanding shares of
Schein Common Stock to amend or repeal, or adopt any provision inconsistent
with, that Article. The Schein Board believes that it is desirable for Schein to
have the ability to amend the Schein Certificate of Incorporation in light of
changing circumstances without having to satisfy an unusually difficult 80%
'supermajority' vote requirement, while at the same time retaining a lesser
supermajority vote required to insure that any amendment adopted has the support
of a substantial majority of Schein's stockholders. Accordingly, the proposed
amendment to Section C that would be effected by the second Schein Certificate
of Incorporation Amendment would decrease the 80% supermajority requirement to
66 2/3% of the outstanding shares of Schein Common Stock.
On August 1, 1997, the Schein Board unanimously adopted a resolution
approving the Schein Certificate of Incorporation Amendments and approving their
submission to Schein's stockholders. The affirmative vote of the holders of 80%
of the outstanding shares of the common stock entitled to vote at the Schein
Special Meeting is required to approve the Schein Certificate of Incorporation
Amendments.
The Schein Board unanimously recommends that the holders of Schein Common
Stock vote FOR the approval of the Schein Certificate of Incorporation
Amendments.
INTENDED APPOINTEES TO THE SCHEIN BOARD
As noted above, Schein proposes to add Robert J. Sullivan and Bruce J.
Haber to the Schein Board, if the first of the proposed Schein Certificate of
Incorporation Amendments is adopted. Robert J. Sullivan, age 66, is one of the
founders of Sullivan and has been Chairman of the Sullivan Board since 1990. He
was Sullivan's Chief Executive Officer from 1985 until 1992. Prior thereto, he
was Sullivan's President, and has also served as its Chief Financial Officer.
Bruce J. Haber became an Executive Vice President of Schein on August 1, 1997 in
connection with Schein's acquisition of Micro Bio-Medics, Inc. Mr. Haber has
been President of Micro Bio-Medics, Inc. since 1983 and a director of Micro
Bio-Medics, Inc. since 1981.
25
RECORD DATE; SHARES ENTITLED TO VOTE
The close of business on September 17, 1997 has been fixed as the Schein
Record Date for determining the holders of Schein Common Stock who are entitled
to notice of and to vote at the Schein Special Meeting. As of the Schein Record
Date, there were 27,351,853 shares of Schein Common Stock outstanding and
entitled to vote, and such shares were held by approximately 450 holders of
record. The holders of record on the Schein Record Date of Schein Common Stock
are entitled to one vote per share of Schein Common Stock on each matter
submitted to a vote at the Schein Special Meeting. The presence in person or by
proxy of the holders of a majority of the outstanding Schein Common Stock
entitled to vote is necessary to constitute a quorum for the transaction of
business at the Schein Special Meeting.
Proxies relating to 'street name' shares that are properly executed and
returned by brokers will be counted as shares present for purposes of
determining the presence of a quorum, but will not be treated as shares having
voted at the Schein Special Meeting as to the Merger Agreement if authority to
vote has been withheld by the broker (a 'broker non-vote'). Abstentions will be
recorded as such by the inspectors of election for the Schein Special Meeting.
In light of the treatment of broker non-votes and abstentions and the fact that
the affirmative vote required to approve the Schein Certificate of Incorporation
Amendments is eighty percent of the total number of outstanding shares of Schein
Common Stock on the Schein Record Date, broker non-votes and abstentions will
have the same effect as votes against approval of the Schein Certificate of
Incorporation Amendments.
REQUIRED VOTE
The affirmative vote of holders of a majority of the shares of Schein
Common Stock voted on the proposed Share Issuance is required for approval of
the Share Issuance. The affirmative vote of the holders of eighty percent (80%)
of the outstanding shares of Schein Common Stock is required for approval of the
Schein Certificate of Incorporation Amendments. As of the Schein Record Date,
the Schein directors and executive officers and their affiliates as a group
beneficially owned or voted shares representing approximately 28.9% of the
outstanding shares of Schein Common Stock. Certain of Schein's current principal
shareholders have executed a Voting Trust Agreement (which expires December 31,
1998 unless terminated earlier) with Stanley M. Bergman, Chairman of the Board,
Chief Executive Officer and President of Schein. Mr. Bergman will own,
immediately prior to the Merger, directly or indirectly, approximately 5.0% of
the outstanding shares of Schein Common Stock and will have the right to vote up
to an aggregate of approximately 15.6% of the outstanding shares of Schein
Common Stock.
PROXIES; PROXY SOLICITATION
Shares of Schein Common Stock represented by properly executed, unrevoked
proxies received at or prior to the Schein Special Meeting will be voted at the
Schein Special Meeting in accordance with the instructions contained therein.
Shares of Schein Common Stock represented by properly executed, unrevoked
proxies for which no instruction is given will be voted FOR approval of the
Share Issuance and FOR the approval of the Schein Certificate of Incorporation
Amendments. Schein stockholders are requested to complete, sign, date and return
promptly the enclosed proxy card in the postage-paid envelope provided for this
purpose to ensure that their shares are voted. A holder of shares of Schein
Common Stock may revoke a proxy by submitting a later dated proxy with respect
to the same shares at any time prior to voting, by delivering written notice of
revocation to the Secretary of Schein at any time prior to such vote, or by
attending the Schein Special Meeting and voting in person. Mere attendance at
the Schein Special Meeting will not in and of itself revoke a proxy.
If the Schein Special Meeting is postponed or adjourned for any reason,
when the Schein Special Meeting is convened or reconvened, all proxies will be
voted in the same manner as such proxies would have been voted at the original
convening of the meeting (except for any proxies which have theretofore
effectively been revoked or withdrawn), notwithstanding that they may have been
effectively voted on the same or any other matter at a previous meeting.
The cost of the solicitation of proxies by the Schein Board for use at the
Schein Special Meeting will be borne by Schein. In addition to solicitation by
mail, directors, officers and employees of Schein may solicit proxies by
telephone, telegram or otherwise. Such directors, officers and employees of
Schein will not be
26
additionally compensated for such solicitation but may be reimbursed by Schein
for out-of-pocket expenses incurred in connection therewith. Brokerage firms,
fiduciaries and other custodians who forward soliciting material to the
beneficial owners of shares of Schein Common Stock held of record by them will
be reimbursed for their reasonable expenses incurred in forwarding such
material. In addition, Schein has retained Georgeson & Company Inc., a proxy
solicitation organization, to assist in the solicitation of proxies for the
Schein Special Meeting for a fee of $11,000, plus reasonable out-of-pocket
expenses.
THE MERGER
BACKGROUND OF THE MERGER
Schein's business strategy includes the acquisition of companies whose
businesses are complementary to Schein's. Consistent with that strategy, in
August of 1996 Stanley M. Bergman, Schein's Chairman, Chief Executive Officer
and President, raised the topic of a potential business combination with Robert
J. Sullivan, the Chairman of the Board and a co-founder of Sullivan. Mr.
Sullivan indicated that Sullivan was not interested in a business combination at
such time. Mr. Sullivan's response was, in part, due to the fact that Sullivan's
stock price had as yet only partially recovered from the low point reached in
the second quarter of 1995 ($8.25) and, consequently, Sullivan was valued below
what management believed to be its true value. In February, 1997, Schein
acquired Dentrix Dental Systems, Inc. ('Dentrix'), a distributor of dental
practice software. Sullivan was a distributor of Dentrix's products and, in this
context, Mr. Bergman renewed his inquiry to Mr. Sullivan about a business
combination of Schein and Sullivan. Mr. Sullivan again indicated that Sullivan
was not interested in a business combination at that time, but he agreed to
discussions between representatives of the two companies to explore whether some
form of business combination between the two companies could result in
operational and strategic benefits and what form such a business combination
would take.
Pursuant thereto, James P. Breslawski, an Executive Vice President of
Schein with primary responsibility for Schein's North American Dental Group, and
Timothy J. Sullivan, Sullivan's President, held intermittent discussions. As a
result of these discussions, senior management of both Schein and Sullivan
formed the view that a business combination integrating the management and sales
forces of Sullivan and Schein would likely result in significant benefits to the
combined entity and its stockholders (see '--Consideration and Recommendation of
the Merger by the Sullivan Board' below). In light of these discussions and,
from Sullivan's point of view, the continued slow recovery of its stock price,
Schein and Sullivan agreed to meet and discuss the potential financial terms of
a business combination involving a stock-for-stock merger. As is discussed
below, a stock-for-stock merger that qualified for pooling of interests
treatment for financial reporting purposes was viewed as the structure most
favorable to Sullivan, Schein and their respective stockholders.
At a meeting held in Milwaukee on July 14, 1997, members of the senior
management of both Sullivan and Schein, including Mr. Sullivan and Mr. Bergman,
began discussions regarding a potential exchange ratio of Schein Common Stock
for Sullivan Common Stock in such a merger. The meeting ended with the parties
significantly apart on price, but with an agreement to continue discussions.
Approximately a week later, after further telephone discussions, Schein and
Sullivan concluded that agreement upon an exchange ratio could be reached, and
decided to suspend further discussions on price pending each party's conduct of
further financial due diligence review of the other. Such due diligence
proceeded, and Schein's attorneys prepared initial drafts of the Merger
Agreement, the Irrevocable Proxy and Termination Rights Agreement and the other
ancillary agreements (including employment agreements for key executives of
Sullivan).
Representatives of Sullivan and Schein, together with their respective
financial advisors, met on July 22, 1997 to negotiate an exchange ratio. These
negotiations continued the next day at Schein's headquarters in Melville, New
York, as did negotiations of the other terms of the draft Merger Agreement, the
Irrevocable Proxy and Termination Rights Agreement and the other ancillary
documents. By the evening of July 28, 1997, the Exchange Ratio had been
tentatively agreed to, contingent upon the satisfactory completion of the Merger
Agreement and the ancillary documents, as to which a number of material issues
remained unresolved. By August 1, 1997, the Merger Agreement, the Irrevocable
Proxy and Termination Rights Agreement and the other ancillary documents were
substantially complete.
27
Both the Sullivan Board and the Schein Board had been kept apprised of the
ongoing negotiations and had authorized their continuation. At separate meetings
of the Sullivan Board and the Schein Board held on August 1, 1997, senior
management presented the Merger Agreement, the Irrevocable Proxy and Termination
Rights Agreement and the other ancillary documents to their respective Boards,
and reviewed with such Boards their reasons for believing that the Merger was in
the best interests of their company and its stockholders. At the Sullivan
Board's meeting, representatives of Cleary Gull presented its financial analysis
of the Merger and delivered an oral opinion that the consideration to be
received pursuant to the Merger Agreement by Sullivan's shareholders was fair,
from a financial point of view, to such shareholders as of such date. Such
opinion was subsequently confirmed in a written opinion dated August 3, 1997, a
copy of which is attached as Annex II to this Joint Proxy Statement/Prospectus.
At the meeting of the Schein Board, Smith Barney made a financial presentation
and rendered to the Schein Board an oral opinion (subsequently confirmed by
delivery of a written opinion dated August 3, 1997) to the effect that, as of
the date of such opinion and based upon and subject to certain matters stated
therein, the Exchange Ratio was fair, from a financial point of view, to Schein.
See '--Opinion of Smith Barney Inc.' Each of the Sullivan Board and the Schein
Board approved the Merger and adopted the Merger Agreement in substantially the
form presented to it in the early evening of Friday, August 1st. Resolution of
the remaining open issues concerning the Merger Agreement and the Irrevocable
Proxy and Termination Rights Agreement took place and such agreements were
executed on Sunday August 3, 1997.
CONSIDERATION AND RECOMMENDATION OF THE MERGER BY THE SULLIVAN BOARD
At the August 1, 1997 meeting of the Sullivan Board, the Sullivan Board
determined that the terms of the Merger Agreement are fair to and in the best
interests of Sullivan and its shareholders and adopted the Merger Agreement and
authorized and directed the appropriate officers of Sullivan to execute the
Merger Agreement on behalf of Sullivan. THE SULLIVAN BOARD HAS UNANIMOUSLY
ADOPTED THE MERGER AGREEMENT, DETERMINED THAT THE MERGER IS IN THE BEST
INTERESTS OF SULLIVAN AND ITS SHAREHOLDERS, AND RECOMMENDED THAT THE
SHAREHOLDERS OF SULLIVAN VOTE FOR THE APPROVAL OF THE MERGER. In making its
determination, the Sullivan Board considered, in addition to Cleary Gull's
opinion, the following actual and potential advantages offered by the Merger:
o The substantial premium, based on the recent market prices for the
Schein Common Stock and the Sullivan Common Stock, that the
Exchange Ratio provides to Sullivan's shareholders.
o The increased liquidity for Sullivan shareholders as Schein Common
Stock has both a higher trading volume and a greater aggregate
number of publicly held shares.
o The combined company will offer a range of products and services
that will permit it to serve as the prime vendor for its customers,
and will potentially increase sales penetration of each existing
customer. This is particularly important given the industry trend
toward prime vendor relationships, which offer customers 'one stop
shopping' for products and services and computerized tracking of
purchases and pricing. Neither Schein nor Sullivan alone has full
prime vendor capabilities.
o The Merger contemplates that key executives of Sullivan will have
primary responsibility for the combined company's United States
dental operations.
o The combined entity will have the benefit of the second largest
sales force in the United States dental industry.
o The potential benefits of being part of a company with a more
diversified business (i.e., medical as well as dental product
distribution) with an international operation and a strong direct
marketing business, features that Sullivan lacks.
o Potential synergies from the combination and rationalization of
Sullivan's and Schein's distribution infrastructures.
o Potential advantages offered by Schein's management and
distribution systems, which were viewed by Sullivan management as
business advantages held by Schein.
o Potential economies of scale from the combined entity's purchasing
power.
28
o The combined entity's enhanced ability to offer value-added
services, including software services.
o Potential exclusivity in offering certain new products.
The Sullivan Board also considered the following actual and potential
negative considerations regarding the Merger:
o The potential volatility of the market values of the Schein Common
Stock. See 'RISK FACTORS--Potential Volatility of Market Value of
Schein Common Stock'.
o The challenges presented to management (and consequent use of
executive time) by the task of combining the operations of Schein
and Sullivan and achieving potential synergistic benefits. These
challenges involve integrating the personnel of Sullivan and
Schein, which have similar but distinct corporate cultures, and
integrating the business and computer systems of Sullivan and
Schein relating to inventory, purchasing, sales, distribution,
personnel practices and other functions. In reviewing this issue,
the Sullivan Board took into account Schein's experience in
consummating and integrating a large number of acquisitions since
Schein's initial public offering in 1995, albeit none as large as
the Merger.
o The inability of the former shareholders of Sullivan, as a group,
to control the management of Schein as a result of their minority
interest in Schein upon completion of the Merger. See 'RISK
FACTORS--Minority Status of Former Sullivan Shareholders; Control
by Insiders'.
o The potential loss of members of the sales force of the combined
company and of suppliers to Schein or Sullivan as a result of the
Merger (a leading manufacturer of chairs and other large dental
equipment which is a Sullivan supplier has stated that it does not
intend to sell products to the combined company).
o The potential business risks associated with Schein's operations
outside the United States as they may be affected by economic,
political and military conditions in foreign countries, currency
exchange fluctuations and exchange control regulations.
In making its determination, the Sullivan Board, assisted by Cleary Gull,
also reviewed publicly available data concerning Schein and considered reports
of interviews with members of Schein's senior management regarding Schein's
recent financial performance, prospects and future plans. The Sullivan Board did
not attempt to quantify or otherwise assign specified weights or values to the
various factors considered, as it did not believe it to be practicable or
desirable to do so. Instead, the Sullivan Board considered all of the factors
together in light of its collective business knowledge, judgment and experience.
The Sullivan Board noted, in particular, the complementary nature of Schein's
and Sullivan's businesses and that the combined entity would have the ability to
compete as a full service provider throughout the United States. These
considerations reinforced the Sullivan Board's view that, in light of the
industry's trends toward consolidation and the development of prime vendor
relationships, the Merger offered potential long term benefits to Sullivan's
shareholders that were unlikely to be matched by any potential business
combination with any other person. The Sullivan Board concluded that these
potential benefits, together with the Exchange Ratio, far outweighed the actual
and potential disadvantages of the Merger, and that the Merger was fair and in
the best interests of Sullivan's shareholders. With respect to the potential
loss of sales representatives and suppliers, the Sullivan Board believes that
the signing bonuses that Schein intends to pay to the combined sales force in
connection with the Merger and the breadth of the combined company's product
offerings should prevent these concerns from having a material adverse impact on
the combined company, while recognizing that no assurance can be given on these
issues.
During its deliberations, the Sullivan Board was cognizant that certain
members of the Sullivan Board had interests in the Merger in addition to their
interests as shareholders of Sullivan. Such additional interests concerned
certain compensation that such individuals would receive upon consummation of
the Merger or as a result of post-consummation services to the surviving
corporation and Schein. The Sullivan Board viewed such compensation as being
earned by such individuals in their respective capacities other than as
shareholders of Sullivan. See '--Interests of Certain Persons in the Merger'.
Furthermore, the Sullivan Board recognized that the execution and delivery
of the Irrevocable Proxy and Termination Rights Agreement by certain of the
Granting Holders decreased their individual interests, as
29
shareholders of Sullivan, in an Acquisition Transaction that might be more
favorable to the other shareholders of Sullivan than the Merger. See 'RISK
FACTORS--Irrevocable Proxy and Termination Rights Agreement'. After reviewing
their fiduciary duties with outside counsel, the Sullivan Board determined that,
given its determination that the Merger was fair to, and in the best interests
of, Sullivan and its shareholders, and that Schein was requiring that the
Granting Holders execute and deliver the Irrevocable Proxy and Termination
Rights Agreement as a condition to Schein's execution and delivery of the Merger
Agreement, that it was appropriate and in the best interests of Sullivan and its
shareholders for such Granting Holders (including members of the Sullivan Board)
to enter into the Irrevocable Proxy and Termination Rights Agreement. The
Irrevocable Proxy and Termination Rights Agreement provides that none of the
Sullivan directors who are parties thereto are making any agreement in their
respective capacities as directors of Sullivan and that they are executing and
delivering the Irrevocable Proxy and Termination Rights Agreement solely in
their respective capacities as the record and beneficial owner of shares of
Sullivan Common Stock. Accordingly, the Sullivan Board does not believe that the
Irrevocable Proxy and Termination Rights Agreement has had or will have any
effect on the ability of those members of the Sullivan Board to discharge its
fiduciary obligations under applicable state law.
As noted above, Cleary Gull has rendered a written opinion to the Sullivan
Board as of August 3, 1997. It is not contemplated that Cleary Gull will render
a supplemental fairness opinion regarding the fairness of the Merger as of any
date other than August 3, 1997. Although the Sullivan Board was cognizant of the
possibility of changing circumstances between the date of Cleary Gull's opinion
and the consummation of the Merger, the Sullivan Board concluded that, inasmuch
as the Merger Agreement provides for a fixed Exchange Ratio--which the Sullivan
Board believes to be more favorable to the shareholders of Sullivan than any
adjustable ratio that would have been agreed to by Schein--and permits Sullivan
to terminate the Merger Agreement (among other circumstances) if events having
certain material adverse effects on Schein and its subsidiaries, taken as a
whole, occur, a supplemental fairness opinion was unnecessary. See 'TERMS OF THE
MERGER AGREEMENT--Termination Rights, Condition to the Merger'.
The Merger Agreement also prohibits Sullivan from soliciting inquiries or
making proposals from or to any third party with respect to any merger,
consolidation, other business combination or acquisition involving Sullivan or
any subsidiary of Sullivan. See 'TERMS OF THE MERGER AGREEMENT--No Solicitation
of Other Offers'. This provision was required by Schein as a condition for it to
enter into the Merger Agreement, and the Sullivan Board viewed such provision to
be reasonable given the substantial efforts that would be required by Sullivan
and Schein to consummate the Merger and the Sullivan Board's opinion that the
Merger is in the best interests of the shareholders of Sullivan.
SCHEIN'S REASONS FOR THE MERGER
Schein's business strategy includes continued acquisitions of companies the
business strategies of which are complementary to Schein's. In recent years, the
healthcare industry has undergone significant change driven by various efforts
to reduce costs, including potential national healthcare reform, trends toward
managed care, cuts in Medicare, consolidation of healthcare distribution
companies and collective purchasing arrangements by office-based healthcare
practitioners. These trends, combined with increased consolidation among
distributors, including through acquisitions or joint ventures, could adversely
affect Schein's operating results unless Schein is able to maintain or increase
its market share.
Schein believes that the Merger will increase its market share and will
more quickly bring about its strategic business goal of becoming a full-service
supplier of dental products, equipment and services throughout the United
States, thereby permitting Schein and its stockholders to realize the potential
benefits of such business strategy more quickly and to a greater extent than
would otherwise be possible. The combined entity, Schein believes, will be able
to compete effectively in establishing prime vendor relationships with customers
and increasing the range of goods and services that it may sell to Schein's and
Sullivan's existing customers. The Merger will provide Schein with the services
of Sullivan's key management team, whose skills will, Schein believes,
complement its own management and distribution systems expertise. The combined
entity will have the second largest sales force in the U.S. dental products
distribution industry as well as the industry's largest direct marketing
operation, and Schein believes that the Merger should result in synergistic
benefits, including as a result of the combination and rationalization of
Schein's and Sullivan's distribution facilities and economies of
30
scale in purchasing products for distribution. The combined company will create
what management believes to be the largest dental products distributor in the
United States.
Schein intends to cause the United States dental business of Schein and
Sullivan to be operated as a single unit by Sullivan's senior management team
under the overall direction of James P. Breslawski, Schein's Executive Vice
President, and James W. Stahly, President of Schein's North American Dental
Group.
OPINION OF CLEARY GULL
Sullivan engaged Cleary Gull to act as its financial advisor in connection
with the transactions contemplated by the Merger Agreement and to render a
fairness opinion. Cleary Gull rendered an oral fairness opinion to the Sullivan
Board on August 1, 1997, the date on which the Sullivan Board considered and
approved the Merger Agreement, that the consideration to be received by the
holders of Sullivan Common Stock pursuant to the Merger Agreement was fair, from
a financial point of view, to such holders as of such date. Such opinion was
subsequently confirmed in a written fairness opinion dated August 3, 1997.
Cleary Gull's opinion is directed only to the fairness, from a financial
point of view, to the holders of Sullivan Common Stock of the consideration to
be received by such holders pursuant to the Merger Agreement, does not address
any other aspect of the Merger or related transactions, and does not constitute
a recommendation to any holder of Sullivan Common Stock as to how such
shareholder should vote at the Sullivan Special Meeting. The full text of Cleary
Gull's fairness opinion dated August 3, 1997, which sets forth the assumptions
made, general procedures followed, matters considered and limits on the review
undertaken is attached hereto as Annex II to this Joint Proxy
Statement/Prospectus. The summary of Cleary Gull's opinion set forth below is
qualified in its entirety by reference to the full text of such opinion attached
hereto as Annex II. SHAREHOLDERS OF SULLIVAN ARE URGED TO READ SUCH OPINION IN
ITS ENTIRETY.
In arriving at its opinion, Cleary Gull reviewed, analyzed and considered
such financial and other factors as it deemed appropriate under the
circumstances, including among others, the following: (i) certain publicly
available business and historical financial information relating to Sullivan and
Schein; (ii) certain internal information, primarily financial in nature,
concerning the business and operations of Sullivan and Schein furnished to
Cleary Gull by Sullivan and Schein, respectively, for purposes of its analysis;
(iii) the business prospects of Sullivan and Schein; (iv) certain publicly
available information concerning the estimates of the future operating and
financial performance of Sullivan and Schein prepared by industry experts
unaffiliated with either Sullivan or Schein ('Analysts' Estimates'); (v) the
historical and current stock market data for Sullivan Common Stock, for Schein
Common Stock and for certain other companies that Cleary Gull believed to be
generally comparable to Sullivan and Schein; (vi) publicly available financial
information with respect to certain other companies that Cleary Gull believed to
be generally comparable to Sullivan and Schein; (vii) the financial impact of
the Merger on Schein's future earnings per share; (viii) an unleveraged
after-tax discounted cash flow analysis of both Sullivan and Schein; (ix) an
analysis of Sullivan's percentage contribution to the operating results for
Schein compared to the implied percentage ownership interest of Sullivan
shareholders in Schein after giving effect to the Merger; (x) a comparison of
the purchase price premium to be paid for the Sullivan Common Stock based on the
Exchange Ratio to certain other similar-sized mergers; (xi) publicly available
information concerning the nature and terms of certain other transactions that
Cleary Gull believed to be relevant on a comparative basis; (xii) a historical
comparison of Sullivan's and Schein's stock market prices; and (xiii) the terms
of the Merger Agreement. Cleary Gull also met with certain officers and
employees of Sullivan and Schein to discuss the foregoing, as well as other
matters Cleary Gull believed relevant to its inquiry.
In preparing its opinion, Cleary Gull relied on the accuracy and
completeness of all information that was publicly available or provided to
Cleary Gull by or on behalf of Sullivan and Schein, and Cleary Gull did not
independently verify such information. Cleary Gull assumed that the financial
forecasts examined by it were reasonably prepared on bases reflecting the best
currently available estimates and good faith judgments of the managements of
Sullivan and Schein as to the future performance of Sullivan and Schein,
respectively. Cleary Gull also assumed that (i) certain strategic and operating
benefits contemplated by the managements of Sullivan and Schein would be
realized as a result of the Merger and (ii) all material liabilities (contingent
or otherwise, known or unknown) of Sullivan and Schein are as set forth in the
financial statements of Sullivan and Schein, respectively, or were disclosed to
Cleary Gull. Cleary Gull did not make an independent evaluation or appraisal
31
of the assets or liabilities (contingent or otherwise) of Sullivan and Schein,
nor was Cleary Gull furnished with any such evaluations or appraisals. Cleary
Gull did not make any physical inspection of the properties or assets of
Sullivan or Schein. Cleary Gull's fairness opinion was based upon economic,
monetary and market conditions existing on the date thereof. Furthermore, Cleary
Gull expressed no opinion as to the price or trading range at which Schein
Common Stock will trade after the Effective Time. Cleary Gull's fairness opinion
does not address the relative merits of the Merger, or the decision of the
Sullivan Board to proceed with the Merger. The Exchange Ratio was determined by
Sullivan and Schein in arm's-length negotiations. Cleary Gull did not, and was
not requested to, make any recommendations as to the form or amount of
consideration to be paid pursuant to the Merger Agreement. Sullivan did not
place any limitations upon Cleary Gull with respect to the procedures followed
or factors considered in rendering its opinion. Cleary Gull assumed, with the
consent of the Sullivan Board, that the Merger will be treated as a pooling of
interests for financial reporting purposes and as a tax-free reorganization for
federal income tax purposes.
The preparation of a fairness opinion involves various determinations as to
the most appropriate and relevant quantitative methods of financial analyses and
the application of those methods to the particular circumstances and, therefore,
such an opinion is not readily susceptible to partial analysis or summary
description. Accordingly, Cleary Gull believes that its analyses must be
considered as a whole and that considering any portion of such analyses and of
the factors considered, without considering all analyses and factors, could
create a misleading or incomplete view of the processes underlying Cleary Gull's
opinion. In its analyses, Cleary Gull made numerous assumptions with respect to
industry performance, general business and economic conditions and other
matters, many of which are beyond the control of Sullivan and Schein. Any
estimates contained in these analyses are not necessarily indicative of actual
values or predictive of future results or values which may be significantly more
or less favorable than as set forth therein. In addition, analyses relating to
the value of businesses do not purport to be appraisals or to reflect the prices
at which businesses may actually be sold. Cleary Gull's opinion and financial
analyses were only one of many factors considered by the Sullivan Board in its
evaluation of the Merger and should not be viewed as determinative of the views
of the Sullivan Board or management with respect to the Exchange Ratio or the
proposed Merger.
In connection with its presentation to the Sullivan Board on August 1,
1997, Cleary Gull advised the Sullivan Board that, in evaluating the
consideration to be received pursuant to the Merger Agreement by the Sullivan
shareholders, Cleary Gull had performed a variety of financial analyses with
respect to Sullivan and Schein. These financial analyses are summarized below.
Analysis of Selected Publicly Traded Comparable Companies to Schein. Using
publicly available information, Cleary Gull analyzed, among other things, the
trading multiples of Schein and selected publicly traded dental and medical
distribution companies including Allegiance Corporation, Gulf South Medical
Supply, Inc., Moore Medical Corp., Owens & Minor, Inc., Patterson Dental Company
and Physicians Sales & Service, Inc. (the 'Public Comparables'). Cleary Gull
compared, with respect to each of the Public Comparables and Schein, equity
market capitalization as a multiple of net income for the latest 12 months
('LTM') and estimated fiscal year 1997 and 1998 net income, and the equity
market capitalization plus total debt less cash and cash equivalents (the
'Adjusted Market Value') as a multiple of LTM net revenue, LTM earnings before
interest and taxes ('EBIT') and LTM earnings before interest, taxes,
depreciation and amortization ('EBITDA'). In addition, Cleary Gull compared the
ratio of (a) the result obtained by dividing the stock market price per share by
the earnings per share ('EPS') estimate for fiscal 1997 (the '1997 P/E Ratio')
to (b) the EPS growth rate between calendar 1997 and 1998 multiplied by 100 (the
'PEG Ratio'). Net income projections for the Public Comparables were based on
either Analysts' Estimates or I/B/E/S and future net income for Schein was based
on Analysts' Estimates. All trading multiples were based on closing stock prices
as of August 1, 1997 (the 'Pricing Date').
Cleary Gull compared the trading multiples of the Public Comparables to the
trading multiples for Schein. Cleary Gull noted that as of the Pricing Date, the
ratio of the price of a share of Schein Common Stock to its LTM EPS and to its
EPS estimate for 1997 were 44.8x and 34.5x, respectively, compared to a range of
13.6x to 40.4x and 14.5x to 28.0x, respectively, for the Public Comparables.
Cleary Gull also calculated the multiples of Schein's Adjusted Market Value to
LTM net revenue, LTM EBIT and LTM EBITDA. Cleary Gull noted that Schein Common
Stock traded at 1.07x its LTM net revenue, 30.0x its LTM EBIT and 23.7x its LTM
EBITDA, compared to a range of 0.22x to 1.76x, 11.2x to 27.4x and 7.3x to 22.4x,
respectively, for the Public
32
Comparables. Cleary Gull also noted that Schein's PEG Ratio as of the Pricing
Date was 130.0% as compared to a range of 78.9% to 154.4% for the Public
Comparables.
Analysis of Selected Comparable Transactions. Cleary Gull reviewed 39
transactions involving the acquisition or proposed acquisition of companies in
similar businesses as Sullivan. Cleary Gull calculated the multiples of Adjusted
Market Value to LTM net revenues and LTM EBITDA (the 'Acquisition Multiples')
for each of these transactions. Cleary Gull compared the multiples based on the
Implied Purchase Price to the Acquisition Multiples. Sullivan's Adjusted Market
Value as a multiple of LTM net revenue and LTM EBITDA based on the Implied
Purchase Price was 1.3x and 15.8x, respectively, as compared to a range of 0.2x
to 1.9x and 8.5x to 21.9x, respectively, for the comparable transactions.
No company, transaction or business used for comparison purposes in the
'Analysis of Selected Publicly Traded Comparable Companies to Schein' or
'Analysis of Selected Comparable Transactions' is identical to Sullivan, Schein
or the Merger. Accordingly, an analysis of the results of the foregoing is not
entirely mathematical; rather, it involves complex considerations and judgments
concerning differences of financial and operating characteristics and other
factors that could affect the acquisition, public trading or other values of the
Public Comparables, the selected comparable transactions or the business
segment, company or transaction to which they are being compared.
Schein Historical Latest Twelve Month Price/Earnings Ratio
Analysis. Cleary Gull calculated the ratio of the price of a share of Schein
Common Stock to Schein's LTM EPS as of that particular date (the 'LTM P/E
Ratio') for the period from November 3, 1995 to the Pricing Date. The range of
Schein's LTM P/E Ratio over the period reviewed was 28.2x to 76.3x. Cleary Gull
noted that as of the Pricing Date, Schein's LTM P/E Ratio was 44.8x.
Earnings Dilution Analysis. Cleary Gull analyzed the potential pro forma
effect of the Merger on Schein's EPS for the fiscal years ending December 31,
1997 and December 31, 1998. In performing this analysis, Cleary Gull assumed (i)
the issuance of 0.735 shares of Schein Common Stock for each outstanding share
of Sullivan Common Stock; (ii) that the Merger would be accounted for under the
pooling of interests method of accounting; (iii) that certain one-time
integration charges in connection with the Merger as projected by the
managements of Sullivan and Schein would be incurred; and (iv) that certain
synergies would be achieved as a result of the Merger based on the estimates of
Sullivan's management. The actual results achieved by the combined company may
vary from projected results and the variations may be material. Cleary Gull
combined Sullivan's future operating results with the corresponding future
operating results of Schein. Cleary Gull then divided the pro forma operating
results by the pro forma shares outstanding. Cleary Gull compared the pro forma
EPS to Schein's stand-alone EPS to determine the impact of the Merger on
Schein's EPS. This analysis suggested that, excluding one-time integration
charges, the Merger would be additive to Schein's EPS for the fiscal years
ending December 31, 1997 and December 31, 1998. Projections of Schein's EPS for
fiscal years 1997 and 1998 were based on Analysts' Estimates.
Discounted Cash Flow Analysis of Schein. Cleary Gull analyzed Schein's
fully diluted per share value based on an unleveraged after-tax discounted cash
flow analysis of the five-year financial performance of Schein. The annual
after-tax cash flows for the five-year period were developed by Cleary Gull
based on discussions with Schein management. The discounted cash flow analysis
determined the discounted present value of the unleveraged after-tax cash flows
generated over the five-year period and then added a terminal value based on a
range of EBIT multiples from 13.0x to 15.0x. The unleveraged after-tax cash
flows and terminal value were discounted using a range of discount rates from
13.0% to 14.0%. Cleary Gull derived the range of EBIT multiples and discount
rates on the basis of multiples of EBIT and estimated risk adjusted costs of
capital for the Public Comparables and based upon an analysis of selected
comparable transactions. Based on this analysis, Cleary Gull derived an equity
value range for Schein of $37.44 to $46.08 per fully diluted share.
Schein Common Stock Price Trading Analysis. Cleary Gull analyzed the
closing sale prices of Schein Common Stock on the Nasdaq National Market over
the twenty-one month period between the date of its initial public offering in
November 1995 and the Pricing Date. The high and low closing sale prices for
Schein Common Stock for the period were $43.50 and $21.75, respectively. Cleary
Gull also reviewed a trading price/trading volume analysis of Schein Common
Stock over that period which indicated that over this time period more than 50%
of the shares of Schein Common Stock had traded in the marketplace at a price
equal to or
33
greater than $33.00 per share and approximately 30% of the shares of Schein
Common Stock had traded in the marketplace at a price equal to or greater than
$36.00 per share.
Schein Common Stock Trading Volume Analysis. Cleary Gull analyzed the
historical daily trading volume of Schein Common Stock over various periods so
that the Sullivan Board could consider the opportunity that Sullivan
shareholders would have to sell all or a portion of their Schein Common Stock to
achieve complete or partial liquidity of their holdings after the Merger. The
20, 30, 60, 90 and 180 day average daily trading volume of Schein Common Stock
was approximately 165,429; 175,419; 134,197; 140,711 and 132,298 shares,
respectively. For Sullivan, the 20, 30, 60, 90 and 180 day average daily trading
volume was approximately 77,740; 63,284; 43,293; 40,331 and 33,106 shares,
respectively.
Analysis of Selected Publicly Traded Comparable Companies of
Sullivan. Cleary Gull compared the implied trading multiples for Sullivan to
the trading multiples for the Public Comparables, assuming a stock market price
of $28.67 per share (the 'Implied Purchase Price') based on the Schein market
price of $39.00 on the Pricing Date multiplied by the Exchange Ratio. Sullivan's
Adjusted Market Value as a multiple of LTM net revenue, LTM EBIT and LTM EBITDA
based on the Implied Purchase Price was 1.27x, 18.lx and 15.8x, respectively, as
compared to a median of 0.79x, 14.4x and 11.7x, respectively, for the Public
Comparables. Sullivan's equity market capitalization based on the Implied
Purchase Price as a multiple of estimated 1997 and estimated 1998 net income was
28.lx and 22.8x, respectively, as compared to a median of 21.4x and 18.7x,
respectively, for the Public Comparables. Projections of Sullivan's net income
for fiscal years 1997 and 1998 were based on estimates provided by Sullivan.
Discounted Cash Flow Analysis of Sullivan. Cleary Gull analyzed Sullivan's
fully diluted per share value based on an unleveraged discounted cash flow
analysis of the future financial performance of Sullivan. Such financial
performance was based on a five-year financial plan provided by Sullivan's
management. The discounted cash flow analysis determined the discounted present
value of the unleveraged after-tax cash flows generated over the five-year
period and then added a terminal value based on a range of EBIT multiples from
13.0x to 15.0x. The unleveraged after-tax cash flows and terminal value were
discounted using a range of discount rates from 16.0% to 17.0%. Cleary Gull
derived the range of EBIT multiples and discount rates on the basis of multiples
of EBIT and estimated risk adjusted costs of capital for the Public Comparables
and based upon an analysis of selected comparable transactions. The discounted
cash flow analysis was calculated both including and excluding the value of the
expected synergies from the Merger. Based on this analysis, Cleary Gull derived
an equity value range for Sullivan of $18.79 to $22.17 per fully diluted share
(excluding synergies) and $23.53 to $27.66 per fully diluted share (including
synergies).
Contribution Analysis. Cleary Gull reviewed certain financial information
(including LTM net revenue and projected fiscal year 1997 and 1998 EBIT and net
income) for Sullivan and Schein and for Schein after giving effect to the
Merger. Based on such review and the fact that each share of Sullivan Common
Stock will be converted into 0.735 shares of Schein Common Stock, Cleary Gull
analyzed the contribution of Sullivan to Schein after giving effect to the
Merger and compared the contribution to the pro forma ownership by Sullivan
stockholders of the combined company. The analysis was conducted both including
and excluding the impact of the expected synergies in 1998. These analyses
indicated that Sullivan, excluding the value of the expected synergies, would
contribute 30.1% and 24.9% of 1997 and 1998 net income, respectively, and 29.8%
of 1997 EBIT. Cleary Gull contrasted these contributions to the 26.0% ownership
of the Sullivan stockholders in the combined company.
Premium Analysis. Cleary Gull compared the premium represented by the
Implied Purchase Price to (a) the closing price of a share of Sullivan Common
Stock on the Pricing Date of $22.25, (b) the average closing prices of Sullivan
Common Stock for the 20-trading day period prior to the Pricing Date of $18.43
per share, and (c) the closing price of a share of Sullivan Common Stock one
week and four weeks prior to the Pricing Date of $19.13 and $17.50 per share,
respectively. Based on the Implied Purchase Price, the premium was 29% of the
closing price on the Pricing Date; 56% of the 20 trading day average closing
price, 50% of the one week prior price and 64% of the four week prior closing
price. Cleary Gull also determined premiums paid in selected transactions having
transaction values of $100 million to $500 million. In these transactions, the
median premium based on the price four weeks before the date of the announcement
of the transaction was 16.6%.
34
Cleary Gull was selected by Sullivan as its financial advisor in connection
with the Merger because of Cleary Gull's reputation and expertise as an
investment banking firm and its expertise and familiarity with the dental and
distribution industries. Cleary Gull, as part of its investment banking
business, is regularly engaged in the valuation of businesses and their
securities in connection with mergers and acquisitions, underwritings of
equities, private placements and valuations for estate, corporate and other
purposes.
Pursuant to an engagement letter between Cleary Gull and Sullivan, Sullivan
paid Cleary Gull a non-refundable retainer of $25,000 upon the signing of the
engagement letter, a fee of $150,000 upon the signing of the Merger Agreement,
and a fee of $500,000 when the Fairness Opinion was delivered to the Sullivan
Board. In addition, Cleary Gull will be paid a fee of $225,000 upon consummation
of the Merger. Sullivan has also agreed to reimburse Cleary Gull for its
reasonable out-of-pocket expenses up to $50,000 and to indemnify it against
certain expenses and liabilities in connection with its services as financial
advisor, including those arising under federal securities laws.
In the ordinary course of its securities business, Cleary Gull actively
trades the equity securities of Sullivan and Schein for Cleary Gull's own
account and the accounts of its customers and, accordingly, may at any time hold
a long or short position in such securities. On March 31, 1992, Cleary Gull was
a comanager for a public offering of 700,000 shares of Sullivan Common Stock for
which Cleary Gull received customary compensation.
OPINION OF SMITH BARNEY INC.
Smith Barney was retained by Schein to act as its financial advisor in
connection with the proposed Merger. In connection with such engagement, Schein
requested that Smith Barney evaluate the fairness, from a financial point of
view, to Schein of the consideration to be paid by Schein in the Merger. On
August 1, 1997, at a meeting of the Board of Directors of Schein held to
evaluate the proposed Merger, Smith Barney delivered an oral opinion (which
opinion was subsequently confirmed by delivery of a written opinion dated August
3, 1997, the date of execution of the Merger Agreement) to the Board of
Directors of Schein to the effect that, as of the date of such opinion and based
upon and subject to certain maters stated therein, the Exchange Ratio was fair,
from a financial point of view, to Schein.
In arriving at its opinion, Smith Barney reviewed the Merger Agreement and
held discussions with certain senior officers, directors and other
representatives and advisors of Schein and certain senior officers and other
representatives and advisors of Sullivan concerning the businesses, operations
and prospects of Schein and Sullivan. Smith Barney examined certain publicly
available business and financial information relating to Schein and Sullivan as
well as certain financial forecasts and other information and data for Schein
and Sullivan which were provided to or otherwise discussed with Smith Barney by
the respective managements of Schein and Sullivan, including information
relating to certain strategic implications and operational benefits anticipated
to result from the Merger. Smith Barney reviewed the financial terms of the
Merger as set forth in the Merger Agreement in relation to, among other things:
current and historical market prices and trading volumes of Schein Common Stock
and Sullivan Common Stock; the historical and projected earnings and other
operating data of Schein and Sullivan; and the capitalization and financial
condition of Schein and Sullivan. Smith Barney also considered, to the extent
publicly available, the financial terms of certain other similar transactions
recently effected which Smith Barney considered relevant in evaluating the
Merger and analyzed certain financial, stock market and other publicly available
information relating to the businesses of other companies whose operations Smith
Barney considered relevant in evaluating those of Schein and Sullivan. Smith
Barney also evaluated the potential pro forma financial impact of the Merger on
Schein. In addition to the foregoing, Smith Barney conducted such other analyses
and examinations and considered such other financial, economic and market
criteria as Smith Barney deemed appropriate in arriving at its opinion. Smith
Barney noted that its opinion was necessarily based upon information available,
and financial, stock market and other conditions and circumstances existing and
disclosed, to Smith Barney as of the date of its opinion.
In rendering its opinion, Smith Barney assumed and relied, without
independent verification, upon the accuracy and completeness of all financial
and other information and data publicly available or furnished to or otherwise
reviewed by or discussed with Smith Barney. With respect to financial forecasts
and other information and data provided to or otherwise reviewed by or discussed
with Smith Barney, the managements of Schein and Sullivan advised Smith Barney
that such forecasts and other information and data were reasonably prepared
35
reflecting the best currently available estimates and judgments of the
respective managements of Schein and Sullivan as to the future financial
performance of Schein and Sullivan and the strategic implications and
operational benefits anticipated to result from the Merger. Smith Barney
assumed, with the consent of the Board of Directors of Schein, that the Merger
will be treated as a pooling of interests in accordance with generally accepted
accounting principles and as a tax-free reorganization for federal income tax
purposes. The opinion of Smith Barney, as set forth therein, relates to the
relative values of Schein and Sullivan. Smith Barney did not express any opinion
as to what the value of the Schein Common Stock actually will be when issued to
Sullivan stockholders pursuant to the Merger or the price at which the Schein
Common Stock will trade subsequent to the Merger. Smith Barney did not make and
was not provided with an independent evaluation or appraisal of the assets or
liabilities (contingent or otherwise) of Schein or Sullivan nor did Smith Barney
make any physical inspection of the properties or assets of Schein or Sullivan.
Smith Barney was not requested to consider, and Smith Barney's opinion does not
address, the relative merits of the Merger as compared to any alternative
business strategies that might exist for Schein or the effect of any other
transaction in which Schein might engage. Although Smith Barney evaluated the
Exchange Ratio from a financial point of view, Smith Barney was not asked to and
did not recommend the specific consideration payable in the Merger, which was
determined through negotiation between Schein and Sullivan. No other limitations
were imposed by Schein on Smith Barney with respect to the investigations made
or procedures followed by Smith Barney in rendering its opinion.
THE FULL TEXT OF THE WRITTEN OPINION OF SMITH BARNEY DATED AUGUST 3, 1997,
WHICH SETS FORTH THE ASSUMPTIONS MADE, MATTERS CONSIDERED AND LIMITATIONS ON THE
REVIEW UNDERTAKEN, IS ATTACHED HERETO AS ANNEX III AND SHOULD BE READ CAREFULLY
IN ITS ENTIRETY. THE OPINION OF SMITH BARNEY IS DIRECTED TO THE BOARD OF
DIRECTORS OF SCHEIN AND RELATES ONLY TO THE FAIRNESS OF THE EXCHANGE RATIO FROM
A FINANCIAL POINT OF VIEW TO SCHEIN, DOES NOT ADDRESS ANY OTHER ASPECTS OF THE
MERGER OR RELATED TRANSACTIONS AND DOES NOT CONSTITUTE A RECOMMENDATION TO ANY
STOCKHOLDER AS TO HOW SUCH STOCKHOLDER SHOULD VOTE AT THE SCHEIN SPECIAL
MEETING. THE SUMMARY OF THE OPINION OF SMITH BARNEY SET FORTH IN THIS JOINT
PROXY STATEMENT/PROSPECTUS IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE FULL
TEXT OF SUCH OPINION.
In preparing its opinion, Smith Barney performed a variety of financial and
comparative analyses, including those described below. The summary of such
analyses does not purport to be a complete description of the analyses
underlying Smith Barney's opinion. The preparation of a fairness opinion is a
complex analytic process involving various determinations as to the most
appropriate and relevant methods of financial analyses and the application of
those methods to the particular circumstances and, therefore, such an opinion is
not readily susceptible to summary description. Accordingly, Smith Barney
believes that its analyses must be considered as a whole and that selecting
portions of its analyses and factors, without considering all analyses and
factors, could create a misleading or incomplete view of the processes
underlying such analyses and opinion. In its analyses, Smith Barney made
numerous assumptions with respect to Schein, Sullivan, industry performance,
general business, economic, market and financial conditions and other matters,
many of which are beyond the control of Schein and Sullivan. The estimates
contained in such analyses and the valuation ranges resulting from any
particular analysis are not necessarily indicative of actual values or
predictive of future results or values, which may be significantly more or less
favorable than those suggested by such analyses. In addition, analyses relating
to the value of businesses or securities do not purport to be appraisals or to
reflect the prices at which businesses or securities actually may be sold.
Accordingly, such analyses and estimates are inherently subject to substantial
uncertainty. Smith Barney's opinion and analyses were only one of many factors
considered by the Board of Directors of Schein in its evaluation of the Merger
and should not be viewed as determinative of the views of the Board of Directors
or management of Schein with respect to the Exchange Ratio or the proposed
Merger.
Selected Company Analysis. Using publicly available information, Smith
Barney analyzed, among other things, the market values and trading multiples of
Sullivan and the following selected publicly traded companies in the medical
distribution industry, consisting of: (i) hospital/medical surgical companies:
Allegiance Corporation; and Owens & Minor, Inc.; (ii) physician office/medical
surgical companies: Schein; and Physician Sales and Service, Inc.; (iii)
long-term care/home care-medical surgical companies: Gulf South Medical Supply,
Inc.; Graham-Field Health Products, Inc.; and Suburban Ostomy Supply Co., Inc.;
(iv) a dental distribution company: Patterson Dental Company; and (v) scientific
products companies: Fisher Scientific International, Inc.; and WWR Scientific
Products Corporation (collectively, the 'Selected Companies'). Smith Barney
compared market values as a multiple of, among other things, estimated calendar
1997 and 1998 net income, and adjusted
36
market values (fully diluted equity value, plus debt, less cash) as a multiple
of, among other things, latest 12 months earnings before interest, taxes,
depreciation and amortization ('EBITDA'). All multiples were based on closing
stock prices as of July 31, 1997. Net income estimates for the Selected
Companies were based on estimates of selected investment banking firms, net
income estimates for Schein were based on internal estimates of the management
of Schein and net income estimates for Sullivan were based both on adjusted
estimates of selected investment banking firms and internal estimates of the
management of Sullivan. Applying a range of multiples for the Selected Companies
of estimated calendar 1997 net income, estimated calendar 1998 net income and
latest 12 months EBITDA of 7.8x to 22.8x, 17.4x to 32.5x and 13.4x to 25.9x,
respectively, to corresponding financial data for Sullivan resulted in an equity
reference range for Sullivan of approximately $15.48 to $33.63 per share, as
compared to the equity value implied by the Exchange Ratio of approximately
$27.20 per share based on a closing stock price of Schein Common Stock on July
31, 1997.
Selected Merger and Acquisition Transactions Analysis. Using publicly
available information, Smith Barney analyzed the purchase price and implied
transaction value multiples paid in selected transactions in the medical
distribution industry, consisting of (acquiror/target): (i) transactions
announced or consummated from November 1996 to March 1997 (the 'Tier I
Transactions'): McKesson Corporation/General Medical Corporation; and Gulf South
Medical Supply, Inc./Gateway Healthcare Corporation; and (ii) transactions
announced or consummated from August 1993 to June 1996 (the 'Tier II
Transactions'): Physician Sales and Service, Inc./Crocker-Fels Company; General
Medical Corporation/Randolph Medical, Inc.; Physician Sales and Service,
Inc./Taylor Medical Co.; General Medical Corporation/F.D. Titus & Sons, Inc.;
General Medical Corporation/Foster Medical Supply Inc.; Owens & Minor,
Inc./Stuart Medical; and Kelso & Company/General Medical Corporation (the Tier I
Transactions and the Tier II Transactions, collectively, the 'Selected
Transactions'). Smith Barney compared, among other things, the transaction
values in the Selected Transactions as multiples of latest 12 months revenue and
EBITDA. All multiples for the Selected Transactions were based on information
available at the time of announcement of the transaction. Applying a range of
multiples (excluding outliers) for the Selected Transactions of latest 12 months
revenue and EBITDA of 0.2x to 0.7x and 8.4x to 22.6x, respectively, to
corresponding financial data for Sullivan resulted in an equity reference range
for Sullivan of approximately $9.78 to $27.33 per share, as compared to the
equity value implied by the Exchange Ratio of approximately $27.20 per share
based on a closing stock price of Schein Common Stock on July 31, 1997.
No company, transaction or business used in the 'Selected Company Analysis'
or 'Selected Merger and Acquisition Transactions Analysis' as a comparison is
identical to Schein, Sullivan or the Merger. Accordingly, an analysis of the
results of the foregoing is not entirely mathematical; rather, it involves
complex considerations and judgments concerning differences in financial and
operating characteristics and other factors that could affect the acquisition,
public trading or other values of the Selected Companies, Selected Transactions
or the business segment, company or transaction to which they are being
compared.
Premium Analysis. Smith Barney analyzed the implied premium payable in the
Merger and the premiums paid in approximately 53 selected transactions having
transaction values of between $200 and $500 million based on, among other
things, stock prices one day, one week and one month prior to announcement of
such transactions. Applying a range of mean premiums for these transactions of
36% to 46% to the closing stock price of Sullivan Common Stock on July 31, 1997
(the date prior to public announcement of the Merger) resulted in an equity
reference range for Sullivan of approximately $28.90 to $31.03 per share, as
compared to the equity value implied by the Exchange Ratio of approximately
$27.20 per share based on a closing stock price of Schein Common Stock on July
31, 1997. The trading range of Sullivan Common Stock over the 52-week period
prior to public announcement of the Merger was between approximately $9.88 and
$21.25 per share.
Contribution Analysis. Smith Barney analyzed the respective contributions
of Schein and Sullivan to the estimated revenue, EBITDA, EBIT and net income of
the combined company for the latest 12 months ended March 31, 1997 (for Schein)
and June 30, 1997 (for Sullivan) and fiscal years 1997 and 1998, based on
internal estimates of the managements of Schein and Sullivan for fiscal year
1997 and on internal estimates of the management of Schein and adjusted
estimates of selected investment banking firms with respect to Sullivan for
fiscal year 1998, after giving effect, in fiscal years 1997 and 1998, to certain
cost savings and other potential synergies anticipated by the managements of
Schein and Sullivan to result from the Merger. This analysis indicated that (i)
for the latest 12 months ended March 31, 1997 (for Schein) and June 30, 1997
(for Sullivan), Schein would have contributed approximately 76.4% of revenues,
67.1% of EBITDA, 65.2% of earnings before
37
interest and taxes ('EBIT') and 65.7% of net income, and Sullivan would have
contributed approximately 23.6% of revenues, 32.9% of EBITDA, 34.8% of EBIT and
34.3% of net income, of the combined company, (ii) in fiscal year 1997, Schein
would contribute approximately 80.0% of revenues, 73.8% of EBITDA, 71.9% of EBIT
and 71.7% of net income, and Sullivan would contribute approximately 20.0% of
revenues, 26.2% of EBITDA, 28.1% of EBIT and 28.3% of net income, of the
combined company, and (iii) in fiscal year 1998, Schein would contribute
approximately 81.1% of revenue, 75.1% of EBITDA, 73.5% of EBIT and 72.5% of net
income, and Sullivan would contribute approximately 18.9% of revenues, 24.9% of
EBITDA, 26.5% of EBIT and 27.5% of net income, of the combined company. Based on
the Exchange Ratio, current stockholders of Schein and Sullivan would own
approximately 74.2% and 25.8%, respectively, of the equity value of the combined
company upon consummation of the Merger, and Schein and Sullivan would
constitute approximately 74.5% and 25.5%, respectively, of the enterprise value
of the combined company.
Discounted Cash Flow Analysis. Smith Barney performed a discounted cash
flow analysis of the projected free cash flow of Sullivan for fiscal years 1998
through 2002, based on adjusted estimates of selected investment banking firms
for fiscal year 1998 and internal estimates of the management of Sullivan for
fiscal years 1999 through 2002 and taking into account certain cost savings and
other potential synergies anticipated by the managements of Schein and Sullivan
to result from the Merger. The stand-alone discounted cash flow analysis of
Sullivan was determined by (i) adding (x) the present value of projected free
cash flows over the five-year period from 1998 to 2002 and (y) the present value
of Sullivan's estimated value in year 2002 and (ii) subtracting the current net
debt of Sullivan. The range of estimated terminal values for Sullivan at the end
of the five-year period was calculated by applying forward earnings multiples of
16.5x to 18.5x to Sullivan's projected 2002 forward earnings, representing
Sullivan's estimated value beyond the year 2002. The cash flows and terminal
values of Sullivan were discounted to present value using discount rates ranging
from 12% to 14%, with particular focus on a discount rate of 13%. Utilizing such
terminal multiples and a discount rate of 13%, this analysis resulted in an
equity reference range for Sullivan of approximately $30.07 to $33.11 per share,
as compared to the equity value implied by the Exchange Ratio of approximately
$27.20 per share based on a closing stock price of Schein Common Stock on July
31, 1997.
Pro Forma Merger Analysis. Smith Barney analyzed certain pro forma effects
resulting from the Merger, including, among other things, the impact of the
Merger on the projected earnings per share ('EPS') of Schein for the fiscal
years ended 1998 and 1999, based on internal estimates of the managements of
Schein and Sullivan. The results of the pro forma merger analysis suggested that
the Merger could be accretive to Schein's EPS in each of the fiscal years
analyzed, assuming certain cost savings and other potential synergies
anticipated by the managements of Schein and Sullivan to result from the Merger
were achieved. The actual results achieved by the combined company may vary from
projected results and the variations may be material.
Exchange Ratio Analysis. Smith Barney compared the Exchange Ratio with the
historical ratio of the daily closing prices of Schein Common Stock and Sullivan
Common Stock over the six-month and 12-month periods ending July 31, 1997. The
average exchange ratios during such periods were 0.492 and 0.410, respectively,
as compared to the Exchange Ratio of 0.735.
Other Factors and Comparative Analyses. In rendering its opinion, Smith
Barney considered certain other factors and conducted certain other comparative
analyses, including, among other things, a review of (i) Schein's and Sullivan's
historical and projected financial results; (ii) the history of trading prices
and volume for Sullivan Common Stock and the relationship between movements in
Sullivan Common Stock, movements in the common stock of comparable companies and
movements in the S&P 500 Index; (iii) selected published analysts' reports on
Sullivan, including analysts' estimates as to the earnings growth potential of
Sullivan; and (iv) the pro forma ownership of the combined company.
Pursuant to the terms of Smith Barney's engagement, Schein has agreed to
pay Smith Barney for its services in connection with the Merger an aggregate
financial advisory fee based on a percentage of the total consideration
(including liabilities assumed) payable in connection with the Merger. The fee
payable to Smith Barney is currently estimated to be approximately $2.5 million.
Schein has also agreed to reimburse Smith Barney for travel and other
out-of-pocket expenses incurred by Smith Barney in performing its services,
including the fees and expenses of its legal counsel, and to indemnify Smith
Barney and related persons against
38
certain liabilities, including liabilities under the federal securities laws,
arising out of Smith Barney's engagement.
Smith Barney has advised Schein that, in the ordinary course of business,
Smith Barney and its affiliates may actively trade or hold the securities of
Schein and Sullivan for their own account or for the account of customers and,
accordingly, may at any time hold a long or short position in such securities.
Smith Barney has in the past provided investment banking services to Schein
unrelated to the proposed Merger, for which services Smith Barney has received
compensation. In addition, Smith Barney and its affiliates (including Travelers
Group Inc. and its affiliates) may maintain relationships with Schein and
Sullivan.
Smith Barney is an internationally recognized investment banking firm and
was selected by Schein based on its experience, expertise and familiarity with
Schein and its business. Smith Barney regularly engages in the valuation of
businesses and their securities in connection with mergers and acquisitions,
negotiated underwritings, competitive bids, secondary distributions of listed
and unlisted securities, private placements and valuations for estate, corporate
and other purposes.
EFFECTIVE TIME
The Merger will become effective at such time as Articles of Merger are
duly filed with the Wisconsin Department of Financial Institutions--Corporations
Division, or at such other time as Schein and Sullivan agree and specify in the
Articles of Merger. The Merger Agreement provides that Merger Sub and Sullivan
will execute and file such articles or other appropriate documents as soon as
practicable after the last of the conditions to the Merger have been fulfilled.
See 'TERMS OF THE MERGER AGREEMENT--Conditions to the Merger'.
EXCHANGE RATIO
At the Effective Time, each share of Sullivan Common Stock issued and
outstanding immediately prior to the Effective Time will be converted into the
right to receive 0.735 shares of Schein Common Stock.
Based upon the Exchange Ratio and the closing sales price of shares of
Schein Common Stock on September 18, 1997, as reported on the Nasdaq National
Market, each outstanding share of Sullivan Common Stock would have been
converted into Schein Common Stock with a then-current market value of $26.46
had the Merger been consummated on that date, and the aggregate then-current
market value of the shares of Schein Common Stock issued in the Merger
(7,560,738 shares assuming no change in the number of shares of Sullivan Common
Stock outstanding as of the Record Date as a result of the exercise of
outstanding options to purchase Sullivan Common Stock) would have been
$272,186,568.
As of the Effective Time, all shares of Sullivan Common Stock shall no
longer be outstanding and shall automatically be canceled and retired and shall
cease to exist, and each holder of a certificate representing any such shares of
Sullivan Common Stock shall cease to have any rights with respect thereto,
except the right to receive shares of Schein Common Stock and cash in lieu of
any fractional share of Schein Common Stock to be issued (or paid) in
consideration therefor upon surrender of such certificate, in each case without
interest. Any treasury shares of Sullivan Common Stock will automatically be
canceled and retired and will cease to exist as of the Effective Time.
EXCHANGE AGENT; EXCHANGE PROCEDURES; DISTRIBUTIONS WITH RESPECT TO UNEXCHANGED
SHARES; NO FURTHER OWNERSHIP RIGHTS IN SULLIVAN COMMON STOCK; NO FRACTIONAL
SHARES OF SCHEIN COMMON STOCK
Exchange Agent. The Merger Agreement requires Schein to deposit as of the
Effective Time, with Continental Stock Transfer & Trust Company (the 'Exchange
Agent'), for the benefit of the holders of shares of Sullivan Common Stock, the
shares of Schein Common Stock issuable in exchange for Sullivan Common Stock.
Exchange Procedures. As soon as reasonably practicable after the Effective
Time, Schein shall cause the Exchange Agent to mail to each holder of record of:
(i) a letter of transmittal (which shall specify that delivery shall be
effected, and risk of loss and title to the Sullivan Certificates shall pass,
only upon delivery of the Sullivan Certificates to the Exchange Agent, and shall
be in such form and have such other provisions as Schein may reasonably specify)
and (ii) instructions for use in effecting the surrender of the Sullivan
Certificates in exchange for certificates representing shares of Schein Common
Stock ('Schein Certificates'). Upon surrender
39
of a Sullivan Certificate for cancellation to the Exchange Agent, together with
such letter of transmittal, duly executed, and such other documents as may
reasonably be required by the Exchange Agent, the holder of such Sullivan
Certificate shall be entitled to receive in exchange therefor Schein
Certificates representing the shares of Schein Common Stock (rounded down to the
nearest whole share) which such holder has the right to receive after taking
into account all the shares of Sullivan Common Stock formerly held by such
holder under all such Sullivan Certificates so surrendered, cash in lieu of
fractional shares of Schein Common Stock, and any dividends or other
distributions to which such holder is entitled, and the Sullivan Certificates so
surrendered shall forthwith be canceled. In the event of a transfer of ownership
of Sullivan Common Stock that is not registered in the transfer records of
Sullivan, a Schein Certificate may be issued to a person other than the person
in whose name the Sullivan Certificate so surrendered is registered if, upon
presentation to the Exchange Agent, such Sullivan Certificate is properly
endorsed or otherwise is in proper form for transfer and the person requesting
such payment pays any transfer or other taxes required by reason of the issuance
of shares of Schein Common Stock to a person other than the registered holder of
such Sullivan Certificate or establishes to the satisfaction of Schein that such
tax has been paid or is not applicable. Until so surrendered, each Sullivan
Certificate shall be deemed at any time after the Effective Time to represent
only the right to receive upon such surrender a certificate representing shares
of Schein Common Stock, cash in lieu of any fractional shares of Schein Common
Stock and any dividends or other distributions to which such holder is entitled
pursuant to the Merger Agreement. No interest will be paid or will accrue on any
cash payable pursuant to the Merger Agreement.
SULLIVAN SHAREHOLDERS SHOULD NOT FORWARD SULLIVAN CERTIFICATES TO THE
EXCHANGE AGENT UNTIL THEY HAVE RECEIVED TRANSMITTAL FORMS. SULLIVAN SHAREHOLDERS
SHOULD NOT RETURN STOCK CERTIFICATES WITH THE ENCLOSED PROXY.
Distributions with Respect to Unexchanged Shares. No dividends or other
distributions with respect to shares of Schein Common Stock with a record date
after the Effective Time shall be paid to the holder of any unsurrendered
Sullivan Certificate with respect to the shares of Schein Common Stock
represented thereby, and no cash payment in lieu of fractional shares of Schein
Common Stock shall be paid to any such holder, until the holder of record of
such Sullivan Certificate shall surrender such Sullivan Certificate. Following
surrender of any such Sullivan Certificate, there shall be paid to the record
holder of the shares of Schein Common Stock issued in exchange therefor, without
interest, (i) at the time of such surrender, the amount of any cash payable in
lieu of a fractional share of Schein Common Stock to which such holder is
entitled and the amount of dividends or other distributions with a record date
after the Effective Time theretofore paid with respect to such whole shares of
Schein Common Stock, and (ii) at the appropriate payment date, the amount of
dividends or other distributions with a record date after the Effective Time but
prior to such surrender and a payment date subsequent to such surrender payable
with respect to such whole shares of Schein Common Stock.
No Further Ownership Rights in Sullivan Common Stock. All shares of Schein
Common Stock issued upon the surrender for exchange of shares of Sullivan Common
Stock in accordance with the terms of the Merger Agreement (including any cash
paid) shall be deemed to have been issued in full satisfaction of all rights
pertaining to such shares of Sullivan Common Stock, and there shall be no
further registration of transfers on the stock transfer books of the Surviving
Corporation of the shares of Sullivan Common Stock which were outstanding
immediately prior to the Effective Time. If, after the Effective Time, Sullivan
Certificates are presented to the Surviving Corporation or the Exchange Agent
for any reason, they shall be canceled and exchanged as provided in the Merger
Agreement.
No Fractional Shares of Schein Common Stock. No certificates representing
fractional shares of Schein Common Stock shall be issued upon the surrender for
exchange of Sullivan Certificates. Each holder of shares of Sullivan Common
Stock exchanged pursuant to the Merger who would otherwise have been entitled to
receive a fraction of a share of Schein Common Stock (after taking into account
all Sullivan Certificates delivered by such holder) will receive, in lieu
thereof, cash (without interest) in an amount determined by multiplying (i) the
fractional interest to which such holder would otherwise be entitled and (ii)
the average of the per share closing sales prices for Schein Common Stock on the
Nasdaq National Market for the five trading days immediately preceding the
Effective Time. In no event shall a holder of Sullivan Common Stock receive cash
in lieu of fractional Shares of Schein Common Stock in an amount greater than
the value of one full share of Schein Common Stock.
40
ADMISSION FOR TRADING ON NASDAQ NATIONAL MARKET
The outstanding shares of Schein Common Stock are presently admitted for
trading on the Nasdaq National Market. It is a condition to each party's
obligation to effect the Merger that the shares of Schein Common Stock issuable
to Sullivan's shareholders pursuant to the Merger Agreement shall have been
admitted for trading on the Nasdaq National Market, subject to official notice
of issuance. See 'TERMS OF THE MERGER AGREEMENT--Conditions to the Merger'.
CESSATION OF NASDAQ NATIONAL MARKET TRADING AND DEREGISTRATION OF SULLIVAN
COMMON STOCK
AFTER THE MERGER
If the Merger is consummated, the Sullivan Common Stock will cease to be
traded on the Nasdaq National Market and will be deregistered under the Exchange
Act. After such delisting and deregistration, Sullivan will no longer be subject
to any reporting obligations under the Exchange Act.
CERTAIN SIGNIFICANT CONSIDERATIONS
In considering whether to approve the Merger Agreement providing for the
Merger, stockholders of Sullivan and Schein should carefully consider those
factors described under 'RISK FACTORS' as well as the fact that the Exchange
Ratio is fixed and will not be adjusted based on changes in the price of the
Schein Common Stock, and the price of the shares of Schein Common Stock at the
Effective Time may vary from the price as of the date of this Joint Proxy
Statement/Prospectus or the date on which shareholders of Sullivan vote on the
Merger due to changes in the business, operations or prospects of Schein, market
assessments of the likelihood that the Merger will be consummated and the timing
thereof, general market and economic conditions, and other factors.
CERTAIN TAX CONSEQUENCES OF THE MERGER
Neither Sullivan nor Schein has requested or will receive advance ruling
from the Internal Revenue Service ('IRS') as to any of the federal income tax
consequences to holders of Sullivan Common Stock of the Merger or of any of the
federal income tax consequences to Sullivan or Schein of the Merger. Instead
Sullivan will rely upon the opinion of Proskauer Rose LLP, counsel to Schein, as
to the federal income tax consequences of the Merger. The opinion of Proskauer
Rose LLP is based entirely upon the Internal Revenue Code of 1986, as amended
(the 'Code'), regulations now in effect thereunder, current administrative
rulings and practice, and judicial authority, all of which are subject to
change, as well as various representations and certificates of officers of
Sullivan and Schein and of the other appropriate persons, and is subject to
various assumptions and qualifications. Unlike a ruling from the IRS, an opinion
is not binding on the IRS and there can be no assurance, and none is hereby
given, that the IRS will not take a position contrary to one or more positions
reflected herein or that the opinion will be upheld by the courts if the
positions set forth therein are challenged by the IRS.
In the opinion of Proskauer Rose LLP, which opinion is based upon various
representations and subject to various assumptions and qualifications, each as
more fully set forth in such opinion letter, the following federal income tax
consequences should result from the Merger:
1. The Merger of Merger Sub with and into Sullivan, with Sullivan
surviving, will qualify as a reorganization under Section 368(a) of
the Code. Sullivan, Schein and Merger Sub will each be a party to a
reorganization within the meaning of Section 368(b) of the Code.
2. No gain or loss will be recognized by the Sullivan shareholders upon
the exchange of their Sullivan Common Stock for Schein Common Stock.
3. The basis of the Schein Common Stock received by a shareholder of
Sullivan in the exchange (including any fractional shares which the
shareholder otherwise might be entitled to receive) will be the same
as the basis of the Sullivan Common Stock exchanged therefor.
4. The holding period of the Schein Common Stock to be received by a
Sullivan shareholder will include the holding period of the Sullivan
shares surrendered by the shareholder in the exchange, provided that
Sullivan shares were held as a capital asset on the date of the
exchange.
41
5. Cash received by a shareholder of Sullivan in lieu of a fractional
share of Schein Common Stock will be treated as if the fractional
shares were received in exchange for such fractional shares, and not
as a dividend. Any gain or loss recognized as a result of the
receipt of such cash will be capital gain or loss, if such stock was
held as a capital asset at the time of the exchange, equal to the
difference between the cash received and the portion of the
shareholder's basis in Sullivan Common Stock for such fractional
share interest.
6. Sullivan will recognize no gain or loss as a result of the Merger.
The opinion of Proskauer Rose LLP (which Proskauer Rose is not required to
reissue or reconfirm as of the Effective Time) does not extend to the income or
other potential tax consequences of the Merger under the laws of any state or
any political subdivision of any state or any other jurisdiction. No legal
opinion as to tax consequences of any nature has been rendered by Wolfe, Wolfe &
Ryd, counsel to Sullivan. See 'Legal Matters'.
THE FOREGOING CONSTITUTES THE MATERIAL FEDERAL INCOME TAX CONSEQUENCES OF
THE MERGER WITHOUT REGARD TO THE PARTICULAR FACTS AND CIRCUMSTANCES OF EACH
SHAREHOLDER OF SULLIVAN. SHAREHOLDERS OF SULLIVAN ARE URGED TO CONSULT THEIR OWN
TAX ADVISORS AS TO THE SPECIFIC TAX CONSEQUENCES TO THEM OF THE MERGER,
INCLUDING THE APPLICABILITY AND EFFECT OF STATE, LOCAL, FOREIGN AND OTHER TAX
LAWS.
ANTICIPATED ACCOUNTING TREATMENT
The Merger is designed to qualify as a pooling of interests for accounting
and financial reporting purposes. Under this method of accounting, the recorded
assets and liabilities of Sullivan and Schein will be carried forward to Schein
at their recorded amounts; income of Schein will include income of Schein and
Sullivan for the entire fiscal year in which the Merger occurs; and the reported
income of the separate corporations for prior periods will be combined and
restated as income of the combined company. The obligations of Schein and Merger
Sub to consummate the Merger are subject to the receipt by Schein, immediately
prior to the Effective Time, of the opinions of BDO Seidman, LLP, the
independent auditors of Schein (whose opinion shall be addressed to Schein) and
Deloitte & Touche LLP, the independent auditors of Sullivan (whose opinion shall
be addressed to Sullivan), that, subject to customary qualifications, the Merger
qualifies as a pooling of interests for financial reporting purposes in
accordance with generally accepted accounting principles. See 'TERMS OF THE
MERGER AGREEMENT--Conditions to the Merger'.
IRREVOCABLE PROXY AND TERMINATION RIGHTS AGREEMENT
As an inducement to Schein to enter into the Merger Agreement, the Granting
Holders entered into the Irrevocable Proxy and Termination Rights Agreement.
Pursuant to the Irrevocable Proxy and Termination Rights Agreement, the Granting
Holders have irrevocably agreed to constitute and appoint Schein or any designee
of Schein as the lawful agent, attorney and proxy of such Granting Holders to
vote substantially all of the shares of Sullivan Common Stock owned by them as a
group at any meeting or in connection with any written consent of Sullivan's
shareholders: (i) in favor of the Merger, (ii) in favor of the Merger Agreement,
as it may be modified or amended from time to time, (iii) against any
Acquisition Transaction (as defined in the Merger Agreement--see 'TERMS OF THE
MERGER--No Solicitation of Other Offers') other than the Merger which provides
for any merger, sale of assets or other business combination between Sullivan
and any other person or entity or any other action that would make it
impractical for Schein to effect a merger or other business combination of
Sullivan with Schein or Merger Sub, and (iv) against any other action or
agreement that would result in a breach of any covenant, representation or
warranty or any other obligation or agreement of Sullivan under the Merger
Agreement or which would result in any of Sullivan's obligations under the
Merger Agreement not being fulfilled. An 'Acquisition Transaction' means any
merger, consolidation or other business combination involving Sullivan or any
subsidiary of Sullivan (excluding certain acquisitions by Sullivan expressly
permitted under the Merger Agreement) or the acquisition of all or any
significant assets or capital stock of Sullivan and its subsidiaries, taken as a
whole.
42
In addition, if any Granting Holder shall sell, exchange or otherwise
dispose of any of his, her or its shares of Schein Common Stock pursuant to an
Acquisition Transaction after the Merger Agreement has been terminated (A) by
Schein due to (i) a breach of any representation or warranty of Sullivan which
individually or together with all other such breaches have a materially adverse
effect on Sullivan, (ii) a material breach of any covenant or agreement set
forth in the Merger Agreement which remains uncured 30 days after notice of the
breach is given by Schein to Sullivan, (iii) the Sullivan Board (x) withdrawing,
amending or modifying in a manner adverse to Schein or the Merger Sub its
recommendation or approval in respect of the Merger Agreement or the Merger, (y)
making a recommendation with respect to an Acquisition Transaction, other than a
recommendation to reject such Acquisition Transaction, or (z) taking any action
that would constitute a violation of the Merger Agreement's prohibition on
solicitation of proposals or inquiries regarding an Acquisition Transaction;
(iv) any Acquiring Person other than Schein, or any affiliate or subsidiary of
Schein, shall have become the beneficial owner of more than 20% of the
outstanding voting equity of Sullivan (either on a primary or fully diluted
basis); provided, however that any corporation, partnership, person other entity
or group which beneficially owned 20% of the outstanding voting equity of
Sullivan (either on a primary or fully diluted basis) on the date of the Merger
Agreement and which has not after such date increased such ownership percentage
by more than an additional one percent of the outstanding voting equity of
Sullivan (either on a primary or fully diluted basis) shall not be deemed to be
an Acquiring Person; (v) an Acquisition Transaction shall have occurred with any
Acquiring Person other than Schein or any affiliate or subsidiary of Schein;
(vi) the failure of the Sullivan Special Meeting to be held by January 31, 1998
(except as a result of a judgment, injunction, order or decree if any competent
authority or events or circumstances beyond the reasonable control of Sullivan,
or (B) by Sullivan (i) in order to permit Sullivan to enter into an Acquisition
Transaction, (ii) due to the failure of Sullivan or Schein to obtain the
required stockholder consents or (iii) as a result of the failure of the Merger
to be consummated prior to January 31, 1998, then such Granting Holder shall pay
or cause to be paid to Schein upon demand an amount equal to the product of (x)
35% of the amount by which the total consideration of all kinds and from all
sources received by such Granting Holder for each share of Schein Common Stock
disposed of by such Granting Holder exceeds the fair market value on the date of
termination of the Merger Agreement of 0.735 of a share of Schein Common Stock
and (y) the aggregate number of Schein Common Stock sold by such Granting
Holder. See 'TERMS OF THE MERGER AGREEMENT--Certain Fees, Expenses and
Liquidation Damages'.
The Irrevocable Proxy and Termination Rights Agreement terminates on the
earlier of (i) the Effective Time and (ii) 12 months; provided, however, that
the appointment of Schein or any designee of Schein as agent, attorney and proxy
automatically terminates upon the termination of the Merger Agreement.
INTERESTS OF CERTAIN PERSONS IN THE MERGER
As of the Sullivan Record Date, the directors and executive officers of
Sullivan owned an aggregate of 2,146,700 shares of Sullivan Common Stock and
options to purchase an aggregate of 645,000 shares of Sullivan Common Stock at a
weighted average exercise price of $7.50 per share. Pursuant to the Merger
Agreement, Sullivan's directors and executive officers will receive the same
consideration for their shares of Sullivan Common Stock as the other Sullivan
shareholders, and all outstanding options to purchase Sullivan Common Stock will
be converted into options to purchase Schein Common Stock as described under
'TERMS OF THE MERGER--Treatment of Sullivan Stock Options.'
Schein has entered into employment agreements (effective as of the
Effective Time) with each of Robert J. Sullivan, Robert E. Doering, Timothy J.
Sullivan, Kevin J. Ackeret, Geoffrey A. Reichhardt, David A. Steck and Kenneth
A. Schwing pursuant to which, Robert J. Sullivan will serve as a Vice Chairman
of Schein, Robert E. Doering will serve as President Emeritus of Schein's U.S.
Dental Division, and Timothy J. Sullivan, Kevin J. Ackeret, Geoffrey A.
Reichardt, David A. Steck and Kenneth A. Schwing will serve as President,
Executive Vice President, Vice President, Vice President--Products Division and
Vice President--Equipment Division, respectively, of Schein's U.S. Dental
Division. Except for those of Robert J. Sullivan and Robert E. Doering, which
each have a term of three years, each of the employment agreements has a term of
five years from the Effective Time.
Robert J. Sullivan's employment agreement provides for, among other things,
base salary at the rate of $250,000 per annum, subject to annual increases, a
signing bonus of $550,000, and options to purchase 60,000
43
shares of Schein Common Stock, subject to vesting, at a per share exercise price
equal to the fair market value of a share of Schein Common Stock at the
Effective Time (the 'Exercise Price'). In addition, Mr. Sullivan has covenanted
not to compete with Schein for a period of five years after the termination of
his employment and, in consideration therefore, will receive the sum of
$550,000.
Robert E. Doering's employment agreement provides for, among other things,
base salary at the rate of $150,000 per annum, subject to annual increases, a
signing bonus of $160,000, and options to purchase 30,000 shares of Schein
Common Stock, subject to vesting, at the Exercise Price. In addition, Mr.
Doering has covenanted not to compete with Schein for a period of five years
after the termination of his employment and, in consideration therefore, will
receive the sum of $550,000.
Timothy J. Sullivan's employment agreement provides for, among other
things, base salary at the rate of $210,000 per annum, subject to annual
increases, a signing bonus of $330,000, incentive compensation in accordance
with Schein's practices, and options to purchase 15,000 shares of Schein Common
Stock, subject to vesting, at the Exercise Price, and a grant of shares of
Schein Common Stock, pursuant to a restricted stock agreement, with a fair
market value (determined in accordance with such agreement) at the Effective
Time of $200,000. In addition, Mr. Sullivan has covenanted not to compete with
Schein for a period of five years after the termination of his employment and,
in consideration therefore, will receive the sum of $950,000.
Kevin J. Ackeret's employment agreement provides for, among other things,
base salary at the rate of $210,000 per annum, subject to annual increases, a
signing bonus of $310,000, incentive compensation in accordance with Schein's
practices, options to purchase 15,000 shares of Schein Common Stock, subject to
vesting, at the Exercise Price, and a grant of shares of Schein Common Stock,
pursuant to a restricted stock agreement, with a fair market value (determined
in accordance with such agreement) at the Effective Time of $200,000. In
addition, Mr. Ackeret has covenanted, subject to substantial lapse under certain
circumstances, not to compete with Schein for a period of five years after the
termination of his employment, and, in consideration therefore, will receive the
sum of $255,000.
Geoffrey A. Reichardt's employment agreement provides for, among other
things, base salary at the rate of $185,000 per annum, subject to annual
increases, a signing bonus of $200,000, incentive compensation in accordance
with Schein's practices, options to purchase 10,000 shares of Schein Common
Stock, subject to vesting, at the Exercise Price, and a grant of shares of
Schein Common Stock, pursuant to a restricted stock agreement, with a fair
market value (determined in accordance with such agreement) at the Effective
Time of $75,000. In addition, Mr. Reichardt has covenanted, subject to
substantial lapse under certain circumstances, not to compete with Schein for a
period of three years after the termination of his employment, if such
termination is by Schein for cause or by Mr. Reichardt voluntarily, and twelve
months if such termination is other than for cause.
David A. Steck's Employment Agreement provides for, among other things,
base salary at the rate of $175,000 per annum, subject to annual increases, a
signing bonus of $195,000, incentive compensation in accordance with Schein's
practices, options to purchase 10,000 shares of Schein Common Stock, subject to
vesting, at the Exercise Price, and a grant of shares of Schein Common Stock,
pursuant to a restricted stock agreement, with a fair market value (determined
in accordance with such agreement) at the Effective Time of $75,000. In
addition, Mr. Steck has covenanted, subject to substantial lapse under certain
circumstances, not to compete with Schein for a period of three years after the
termination of his employment, if such termination is by Schein for cause or by
Mr. Steck voluntarily, and twelve months if such termination is other than for
cause.
Kenneth A. Schwing's Employment Agreement provides for, among other things,
base salary at the rate of $175,000 per annum, subject to annual increases, a
signing bonus of $195,000, incentive compensation in accordance with Schein's
practices, options to purchase 10,000 shares of Schein Common Stock, subject to
vesting, at the Exercise Price, and a grant of shares of Schein Common Stock,
pursuant to a restricted stock agreement, with a fair market value (determined
in accordance with such agreement) at the Effective Time of $75,000. In
addition, Mr. Schwing has covenanted, subject to substantial lapse under certain
circumstances, not to compete with Schein for a period of three years after the
termination of his employment, if such termination is by Schein for cause or by
Mr. Schwing voluntarily, and twelve months if such termination is other than for
cause.
44
Each of Timothy J. Sullivan and Kevin J. Ackeret will also enter into
agreements with Schein pursuant to which, if his employment is terminated by him
or Schein within two years after the occurrence of certain events involving a
change in control of Schein, he will be entitled to receive a lump sum payment
equal to (i) the product of the aggregate amount of base salary and car
allowance paid to him during the three months preceding such termination and the
number of months for which he was employed by Schein or Sullivan (with a maximum
benefit of 36 months' base salary and car allowance) and (ii) three times the
higher of his last annual bonus or his last bonus prior to the change in
control, but only to the extent that all such payments would not be subject to
an excise tax.
Pursuant to the Merger Agreement, Schein has agreed, for a period of not
less than six years after the Effective Time, to cause the Surviving Corporation
to indemnify, defend and hold harmless the present and former directors,
officers, employees and agents of Sullivan (each, an 'Indemnified Party')
against any and all losses, costs, damages, claims and liabilities (including
reasonable attorneys' fees) arising out of the Indemnified Party's service or
services as a director, officer, employee or agent of Sullivan or, if at
Sullivan's request, of another corporation, partnership, joint venture, trust or
other enterprise occurring at or prior to the Effective Time (including the
transactions contemplated by or related to the Merger Agreement) to the full
extent provided in Sullivan's Articles of Incorporation and By-laws, including
provisions relating to advances of expenses incurred in the defense of any
litigation, action, claim or proceeding and whether or not Schein or the
Surviving Corporation is insured against any such matter. Schein also agreed to
use its reasonable best efforts to maintain in effect, for at least six years
from the Effective Time in the case of claims made policies, directors' and
officers' liability insurance policies providing coverage in an aggregate amount
of at least $4,000,000 and with a carrier(s) having a rating of at least 'A' by
A.M. Best, an independent nationally recognized insurance publishing and rating
service, covering directors and officers of Sullivan serving as of or after
December 1, 1990 with respect to claims arising from occurrences prior to or at
the Effective Time (including the transactions contemplated by or related to the
Merger Agreement).
Howard O. Wolfe, a director and shareholder of Sullivan, and Kerry B.
Wolfe, a director and shareholder of Sullivan, are members of the law firm of
Wolfe, Wolfe & Ryd, which is Sullivan's general counsel. A portion of the legal
fees of Wolfe, Wolfe & Ryd for services provided in connection with the Merger
will be paid only upon consummation of the Merger.
OPERATIONS AFTER THE MERGER
At the Effective Time, Merger Sub will be merged with and into Sullivan,
and Sullivan, as the Surviving Corporation in the Merger, will become a wholly
owned subsidiary of Schein. Schein plans to cause Sullivan and the US Dental
Division to be managed as a single unit under the immediate direction of Timothy
Sullivan, Sullivan's President, and become part of the same consolidated tax
return group.
DIVIDENDS
Sullivan declared (and subsequently paid) a cash dividend of $.05 per share
on the Sullivan Common Stock for each of the first and second quarters of 1997
and each quarter of 1996, and paid one cash dividend of $.20 on the Sullivan
Common Stock during 1995. Except for a dividend paid in 1992 at the time of the
Reorganization (see 'SCHEIN--Reorganization'), Schein has never paid a cash
dividend on its Common Stock. Schein does not anticipate paying any cash
dividends on the Schein Common Stock in the foreseeable future; it intends to
retain its earnings to finance the expansion of its business and for general
corporate purposes. Following the Merger, any payment of dividends will be at
the discretion of Schein's Board of Directors and will depend upon the earnings,
financial condition, capital requirements, level of indebtedness, contractual
restrictions with respect to payment of dividends and other factors. Schein's
revolving credit agreement and a note issued in connection with Schein's
acquisition of a Netherlands company limit the distribution of dividends without
the prior written consent of the lenders.
45
TREATMENT OF SULLIVAN STOCK OPTIONS
At the Effective Time, each outstanding option to purchase Sullivan Common
Stock will be automatically assumed by Schein and converted into an option
('Converted Option') to purchase shares of Schein Common Stock in an amount and
at an exercise price determined by adjusting the original terms of the option to
reflect the Exchange Ratio.
As of the Record Date, there were outstanding options to purchase an
aggregate of approximately 1,674,825 shares of Sullivan Common Stock, excluding
options that will expire in accordance with their terms prior to the date of the
Sullivan Special Meeting. Assuming all such options were to remain outstanding
at the Effective Time, an aggregate of approximately 1,230,966 shares of Schein
Common Stock will thereafter be issuable upon the exercise of such Converted
Options.
Except as noted above, the terms and conditions of the Converted Options
will not be modified as a result of the Merger. Schein intends to register the
issuance of shares of Schein Common Stock pursuant to the exercise of the
Converted Options on Form S-8 upon the consummation of the Merger.
RIGHT OF THE SULLIVAN BOARD TO WITHDRAW RECOMMENDATION
Under the Merger Agreement, the Sullivan Board may not, among other things,
(i) withdraw or modify, in a manner adverse to Schein or Merger Sub, the
Sullivan Board's approval or recommendation of the Merger Agreement or the
Merger, (ii) approve or recommend any Acquisition Transaction, or (iii) cause
Sullivan to enter into any agreement with respect to any Acquisition
Transaction. Notwithstanding the foregoing, if the Sullivan Board determines in
its good faith reasonable judgment by a majority vote, after consultation with
Sullivan's financial advisor, that such Acquisition Transaction is more
favorable to the shareholders of Sullivan than the Merger and, based upon the
advice of outside counsel to Sullivan, that such action is required by its
fiduciary duties, the Sullivan Board may withdraw or modify its approval or
recommendation of the Merger Agreement or the Merger, approve or recommend an
Acquisition Transaction, or, subject to the payment of any applicable
Termination Fee, cause Sullivan to enter into an agreement with respect to an
Acquisition Transaction. The Merger Agreement requires Sullivan to provide
reasonable prior notice to Schein to the effect that it is taking such action.
If during the notice period Schein makes a counterproposal to such Acquisition
Transaction, Sullivan is obligated to consider such proposal in good faith.
REGULATORY FILINGS AND APPROVALS
Antitrust. The Merger is subject to the requirements of the HSR Act and
the rules and regulations thereunder, which provide that certain transactions
may not be consummated until required information and materials have been
furnished to the Antitrust Division and the FTC and certain waiting periods have
expired or been terminated. Schein and Sullivan filed the required information
and materials with the Antitrust Division and the FTC on August 19, 1997. Early
termination of the statutory waiting period under the HSR Act was granted on
September 16, 1997.
The Antitrust Division and the FTC frequently scrutinize the legality under
the antitrust laws of transactions such as the Merger. At any time before or
after the Effective Time, either the Antitrust Division or the FTC could take
such action under the antitrust laws as it deems necessary or desirable in the
public interest, or certain other persons could take action under the antitrust
laws, including seeking to enjoin the Merger.
RESALE OF SCHEIN COMMON STOCK RECEIVED IN THE MERGER
All Schein Common Stock received by holders of Sullivan Common Stock in the
Merger will have been registered under the Securities Act and will be freely
transferable, except that shares of Schein Common Stock received by persons who
are deemed to be affiliates of Sullivan (for purposes of Rule 145 promulgated by
the SEC under the Securities Act) prior to the Merger may be resold by them only
in transactions permitted by the resale provisions of Rule 145 promulgated under
the Securities Act (or Rule 144 in the case of such persons who become
affiliates of Schein) or as otherwise permitted by the Securities Act. Persons
who may be deemed to be affiliates of Sullivan or Schein, as the case may be,
generally include individuals or entities that control, are controlled by, or
are under common control with, such party and may include certain officers and
directors of
46
such party as well as principal stockholders of such party. The rights of
affiliates of Sullivan to receive Schein Common Stock in the Merger are
conditioned upon the execution by each of such affiliates of a written agreement
to the effect that such person will not offer or sell or otherwise dispose of
any of the Schein Common Stock issued to such person in the Merger either in
violation of the Securities Act or the rules and regulations promulgated
thereunder or at any time during the period beginning 30 days before the Merger
and ending when financial results covering at least 30 days of post-merger
operations of the combined entity have been published. The Schein Common Stock
received in the Merger by such affiliates will bear a restrictive legend to such
effect.
DESCRIPTION OF SCHEIN
GENERAL
Schein is the largest direct marketer of healthcare products and services
to office-based healthcare practitioners in the combined North American and
European markets. Schein has operations in the United States, Canada, the United
Kingdom, The Netherlands, Belgium, Germany, France, the Republic of Ireland and
Spain. Schein sells products and services to over 230,000 customers, primarily
dental practices and dental laboratories, as well as physician practices,
veterinary clinics and institutions. In 1996, Schein sold products to over 65%
of the estimated 100,000 dental practices in the United States. Schein believes
that there is strong awareness of the 'Henry Schein' name among office-based
healthcare practitioners due to its more than 60 years of experience in
distributing healthcare products. Through its comprehensive catalogs and other
direct sales and marketing programs, Schein offers its customers a broad product
selection of both branded and private brand products which include approximately
50,000 stock keeping units ('SKUs') in North America and approximately 40,000
SKUs in Europe at published prices that Schein believes are below those of many
of its competitors. Schein also offers various value-added products and
services, such as practice management software. As of December 28, 1996, Schein
had sold over 18,000 dental practice management software systems, more than any
of its competitors. On February 28, 1997, Schein acquired all of the outstanding
common stock of Dentrix Dental Systems, Inc., a leading provider of
clinically-based dental practice management systems, with 1996 net sales of
approximately $10.2 million and a 3,500 installed user base. On August 1, 1997,
Schein acquired all of the outstanding common stock of Micro BioMedics, Inc., a
distributor of medical supplies to physicians and other healthcare providers,
primarily in the Northeastern United States, with 1996 net sales of
approximately $150 million. Both of the aforementioned transactions were
accounted for as a pooling of interests.
During 1996 Schein distributed over 9.0 million pieces of direct marketing
materials (such as catalogs, flyers and order stuffers) to approximately 500,000
office-based healthcare practitioners. Schein supports its direct marketing
efforts with approximately 400 telesales representatives who facilitate order
processing and generate sales through direct and frequent contact with customers
and with over 300 field sales consultants. Schein utilizes database segmentation
techniques to more effectively market its products and services to customers. In
recent years, Schein has continued to expand its management information systems
and has established strategically located distribution centers in the United
States and Europe to enable it to better serve its customers and increase its
operating efficiency. Schein believes that these investments, coupled with its
broad product offerings, enable Schein to provide its customers with a single
source of supply for substantially all their healthcare product needs and
provide them with convenient ordering and rapid, accurate and complete order
fulfillment. Schein estimates that approximately 99% of all orders in the United
States and Canada received before 7:00 p.m. and 4:00 p.m., respectively, are
shipped on the same day the order is received and approximately 90% of orders
are received by the customer within two days of placing the order. In addition,
Schein estimates that approximately 99% of all items ordered in the United
States and Canada are shipped without back ordering.
Schein believes that there has been consolidation among healthcare products
distributors serving office-based healthcare practitioners and that this
consolidation will continue to create opportunities for Schein to expand through
acquisitions and joint ventures. In recent years, Schein has acquired or entered
into joint ventures with a number of companies engaged in businesses that are
complementary to those of Schein. Schein's acquisition and joint venture
strategies include acquiring additional sales that will be channeled through
Schein's existing infrastructure, acquiring access to additional product lines,
acquiring regional distributors with networks of field sales consultants and
international expansion. For information with respect to Schein's acquisitions
in
47
1996 and 1997, see 'SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITIONS AND RESULTS OF OPERATIONS--Recent Developments'.
REORGANIZATION
Schein was formed on December 23, 1992 as a wholly-owned subsidiary of
Schein Holdings, Inc. ('Schein Holdings'). At that time, Schein Holdings
conducted the business in which Schein is now engaged and owned 100% of the
outstanding capital stock of Schein Pharmaceutical, Inc. ('Schein
Pharmaceutical'), a company engaged in the manufacture and distribution of
multi-source pharmaceutical products.
In December 1992, Schein Holdings separated Schein's business from Schein
Pharmaceutical by transferring to Schein all of the assets and liabilities of
the healthcare distribution business now conducted by Schein, including Schein
Holdings' 50% interest in HS Pharmaceutical, Inc. ('HS Pharmaceutical'), a
manufacturer and distributor of generic pharmaceuticals (together with the
events described below, the 'Reorganization'). No other assets or liabilities,
including the assets and liabilities associated with Schein Pharmaceutical's
business, were transferred to Schein. In connection with the Reorganization,
Schein agreed to indemnify Schein Holdings for all of the liabilities assumed by
Schein, and Schein Holdings agreed to indemnify Schein for the liabilities
associated with Schein Pharmaceutical's business of manufacturing and
distributing generic pharmaceuticals. Other than certain common stockholders,
there is no affiliation between Schein and Schein Pharmaceutical, and all
transactions between Schein and Schein Pharmaceutical are on an arm's-length
basis.
In February 1994, Schein, Schein Holdings, Stanley M. Bergman, Marvin H.
Schein, Pamela Joseph, Pamela Schein, Steven Paladino, James P. Breslawski,
Martin Sperber (the Chief Executive Officer of Schein Pharmaceutical) and
certain other parties entered into a number of agreements as part of the
Reorganization (the 'Reorganization Agreements'). In September 1994, pursuant to
the Reorganization Agreements, all of the shares of Schein Common Stock held by
Schein Holdings was distributed to certain of the current stockholders of
Schein. Marvin H. Schein, Pamela Schein and Pamela Joseph have agreed to
severally indemnify Schein against certain potential costs and claims, if any,
which might be incurred by Schein in the future from the transactions related to
the Reorganization. Schein and Schein Pharmaceutical also agreed that, after
September 1994, Schein would be entitled to use the 'Henry Schein' name in
activities involving non-pharmaceutical products and pharmaceuticals for dental
and veterinary purposes, which activities may include marketing, distributing,
labeling, packaging, and manufacturing (such as HS Pharmaceutical's
manufacturing of generic pharmaceuticals and Schein Dental Equipment's
manufacturing of large dental equipment), which are the principal manufacturing
activities currently conducted by Schein, its subsidiaries and 50%-or-less owned
entities selling such products. Schein and Schein Pharmaceutical also agreed
that after September 1994, Schein Pharmaceutical would be entitled to use the
'Schein Pharmaceutical' name in similar activities involving pharmaceuticals for
non-dental human treatment. Schein Pharmaceutical is not permitted to use the
name 'Henry Schein.'
One of the Reorganization Agreements, a Voting Trust Agreement (the 'Voting
Trust'), gives Stanley M. Bergman (or his successor trustee), as Voting Trustee,
the right to vote all of the shares of Schein Common Stock owned by certain
stockholders of the Company, which will be approximately 15.6% of the
outstanding shares of Schein Common Stock immediately after the consummation of
the Merger. Another of the Reorganization Agreements, the Amended and Restated
HSI Agreement (the 'Global Agreement'), provides that the Schein Board consist
of up to 11 members, and that until the earlier of January 1, 1999 or the
termination of the Voting Trust, Mr. Bergman (or his successor trustee) has the
right to nominate all but three of the nominees to the Schein Board. Marvin H.
Schein, Pamela Joseph and Pamela Schein have the right to serve as or nominate
the remaining three directors. In general, from January 1, 1999 (at which time
the number of directors constituting the entire Schein Board will be reduced to
nine unless the first of the proposed Schein Certificate of Incorporation
Amendments are adopted), unless the Voting Trust has terminated prior thereto,
until the earlier of January 1, 2004 or the first date on which Marvin H. Schein
and his family group no longer beneficially own at least 25% of the outstanding
Schein Common Stock that they owned immediately after the Reorganization or the
date of certain changes in Schein management, Mr. Bergman (or his successor
trustee) has the right to nominate all of the nominees to the Schein Board,
provided, that if Marvin H. Schein does not approve such nominations, Mr.
Bergman (or his successor trustee) and Mr. Schein will each nominate four
nominees (of which one will be an independent nominee) and the ninth nominee
will be selected by the two independent nominees. As a result of
48
the foregoing, until December 31, 1998, Mr. Bergman, as a practical matter, will
be able to significantly influence all matters requiring stockholder approval,
including the election of directors, and until January 1, 2004, Mr. Bergman will
have the ability to significantly influence the election of all or a substantial
number of the directors of Schein.
The Global Agreement also requires the parties to the Voting Trust and
Marvin H. Schein to vote in favor of the individuals so nominated as first
described above until the earlier of January 1, 1999 or the termination of the
Voting Trust, and thereafter (assuming no prior termination of the Voting Trust)
to vote their shares in favor of the nominees of Stanley M. Bergman and, if
applicable, Marvin H. Schein, until January 1, 2004. The Voting Trust terminates
on December 31, 1998, but is subject to earlier termination if, among other
things, Stanley M. Bergman ceases to be employed by or serve as a director of
Schein (unless certain other members of current management are serving as senior
executives of Schein) or Schein consummates a business combination which results
in Marvin H. Schein (including his family members) owning less than 5% of the
voting securities of the surviving corporation.
The Global Agreement affords Marvin H. Schein or his designee the right to
serve on each committee of the Board of Directors to which the Schein Board has
delegated decision-making authority and the right to call a special meeting of
the Schein Board. The Global Agreement also limits Schein's ability to adopt a
stockholder rights plan or 'fair price amendment,' if such plan or amendment
would affect Marvin H. Schein or Pamela Schein (including their respective
family members), as long as Marvin H. Schein or Pamela Schein own certain
specified percentages of the outstanding Schein Common Stock. The Global
Agreement also limits the ability of Marvin H. Schein, Pamela Schein and Pamela
Joseph to participate in any solicitation of proxies or any election contest.
The Global Agreement places certain restrictions on the ability of the
parties thereto to transfer any of the shares of Common Stock owned by them and
further provides that Schein may not, prior to the earlier of December 31, 2003
or the first date on which neither Marvin H. Schein nor Pamela Schein (including
their respective family members) own at least 5% of the outstanding shares of
Common Stock; (i) issue in one or more private transactions securities having
more than 20% of the total votes that can be cast in any election of directors
of Schein without first offering Marvin H. Schein and Pamela Schein (including
their respective family members) the right to purchase such securities; (ii)
issue securities in connection with a business combination having more than 20%,
or resulting in a person owning more than 20%, of the total votes that can be
cast in any election of directors without the consent of Marvin H. Schein; or
(iii) issue preferred stock having the right to cast more than 20% of the total
votes that can be cast in any election of directors of Schein. In addition,
certain members of management have agreed not to transfer their shares until
November 3, 1998, subject to acceleration in Mr. Bergman's discretion.
Restrictions on the ability of stockholders to transfer their stock may make it
more difficult for a third party to acquire, or may discourage acquisition bids
for, Schein, and could limit the price that certain investors might be willing
to pay in the future for Schein Common Stock.
The Global Agreement provides that Schein will indemnify each of the other
parties to the Reorganization agreements, and their family groups, from damages
resulting from (i) claims asserted by third parties relating to the
Reorganization agreements and (ii) any material breach of a representation,
warranty or covenant made by Schein in any of the Reorganization agreements.
Marvin H. Schein has agreed to consult with Pamela Schein prior to the exercise
of certain of his rights of approval and consent under the Reorganization
agreements.
As described above in 'SCHEIN SPECIAL MEETING--Approval of the Schein
Certificate of Incorporation Amendments', Schein is proposing amendments to its
Certificate of Incorporation that would, among other things, allow the Schein
Board to increase the number of directors. If such amendment to the Schein
Certificate of Incorporation is adopted, it is anticipated that the parties to
the Voting Trust and the Global Agreement will amend such agreements to take
such amendment into account.
49
MANAGEMENT OF SCHEIN
DIRECTORS AND EXECUTIVE OFFICERS
The following table sets forth certain information regarding the current
directors and executive officers of Schein. As described above under 'SCHEIN
SPECIAL MEETING--Approval of the Schein Certificate of Incorporation
Amendments', if the proposed amendment to the Schein Certificate of
Incorporation relating to the Schein Board is adopted, the Schein Board intends
to appoint Robert J. Sullivan, the Chairman of the Board of Sullivan, and Bruce
J. Haber, an Executive Vice President of Schein and President of Schein's Micro
BioMedics subsidiary, to the Schein Board. Reference is made to the information
set forth therein for additional information about such individuals.
NAME AGE POSITION
- ------------------------------------------------ --- ------------------------------------------------
CORPORATE
Stanley M. Bergman.............................. 47 Chairman, Chief Executive Officer, President and
Director
James P. Breslawski............................. 43 Executive Vice President and Director
Bruce J. Haber.................................. 44 Executive Vice President and President of
Schein's Medical Group
Gerald A. Benjamin.............................. 45 Senior Vice President-Administration and
Customer Satisfaction and Director
Leonard A. David................................ 49 Vice President-Human Resources, Special Counsel
and Director
Diane Forrest................................... 50 Senior Vice President-Information Services and
Chief Information Officer
Stephen R. LaHood............................... 50 Senior Vice President-Distribution Services
Mark E. Mlotek.................................. 42 Vice President, General Counsel, Secretary and
Director
Steven Paladino................................. 40 Senior Vice President, Chief Financial Officer
and Director
BUSINESS UNITS
Larry M. Gibson................................. 50 President-Practice Management Technologies
Division
James W. Stahly................................. 49 President-North American Dental Group
Michael Zack.................................... 45 Senior Vice President-International Group
OTHER DIRECTORS
Barry J. Alperin................................ 57 Director
Pamela Joseph................................... 54 Director
Donald J. Kabat................................. 61 Director
Marvin H. Schein................................ 55 Founder, Schein Dental Equipment and Director
Irving Shafran.................................. 54 Director
BACKGROUND OF DIRECTORS AND EXECUTIVE OFFICERS
Stanley M. Bergman has been Chairman, Chief Executive Officer and President
since 1989, and a director of Schein since 1982. Mr. Bergman held the position
of Executive Vice President of Schein and Schein Pharmaceutical, Inc., from 1985
to 1989 and Vice President of Finance and Administration of Schein from 1980 to
1985. Mr. Bergman is a certified public accountant.
James P. Breslawski has been an Executive Vice President of Schein since
1990, with primary responsibility for the North American Dental Group, the
Veterinary Group and corporate creative services, and a director of Schein since
1990. Between 1980 and 1990, Mr. Breslawki held various positions with Schein,
including Chief Financial Officer, Vice President of Finance and Administration
and Controller. Mr. Breslawski is a certified public accountant.
50
Bruce J. Haber has been an Executive Vice President of Schein and President
of Schein's Medical Group since August 1, 1997, the date on which Schein
acquired Micro Bio-Medics, Inc. ('MBM'). Schein has agreed to use its reasonable
best efforts to cause Bruce Haber to be elected to Schein's Board of Directors.
Bruce Haber has been President of MBM since 1983 and a director of MBM since
1981.
Gerald A. Benjamin has been Senior Vice President of Administration and
Customer Satisfaction since 1993, including responsibility for the worldwide
human resource function, and has been a director of Schein since September 1994.
Prior to holding his current position, Mr. Benjamin was Vice President of
Distribution Operations of Schein from 1990 to 1992 and Director of Materials
Management of Schein from 1988 to 1990. Before joining Schein, Mr. Benjamin was
employed for 13 years in various management positions at Estee Lauder, where his
last position was Director of Materials Planning and Control.
Leonard A. David has been Vice President of Human Resources and Special
Counsel since January 1995. Mr. David held the office of Vice President, General
Counsel and Secretary from 1990 to 1995 and practiced corporate and business law
for eight years prior to joining Schein. Mr. David has been a director of Schein
since September 1994.
Diane Forrest joined Schein in 1994 as Senior Vice President of Information
Services and Chief Information Officer. Prior to joining Schein, Ms. Forrest was
employed by Tambrands Inc. as Vice President of Information Services from 1987
to 1994, KPMG Peat Marwick as Senior Manager in the management consulting
division from 1982 to 1987 and Nabisco Brands, Inc. as Corporate Manager of
Manufacturing Systems from 1978 to 1982.
Stephen R. LaHood joined Schein in 1992 as Senior Vice President of
Distribution Services and also responsible for purchasing. Prior to joining
Schein, Mr. LaHood was employed by Lex/Schweber Electronics Inc. as Vice
President of Operations and Quality from 1988 to 1991. Mr. LaHood also spent ten
years at Johnson & Johnson Products, Inc., where his last position was Manager
of Corporate Business Planning and thereafter, seven years at Schering-Plough
Corporation where his last position was Senior Director of Manufacturing
Operations.
Mark E. Mlotek joined Schein in December 1994 as Vice President, General
Counsel and Secretary, and became a director of Schein in September 1995. Prior
to joining Schein, Mr. Mlotek was a partner in the law firm of Proskauer Rose
LLP, counsel to Schein, specializing in mergers and acquisitions, corporate
reorganizations and tax law from 1989 to 1994.
Steven Paladino has been Senior Vice President and Chief Financial Officer
of Schein since 1993, and has been a director of Schein since 1992. From 1990 to
1992, Mr. Paladino served as Vice President and Treasurer and from 1987 to 1990
served as Corporate Controller of Schein. Before joining Schein, Mr. Paladino
was employed as a public accountant for seven years and most recently was with
the international accounting firm of BDO Seidman, LLP. Mr. Paladino is a
certified public accountant.
Larry M. Gibson joined Schein as President of the Practice Management
Technologies Division on February 24, 1997, concurrent with Schein's acquisition
of Dentrix. Before joining Schein, Mr. Gibson was Chairman and Chief Executive
Officer of Dentrix, which he founded in 1980. Prior to his employment with
Dentrix, Mr. Gibson was employed by Weidner Communication Systems from 1978.
James W. Stahly joined Schein in 1994 as President of the North American
Dental Group of Schein. Before joining Schein, Mr. Stahly was employed by Fox
Meyer Corporation for seven years where his last position was Senior Vice
President-Hospital and Alternate Care Sales. Prior to his employment with Fox
Meyer, Mr. Stahly spent 16 years at McKesson Drug Company.
Michael Zack has been responsible for the International Group of Schein
since 1989. Mr. Zack was employed by Polymer Technology (a subsidiary of Bausch
& Lomb) as Vice President of International Operations from 1984 to 1989 and by
Gruenthal GmbH as Manager of International Subsidiaries from 1975 to 1984.
Barry J. Alperin has been a director of Schein since May 1996. Mr. Alperin
has also been a private consultant since August 1995. Mr. Alperin served as a
director of Hasbro, Inc. from 1986 through May 1996 and as Vice Chairman of
Hasbro, Inc. from 1990 through July 1995. Mr. Alperin served as Co-Chief
Operating
51
Officer of Hasbro, Inc. from 1989 through 1990 and as its Senior Vice President
and Executive Vice President from 1985 through 1989. Mr. Alperin recently served
as Chairman of the Board for Toy Manufacturers of America, an industry trade
association. Mr. Alperin currently serves as a director for Seaman Furniture
Co., Inc. and K'nex Industries, Inc.
Pamela Joseph has been a director of Schein since September 1994. For the
past five years Ms. Joseph has been a self-employed artist, and is president of
MA Nose Studios, Inc. Ms. Joseph is also a trustee of Alfred University.
Donald J. Kabat has been a director of Schein since May 1996. From 1992
until the present, Mr. Kabat has served as President of D.K. Consulting
Services, Inc. and Chief Financial Officer of Central Park Skaters, Inc. From
1970 to 1992, Mr. Kabat was a partner in Andersen Consulting, an affiliate of
Arthur Andersen, LLP.
Marvin H. Schein has been a director of Schein since September 1994 and has
provided consulting services to Schein since 1982. Mr. Schein founded Schein
Dental Equipment and had been its President for more than 15 years. Prior to
founding Schein Dental Equipment, Mr. Schein held various management and
executive positions with Schein.
Irving Shafran has been a director of Schein since September 1994 and was
nominated by Pamela Schein as her designee for director of Schein. Mr. Shafran
has been an attorney in private practice for more than twenty-five years. From
1992 through mid-1995, Mr. Shafran was a partner in the law firm of Anderson
Kill Olick and Oshinsky, P.C.
Schein's Board of Directors is currently composed of eleven directors, six
of whom are employees of Schein. Directors serve until the next annual
stockholders' meeting or until their successors have been duly elected and
qualified.
52
DESCRIPTION OF SULLIVAN
Sullivan is a Wisconsin corporation that was originally incorporated as an
Illinois corporation in 1980. Sullivan distributes consumable dental supplies to
dentists using a marketing strategy which combines personal visits by sales
representatives with a catalog of competitively priced items. Sullivan believes
that its catalog includes substantially all of the product categories used in
general dentistry. Sullivan also sells, installs and services dental equipment
through 52 sales and service centers located throughout the United States.
Sullivan currently sells approximately 12,000 items, including aseptic
products, small equipment, hygiene supplies, impression materials, x-ray films,
composite restoratives, hand instruments, disposable paper and plastic bulk,
latex exam gloves and carbide burs. Sullivan's equipment lines include x-ray
units, patient chairs, imaging systems, instrument delivery systems, cabinetry,
operating lights, package items, sterilizers, film processors, vacuum systems
and intra-oral cameras. Most products are sold under trademarks and trade names
of suppliers. However, in the third quarter of 1994, Sullivan began instituting
a private label program to introduce Sullivan brand products. In 1996, Sullivan
had 325 Sullivan brand products resulting in private label sales of
approximately $12,270,000.
The following table shows the approximate percentages of net sales
contributed by sales category for each of the years indicated:
YEAR ENDED DECEMBER 31,
-----------------------
1996 1995 1994
----- ----- -----
Supplies............................................................. 65.9% 67.3% 68.1%
Equipment............................................................ 27.7 26.1 25.0
Repair service and parts............................................. 6.4 6.6 6.9
Total......................................................... 100.0% 100.0% 100.0%
Sales contributed by sales of equipment and sales of repair service and parts
have represented an increasing percentage of total sales over the past three
years, primarily as a result of a net increase of 20 in the number of equipment
sales and service centers operated by Sullivan during such period.
SALES AND SERVICE
Sullivan currently sells its products to approximately 40,000 customers.
Almost all of Sullivan's customers are individual dentists or dental practice
groups. Other types of customers include dental laboratories, schools and
governmental agencies. During 1996, no single customer accounted for as much as
1% of total sales.
Sullivan's sales force currently operates in 48 states. As of September 5,
1997, the sales organization consisted of 397 sales representatives, including
18 independent sales representatives. As of that date, Sullivan's work force
totaled 1,071 people. Sullivan's sales representatives work primarily on a
commission basis. Sullivan believes that all of its independent sales
representatives have income from sources other than Sullivan. Sullivan's
independent sales representatives are not employees of Sullivan.
SOURCES OF SUPPLY
Sullivan distributes selected items from substantially all major lines of
dental supplies and equipment. Sullivan does not, however, carry the full
selection of products offered by any single major dental supplies manufacturer.
Sullivan carefully limits the products which it sells to those likely to have
reasonably high turnover. Sullivan believes the products it carries account for
substantially all of the products categories used in general dentistry. Of the
approximately 385 vendors used by Sullivan, the largest accounted for less than
6% of products sold in 1996. Sullivan has no long-term purchase contracts, but
has experienced no difficulty in obtaining adequate quantities. For most of the
categories of products it distributes, Sullivan has more than one source of
supply. Sullivan attempts to minimize its investment in inventory by product
turnover analysis and times its purchases to take advantage of special pricing
programs available from time to time.
53
COMPARATIVE STOCK PRICES AND DIVIDENDS
Both the Schein Common Stock (symbol: HSIC), and the Sullivan Common Stock
(symbol: SULL) are admitted for trading on the Nasdaq National Market.
The following table sets forth the high and low sales prices per share of
the Schein Common Stock and the Sullivan Common Stock (on a historical and
equivalent per share basis) on the Nasdaq National Market on August 1, 1997, the
last trading day prior to public announcement of the signing of the Merger
Agreement:
HIGH LOW
---- ---
Schein Common Stock............................................................ $39 $37
Sullivan Common Stock.......................................................... 22 1/2 21 1/2
Equivalent share basis (1)..................................................... 28 5/8 27 3/16
- ------------------
(1) Equivalent share basis is determined by multiplying the applicable Schein
Common Stock price by 0.735 to reflect the terms of the Merger Agreement.
SCHEIN COMMON STOCK
The following table sets forth for the periods indicated the high and low
reported sales prices of the Schein Common Stock on the Nasdaq National Market
since November 3, 1995, the date of the commencement of Schein's initial public
offering:
HIGH LOW
---- ---
YEAR ENDED DECEMBER 30, 1995:
Fourth Quarter (from November 3, 1995)......................................... $29 1/2 $20 3/8
YEAR ENDED DECEMBER 28, 1996:
First Quarter.................................................................. 30 3/4 23 1/2
Second Quarter................................................................. 43 1/2 27 1/2
Third Quarter.................................................................. 40 1/4 31 1/4
Fourth Quarter................................................................. 41 1/4 32 3/4
YEAR ENDING DECEMBER 27, 1997:
First Quarter.................................................................. 39 24 1/2
Second Quarter................................................................. 37 26 7/8
Third Quarter (through September 18, 1997)..................................... 40 1/2 30 1/4
On September 17, 1997, there were approximately 450 holders of record of
Schein Common Stock. On August 1, 1997, the last full trading day before the
announcement of the Merger, the last reported sales price per share of Schein
Common Stock was $39.
Schein does not anticipate paying any cash dividends on the Schein Common
Stock in the foreseeable future; it intends to retain its earnings to finance
the expansion of its business and for general corporate purposes. Any payment of
dividends will be at the discretion of the Schein Board and will depend upon the
earnings, financial condition, capital requirements, level of indebtedness,
contractual restrictions with respect to payment of dividends and other factors.
Schein's revolving credit agreement and a note issued in connection with an
acquisition in The Netherlands limit the distribution of dividends without the
prior written consent of the lenders.
54
SULLIVAN COMMON STOCK
The following table sets forth, for the periods indicated, the high and low
sales prices of the Sullivan Common Stock as reported on the Nasdaq National
Market:
HIGH LOW
---- ---
YEAR ENDED DECEMBER 31, 1995:
First Quarter.................................................................. $16 3/4 $13 3/4
Second Quarter................................................................. 16 1/8 8 1/4
Third Quarter.................................................................. 11 1/8 8 1/2
Fourth Quarter................................................................. 10 5/8 9
YEAR ENDED DECEMBER 31, 1996:
First Quarter.................................................................. $12 1/4 $ 9 1/2
Second Quarter................................................................. 12 1/4 9 3/4
Third Quarter.................................................................. 11 1/2 9 7/8
Fourth Quarter................................................................. 13 7/8 11 1/8
YEAR ENDING DECEMBER 31, 1997:
First Quarter.................................................................. 16 12 3/4
Second Quarter................................................................. 19 13
Third Quarter (through September 18, 1997)..................................... 28 3/4 16 1/2
As of September 17, 1997, there were approximately 364 record holders of
Sullivan Common Stock. On August 1, 1997, the last full trading day prior to the
announcement of the Merger Agreement, the last reported sales price per share of
Sullivan Common Stock was $22-1/4. Cash dividends of $.05 were declared (and
subsequently paid) on the Sullivan Common Stock for each of the first two
quarters of 1997. Quarterly cash dividends of $.05 per share were paid on the
Sullivan Common Stock for 1996 and one dividend of $.20 per share was paid on
the Sullivan Common Stock for 1995. Prior to the consummation or termination of
the Merger Agreement, Sullivan may not pay any dividends without Schein's
consent, and it is not contemplated that any dividends will be paid.
55
UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL STATEMENTS
The following unaudited pro forma combined condensed financial statements
give effect to the Merger using the 'pooling of interests' method of accounting,
after giving effect to the pro forma adjustments described in the accompanying
notes. These unaudited pro forma combined condensed financial statements have
been prepared from, and should be read in conjunction with, the historical
consolidated (in the case of Schein) financial statements and notes thereto of
Schein and Sullivan, which are incorporated by reference in this Joint Proxy
Statement/Prospectus.
The unaudited pro forma combined condensed statements are presented for
illustrative purposes only and are not necessarily indicative of the operating
results or financial position that would have occurred had the Merger been
consummated at the dates indicated, nor is it necessarily indicative of future
operating results or financial position of the merged companies.
The Unaudited Pro Forma Combined Condensed Balance Sheet gives effect to
the Merger as if it had occurred on June 28, 1997, combining the balance sheets
of Schein at June 28, 1997 with that of Sullivan as of June 30, 1997. The
Unaudited Pro Forma Combined Condensed Statements of Operations give effect to
the Merger as if it had occurred at the beginning of the earliest period
presented, combining the results of Schein for each year in the three-year
period ended December 28, 1996 and the six-month period ended June 28, 1997 with
those of Sullivan for each year in the three-year period ended December 31, 1996
and the six-month period ended June 30, 1997.
As a result of the Merger, the merged companies will incur certain
acquisition and transition related costs in connection with consummating the
transaction and integrating the operations of Schein and Sullivan. The
acquisition and transition related costs consist principally of compensation
arrangement costs (sales force and certain senior management signing bonuses),
professional and registration fees, systems modification costs and other costs
associated with the integration of the two businesses resulting from the Merger.
While the exact timing, nature and amount of these acquisition and transition
related costs are subject to change, Schein anticipates that a one-time pre-tax
charge of approximately $16.0 million for direct incremental acquisition-related
costs will be recorded in the quarter in which the Merger is consummated.
The estimate is comprised of the following amounts:
(IN THOUSANDS)
--------------
Compensation arrangements.................................. $ 9,000
Professional services...................................... 4,500
Registration and other regulatory costs.................... 1,500
Taxes and other............................................ 1,000
--------------
$ 16,000
--------------
--------------
The direct incremental acquisition-related costs have been reflected as an
increase in accounts payable and accrued expenses in the Unaudited Pro Forma
Combined Condensed Balance Sheet as of June 28, 1997. The after-tax cost of this
anticipated charge ($13.2 million) has been reflected as a reduction in retained
earnings in the Unaudited Pro Forma Combined Condensed Balance Sheet as of June
28, 1997.
In addition to the one-time pretax charge of approximately $16.0 million
for direct incremental acquisition-related costs, Schein also expects to record
additional special costs associated with systems modifications and other
integration related charges after the Merger. Such pretax charges are currently
not estimable, but could be in the range of $6.0 million to $10.0 million. The
ultimate amount of such costs and the periods in which they will be charged to
expense will vary depending on a number of factors, including the timing and
extent of the integration of the businesses.
The unaudited pro forma combined condensed financial statements do not
reflect the special costs associated with systems modifications and other
integration related charges described above to be incurred during the remainder
of 1997 and thereafter, or any of the anticipated recurring expense savings.
56
UNAUDITED PRO FORMA COMBINED CONDENSED BALANCE SHEET
JUNE 28, 1997
(IN THOUSANDS)
HISTORICAL HISTORICAL PRO FORMA PRO FORMA
SCHEIN SULLIVAN ADJUSTMENTS COMBINED
---------- ---------- ----------- ---------
ASSETS
Current assets:
Cash and cash equivalents.............................. $ 20,298 $ 188 $-- $ 20,486
Accounts receivable, net............................... 163,327 37,388 -- 200,715
Inventories............................................ 118,199 41,650 -- 159,849
Deferred income taxes.................................. 7,056 973 -- 8,029
Other.................................................. 32,387 1,648 -- 34,035
---------- ---------- ----------- ---------
Total current assets................................ 341,267 81,847 -- 423,114
Property and equipment, net............................ 40,503 6,868 -- 47,371
Goodwill and other intangibles, net.................... 73,226 19,546 -- 92,772
Investments and other.................................. 29,757 145 -- 29,902
---------- ---------- ----------- ---------
$ 484,753 $ 108,406 $-- $ 593,159
---------- ---------- ----------- ---------
---------- ---------- ----------- ---------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses.................. $ 111,856 $ 23,173 $16,000 (2b) $ 148,229
(2,800)(2c)
Bank credit lines...................................... 7,395 -- -- 7,395
Current maturities of long-term debt................... 12,244 -- -- 12,244
---------- ---------- ----------- ---------
Total current liabilities........................... 131,495 23,173 13,200 167,868
Long-term debt......................................... 41,581 -- -- 41,581
Other liabilities...................................... 4,650 816 -- 5,466
---------- ---------- ----------- ---------
Total liabilities................................... 177,726 23,989 13,200 214,915
---------- ---------- ----------- ---------
Minority interest...................................... 2,448 -- -- 2,448
---------- ---------- ----------- ---------
Common stock........................................... 242 101 (27)(2a) 316
Additional paid-in capital............................. 256,648 41,168 (906)(2a) 296,910
Retained earnings...................................... 50,547 44,081 (13,200)(2b)(2c) 81,428
Treasury stock......................................... (1,156) (933) 933 (2a) (1,156)
Foreign currency translation adjustment................ (1,702) -- -- (1,702)
---------- ---------- ----------- ---------
Total stockholders' equity.......................... 304,579 84,417 (13,200) 375,796
---------- ---------- ----------- ---------
$ 484,753 $ 108,406 $-- $ 593,159
---------- ---------- ----------- ---------
---------- ---------- ----------- ---------
57
UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 28, 1997
(IN THOUSANDS, EXCEPT PER SHARE DATA)
HISTORICAL HISTORICAL PRO FORMA
SCHEIN SULLIVAN COMBINED
---------- ---------- ---------
Net sales.................................................................... $ 503,605 $ 128,392 $ 631,997
Cost of sales................................................................ 352,841 84,150 436,991
---------- ---------- ---------
Gross profit................................................................. 150,764 44,242 195,006
Selling, general and administrative expenses................................. 133,175 36,960 170,135
Merger costs................................................................. 4,353 -- 4,353
---------- ---------- ---------
Operating income............................................................. 13,236 7,282 20,518
Interest income (expense)--net............................................... (835) 488 (347)
Other--net................................................................... 80 (86) (6)
---------- ---------- ---------
Income before taxes on income, minority interest and equity in earnings of
affiliates................................................................. 12,481 7,684 20,165
Taxes on income.............................................................. 6,138 3,074 9,212
Minority interest in net (loss) of subsidiaries.............................. (129) -- (129)
Equity in earnings of affiliates............................................. 331 -- 331
---------- ---------- ---------
Net income................................................................... $ 6,803 $ 4,610 $ 11,413
---------- ---------- ---------
---------- ---------- ---------
Net income per common share (1).............................................. $ 0.28 $ 0.44 $ 0.36
---------- ---------- ---------
---------- ---------- ---------
Weighted average common and common equivalent shares outstanding (1)......... 23,997 10,521 31,730
---------- ---------- ---------
---------- ---------- ---------
58
UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 28, 1996
(IN THOUSANDS, EXCEPT PER SHARE DATA)
HISTORICAL HISTORICAL PRO FORMA
SCHEIN SULLIVAN COMBINED
---------- ---------- ----------
Net sales.................................................................. $ 840,122 $ 241,583 $1,081,705
Cost of sales.............................................................. 587,013 158,937 745,950
---------- ---------- ----------
Gross profit............................................................... 253,109 82,646 335,755
Selling, general and administrative expenses............................... 220,500 68,901 289,401
---------- ---------- ----------
Operating income........................................................... 32,609 13,745 46,354
Interest income (expense)--net............................................. (863) 482 (381)
Other--net................................................................. 771 214 985
---------- ---------- ----------
Income before taxes on income, minority interest and equity in
earnings of affiliates................................................... 32,517 14,441 46,958
Taxes on income............................................................ 11,343 5,776 17,119
Minority interest in net income of subsidiaries............................ 246 -- 246
Equity in earnings of affiliates........................................... 1,595 -- 1,595
---------- ---------- ----------
Net income................................................................. $ 22,523 $ 8,665 $ 31,188
---------- ---------- ----------
---------- ---------- ----------
Pro forma:
Historical net income.................................................... $ 22,523 $ 8,665 $ 31,188
Pro forma adjustment:
Provision for income taxes on previously untaxed earnings of
an acquisition........................................................ (1,197) -- (1,197)
---------- ---------- ----------
Pro forma net income....................................................... $ 21,326 $ 8,665 $ 29,991
---------- ---------- ----------
---------- ---------- ----------
Pro forma net income per common share(1)................................... $ 0.98 $ 0.91 $ 1.04
---------- ---------- ----------
---------- ---------- ----------
Pro forma weighted average common and common equivalent
shares outstanding(1).................................................... 21,794 9,523 28,793
---------- ---------- ----------
---------- ---------- ----------
59
UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 30, 1995
(IN THOUSANDS, EXCEPT PER SHARE DATA)
HISTORICAL HISTORICAL PRO FORMA
SCHEIN SULLIVAN COMBINED
---------- ---------- ---------
Net sales.................................................................... $ 623,302 $ 215,568 $ 838,870
Cost of sales................................................................ 427,448 141,753 569,201
---------- ---------- ---------
Gross profit................................................................. 195,854 73,815 269,669
Selling, general and administrative expenses................................. 174,867 62,465 237,332
Special charges.............................................................. 20,797 -- 20,797
---------- ---------- ---------
Operating income............................................................. 190 11,350 11,540
Interest income (expense)--net............................................... (5,283) 654 (4,629)
Other--net................................................................... 390 63 453
---------- ---------- ---------
Income (loss) before taxes on income, minority interest and equity in
earnings of affiliates..................................................... (4,703) 12,067 7,364
Taxes on income.............................................................. 5,126 4,827 9,953
Minority interest in net income of subsidiaries.............................. 509 -- 509
Equity in earnings of affiliates............................................. 1,537 -- 1,537
---------- ---------- ---------
Net income (loss)............................................................ $ (8,801) $ 7,240 $ (1,561)
---------- ---------- ---------
---------- ---------- ---------
Pro forma:
Historical net income (loss)............................................... $ (8,801) $ 7,240 $ (1,561)
Pro forma adjustments:
Special management compensation and professional fees...................... 20,797 -- 20,797
Tax effect of above........................................................ (1,174) -- (1,174)
Provision for income on previously untaxed earnings of
an acquisition.......................................................... (533) -- (533)
---------- ---------- ---------
Pro forma net income......................................................... $ 10,289 $ 7,240 $ 17,529
---------- ---------- ---------
---------- ---------- ---------
Pro forma net income per common share(1)..................................... $ 0.71 $ 0.77 $ 0.82
---------- ---------- ---------
---------- ---------- ---------
Pro forma weighted average common and common equivalent
shares outstanding(1)...................................................... 14,517 9,405 21,430
---------- ---------- ---------
---------- ---------- ---------
60
UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 1994
(IN THOUSANDS, EXCEPT PER SHARE DATA)
HISTORICAL HISTORICAL PRO FORMA
SCHEIN SULLIVAN COMBINED
---------- ---------- ---------
Net sales.................................................................... $ 490,834 $ 203,602 $ 694,436
Cost of sales................................................................ 344,868 133,985 478,853
---------- ---------- ---------
Gross profit................................................................. 145,966 69,617 215,583
Selling, general and administrative expenses................................. 131,009 57,247 188,256
Special charges.............................................................. 23,603 -- 23,603
---------- ---------- ---------
Operating income............................................................. (8,646) 12,370 3,724
Interest income (expense)--net............................................... (3,524) 358 (3,166)
Other--net................................................................... 542 35 577
---------- ---------- ---------
Income (loss) before taxes on income, minority interest and equity in
earnings of affiliates..................................................... (11,628) 12,763 1,135
Taxes on income (recovery)................................................... (1,630) 5,086 3,456
Minority interest in net income of subsidiaries.............................. 561 -- 561
Equity in earnings of affiliates............................................. 494 -- 494
---------- ---------- ---------
Net income (loss)............................................................ $ (10,065) $ 7,677 $ (2,388)
---------- ---------- ---------
---------- ---------- ---------
Pro forma:
Historical net income (loss)............................................... $ (10,065) $ 7,677 $ (2,388)
Pro forma adjustments:
Special management compensation and professional fees...................... 23,603 -- 23,603
Tax effect of above........................................................ (5,749) -- (5,749)
Provision for income taxes on previously untaxed earnings of
an acquisition.......................................................... (306) -- (306)
---------- ---------- ---------
Pro forma net income......................................................... $ 7,483 $ 7,677 $ 15,160
---------- ---------- ---------
---------- ---------- ---------
Pro forma net income per common share(1)..................................... $ 0.57 $ 0.82 $ 0.75
---------- ---------- ---------
---------- ---------- ---------
Pro forma weighted average common and common equivalent
shares outstanding(1)...................................................... 13,197 9,409 20,113
---------- ---------- ---------
---------- ---------- ---------
61
NOTES TO UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL STATEMENTS
(IN THOUSANDS)
NOTE 1--EXCHANGE RATIO
Under the Merger Agreement, each outstanding share of Sullivan Common Stock
will be converted into 0.735 shares of Schein Common Stock. This exchange ratio
was used in computing share and per share amounts in the accompanying unaudited
pro forma combined condensed financial statements.
NOTE 2--PRO FORMA ADJUSTMENTS
(a) A pro forma adjustment has been made to reflect the issuance of shares
in the exchange ratio stated in Note 1 above and the cancellation of Sullivan
treasury stock, in accordance with the Merger Agreement.
(b) A pro forma adjustment has been made for certain acquisition-related
costs and expenses including as described in the fourth paragraph under
'Unaudited Pro Forma Combined Condensed Financial Statements'.
(c) A pro forma adjustment has been made for the estimated tax effects of
the adjustments discussed in (b) above.
62
SCHEIN CONSOLIDATED SELECTED HISTORICAL FINANCIAL
INFORMATION AND OPERATING DATA
The following consolidated selected financial data with respect to Schein's
financial position and its results of operations for each of the five years in
the period ended December 28, 1996 set forth below has been derived from
Schein's audited consolidated financial statements, which have previously been
filed with the SEC. The related financial information for the six months ended
June 28, 1997 and June 29, 1996 have been derived from the unaudited statements
of Schein and, in Schein's opinion, include all adjustments (consisting of only
normal recurring adjustments) necessary for a fair presentation of the
information. The results for the six months ended June 28, 1997 are not
necessarily indicative of the results that may be expected for any other period.
The consolidated selected financial data presented below should be read in
conjunction with such audited consolidated financial statements and related
notes and the other information set forth in this Joint Proxy
Statement/Prospectus or incorporated by reference herein. See 'SCHEIN
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS'. The Selected Operating Data and Net Sales by Market Data presented
below have not been audited.
YEARS ENDED
------------------------------------------------------------------------
DECEMBER 28, DECEMBER 30, DECEMBER 31, DECEMBER 25, DECEMBER 26,
1996 1995 1994 1993 1992
------------ ------------ ------------ ------------ ------------
(IN THOUSANDS, EXCEPT PER SHARE AND SELECTED OPERATING DATA)
STATEMENT OF OPERATIONS DATA:
Net sales................................ $ 840,122 $ 623,302 $ 490,834 $ 417,838 $ 363,477
Cost of sales............................ 587,013 427,448 344,868 294,954 257,262
------------ ------------ ------------ ------------ ------------
Gross profit............................. 253,109 195,854 145,966 122,884 106,215
Selling, general and administrative
expenses.............................. 220,500 174,867 131,009 111,214 96,853
Special management compensation(1)....... -- 20,797 21,596 617 5,283
Special contingent consideration(2)...... -- -- -- 3,216 --
Special professional fees(3)............. -- -- 2,007 2,224 2,227
------------ ------------ ------------ ------------ ------------
Operating income (loss).................. 32,609 190 (8,646) 5,613 1,852
Interest income.......................... 2,558 552 251 856 1,210
Interest expense......................... (3,421) (5,835) (3,775) (3,228) (2,971)
Other income (expense)--net.............. 771 390 542 (634) 255
------------ ------------ ------------ ------------ ------------
Income (loss) before taxes on income
(recovery), minority interest and
equity in earnings of affiliates...... 32,517 (4,703) (11,628) 2,607 346
Taxes on income (recovery)............... 11,343 5,126 (1,630) 1,351 622
Minority interest in net income (loss) of
subsidiaries.......................... 246 509 561 318 (249)
Equity in earnings of affiliates......... 1,595 1,537 494 1,296 514
------------ ------------ ------------ ------------ ------------
Income (loss) before cumulative effect of
accounting change..................... 22,523 (8,801) (10,065) 2,234 487
Cumulative effect of accounting change... -- -- -- 1,891 --
------------ ------------ ------------ ------------ ------------
Net income (loss)..................... $ 22,523 $ (8,801) $ (10,065) $ 4,125 $ 487
------------ ------------ ------------ ------------ ------------
------------ ------------ ------------ ------------ ------------
PRO FORMA INCOME DATA(4):
Pro forma operating income............... $ 32,609 $ 20,987 $ 14,957
Pro forma net income..................... $ 21,326 $ 10,289 $ 7,483
Pro forma net income per common share.... $ 0.98 $ 0.71 $ 0.57
Pro forma average shares outstanding..... 21,794 14,517 13,197
SELECTED OPERATING DATA:
Number of orders shipped................. 3,079,000 2,630,000 2,275,000 2,044,000 1,824,000
Average order size....................... $ 273 $ 237 $ 216 $ 204 $ 199
63
YEARS ENDED
------------------------------------------------------------------------
DECEMBER 28, DECEMBER 30, DECEMBER 31, DECEMBER 25, DECEMBER 26,
1996 1995 1994 1993 1992
------------ ------------ ------------ ------------ ------------
(IN THOUSANDS, EXCEPT PER SHARE AND SELECTED OPERATING DATA)
NET SALES BY MARKET DATA(5):
Dental(6)................................ $ 435,643 $ 327,697 $ 274,337 $ 253,223 $ 234,655
Medical.................................. 191,186 125,565 89,789 71,021 51,923
Veterinary............................... 35,329 29,330 27,872 24,312 19,481
Technology(7)............................ 30,965 33,007 14,909 9,866 6,377
International(8)......................... 146,999 107,703 83,927 59,416 51,041
------------ ------------ ------------ ------------ ------------
$ 840,122 $ 623,302 $ 490,834 $ 417,838 $ 363,477
------------ ------------ ------------ ------------ ------------
------------ ------------ ------------ ------------ ------------
BALANCE SHEET DATA (AT PERIOD END):
Working capital.......................... $ 204,575 $ 104,455 $ 76,814 $ 74,167 $ 28,066
Total assets............................. 467,450 299,364 191,373 161,437 138,043
Total debt............................... 39,746 43,049 61,138 56,712 41,526
Redeemable stock(9)...................... -- -- 14,745 -- --
Minority interest........................ 5,289 4,547 1,823 1,051 411
Stockholders' equity..................... 292,016 143,865 40,266 43,896 39,927
SIX MONTHS ENDED
------------------------------
JUNE 28, 1997 JUNE 29, 1996
------------- -------------
STATEMENT OF OPERATIONS DATA:
Net Sales......................................................................... $ 503,605 $ 384,595
Gross Profit...................................................................... 150,764 116,426
Selling, general and administrative expenses...................................... 133,175 104,140
Merger and integration costs(10).................................................. 4,353 --
Operating income.................................................................. 13,236 12,286
Net income........................................................................ $ 6,803 $ 7,820
Net income per common share....................................................... $ 0.28
Average shares outstanding........................................................ 23,997
PRO FORMA INCOME DATA(11):
Pro forma net income.............................................................. $ 7,390
Pro forma net income per common share............................................. $ 0.37
Pro forma average shares outstanding.............................................. 19,957
NET SALES BY MARKET DATA(5):
Dental(6)......................................................................... $ 257,997 $ 200,378
Medical........................................................................... 121,532 81,522
Veterinary........................................................................ 20,057 17,512
Technology(7)..................................................................... 20,795 15,588
International(8).................................................................. 83,224 69,595
------------- -------------
$ 503,605 $ 384,595
------------- -------------
------------- -------------
BALANCE SHEET DATA (AT PERIOD END):
Working capital................................................................... $ 209,772
Total assets...................................................................... 484,753
Total debt........................................................................ 61,220
Minority interest................................................................. 2,448
Stockholders' equity.............................................................. 304,579
- ------------------
(1) Includes: (a) for 1995, non-cash special management compensation charges of
$17.5 million arising from final mark-to-market adjustments (reflecting an
increase in estimated market value from 1994 to the initial public offering
price of $16.00 per share of Schein Common Stock) for stock grants made to
an executive officer of Schein in 1992 and other stock issuances made to
certain other senior management of Schein (because of certain repurchase
features which expired with Schein's initial public offering), an
approximate
(Footnotes continued on next page)
64
(Footnotes continued from previous page)
$2.8 million non-cash special management compensation charge (also based on
the initial public offering price of $16.00 per share) relating to
compensatory options granted in 1995, and a cash payment of $0.5 million
for additional income taxes resulting from such stock issuances; (b) for
1994, non-cash special management compensation arising from accelerated
amortization of deferred compensation arising from the 1992 stock grants to
an executive officer of Schein of $17.3 million, which included a 1994
mark-to-market adjustment (because of the repurchase features referred to
above) of $9.1 million, due to the resolution, with the closing of the
Reorganization, of certain contingencies surrounding the issuance of the
stock grants, non-cash special management compensation charges of $1.6
million (net of prior accruals of approximately $1.9 million under an
executive incentive plan) arising from stock issuances to certain other
senior management of Schein, valued at $3.5 million, and cash payments for
income taxes of approximately $2.4 million resulting from these stock
issuances and $0.3 million for additional income taxes resulting from the
1992 stock grants; (c) for 1993, non-cash special management compensation
charges of $0.6 million in amortization of deferred compensation arising
from the 1992 stock grants; and (d) for 1992, cash payments of $5.3 million
for income taxes resulting from stock grants made to an executive officer
of Schein. See 'SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--Overview'.
(2) Includes $0.7 million paid in connection with an acquisition and $2.5
million resulting from the buyout of employees' rights to future income
contained in their employment agreements. See 'SCHEIN MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS--Overview.'
(3) Includes special professional fees incurred by Schein in connection with
the Reorganization. See 'SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS--Overview'.
(4) Reflects the pro forma elimination of special charges incurred in 1995 and
1994 for special management compensation of $20.8 million and $21.6
million, respectively, and special professional fees incurred in 1994 of
$2.0 million, arising from the Reorganization, and the related tax effects
of $1.2 million and $5.8 million for 1995 and 1994, respectively. See
'SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS--Overview'.
(5) Restated to conform to 1996 presentation.
(6) Dental consists of Schein's dental business in the United States and
Canada.
(7) Technology consists of Schein's practice management software business and
certain other value-added products and services.
(8) International consists of Schein's business (substantially all dental)
outside the United States and Canada, primarily in Europe.
(9) Redeemable stock includes stock issued for compensation which was subject
to repurchase by Schein at fair market value in the event of termination of
employment of the holder of such shares, as well as shares purchased by the
trust for Schein's ESOP and allocable to the ESOP participants. With the
completion of Schein's initial public offering, the stock issued for
compensation and the ESOP Common Stock were no longer subject to
repurchase. See 'SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--Overview'.
(10) During the six months ended June 28, 1997, Schein issued 1,916,866 shares
of Common Stock in connection with four acquisitions accounted for under
the pooling of interests method of accounting. In connection with these
acquisitions Schein incurred certain merger and integration costs of
approximately $4.4 million. Net of taxes, merger and integration costs were
approximately $0.17 per share. Merger and integration costs consist
primarily of investment banking, legal, accounting and advisory fees, as
well as certain other integration costs associated with these mergers.
(11) Reflects the pro forma provision for income taxes of $0.4 million on
previously untaxed earnings of an acquisition.
65
SCHEIN MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of Schein's consolidated financial
condition and consolidated results of operations should be read in conjunction
with Schein's consolidated historical financial statements and notes thereto.
See 'SCHEIN'S CONSOLIDATED SELECTED HISTORICAL FINANCIAL DATA'.
OVERVIEW
Schein's results of operations in recent years have been significantly
impacted by strategies and transactions undertaken by Schein to expand its
business, both domestically and internationally, in part to address significant
changes in the healthcare industry, including potential national healthcare
reform, trends toward managed care, cuts in Medicare, consolidation of
healthcare distribution companies and collective purchasing arrangements.
Schein's results of operations in recent years have also been impacted by the
Reorganization.
From 1992 through 1994, Schein was a party to a series of transactions
leading to the Reorganization that resulted in, among other things, Schein being
separated from Schein Holdings and the distribution of shares of the Schein
Common Stock to its then current stockholders. In December 1992, an executive
officer of Schein received certain stock grants in Schein and Schein
Pharmaceutical, Inc. valued at approximately $6.2 million and $2.6 million,
respectively, and cash of approximately $5.3 million to pay income taxes on the
stock grants received. These stock grants were subject to the occurrence of
certain future events, including the fulfillment of the employment term by the
executive officer. Accordingly, these stock grants, totaling $8.8 million, were
treated as deferred compensation while the cash payments were charged to
earnings as special management compensation in the year ended December 26, 1992.
During 1993, Schein amortized the deferred compensation relating to stock grants
by Schein to the executive officer resulting in a charge to earnings of $0.6
million. In 1994, the contingencies relating to the stock granted to the
executive officer were eliminated, such that these shares became fully vested.
Accordingly, deferred compensation of $8.8 million, less the 1993 amortization
of $0.6 million, plus a mark-to-market adjustment (because of certain repurchase
features) of approximately $9.1 million, along with a $0.3 million cash payment
for income taxes relating to the 1992 stock grants, was expensed in 1994 as
special management compensation.
In addition, in connection with the Reorganization, certain senior
management of Schein were issued shares of Schein Common Stock in 1994 and 1995
to extinguish an obligation under a pre-existing long-term incentive plan and to
provide them with an ownership interest in Schein. In connection with the
issuance of the shares, a cash payment for income taxes relating to such stock
issuances of approximately $2.4 million was paid. This cash bonus, plus $3.5
million, the fair value of the related stock issued, net of amounts accrued
under the long-term incentive plan of approximately $1.9 million, resulted in an
additional special management compensation charge to Schein of approximately
$4.0 million in 1994. Charges to earnings for the year ended 1995 related to a
mark-to-market adjustment (because of certain repurchase features) for stock
grants made to an executive officer of Schein and the stock issuances to other
members of senior management of approximately $17.5 million and cash payments of
$0.5 million for income taxes related to the stock issuances.
Additionally, Schein has granted certain employees options for shares of
Schein Common Stock, which became exercisable upon Schein's initial public
offering on November 3, 1995, at which time substantially all such options
vested. Non-recurring special compensation charges for the options issued to
employees recorded in the fourth quarter of 1995 amounted to approximately $2.8
million. In addition, Schein recorded an approximate $1.1 million related tax
benefit.
Special charges for special management compensation and special
professional fees incurred in connection with the Reorganization aggregated
$20.8 million and $23.6 million for 1995 and 1994, respectively.
RECENT DEVELOPMENTS
During the year ended December 28, 1996, Schein acquired seventeen
healthcare distribution businesses. The 1996 acquisitions included 10 dental and
three medical companies, a veterinary supply distributor and three international
dental companies, with aggregate net sales in their most recent fiscal years of
approximately $104.0 million. All of these acquisitions were accounted for using
the purchase method of accounting. The total amount of cash paid and promissory
notes issued for these acquisitions was approximately $33.4 million. Schein also
issued 155,183 shares of common stock in 1996 in connection with two of these
acquisitions. Operations of
66
these businesses have been included in the consolidated financial statements
from their respective acquisition dates. No single 1996 acquisition was
material.
In the six months ended June 28, 1997, Schein completed 11 acquisitions and
entered into definitive agreements for four additional acquisitions, of which
all subsequently closed. The acquisitions completed in the first six months of
fiscal 1997 included three medical and three dental supply companies with
aggregate net sales for their most recently completed fiscal years of
approximately $32.0 million and $17.1 million, respectively, two international
dental supply companies with aggregate net sales of approximately $5.3 million,
and three technology and value-added product companies with aggregate net sales
of approximately $20.3 million. Of the 11 completed acquisitions, four were
accounted for under the pooling of interests method and the remainder were
accounted for under the purchase method of accounting. The financial statements
have been restated to give retroactive effect to one of the pooling transactions
as the remaining three transactions were not material and have been included in
the consolidated financial statements from the beginning of the quarter in which
the acquisition occurred. The total amount of cash paid and promissory notes
issued in the acquisitions completed in the first half of fiscal 1997 that were
accounted for under the purchase method of accounting was approximately $22.2
million. The excess of the acquisition costs over the fair value of identifiable
net assets acquired for these acquisitions will be amortized on a straight-line
basis over a period not to exceed 30 years. Schein also issued 1,916,866 shares
of common stock in connection with the four pooling transactions.
Operations of the acquisitions completed in the first six months of fiscal
1997, accounted for under the purchase method of accounting, have been included
in the consolidated financial statements from their respective acquisition
dates. These acquisitions, together with the immaterial pooling transactions,
had net sales for the six months ended June 29, 1996 of approximately $26.5
million. No single acquisition completed in the six months ended June 28, 1997
was material.
Included in the transactions completed after June 28, 1997 is the
acquisition of Micro Bio-Medics, Inc. ('MBM'), which closed on August 1, 1997.
Pursuant to acquisition, MBM merged into a wholly-owned subsidiary of Schein and
each share of MBM common stock was converted into 0.62 shares of Schein Common
Stock. MBM distributes medical supplies to physicians and hospitals in the New
York metropolitan area, as well as to healthcare professionals in sports
medicine, emergency medicine, school health, industrial safety, government and
laboratory markets nationwide. MBM had net sales of approximately $150.0 million
and earnings of approximately $1.7 million for its fiscal year ended November
30, 1996.
In connection with the acquisitions accounted for under the pooling of
interests method of accounting, during the six and three months ended June 28,
1997, Schein incurred certain merger and integration costs of approximately $4.4
million and $1.8 million, respectively. Net of taxes, for the six and three
months ended June 28, 1997, merger and integration costs were approximately
$0.17 and $0.06 per share, respectively. Merger and integration costs consist
primarily of investment banking, legal, accounting and advisory fees, as well as
certain other integration costs associated with these mergers.
Excluding the merger and integration costs, net income and net income per
common share would have been $10.8 million and $0.45, respectively, for the six
months ended June 28, 1997, and $6.8 million and $0.28 respectively, for the
three months then ended.
Schein uses UPS for delivery of substantially all of its domestic orders.
In August 1997, the Teamsters' Union went on strike against UPS, thereby
substantially reducing UPS's ability to fulfill shipments of its customers'
orders. In order to maintain customer service levels, Schein had to make
alternative arrangements for its deliveries. The transportation costs associated
with the alternative arrangements for delivery were substantially higher than
that which would have been incurred if UPS had been able to fulfill
substantially all of Schein's domestic orders. In addition, Schein experienced
increases in other operating costs, primarily payroll, as a result of having to
sort customer orders for distribution to various regional couriers.
Additionally, after the strike payroll costs continued to run at rates higher
than would otherwise be expected for several days in order to handle inbound
freight that was backlogged as a result of the UPS strike. None of these
incremental costs incurred by Schein were passed along to its customers.
Schein currently estimates that it incurred approximately $1.0 million to
$2.0 million of additional one-time operating expenses during the third quarter
of 1997 as a result of the strike, which consisted primarily of incremental
freight and payroll costs. The UPS strike did not significantly impact sales.
Subsequently, freight and payroll costs returned to normal pre-strike levels.
67
RESULTS OF OPERATIONS
The following table sets forth for the periods indicated the percentage of
net sales by market of Schein and the percentage change in such items for the
six months ended June 28, 1997 and June 29, 1996 and for the years ended 1996,
1995 and 1994.
PERCENTAGE INCREASE
(DECREASE)
PERCENTAGE OF NET SALES ------------------------
----------------------------------------------------------------- SIX MONTHS
ENDED JUNE
SIX MONTHS ENDED YEARS ENDED 28, 1997 TO
-------------------- ------------------------------------------ SIX MONTHS
JUNE 28, JUNE 29, DECEMBER 28, DECEMBER 30, DECEMBER 31, ENDED JUNE 29, 1996 TO
1997 1996 1996 1995 1994 1996 1995
-------- -------- ------------ ------------ ------------ -------------- -------
NET SALES BY MARKET(1):
Dental(2).................. 51.3% 52.1% 51.8% 52.6% 55.9% 28.8% 32.9%
Medical.................... 24.1 21.2 22.8 20.1 18.3 49.1 52.3
Veterinary................. 4.0 4.6 4.2 4.7 5.7 14.5 20.5
Technology(3).............. 4.1 4.1 3.7 5.3 3.0 33.4 (6.2)
International(4)........... 16.5 18.0 17.5 17.3 17.1 19.6 36.5
------- ------- ------ ------ ------
100.0% 100.0% 100.0% 100.0% 100.0% 30.9 34.8
------- ------- ------ ------ ------
------- ------- ------ ------ ------
1995 TO
1994
-------
NET SALES BY MARKET(1):
Dental(2).................. 19.5%
Medical.................... 39.8
Veterinary................. 5.2
Technology(3).............. 121.4
International(4)........... 28.3
27.0
- ------------------
(1) Restated to conform to 1996 presentation.
(2) Dental consists of Schein's dental business in the United States and Canada.
(3) Technology consists of Schein's practice management software business and
certain other value-added products and services.
(4) International consists of Schein's business (substantially all dental)
outside the United States and Canada, primarily in Europe.
SIX MONTHS ENDED JUNE 28, 1997 COMPARED TO SIX MONTHS ENDED JUNE 29, 1996
Net sales increased $119.0 million, or 30.9%, to $503.6 million for the six
months ended June 28, 1997 from $384.6 million for the six months ended June 29,
1996. Schein estimates that overall approximately 16.0% of the increase was due
to internal growth, while the remaining 14.9% was due to acquisitions. Of the
$119.0 million increase, approximately $57.6 million represented a 28.8%
increase in Schein's dental business, $40.0 million represented a 49.1% increase
in its medical business, $13.6 million represented a 19.6% increase in its
international business, $2.6 million represented a 14.5% increase in Schein's
veterinary business and $5.2 million represented a 33.4% increase in its
technology business. The increase in dental net sales was primarily the result
of the continuing favorable impact of Schein's integrated sales and marketing
approach (which coordinates the efforts of its field sales consultants with its
direct marketing and telesales personnel), acquisitions, continued success in
Schein's target marketing programs and increased sales in the large dental
equipment market. The increase in medical net sales was primarily due to
acquisitions, increased net sales to renal dialysis centers and net sales to
customers enrolled in the AMA Purchase Link program. In the international
market, the increase in net sales was due equally to acquisitions and increased
unit volume growth. Unfavorable exchange rate translation adjustments resulted
in a net sales decrease of approximately $2.9 million dollars. Had net sales for
the international market been translated at the same exchange rates in effect
during 1996, net sales would have increased by an additional 4.2%. In the
veterinary market, the increase in net sales was primarily due to increased
account penetration with corporate accounts. The increase in technology sales
was primarily due to 1997 acquisitions.
Gross profit increased by $34.4 million, or 29.5%, to $150.8 million for
the six months ended June 28, 1997 from $116.4 million for the six months ended
June 29, 1996, while gross profit margin decreased to 29.9% from 30.3%. The
$34.4 million increase in gross profit was primarily due to increased sales
volume and acquisitions. The decrease in gross profit margin was primary due to
lower technology sales as a percentage of total net sales and other sales mix
changes.
Selling, general and administrative expenses increased by $29.1 million, or
28.0%, to $133.2 million for the six months ended June 28, 1997 compared to
$104.1 million for the six months ended June 29, 1996. Selling and shipping
express increased by $17.3 million, or 24.5%, to $87.9 million for the six
months ended June 28, 1997 from $70.6 million for the six months ended June 29,
1996. As a percentage of net sales, selling and shipping
68
expenses decreased 0.9% to 17.5% for the six months ended June 28, 1997 from
18.4% for the six months ended June 29, 1996. This decrease was primarily due to
leveraging of Schein's distribution infrastructure, partially offset by an
increase in selling expenses. General and administrative expenses increased
$11.8 million, or 35.2%, to $45.3 million for the six months ended June 28, 1997
from $33.5 million for the six months ended June 29, 1996, primarily as a result
of acquisitions. As a percentage of net sales, general and administrative
expenses increased 0.3% to 9.0% for the six months ended June 28, 1997 from 8.7%
for the six months ended June 29, 1996.
Other income (expense)-net decreased by $0.3 million, or 27.3%, to ($0.8)
million for the six months ended June 28, 1997 from ($1.1) million for the six
months ended June 29, 1996. This decrease was primarily due to a decrease in
average borrowings, which were partially paid off with proceeds from Schein's
follow-on offering in June 1996, combined with an increase in imputed interest
income arising from non-interest bearing extended payment term date.
For the six months ended June 28, 1997, Schein's effective tax rate was
49.2%. Excluding merger and integration costs, substantially all of which are
not deductible for income tax purposes, Schein's effective tax rate would have
been 38.4%. The difference between the effective tax rate and the federal
statutory rate relates primarily to state income taxes. For the six months ended
June 29, 1996, Schein's effective rate was 34.6%, and on a pro forma basis was
38.5%, which was higher than the federal statutory rate, primarily due to state
income taxes.
1996 COMPARED TO 1995
Net sales increased $216.8 million, or 34.8%, to $840.1 million in 1996
from $623.3 million in 1995. Of the $216.8 million increase, approximately
$107.9 million represented a 32.9% increase in Schein's dental business, $65.6
million represented a 52.3% increase in its medical business, $39.3 million
represented a 36.5% increase in its international business and $6.0 million
represented a 20.5% increase in Schein's veterinary business, offset by a $2.0
million, or 6.2%, decrease in its technology business. The dental net sales
increase was primarily the result of Schein's continued emphasis on its
integrated sales and marketing approach (which coordinates the efforts of its
field sales consultants with its direct marketing and telesales personnel),
expansion into the U.S. market for large dental equipment and acquisitions. Of
the approximately $65.6 million increase in medical net sales, approximately
$20.9 million, or 31.9%, represents incremental net sales to renal dialysis
centers, with the effects of acquisitions and increased outbound telesales
activity primarily accounting for the balance of the increase in medical net
sales. In the international market, the increase in net sales was due to
acquisitions, primarily in France, and increased account penetration in Germany
and the United Kingdom. Unfavorable exchange rate translation adjustments
resulted in a net sales decrease of approximately $4.4 million. Had net sales
for the International market been translated at the same exchange rates in
effect during 1995, net sales would have increased by an additional 4.1%. In the
veterinary market, the increase in net sales was due to the full year impact of
new product lines introduced in the fourth quarter of 1995, increased account
penetration and continued volume growth to customers of a veterinary-sponsored
purchasing service. As anticipated, net sales in Schein's technology group was
below last year's sales volume levels because of unusually high sales volume in
the fourth quarter of 1995 due to the introductory launch, at that time, of
Schein's Easy Dental(Registered) Plus For Windows(Registered) based product;
offset due to increase in sales of Dentrix software systems.
Gross profit increased by $57.2 million, or 29.2%, to $253.1 million in
1996, from $195.9 million in 1995, while gross profit margin decreased by 1.3%
to 30.1% from 31.4% for the same period. The decrease in gross profit margin was
primarily due to product mix as fewer high margin Easy Dental(Registered) Plus
for Windows(Registered) products were sold in 1996. Excluding gross profit
margin for Schein's technology group, which was 69.0% for 1996 as compared to
79.3% for 1995, gross profit margins were relatively unchanged at 28.6% for 1996
as compared to 28.7% for 1995.
Selling, general and administrative expenses increased by $45.6 million, or
26.1%, to $220.5 million in 1996 from $174.9 million in 1995. Selling and
shipping expenses increased by $38.2 million, or 33.6%, to $151.8 million in
1996 from $113.6 million in 1995. As a percentage of net sales, selling and
shipping expenses decreased 0.1% to 18.1 % in 1996 from 18.2% in 1995. The
decrease in selling and shipping expenses as a percentage of net sales was
primarily due to reductions in sales promotions offered by Schein's technology
group in conjunction with the introductory promotion of Easy Dental(Registered)
Plus for Windows(Registered) version which occurred
69
during 1995. These introductory promotional expenses represented 0.6% of net
sales in 1995. Excluding these expenses from 1995, selling and shipping
expenses, as a percentage of net sales, would have been 0.4% higher than last
year. This increase was due primarily to various promotional programs and
incremental field sales and marketing personnel. General and administrative
expenses increased $7.4 million, or 12.1%, to $68.7 million in 1996 from $61.3
million in 1995, primarily as a result of acquisitions. As a percentage of net
sales, general and administrative expenses decreased 1.6% to 8.2% in 1996 from
9.8% in 1995 due primarily to the relatively fixed nature of general and
administrative expenses when compared to the 34.8% increase in sales volume for
the same period.
Net interest expense decreased $4.4 million to $0.9 million in 1996 from
$5.3 million in 1995. This decrease primarily resulted from the use of the
proceeds of Schein's follow-on offering in June 1996 to reduce debt and an
increase in interest income arising from the temporary investment of proceeds in
excess of debt and imputed interest income arising from non-interest bearing
extended payment term sales, offset in part by an increase in average interest
rates.
For 1996, Schein's provision for taxes was $11.3 million, while the pre-tax
income was $32.6 million. The difference between Schein's effective tax rate and
the Federal statutory rate relates primarily to state income taxes offset by
tax-exempt interest on municipal securities. In 1995, Schein's provision for
taxes was $5.1 million, while the pre-tax loss was $4.7 million. The difference
between the tax provision and the amount that would have been recoverable by
applying the statutory rate to pre-tax loss was attributable substantially to
the non-deductibility for income tax purposes of the $17.5 million appreciation
in the value of the stock issued to an executive officer and other senior
management of Schein. On a pro forma basis, excluding special charges and
adjusting for a provision for taxes on the previously untaxed earnings of
Dentrix Dental Systems, Inc. (which Schein acquired in 1996) included in 1995's
results, taxes on income for 1995 were $6.8 million, resulting in an effective
tax rate of 42.5%. The difference between the pro forma effective tax rate and
the Federal statutory rate relates primarily to state income taxes and currently
non-deductible net operating losses of certain foreign subsidiaries, primarily
in France, which are not included in Schein's consolidated tax return.
In the fourth quarter of 1996, Schein made adjustments which increased net
income by approximately $2.4 million. These adjustments, which related
predominantly to estimated reserves for premium coupon redemptions, finance
charges receivable and income taxes, resulted from management's updated
evaluations of historical trends (reflecting changes in business practices and
other factors) and other assumptions underlying such estimates. The amounts of
such reserves in prior quarters were based on reasonable estimates reflecting
available facts and circumstances.
1995 COMPARED TO 1994
Net sales increased $132.5 million, or 27.0%, to $623.3 million in 1995
from $490.8 million in 1994. Of the $132.5 million increase, approximately $53.4
million represented a 19.5% increase in Schein's dental business, $35.8 million
represented a 39.8% increase in its medical business, $23.8 million represented
a 28.3% increase in its international business, $18.1 million represented a
121.4% increase in its technology business and $1.4 million represented a 5.2%
increase in Schein's veterinary business. The dental net sales increase, after
taking into consideration acquisitions, was primarily due to Schein's increase
in field sales consultants and telesales personnel, database marketing programs
and promotional activities. Of the approximately $35.8 million increase in
medical net sales, approximately $17.0 million, or 47.5%, represents incremental
net sales to renal dialysis centers, with the effects of acquisitions and
increased telesales personnel accounting for the other major increase in net
sales. In the international market, the increase in net sales was due to the
full year benefit of an acquisition made in France in July 1994, acquisitions
made in 1995, increased unit volume growth and favorable exchange rate
translation adjustments. The increase in net sales for Schein's technology
market was primarily the result of an increase in unit sales due to the release
of the new Windows(Registered) version of Easy Dental(Registered) Plus software
in December 1995 and substantial price increases. The increased pricing on the
Easy Dental(Registered) Plus software product was accompanied by substantial
sales promotions and related expense, offset by increased Dentrix software
sales. In the veterinary market, Schein now earns a commission on certain
products which the manufacturer now sells direct. Including those sales on a
basis similar to 1994, sales to the veterinary market would have increased by
approximately 19.0%.
70
Gross profit increased by $49.9 million, or 34.2%, to $195.9 million in
1995, from $146.0 million in 1994, while gross profit margin increased by 1.7%
to 31.4% from 29.7% for the same period. Of the 1.7% increase in gross profit
margin, approximately 24.9%, or 1.4%, was primarily attributed to increased
sales volume of Schein's Easy Dental(Registered) Plus software, which carried a
higher gross profit margin than other products sold by Schein. The higher net
sales volume for Schein's technology business, up 121.4% to $33.0 million from
$14.9 million for the same period last year, was primarily due to the release of
the new Windows(Registered) version of Easy Dental(Registered) Plus software,
which increased unit sales, coupled with substantial price increases. The
increased pricing on the Easy Dental(Registered) Plus software product was
accompanied with substantial sales promotions. The balance of the change in
gross profit margin was due to changes in product mix.
Selling, general and administrative expenses increased by $43.9 million, or
33.5%, to $174.9 million in 1995 from $131.0 million in 1994. Selling and
shipping expenses increased by $35.3 million, or 45.1%, to $113.6 million in
1995 from $78.3 million in 1994. As a percentage of net sales, selling and
shipping expenses increased 2.2% to 18.2% in 1995 from 16.0% in 1994. The
increase in selling and shipping expenses as a percentage of net sales was
primarily due to substantial sales promotions offered by Schein's technology
group in conjunction with the promotion of Easy Dental(Registered) Plus software
and the new Windows(Registered) version released in December 1995, which
accounted for approximately 0.9% of the 2.2% increase in selling and shipping
expenses as a percentage of net sales. The balance of the increase was due
primarily to various promotional programs and incremental field sales and
marketing personnel. General and administrative expenses increased $8.6 million,
or 16.3%, to $61.3 million in 1995 from $52.7 million in 1994, primarily as a
result of acquisitions. As a percentage of net sales, general and administrative
expenses decreased 0.9% to 9.8% in 1995 from 10.7% in 1994 due primarily to the
relatively fixed nature of general and administrative expenses when compared to
the 27.0% increase in sales volume for the same period.
Interest expense--net increased $1.8 million, or 51.4%, to $5.3 million in
1995 from $3.5 million in 1994. This increase was due to two factors: average
interest rates rose to 8.3% in 1995 from 6.4% in 1994, and Schein's
average borrowings increased by $11.6 million in 1995 as compared to 1994 as a
result of higher working capital requirements and financing of acquisitions.
Equity in earnings of affiliates increased by $1.0 million, or 200.0%, to
$1.5 million in 1995 from $0.5 million in 1994. This increase in equity in
earnings of affiliates was primarily due to an increase in earnings of one
unconsolidated affiliate which was the result of increased sales volume and the
acquisition of another unconsolidated affiliate during the fourth quarter of
1995.
In 1995, Schein's provision for taxes was $5.1 million, while the pre-tax
loss was $4.7 million. The difference between the tax provision and the amount
that would have been recoverable by applying the statutory rate to pre-tax loss
was attributable substantially to the non-deductibility for income tax purposes
of the $17.5 million appreciation in the value of the stock issued to an
executive officer and other senior management of Schein. On a pro forma basis,
to give effect to special charges, taxes on income for 1995 were $6.8 million,
resulting in an effective tax rate of 42.5%. The difference between the pro
forma effective tax rate and the Federal statutory rate relates primarily to
state income taxes and currently non-deductible net operating losses of certain
foreign subsidiaries, primarily in France, which are not included in Schein's
consolidated tax return. In 1994, the income tax recovery was $1.6 million,
while the pre-tax loss was $11.6 million. The effective tax rate of Schein for
1994 differed from the Federal statutory rate, primarily due to non-deductible
special charges of approximately $9.1 million arising from the appreciation in
the value of stock issued to an executive officer of Schein and currently
non-deductible net operating losses of certain foreign subsidiaries.
INFLATION
Schein's Management does not believe inflation had a material adverse
effect on the financial statements for the periods presented.
RISK MANAGEMENT
Schein has operations in the United States, Canada, the United Kingdom, The
Netherlands, Belgium, Germany, France, the Republic of Ireland and Spain. Each
of Schein's operations endeavors to protect its margins by using foreign
currency forward contracts to hedge the estimated foreign currency payments to
foreign
71
vendors. The total U.S. dollar equivalent of all foreign currency forward
contracts hedging vendor payments was $5.0 million as of the 1996 fiscal
year-end.
Schein considers its investment in foreign operations to be both long-term
and strategic. As a result, Schein does not hedge the long-term translation
exposure to its balance sheet. Schein experienced a negative translation
adjustment of $0.5 million in 1996 and a positive translation adjustment of $0.3
million in 1995, which adjustments were reflected in the balance sheet as an
adjustment to stockholders' equity. The cumulative translation adjustment at the
end of 1996 showed a net negative translation adjustment of $0.6 million.
Schein issues a Canadian catalog once a year with prices stated in Canadian
dollars; however, orders are shipped from Schein's United States warehouses
resulting in U.S. dollar costs for Canadian dollar sales. To minimize the
exposure to fluctuations in foreign currency exchange rates, Schein enters into
foreign currency forward contracts with major international banks and an
unconsolidated 50%--owned company to convert estimated monthly Canadian dollar
receipts into U.S. dollars. Schein usually enters into the forward contract
prior to the issuance of its Canadian catalog and for the expected life of the
catalog. As of December 28, 1996, Schein had 28 forward contracts outstanding
for the forward sale of 5.2 million Canadian dollars. The last of the contracts
expires on October 31, 1997; however, Schein anticipates entering into new
contracts in the normal course of its business.
Schein borrowed money in U.S. dollars under a term loan related to the
acquisition of Van den Braak, a Netherlands company. Schein loaned the proceeds
to Henry Schein B.V. in Netherland Guilders ('NLGs') with principal and interest
payable in NLGs. To minimize the resultant exposure to fluctuations in foreign
currency exchange rates between the U.S. dollar and The Netherland Guilder,
Schein entered into a series of foreign currency forward contracts to sell NLGs
for U.S. dollars. As of December 28, 1996, Schein had 5 contracts outstanding
for the forward sale of NLG 7.1 million. The last contract expires on October
31, 1997.
Schein entered into two interest rate swaps with major financial
institutions to exchange variable rate interest for fixed rate interest. The net
result was to substitute a weighted average fixed interest rate of 7.81% for the
variable LIBOR rate on $13.0 million of Schein's debt. The interest rate swaps
expire in October and November of 2001.
LIQUIDITY AND CAPITAL RESOURCES
Schein's principal capital requirements have been to fund (a) working
capital needs resulting from increased sales, extended payment terms on various
products and special inventory forward buy-in opportunities, (b) acquisitions,
and (c) capital expenditures. Since sales have traditionally been strongest
during the fourth quarter and special inventory forward buy-in opportunities
have traditionally been most prevalent just before the end of the year, Schein's
working capital requirements are generally higher from the end of the third
quarter to the end of the first quarter of the following year. Schein has
financed its business primarily through revolving credit facilities and stock
issuances.
Net cash used in operating activities for the six months ended June 28,
1997 of $15.4 million resulted primarily from a net increase in working capital
of $30.5 million offset, in part, by net income adjusted for non-cash charges
relating primarily to depreciation and amortization of $15.1 million. The
increase in working capital was primarily due to (i) a decrease in account
payable and other accrued expenses of $19.5 million resulting primarily from
payments to vendors for inventory purchased as part of Schein's year-end
inventory forward buy-in program and, (ii) a $18.9 million increase in accounts
receivable resulting from increased sales and extended payment terms, (iii) a
$2.5 million increase in other current assets, offset by a $10.5 million
decrease in inventory. Schein anticipates future increases in working capital as
a result of its continued sales growth.
Net cash used in investing activities for the six months ended June 28,
1997 of $18.6 million resulted primarily from cash outlays for acquisitions of
$13.1 million and capital expenditures of $5.4 million. Capital expenditures are
comparable with the prior year period as Schein continues developing new
computer systems as well as incurring expenditures for additional operating
facilities. Schein expects that it will continue to invest in excess of $10.0
million per year in capital projects to modernize and expand its facilities and
infrastructure systems.
Net cash provided by financing activities for the six months ended June 28,
1997 of $10.6 million resulted primarily from net cash borrowings on bank credit
lines partially offset by net payments on long-term debt.
72
A balloon payment of approximately $3.5 million is due on October 31, 1997
under a term loan associated with a foreign acquisition. In addition, with
respect to certain acquisitions and joint ventures, holders of minority interest
in the acquired entities or ventures have the right at certain times to require
Schein to acquire their interest at either fair market value or a formula price
based on earnings of the entity.
Pursuant to a stockholders' agreement, certain minority stockholders of a
subsidiary of Schein exercised their option to sell their shares in the
subsidiary to Schein. The value of the shares put to Schein was approximately
$11.8 million, of which approximately $3.2 million was paid for in cash, with
the remainder payable over two years in equal annual installments.
Schein's cash and cash equivalents as of June 28, 1997 of $20.3 million are
invested primarily in short-term bank deposits. These investments have staggered
maturity dates, none greater than three months, and have a high degree of
liquidity since the securities are actively traded in public markets.
Schein entered into an amended revolving credit facility on January 31,
1997 that increased its main credit facility from $65.0 million to $100.0
million, extended the facility termination to January 30, 2002 and reduced the
interest rate on Schein's borrowings under the facility. Borrowings under the
credit facility were $31.3 million at June 28, 1997. Certain of Schein's
subsidiaries have revolving credit facilities that total approximately $11.0
million under which $7.4 million has been borrowed at June 28, 1997.
Schein believes that its cash and cash equivalents, its anticipated cash
flow from operations, its ability to access public debt and equity markets, and
the availability of funds under its existing credit agreements will provide it
with sufficient liquidity to meet its currently foreseeable short-term and
long-term capital needs.
EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS
In February 1997, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 128 ('SFAS No. 128'), 'Earnings Per
Share.' SFAS No. 128 specifies the computation, presentation and disclosure
requirements for earnings per share. SFAS No. 128 is effective for periods
ending after December 15, 1997. The adoption of this statement is not expected
to have a material effect on Schein's consolidated financial statements.
In June 1997, the Financial Accounting Standards Board issued two new
disclosure standards. Results of operations and financial position will be
unaffected by implementation of these new standards.
Statement of Financial Accounting Standards No. 130 ('SFAS No. 130'),
Reporting Comprehensive Income, establishes standards for reporting and display
of comprehensive income, its components and accumulated balances. Comprehensive
income is defined to include all changes in equity except those resulting from
investments by owners and distributions to owners. Among other disclosures, SFAS
No. 130 requires that all items that are required to be recognized under current
accounting standards as components of comprehensive income be reported in a
financial statement that is displayed with the same prominence as other
financial statements.
Statement of Accounting Standards No. 131 ('SFAS No. 131'), Disclosures
about Segments of an Enterprise and Related Information, which supersedes SFAS
No. 14. Financial Reporting for Segments of a Business Enterprise, establishes
standards for the way that public enterprises report information about operating
segments in annual financial statements and requires reporting of selected
information about operating segments in interim financial statements issued to
the public. It also establishes standards for disclosures regarding products and
services, geographic areas and major customers. SFAS No. 131 defines operating
segments as components of an enterprise about which separate financial
information is available that is evaluated regularly by the chief operating
decision maker in deciding how to allocate resources and in assessing
performance.
Both of these new standards are effective for financial statements for
periods beginning after December 15, 1997 and require comparative information
for earlier years to be restated. Due to the recent issuance of these standards,
Schein's management has been unable to fully evaluate the impact, if any, they
may have on future financial statement disclosures.
73
SULLIVAN SELECTED HISTORICAL FINANCIAL INFORMATION
The following selected historical financial information with respect to
Sullivan's financial position and its results of operations for each of the five
years in the period ended December 31, 1996 set forth below has been derived
from the audited financial statements of Sullivan, which have previously been
filed with the SEC. The related financial information for the six months ended
June 30, 1997 and June 30, 1996 have been derived from the unaudited statements
of Sullivan and, in Sullivan's opinion, include all adjustments (consisting of
only normal recurring adjustments) necessary for a fair presentation of the
information. The results for the six-month period ended June 30, 1997 are not
necessarily indicative of the results that may be expected for the year ending
December 31, 1997. The selected financial information presented below should be
read in conjunction with such audited historical financial statements and
related notes and the other information set forth in this Joint Proxy
Statement/Prospectus or incorporated herein by reference. See 'SULLIVAN
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS'.
YEARS ENDED DECEMBER 31,
--------------------------------------------------------
1996 1995 1994 1993 1992
-------- -------- -------- -------- --------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
INCOME STATEMENT DATA:
Net sales.......................................... $241,583 $215,568 $203,602 $169,000 $118,022
Cost of sales...................................... 158,937 141,753 133,985 111,530 77,680
-------- -------- -------- -------- --------
Gross profit....................................... 82,646 73,815 69,617 57,470 40,342
Operating expenses................................. 68,901 62,466 57,247 47,362 31,486
-------- -------- -------- -------- --------
Operating income................................... 13,745 11,350 12,370 10,108 8,856
Interest expense................................... (279) (94) (6) (28) (72)
Other income, principally interest................. 975 811 399 95 216
-------- -------- -------- -------- --------
Income before provision for income taxes........... 14,441 12,067 12,763 10,175 9,000
Provision for income taxes......................... 5,776 4,827 5,086 3,999 3,555
-------- -------- -------- -------- --------
Net Income...................................... $ 8,665 $ 7,240 $ 7,677 $ 6,176 $ 5,445
-------- -------- -------- -------- --------
-------- -------- -------- -------- --------
Net income per common and common equivalent
share........................................... $ 0.91 $ 0.77 $ 0.82 $ 0.66 $ 0.60
Cash dividend per common share..................... $ 0.20 $ 0.20 -- -- --
Weighted average common shares..................... 9,523 9,405 9,409 9,415 9,049
BALANCE SHEET DATA (AT PERIOD END):
Working capital.................................... $ 54,201 $ 47,028 $ 45,536 $ 37,577 $ 32,217
Total assets....................................... 101,050 96,915 81,105 68,604 54,448
Short-term bank debt............................... -- 9,900 -- 2,600 1,000
Stockholders' equity............................... 76,459 62,453 57,617 49,274 42,319
74
SIX MONTHS ENDED
--------------------
JUNE 30, JUNE 30,
1997 1996
-------- --------
(IN THOUSANDS,
EXCEPT PER SHARE
DATA)
STATEMENT OF OPERATIONS DATA:
Net sales............................................................................... $128,392 $112,957
Cost of goods sold...................................................................... 84,150 74,439
-------- --------
Gross profit............................................................................ 44,242 38,518
Expenses:
Selling, shipping and warehouse...................................................... 21,872 19,375
General and administrative........................................................... 15,088 13,974
Interest and financing costs--net.................................................... (402) (212)
-------- --------
Total expenses..................................................................... 36,558 33,137
-------- --------
Income before provision for income tax.................................................. 7,684 5,381
Provision for income taxes.............................................................. 3,074 2,153
-------- --------
Net income.............................................................................. $ 4,610 $ 3,228
-------- --------
-------- --------
Earnings per common and common equivalent share......................................... $ 0.44 $ 0.35
-------- --------
-------- --------
Average number of shares used to compute earnings per
common and common equivalent share................................................... 10,521 9,351
-------- --------
-------- --------
BALANCE SHEET DATA (AT PERIOD END):
Dividends paid.......................................................................... $ 982 $ 452
Working capital......................................................................... $ 58,673 $ 49,002
Long-term debt (net of current maturities).............................................. -- --
Total assets............................................................................ 108,406 89,368
Stockholders' equity.................................................................... 84,417 64,300
75
SULLIVAN MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
SIX MONTHS ENDED JUNE 30, 1997 COMPARED TO SIX MONTHS ENDED JUNE 30, 1996
Net sales for the six months ended June 30, 1997 ('Current Period') were
$128,392,000, an increase of $15,435,000, or 13.7%, over the six months ended
June 30, 1996 ('Prior Period'). The $15,435,000 increase in net sales was
substantially due to increased unit sales and, to a lesser extent, price
increases. The growth in unit sales was generated largely by increased
penetration in existing markets.
Sales of dental supplies comprised 67.2% of net sales in the first half of
1997 versus 69.1% during the same period in 1996. Sales of dental equipment
constituted 26.5% of net sales in the Current Period versus 24.1% in the Prior
Period.
Gross profit rose $5,724,000, or 14.9%, in the first half of 1997, compared
to the same period last year, primarily as a result of increased sales. Gross
profit as a percentage of net sales increased in the Current Period to 34.5%
from 34.1% for the Prior Period primarily as a result of more efficient buying
programs and the equipment leasing operation that was developed in conjunction
with the acquisition of Omega Professional Services, Inc., a Utah based
equipment leasing company ('Omega').
Operating expenses for the Current Period rose $3,612,000, or 10.8%,
compared to the Prior Period but, more significantly, decreased as a percentage
of net sales to 28.8% from 29.5% over the same period last year. Of this
increase in operating expenses, $2,498,000 resulted from increased salaries and
commissions due to higher sales creating higher commissions.
Operating income in the Current Period increased from the Prior Period by
$2,112,000 to $7,282,000 due to the factors identified above. Interest expenses
decreased by $192,000 to $15,000 due to reduced use of Sullivan's credit line.
Net income increased by $1,382,000, or 42.8%, in the first half of 1997 as
compared to the same period last year. Net income per share increased to $.44
per share from $.35 per share during the Current Period compared to the Prior
Period. Such increases to net income and income per share are due to the factors
identified above.
FISCAL 1996 COMPARED TO FISCAL 1995
Net sales for the year ended December 31, 1996 were $241,583,000, an
increase of $26,015,000, or 12.1%, over 1995. The $26,015,000 increase in the
net sales in 1996 was substantially due to increased unit sales and, to a lesser
extent, price increases. The growth in unit sales was generated largely by
increased penetration into existing markets, the acquisitions of Mountain West
Dental Company, Inc. and Capitol Dental Supply, Inc. and, to a lesser extent, by
increased sales to existing customers. No individual customer accounted for more
than 1%, or single product accounted for more than 2% of net sales for 1996 or
1995.
Sales of dental supplies comprised 65.9% of net sales in 1996 compared to
67.3% in 1995. Sales of dental equipment constituted 27.7% of net sales in 1996
compared to 26.1% in 1995. Sales of repair service and parts constituted 6.4% of
net sales in 1996 versus 6.6% in 1995. The increase in the amount of equipment
sales as a percentage of net sales was substantially due to Sullivan's opening
of a net of six new Equipment Sales and Service Centers during 1996 (eight new
centers were opened and two were closed), an increase of fourteen new equipment
specialists from 1995 to 1996 as well as increased sales of intra-oral cameras.
Gross profit rose $8,831,000, or 12.0%, in 1996 compared to 1995, primarily
as a result of increased sales. Gross profit as a percentage of net sales
remained at 34.2% in 1996.
Operating expenses rose $6,436,000, or 10.3%, to $68,901,000 in 1996
compared to $62,465,000 in 1995 but, more significantly, decreased as a
percentage of net sales to 28.5% in 1996 from 29.0% in 1995. Of this increase in
operating expenses, $3,607,000 resulted from increased salaries and commissions
primarily due to higher sales generating higher commissions.
76
For the year ended December 31, 1996, operating income increased
$2,395,000, or 21.1%, due to increased sales and more focused management of
operating expenses. Interest expense increased by $185,000 to $279,000 for the
year ended December 31, 1996, primarily due to the increased use of Sullivan's
lines of credit in December of 1995 to increase inventories and the continued
use of those lines for a portion of 1996. The weighted average interest rate
paid in 1996 decreased to 6.4% from 7.0% in 1995, primarily due to fluctuations
in the federal funds rate.
The provisions for income taxes for 1996 increased $949,000, or 19.7%,
primarily due to higher profits. The provision for income taxes reflected an
effective rate of 40% for 1996 and 1995. Net income increased by $1,425,000, or
19.7%, in 1996 compared to 1995 and net income per share increased to $.91 per
share in 1996 from $.77 per share in 1995, primarily due to the factors
identified above.
FISCAL 1995 COMPARED TO FISCAL 1994
Net sales for the year ended December 31, 1995 were $215,568,000, an
increase of $11,965,000, or 5.9% over 1994. The $11,965,000 increase in net
sales in 1995 was substantially due to increased unit sales and, to a lesser
extent, price increases. The growth in unit sales was generated largely by
increased penetration in existing markets and the acquisition of Inglis Dental
Supply, Inc., a Fort Worth based dental supply and equipment company, and, to a
lesser extent, by increased sales to existing customers. No individual customer
accounted for more than 1%, or single product sold accounted for more than 2%,
of net sales for 1995 or 1994.
Sales of dental supplies comprised 67.3% of net sales in 1995 versus 68.1%
in 1994, with dental equipment sales and sales of repair service and parts
accounting for the balance in each year. Sales of dental equipment constituted
26.1% of net sales in 1995 versus 25.0% in 1994. Sales of repair service and
parts constituted 6.6% of net sales in 1995 versus 6.9% in 1994. The increase in
the amount of equipment sales as a percentage of net sales was substantially due
to Sullivan's opening or acquisition of four equipment sales and service centers
during 1995 as well as increased sales of intra-oral cameras.
Gross profit rose $4,198,000, or 6.0%, in 1995 compared to 1994, primarily
as the result of increased sales. Gross profit as a percentage of net sales
remained at 34.2% in 1995.
Operating expenses rose $5,217,000, or 9.1%, to $62,465,000 in 1995
compared to $57,248,000 in 1994 and increased as a percentage of net sales to
29.0% from 28.1% over the same period. Of this increase in operating expenses,
$2,473,000 resulted from increased salaries and commissions due to an increase
in sales creating higher commissions and salaries paid to new sales trainees and
support staff.
For the year ended December 31, 1995, operating income decreased from the
previous year by $1,020,000, or 8.2%, to $11,350,000 due to increases in
operating expenses. Interest expense increased by $88,000 to $94,000 for the
year ended December 31, 1995, primarily due to use of Sullivan's credit line to
build inventories at the new regional distribution center as well as year-end
purchases to avoid price increases and to satisfy Sullivan's buying commitments
to qualify for rebates from Sullivan's vendors. The weighted average interest
rate paid in 1995 rose to 7.0% from 6.5% in 1994, primarily due to an increase
in borrowing rates generally. Other income, consisting primarily of service
charges and investment income, increased by $412,000 in 1995 compared to 1994.
The provision for income taxes for 1995 decreased $259,000, or 5.1%,
primarily due to lower profits. The provision for income taxes reflected an
effective rate of 40.0% for 1995 compared to 39.9% in 1994. Net income decreased
by $437,000, or 5.7%, in 1995 compared to 1994, and net income per share
decreased from $.82 in 1994 to $.77 in 1995, primarily due to the factors
identified above.
LIQUIDITY AND CAPITAL RESOURCES
Sullivan, pursuant to a stock repurchase plan which authorized the purchase
of up to 500,000 shares, has to date repurchased 320,000 shares of its common
stock from the public at various prices with an average price of approximately
$9.66 per share, which repurchases total $3,091,253.
Sullivan had no short-term investments at June 30, 1997, compared to
$500,000 at December 31, 1996.
Accounts receivable of $37,388,000 at June 30, 1997, increased $2,295,000,
or 6.5%, compared to December 31, 1996.
77
Inventories increased $1,250,000, or 3.1%, from December 31, 1996.
Working capital at June 30, 1997 was $58,673,000, an increase of $4,472,000
over December 31, 1996, reflecting net income of $4,610,000 increased by stock
options exercised of $1,188,000, reduced by dividends of $998,000 and the
purchase of treasury stock of $553,000.
Cash and cash equivalents as of June 30, 1997 decreased by $363,000 from
December 31, 1996. Cash was used for equipment purchases ($1,120,000), purchase
of treasury stock ($553,000) and to pay dividends ($982,000) and was primarily
provided by operations ($1,086,000) and stock options exercised ($984,000).
Net cash provided by operating activities for the six months ended June 30,
1997, of $1,086,000 was primarily as a result of net income adjusted for
depreciation and bad debts offset by increases in accounts receivable, inventory
and prepaid expenses.
Other assets, net of amortization, as of June 30, 1997 increased $3,307,000
to $19,691,000 compared to $16,384,000 at December 31, 1996. This increase is
due to the goodwill attributable to the acquisition of Omega in the amount of
$2,814,000 and S.B. Service in the amount of $934,000 offset by the amortization
of goodwill and customer lists in the amount of $444,000.
Sullivan expects that the $23,000,000 of available lines of credit, against
which there were no borrowings as of June 30, 1997, together with internally
generated funds, is sufficient to meet its currently foreseeable short-term and
long-term liquidity and capital needs of Sullivan for the next twelve months.
On February 14, 1997, Sullivan purchased substantially all of the assets
and assumed certain liabilities of Omega in exchange for 200,000 shares of
common stock of Sullivan.
On February 21, 1997, Sullivan purchased substantially all of the assets
and assumed certain liabilities of S.B. Service, a Connecticut based
sterilization equipment repair company, in exchange for 65,000 shares of common
stock of Sullivan.
On March 20, 1997, Sullivan declared a cash dividend of $.05 per share for
shareholders of record on April 10, 1997, which dividend was paid on April 21,
1997.
On June 20, 1997, Sullivan declared a cash dividend of $.05 per share for
shareholders of record on July 10, 1997, which dividend was paid on July 21,
1997.
Sullivan uses UPS for delivery of substantially all of its orders. In
August 1997, the Teamsters' Union went on strike against UPS, thereby
substantially reducing UPS's ability to fulfill shipments of its customers'
orders. Accordingly, Sullivan had to make alternative arrangements for its
deliveries. The cost of the alternative means of delivery that Sullivan used
during the strike was incrementally higher than that which would have been
incurred if UPS had delivered substantially all of Sullivan's orders. However,
because a significant portion of Sullivan's orders were shipped in bulk to its
various sales and service centers and then delivered to its customers by the
local sales representatives, the overall effect of the UPS strike on Sullivan
was not material.
NEW ACCOUNTING PRONOUNCEMENTS
In February 1997, the Financial Accounting Standards Board (FASB) issued
Statements No. 128, 'Earnings Per Share' and No. 129, 'Disclosure of Information
About Capital Structure'. Also in June 1997, Statements No. 130, 'Reporting
Comprehensive Income' and No. 131, 'Disclosures About Segments of an Enterprise
and Related Information' were issued.
Statements No. 128 and 129 are effective for years ending after December
15, 1997 and Statements No. 130 and 131 are effective for years beginning after
December 15, 1997. Sullivan's management is in the process of evaluating the
accounting and disclosure effects, if any, of these statements.
78
TERMS OF THE MERGER AGREEMENT
The following description of certain provisions of the Merger Agreement is
only a summary and does not purport to be complete. This discussion is qualified
in its entirety by reference to the complete text of the Merger Agreement, which
is attached to this Joint Proxy Statement/Prospectus as Annex I and incorporated
by reference herein.
THE MERGER; EXCHANGE AND CONVERSION OF SHARES
Pursuant to and subject to the terms and conditions of the Merger
Agreement, at the Effective Time, the Merger Sub will be merged with and into
Sullivan. Sullivan will be the surviving corporation in the Merger (the
'Surviving Corporation'). Each outstanding share of Sullivan Common Stock shall
automatically be converted into the right to receive the Exchange Ratio, payable
upon the surrender of the certificates formerly representing such share of
Sullivan Common Stock. Any shares of Sullivan Common Stock that are held in
Sullivan's treasury shall be canceled and retired prior to the Effective Time
and no securities of Schein or other consideration shall be delivered in
exchange therefor.
Based on the number of shares of Sullivan Common Stock outstanding as of
the Sullivan Record Date, approximately 7,560,738 shares of Schein Common Stock
will be issued in the Merger (without taking into account the shares of Schein
Common Stock that will be issuable upon the exercise of options to purchase
shares of Sullivan Common Stock as described in '-- Treatment of Sullivan Stock
Options'), representing approximately 22% of the shares of Schein Common Stock
to be outstanding immediately after the Effective Time.
No fractional shares of Schein Common Stock will be issued in connection
with the Merger. If a holder of shares of Sullivan Common Stock would otherwise
be entitled at the Effective Time to a fraction of a share of Schein Common
Stock, such shareholder will be entitled to receive from the Exchange Agent an
amount in cash in lieu of such fractional share of Sullivan Common Stock,
determined by multiplying (i) the fractional interest to which such holder would
otherwise be entitled and (ii) the average of the per share closing prices for
Schein Common Stock on the Nasdaq National Market for the five trading days
immediately preceding the Effective Time. In no event shall a holder of Sullivan
Common Stock receive cash in lieu of fractional shares of Schein Common Stock in
an amount greater than the value of one full share of Schein Common Stock. The
payment of cash in lieu of fractional shares is solely for the purpose of
avoiding the expense and inconvenience to Schein of issuing fractional shares
and does not represent separately bargained-for consideration.
EXCHANGE OF SHARE CERTIFICATES
At the Effective Time, each Sullivan Certificate will represent solely the
right to receive the number of shares of Schein Common Stock (and the amount of
cash in lieu of any fractional share of Schein Common Stock) determined as
described above. Until shares of Sullivan Common Stock are converted into shares
of Schein Common Stock, such shares of Sullivan Common Stock will have no voting
rights with respect to matters considered by Schein's stockholders.
As soon as practicable after the Effective Time, Schein will cause the
Exchange Agent to mail or make available a notice and letter of transmittal to
each holder of record of shares of Sullivan Common Stock at the Effective Time,
specifying that delivery shall be effected, and risk of loss and title to the
Sullivan Certificates shall pass, only upon proper delivery of the Sullivan
Certificates to the Exchange Agent, and advising such record holder of the
procedures for surrendering to the Exchange Agent any Sullivan Certificates for
exchange.
Each holder of shares of Sullivan Common Stock so converted, upon surrender
to the Exchange Agent of one or more Sullivan Certificates for cancellation
together with a properly completed letter of transmittal, will be entitled to
receive (i) a certificate representing 0.735 of a share of Schein Common Stock
with respect to each share of Sullivan Common Stock and (ii) cash in lieu of any
fractional shares of Schein Common Stock, in an amount calculated as described
above after giving effect to any tax withholdings. In the event of a transfer of
ownership of Sullivan Common Stock which is not registered in the transfer
records of Sullivan, a certificate representing the proper number of shares of
Schein Common Stock may be issued to the transferee if the Sullivan Certificate
representing such Sullivan Common Stock is presented to the Exchange Agent,
accompanied by all
79
documents required to evidence and effect such transfer, and by evidence that
any applicable stock transfer taxes have been paid.
No dividends or other distributions declared on shares of Schein Common
Stock, if any, will be paid to any person entitled to receive certificates
representing shares of Schein Common Stock ('Schein Certificates') until such
person surrenders his, her or its Sullivan Certificates. Upon such surrender,
there shall be paid, without interest, to the person in whose name the Schein
Certificates shall be issued, any dividends and other distributions payable with
respect to such securities which have a record date after the Effective Time and
shall have become payable between the Effective Time and the time of such
surrender. It is not anticipated that Schein will pay cash dividends in the
foreseeable future. See 'COMPARATIVE STOCK PRICES AND DIVIDENDS.'
Six months after the Effective Time, the Exchange Agent shall deliver to
Schein all cash, Schein Certificates and other documents in its possession
relating to the Merger, and any holders of Sullivan Common Stock who have not
surrendered their certificates shall look only to Schein for any shares of
Schein Common Stock, any dividends or distributions thereon, and any cash in
lieu of fractional shares to which they are entitled. Notwithstanding the
foregoing, neither the Exchange Agent nor any party to the Merger Agreement
shall be liable to a holder of Sullivan Common Stock for any shares of Schein
Common Stock, any dividends or distributions thereon or any cash in lieu of
fractional shares delivered to a public official pursuant to applicable
abandoned property, escheat or other similar laws.
TREATMENT OF SULLIVAN STOCK OPTIONS
At the Effective Time, each outstanding option to purchase Sullivan Common
Stock shall be assumed by Schein and converted automatically into an option (a
'Converted Option') to purchase shares of Schein Common Stock in an amount, and
at an exercise price, determined as follows: (a) the number of shares of Schein
Common Stock to be subject to such converted option shall be equal to the
product of the number of shares of Sullivan Common Stock remaining subject to
the original option and the Exchange Ratio, provided that any fractional shares
of Schein Common Stock resulting from such multiplication shall be rounded down
to the nearest share; and (b) the exercise price per share of Schein Common
Stock under such converted option shall be equal to the exercise price per share
of Sullivan Common Stock under the original option divided by the Exchange
Ratio, provided that such exercise price shall be rounded down to the nearest
cent.
After the Effective Time, each Converted Option shall be exercisable and
shall vest upon the same terms and conditions as were applicable to the related
Sullivan stock option immediately prior to the Effective Time, except that all
references to Sullivan shall be deemed to be references to Schein. Schein shall
file with the SEC a registration statement on Form S-8 (or other appropriate
form) and shall take any action required under state securities 'blue sky' laws
for purposes of registering all shares of Schein Common Stock issuable after the
Effective Time upon exercise of the Converted Options.
Each vote by a holder of Sullivan Common Stock in favor of the Merger shall
be deemed to be a vote by such holder in favor of the conversion of the
outstanding options to purchase Sullivan Common Stock for the purposes of all
shareholder consent requirements under applicable law.
EFFECTIVE TIME
The Effective Time of the Merger, at which time the closing of the Merger
will occur and the conversion of the shares of Sullivan Common Stock will become
effective, will be the time of the filing of Articles of Merger with the
Wisconsin Department of Financial Institutions--Corporation Division, or at such
later time as is provided in the Articles of Merger. This filing will occur as
soon as practicable following the approval of the Merger Agreement and the Share
Issuance by the stockholders of Sullivan and Schein, respectively, and the
satisfaction or waiver of other conditions precedent set forth in the Merger
Agreement. The Effective Time is currently expected to take place on or about
November 12, 1997. See '--Termination Rights' and '--Conditions to the Merger'.
80
TERMINATION RIGHTS
1. The Merger Agreement may be terminated at any time prior to the
Effective Time by mutual consent of Sullivan, on the one hand, and of Schein, on
the other hand, or by either Sullivan or Schein, if:
(a) the Merger is not consummated before January 31, 1998, or the
approval of the stockholders of each of Sullivan and Schein shall not have
been obtained (unless such failure to consummate the Merger or to obtain
such stockholder approval is caused by the act or omission of the party
seeking to terminate the Merger Agreement, which act or omission
constitutes a breach of the Merger Agreement); provided, however, that the
Merger Agreement may be extended for up to 90 days by either party upon
written notice to the other party if the Merger has not been consummated
due to the failure to obtain HSR approval or any other required approval or
consent from a Governmental Entity (as defined in the Merger Agreement),
but only if no permanent injunction or other order of a Governmental Entity
shall have been issued and the failure of such conditions to be satisfied
shall not have been caused by a breach of the Merger Agreement by the party
seeking the extension; or
(b) there is any permanent injunction or action by any Governmental
Entity of competent authority preventing consummation of the Merger which
has become final and nonappealable (provided that the party seeking to
terminate the Merger Agreement has used all reasonable efforts to remove
such injunction or overturn such action); or
(c) there is a breach of any covenant or a breach of any
representation or warranty in the Merger Agreement on the part of the
other, which breach of representation or warranty, individually or together
with all other such breaches, materially and adversely affects the
financial condition, results of operations, assets, liabilities or
properties of the breaching party; or
(d) there is a breach in any material respect of any of the covenants
or agreements set forth in the Merger Agreement which is not cured within
30 business days following receipt by the breaching party of notice of such
breach.
2. The Merger Agreement may be terminated by Sullivan if:
(a) such termination is necessary to allow Sullivan to enter into an
Acquisition Transaction (as defined below in '--No Solicitation of Other
Offers') with any Acquiring Person. Sullivan may enter into such
Acquisition Transaction only if: (i) the Sullivan Board determines in good
faith, by a majority of vote, after consultation with its financial
advisor, Cleary Gull, that the Acquisition Transaction is more favorable to
the shareholders of Sullivan than the Merger and, based upon the advice of
outside counsel to Sullivan, that such action is required by the fiduciary
duties of the Board of Directors; and, (ii) prior to taking such action,
Sullivan provides at least five business days' prior written notice to
Schein. During such notice period, Sullivan is obligated to consider in
good faith any counterproposal to the Acquisition Transaction made by
Schein (see 'No Solicitation of Other Offers'); or
(b) the Schein Special Meeting is canceled or is otherwise not held
prior to January 31, 1998 (or such later date to which the date for
termination of the Merger Agreement has been extended in accordance with
the terms thereof) except as a result of a judgment, injunction, order or
decree of any competent authority or events or circumstances beyond the
reasonable control of Schein.
3. The Merger Agreement may be terminated by Schein if:
(a) the Board of Directors of Sullivan (i) withdraws or amends or
modifies in a manner adverse to Schein or Merger Sub its recommendation or
approval in respect of the Merger Agreement or the Merger, (ii) makes any
recommendation with respect to an Acquisition Transaction other than a
recommendation to reject such Acquisition Transaction, or (iii) directly or
indirectly solicits, initiates, facilitates or encourages any inquiries or
the making of any proposal with respect to an Acquisition Transaction, or
enters into any agreement with respect to such Acquisition Transaction or
which would require it to abandon, terminate or fail to consummate the
Merger or any transaction contemplated by the Merger Agreement; or
(b) any corporation, partnership, person or other entity or group (an
'Acquiring Person'), other than Schein or any affiliate or subsidiary of
Schein, becomes the beneficial owner of more than 20% of the
81
outstanding voting equity of Sullivan (either on primary or a fully diluted
basis); provided, however that 'Acquiring Person' shall not include any
corporation, partnership, person, other entity or group which beneficially
owns as of August 3, 1997 (either on a primary or fully diluted basis) more
than 20% of the outstanding voting equity of Sullivan and which has not
after August 3, 1997 increased such ownership percentage by more than an
additional 1% of the outstanding voting equity of Sullivan (either on a
primary or fully diluted basis); or
(c) any other Acquisition Transaction occurs with any Acquiring Person
other than Schein, or any affiliate or subsidiary of Schein; or
(d) the Sullivan Special Meeting is canceled or is otherwise not held
prior to January 31, 1998 (or such later date to which the date for
termination of the Merger Agreement has been extended in accordance with
the terms thereof) except as a result of a judgment, injunction, order or
decree of any competent authority or events or circumstances beyond the
reasonable control of Sullivan.
4. Upon termination, the Merger shall be deemed abandoned and the Merger
Agreement shall become void and have no effect, and there shall be no liability
thereunder on the part of Schein, Merger Sub or Sullivan, except as provided
below:
(a) the provisions governing confidentiality of information, expenses
and recruitment shall survive any termination of the Merger Agreement;
(b) if Schein terminates the Merger Agreement under the circumstances
described in paragraph 1(c), 1(d) or 3(d) above, then Sullivan shall pay to
Schein, as liquidated damages and not as a penalty, seven million dollars;
if Sullivan terminates the Merger Agreement under the circumstances
described in paragraph 1(c), 1(d) or 2(b) above, then Schein shall pay to
Sullivan, as liquidated damages and not as a penalty, seven million
dollars.
(c) if (i) Schein terminates the Merger Agreement in the circumstances
described in paragraphs 3(a), 3(b), or 3(c) above, or (ii) either (x)
Sullivan terminates the Merger Agreement under the circumstances described
in paragraph 1(a) above, or (y) Schein terminates the Merger Agreement
under the circumstances described in paragraph 1(c), 1(d) or 3(d) above and
within six months after any such termination Sullivan enters into a
definitive agreement for or has consummated an Acquisition Transaction, or
(z) Sullivan terminates the Merger Agreement under the circumstances
described in paragraph 2(a) above, then Sullivan shall promptly pay Schein
a termination fee of twelve million dollars; provided, however, that any
liquidated damage amounts previously paid by Sullivan to Schein (described
in paragraph 4(b) above) shall be credited against such termination fee.
CERTAIN FEES AND EXPENSES
Except as provided in 'Termination Rights' above, whether or not the Merger
is consummated, all costs and expenses incurred in connection with the Merger
Agreement and the transactions contemplated thereby shall be paid by the party
incurring such costs and expenses, except that (i) the filing fee in connection
with filings under the HSR Act by Schein or Sullivan shall be the expense solely
of Schein and (ii) the expenses incurred in connection with printing the Joint
Proxy Statement/Prospectus and the Registration Statement and the filing fee
with the SEC relating therewith will be shared equally by Schein and Sullivan.
CONDITION TO THE MERGER
The parties' obligations to effect the Merger are subject to the
satisfaction or waiver at or prior to the Effective Time of various conditions,
including: (i) approval and adoption of the Merger Agreement by the requisite
holders of the Sullivan Common Stock and of the Share Issuance by the holders of
the Schein Common Stock in accordance with applicable law; (ii) any waiting
period (and any extension thereof) under the HSR Act applicable to the Merger
having expired or been terminated; (iii) no preliminary or permanent injunction
or other order having been issued by any court or by any governmental or
regulatory agency, body or authority which enjoins, restrains or prohibits the
consummation of the Merger or has the effect of making the Merger illegal and
which is in effect at the Effective Time (each party has agreed to use its best
efforts to have any such injunction or order lifted); (iv) the absence of any
statute, rule, regulation, executive order, decree or order of any kind
82
which prohibits the consummation of the Merger or has the effect of making the
Merger illegal; (v) the authorization of the shares of Schein Common Stock
issuable to the holders of Sullivan Common Stock for listing on the Nasdaq
National Market; (vi) the effectiveness of the Registration Statement and the
absence of any stop order or proceeding for a stop order; (vii) other than the
filing of Merger documents in accordance with the WBCL, all authorizations,
consents or waivers having been obtained from any government bodies and
authorities which are required in order to consummate the Merger and the other
transactions contemplated by the Merger Agreement, the failure of which to
obtain would have a material adverse effect on the condition (financial or
otherwise) of Schein and its subsidiaries taken as a whole after giving effect
to the Merger; Schein shall have received all state securities or 'blue sky'
permits and other authorizations necessary to issue the shares of Schein Common
Stock; and (viii) no general suspension or limitation of trading having been
imposed on Schein Common Stock or on securities generally on the Nasdaq National
Market;
Further conditions precedent to the obligations of Schein and Merger Sub to
effect the Merger are: (i) the representations and warranties of Sullivan being
true and correct in all material respects, except to the extent that the
aggregate effect of all inaccuracies in the representations and warranties of
Sullivan does not and would not reasonably be expected to have a material
adverse effect on the value of Sullivan; (ii) the performance in all material
respects of all obligations of Sullivan contained in the Merger Agreement to be
performed by it at or prior to the Effective Time; (iii) all persons who are
'affiliates' of Sullivan for purposes of Rule 145 under the Securities Act
having delivered a written agreement in form and substance satisfactory to
Schein with respect to Rule 145 of the Securities Act and the pooling of
interests requirements; (iv) Schein having received opinions from BDO Seidman,
LLP and Deloitte & Touche LLP, stating that the Merger qualifies for 'pooling of
interests' treatment for financial reporting purposes in accordance with GAAP;
(v) Schein having received an opinion in form and substance satisfactory to it
from Proskauer Rose LLP, counsel to Schein, to the effect that the Merger will
be treated for United States Federal income tax purposes as a reorganization
with the meaning of Section 368(a) of the Code; (vi) Schein and Merger Sub
having received letters of resignation addressed to Sullivan from the members of
Sullivan's board of directors, which resignations shall be effective as of the
Effective Time; and (vii) Schein having received the opinion of Wolfe, Wolfe &
Ryd.
Further conditions precedent to the obligations of Sullivan to effect the
Merger are: (i) the representations and warranties of Schein being true and
correct in all material respects, except to the extent that the aggregate effect
of all inaccuracies in the representations and warranties of Schein having no
material adverse effect on the value of Schein, and (ii) the performance in all
material respects of all obligations of Schein and Merger Sub contained in the
Merger Agreement to be performed by it at or prior to the Effective Time; and
(iii) Sullivan having received the opinion of Proskauer Rose LLP.
REPRESENTATIONS AND WARRANTIES
The Merger Agreement contains various customary representations and
warranties relating to, among other things, (i) each of Sullivan's and Schein's
organization, capital structure and similar corporate matters, (ii) the
financial statements of each of Sullivan and Schein, (iii) the authorization of
the Merger Agreement by each of Sullivan and Schein and related matters, (iv)
the absence of any conflicts or defaults under charters or by-laws, receipt of
required consents or approvals, and absence of violations of any instruments or
law, (v) documents filed by Sullivan and Schein with the SEC and the accuracy of
information contained therein, (vi) the absence of a material adverse change in
the properties, assets, liabilities, results of operations or condition of
Sullivan and its subsidiaries taken as a whole and Schein and its subsidiaries
taken as a whole, each since certain specified dates, (i) Employee Benefit Plans
and ERISA matters, (ii) certain environmental matters, (iii) litigation, (iv)
compliance with law, (v) the stockholders' vote required, (vi) broker's or
finder's fees, (vii) absence of undisclosed liabilities, (viii) tax matters and
(ix) Intellectual Property. The representations and warranties in the Merger
Agreement (other than those relating to broker's or finder's fees) will not
survive the Effective Time.
INDEMNIFICATION; OFFICERS' AND DIRECTORS' LIABILITY INSURANCE
Schein will, for a period of at least six years commencing at the Effective
Time, indemnify the directors, officers, employees and agents of Sullivan with
respect to acts and omissions occurring through the Effective Time, to the full
extent provided in Sullivan's Articles of Incorporation or By-laws, or in any
written agreement between Sullivan and such indemnified person. The Surviving
Corporation or Schein shall use its reasonable best
83
efforts to maintain directors' and officers' liability insurance policies,
providing coverage of an aggregate amount of at least $4,000,000 and with a
carrier(s) having a rating from A.M. Best of at least 'A', covering directors
and officers of Sullivan serving as of or after December 1, 1990 with respect to
acts and omissions occurring prior to or at the Effective Time.
CERTAIN COVENANTS OF SULLIVAN
Sullivan has agreed, among other things, that, during the period from the
date of the Merger Agreement until the Effective Time, unless Schein shall
otherwise agree in writing, Sullivan will conduct its business only in the
ordinary and usual course and will use its reasonable efforts to preserve intact
its business organizations, to keep available the services of its present
officers and key employees, and preserve the goodwill of those having business
relationships with it. Sullivan has also agreed that neither it nor any of its
subsidiaries will during such period (i) make any change in or amendment to its
charter or by-laws; (ii) split, combine or reclassify any shares of its
outstanding capital stock, (iii) declare, set aside or pay any dividend or other
distribution in cash, stock or property, (iv) redeem or otherwise acquire any
shares of its capital stock or shares of the capital stock of any of its
subsidiaries; (v) sell any shares of its capital stock or Rights (as defined in
the Merger Agreement), except for (x) the issuance of shares of Sullivan Common
Stock upon the exercise of Sullivan stock options outstanding on the date of the
Merger Agreement; (y) the issuance of shares in connection with certain
transactions approved by Schein and (z) the issuance of options in connection
with the hiring of sales representatives consistent with past practice; (vi)
merge or consolidate with another entity; (vii) acquire or purchase an equity
interest in or a substantial portion of the assets of another corporation,
partnership or other business organization (except for such potential
acquisitions, and on substantially such terms, as have been provided on the
schedules to the Merger Agreement) or otherwise acquire any assets outside the
ordinary and usual course of business and consistent with past practice or
otherwise enter into any material contract, commitment or transaction outside
the ordinary and usual course of business consistent with past practice; (vii)
sell, lease, license, waive, release, transfer, encumber or otherwise dispose of
any of its assets outside the ordinary and usual course of business and
consistent with past practice; (viii) incur, assume or prepay any material
indebtedness or any other material liabilities other than in the ordinary course
of business and consistent with past practice; (ix) assume, guarantee, endorse
or otherwise become liable or responsible for the obligations of any other
person other than a subsidiary of Sullivan, in each case in the ordinary course
of business and consistent with past practice; (x) make any loans, advances or
capital contributions to, or investments in, any other person, other than to
subsidiaries of Sullivan; (xi) authorize or make capital expenditures in excess
of the budgeted amounts; (xii) permit any insurance policy naming Sullivan or
any subsidiary a beneficiary or a loss payee to be canceled or terminated other
than in the ordinary course of business; (xiii) adopt, enter into, terminate or
amend (except as may be required by applicable law) any Sullivan arrangement for
the current or future benefit or welfare of any director, officer or current or
former employee, (xiv) increase in any manner the compensation or fringe
benefits of, or pay any bonus to, any director, officer or employee (except for
normal increases in compensation in the ordinary course of business consistent
with past practice), (xv) take any action to fund or in any other way secure, or
to accelerate or otherwise remove restrictions with respect to, the payment of
compensation or benefits under any employee plan, stock option plan, agreement,
contract, or arrangement; (xvi) take any action with respect to, or make any
material change in, its accounting or tax policies or procedures, except as
required by law or to comply with GAAP; (xvii) take any action which would
jeopardize the treatment of Schein's acquisition of Sullivan as a pooling of
interests for accounting purposes; or (xviii) take any action which would
jeopardize qualification of the Merger as a reorganization within the meaning of
Section 368(a) of the Code. In addition, Sullivan, acting through its Board of
Directors, shall promptly call, give notice and, as soon as practicable
following the date of effectiveness of the Registration Statement of which this
Joint Proxy Statement/Prospectus is a part, hold a meeting of the Sullivan
Shareholders for the purpose of voting to approve and adopt the Merger Agreement
and the transactions contemplated thereby.
CERTAIN COVENANTS OF SCHEIN
Schein has agreed, among other things, that, during the period from the
date of the Merger Agreement until the Effective Time, unless Sullivan shall
otherwise agree in writing, Schein shall conduct its business and the business
of its subsidiaries in a manner designed, in the good faith judgment of its
Board of Directors, to enhance the long-term value of the Schein Common Stock
and the business prospects of Schein and its subsidiaries.
84
Schein has also agreed that neither Schein nor any of its subsidiaries shall (i)
authorize for issuance, issue or sell, or agree to issue or sell, any shares of
its capital stock or Rights, except for shares of Schein Common Stock upon the
exercise of Schein stock options or other Rights outstanding as of August 3,
1997 or upon the exercise of options or other Rights described in the
immediately following clause; (ii) issue options or other Rights pursuant to
existing employee benefit plans or arrangements other than in a manner
consistent with past practice, and (iii) issue shares of Schein Common Stock
other than in connection with arms' length acquisitions with non-affiliates;
(iv) split, combine or reclassify any shares of its outstanding capital stock,
or declare, set aside or pay any dividend or other distribution payable in cash,
stock or property; (v) take any action which would jeopardize the treatment of
Schein's acquisition of Sullivan as a 'pooling of interests' for accounting
purposes; or (vi) take any action which would jeopardize qualification of the
Merger as a reorganization within the meaning of Section 368(a) of the Code. In
addition, Schein will use its reasonable best efforts to cause the shares of
Schein Common Stock (as well as the shares of Schein Common Stock issuable afer
the Effective Time upon exercise of Schein stock options) to be listed for
quotation and trading on the Nasdaq National Market. Furthermore, Schein, acting
through its Board of Directors, shall promptly call, give notice and, as soon as
practicable following the date of effectiveness of the Registration Statement of
which this Joint Proxy Statement/Prospectus is a part, hold a meeting of the
Schein Stockholders for the purpose of voting to approve and adopt the Merger
Agreement and the transactions contemplated hereby.
CERTAIN COVENANTS OF SULLIVAN AND SCHEIN
Prior to the Effective Time, each of Sullivan and Schein have agreed that
they will afford to the other and to the other's representatives reasonable
access to its properties, books and records during normal business hours and to
furnish a copy of each report or document filed or received by it pursuant to
the requirements of federal securities laws. Unless otherwise required by law,
each of Sullivan and Schein agrees that it (and its respective subsidiaries and
representatives) shall hold in confidence all non-public information so acquired
in accordance with the terms of the confidentiality agreement between Schein and
Sullivan dated July 1, 1997. In addition, both Sullivan and Schein have agreed
to cooperate in filing the Registration Statement of which this Joint Proxy
Statement/Prospectus is a part and to use their best efforts to procure its
effectiveness.
NO SOLICITATION OF OTHER OFFERS
Sullivan has agreed that prior to the Effective Time, neither it, any of
its subsidiaries or its affiliates, nor any of the respective directors,
officers, employees, affiliates, agents or representatives of the foregoing
will, directly or indirectly, facilitate or encourage any inquiries or the
making of any proposal with respect to any Acquisition Transaction or negotiate,
explore or otherwise engage in discussions with any corporation, partnership,
person, other entity or group (other than Schein and its representatives) with
respect to any Acquisition Transaction, or enter into any agreement with respect
to any such Acquisition Transaction or which would require it to abandon,
terminate or fail to consummate the Merger or any other transaction contemplated
by the Merger Agreement; provided, however, that (i) Sullivan may, in response
to an unsolicited written proposal from a third party, furnish information to
and engage in discussions with such third party (subject to the following
conditions), and (ii) the Board of Directors of Sullivan may withdraw or modify
its approval or recommendation of the Merger Agreement or the Merger, approve
any Acquisition Transaction, or cause Sullivan to enter into any agreement with
respect to any Acquisition Transaction, in each case only if the Board of
Directors of Sullivan reasonably determines in good faith, by majority vote,
after consultation with its financial advisor, that the Acquisition Transaction
is more favorable to Sullivan's shareholders than the Merger, and, based upon
the advice of outside counsel, that failure to take such action would result in
a breach of the fiduciary duties of the Board of Directors and, prior to taking
such action, Sullivan (x) provides reasonable notice to Schein to the effect
that it is taking such action and (y) receives from the Acquiring Person (and
delivers to Schein) a confidentiality agreement in a customary form.
Sullivan has agreed that it, its subsidiaries and affiliates, and
respective directors, officers, employees, agents and representatives of the
foregoing, shall immediately cease and cause to be terminated any existing
activities, discussions or negotiations with any third party with respect to any
Acquisition Transaction. Sullivan will immediately advise Schein of any terms of
any inquiries received by, proposals from, negotiations, or discussions with a
third party with respect to an Acquisition Transaction, including the identity
of such third
85
party, and update on an ongoing basis or upon Schein's request, the status
thereof, as well as any actions taken or other developments. In no event shall
Sullivan (i) disclose any information received by it or any of its directors,
officers, employees, agents or representatives pursuant to the Confidentiality
Agreement or any other confidentiality or other similar agreement between
Sullivan and Schein to any person in violation of such agreement and (ii) be
obligated to disclose to Schein any confidential information provided to
Sullivan by any third party in violation of any confidentiality agreement
between Sullivan and such third party.
SOLICITATION OF EMPLOYEES
Except as noted below, each of Schein and Sullivan have agreed that, if the
Merger Agreement is terminated for any reason (i) for a period of six months
following the date of termination it will not hire any individual who is then an
employee or independent sales representative or who was an employee or
independent sale representative of the other party at any time during the
three-month period immediately preceding August 3, 1997 and (ii) for a period of
twelve months following the date of termination, it will not directly or
indirectly solicit any such individual. Such covenants, however, shall not be
binding upon Schein or Sullivan, as the case may be, from and after the time
that such party becomes entitled to a fee described in paragraph 4(b) or 4(c)
under '--Termination Rights.'
AMENDMENTS
Any provision of the Merger Agreement may be amended or waived in writing
by the appropriate parties thereto before the Effective Time (notwithstanding
any stockholder approval), provided that after any such stockholder approval, no
such amendment or waiver shall be made which by law requires further approval by
such stockholders without obtaining such further approval.
86
COMPARISON OF RIGHTS OF STOCKHOLDERS OF SULLIVAN AND SCHEIN
CERTAIN PROVISIONS OF DELAWARE AND WISCONSIN LAW
Upon consummation of the Merger, the shareholders of Sullivan, which is a
Wisconsin corporation, will become stockholders of Schein, which is a Delaware
corporation. The Sullivan shareholders' rights will thereafter be governed by
Delaware General Corporation Law (the 'DGCL'), the Schein Certificate of
Incorporation and Schein's By-laws, which differ in certain material respects
from Wisconsin Business Corporation Law (the 'WBCL'), Sullivan's Articles of
Incorporation (the 'Sullivan Articles of Incorporation'), and Sullivan's
By-laws.
Although it is not practical to compare all differences between (i) the
DGCL, the Schein Certificate of Incorporation and Schein's By-laws and (ii) the
WBCL, the Sullivan Articles of Incorporation and Sullivan's By-laws, the
following is a summary of certain differences which may significantly affect the
rights of Sullivan's shareholders. This discussion is not intended to be
complete and is qualified in its entirety by references to the Sullivan Articles
of Incorporation and Sullivan's By-laws and the Schein Certificate of
Incorporation and Schein's By-laws. Copies of the Schein Certificate of
Incorporation and Schein's By-laws and the Sullivan Articles of Incorporation
and Sullivan's By-laws are available for inspection at the principal executive
offices of Sullivan and copies will be sent to Sullivan's shareholders upon
request.
Under the DGCL, holders of equity interests in a corporation are referred
to as 'stockholders.' The WBCL refers to such persons as 'shareholders.' In this
section, the term 'stockholders' shall be used in references to the DGCL and in
references to holders of Schein Common Stock. The term 'shareholders' shall be
used in references to the WBCL and in references to holders of Sullivan Common
Stock, except that the term 'stockholders' will also be used in joint references
to the DGCL and WBCL and in joint references to holders of Schein Common Stock
and Sullivan Common Stock.
AUTHORIZED CAPITAL STOCK
The authorized capital stock of Schein consists of 61,000,000 shares,
consisting of 60,000,000 shares of common stock having a par value of $.01 per
share ('Schein Common Stock') and 1,000,000 shares of preferred stock having a
par value of $.01 per share ('Schein Preferred Stock'). As of the Record Date,
approximately 27,351,853 shares of Schein Common Stock and no shares of Schein
Preferred Stock were issued and outstanding. Holders of Schein Common Stock or
Schein Preferred Stock do not have preemptive rights.
The authorized capital stock of Sullivan consists of 30,500,000 shares,
consisting of 30,000,000 shares of common stock having a par value of $.01 per
share ('Sullivan Common Stock'), and 500,000 shares of preferred stock, having a
par value of $.01 per share ('Sullivan Preferred Stock'). As of the Record Date,
10,286,719 shares of Sullivan Common Stock and no shares of Sullivan Preferred
Stock were issued and outstanding. Holders of Sullivan Common Stock or Sullivan
Preferred Stock do not have preemptive rights.
Under the Schein Certificate of Incorporation and the Sullivan Articles of
Incorporation, the Schein Board and the Sullivan Board, respectively, are
authorized, without further stockholder approval (subject to certain limitations
by the DGCL or WBCL, as applicable), to issue from time to time up to an
aggregate of 1,000,000 shares and 500,000, respectively, of Schein Preferred
Stock or Sullivan Preferred Stock, as the case may be, in one or more series
with such designations and such powers, preferences and rights, and such
qualifications, limitations or restrictions as the Schein Board or the Sullivan
Board, as applicable, may fix by resolution. Unless otherwise provided by board
resolution, the consent of holders of any class or series of Schein Preferred
Stock or Sullivan Preferred Stock shall not be required for the issuance by the
Schein Board or Sullivan Board, as applicable, of any other series of Schein
Preferred Stock or Sullivan Preferred Stock, as the case may be. The Schein
Certificate of Incorporation provides that no dividend may be declared on any
series of Schein Preferred Stock unless a dividend is declared on all shares of
Schein Preferred Stock of each other series entitled to cumulative dividends
then outstanding which rank senior to or equally as to dividends with the series
in question.
87
DIRECTORS
The DGCL permits a corporation to divide directors into one, two or three
classes, the terms of which expire in different years. The Schein Certificate of
Incorporation does not provide for classes of directors.
The WBCL permits the staggering of terms of directors by dividing the
directors into two or three groups if the corporation's articles of
incorporation or By-laws so provide. The Sullivan Articles of Incorporation and
Sullivan's By-laws do not provide for classes of directors.
NUMBER OF DIRECTORS; CUMULATIVE VOTING
Under the DGCL, the number of directors shall be fixed by, or in the manner
provided by, the by-laws of the corporation unless the certificate of
incorporation fixes the number of directors, in which case a change in the
number of directors may be made only by amendment of the certificate. Under the
Schein Certificate of Incorporation, the Schein Board shall consist of not less
than five nor more than eleven directors with the actual number being fixed from
time to time by resolution of the Schein Board through December 31, 1998, and
thereafter, the maximum number of directors shall be nine. Among the Schein
Certificate of Incorporation Amendments being considered and voted upon by
Schein's stockholders at the Schein Special Meeting is an amendment to increase
the maximum number of directors of Schein to nineteen, with the number of
directors to be as fixed from time to time by resolution of the Schein Board.
This amendment would, among other things, give the Schein Board the flexibility
to appoint Bruce J. Haber, Executive Vice President of Schein and President of
Schein's Medical Division since August 1, 1997, and Robert J. Sullivan,
Sullivan's Chairman of the Board, to the Schein Board.
Under the WBCL, the authorized number of directors constituting the Board
of Directors is specified in, or fixed in accordance with, the articles of
incorporation or by-laws and may be increased or decreased by amendment to, or
in a manner provided in, the articles of incorporation or the by-laws. Under the
Sullivan By-laws, the number of directors is seven, or such other number as may
be determined by the Sullivan Board from time to time.
Cumulative voting, which enhances the ability of minority stockholders to
elect directors, is not available under either the WBCL or the DGCL unless
provided for in the corporation's articles of incorporation or certificate of
incorporation, as the case may be. Neither the Schein Certificate of
Incorporation nor the Sullivan Articles of Incorporation provide for cumulative
voting.
REMOVAL OF DIRECTORS; FILLING VACANCIES ON THE BOARD OF DIRECTORS
Under the DGCL, in the case of a corporation whose board is classified, a
director may be removed only for cause by the holders of a majority of the
outstanding shares entitled to vote for the election of directors, unless the
certificate of incorporation provides otherwise. As noted above, the Schein
Board is not classified. Schein's By-laws provide that any director or directors
of the corporation may be removed with or without cause upon the affirmative
vote of holders of two-thirds of the shares entitled to vote at a special
meeting of the stockholders called for that purpose.
Under the WBCL, a director may generally be removed by the shareholders,
with or without cause, if the number of votes cast to remove the director
exceeds the number of votes cast not to remove him or her, unless the articles
of incorporation, or By-laws adopted under authority granted in the articles of
incorporation, provide for a greater voting requirement or provide that
directors may only be removed for cause. The Sullivan By-laws provide that a
director may be removed with or without cause by a majority of the outstanding
shares entitled to vote at an election of directors.
Under the WBCL, the circuit court for the county where a corporation's
principal office or registered office is located may remove a director of the
corporation from office in a proceeding brought either by the corporation or by
shareholders holding at least 10% of the outstanding shares of any class, if the
court finds that the director engaged in fraudulent or dishonest conduct or
gross abuse of authority or discretion with respect to the corporation and that
removal is in the best interests of the corporation. The DGCL contains no
similar provision.
Under the DGCL, unless otherwise provided in the certificate of
incorporation or By-laws, vacancies and newly created directorships resulting
from an increase in the authorized number of directors elected by all of the
88
stockholders having the right to vote as a single class may be filled by a
majority of the directors then in office or by the sole remaining director.
Schein's By-laws provide that vacancies created by the removal, resignation or
death of a director or otherwise, may be filled only by the affirmative vote of
two-thirds of the shares entitled to vote in any election of directors, and any
director so chosen shall hold office for the remainder of the full term of the
director whose place he or she has been elected to fill and until his or her
successor shall be elected and qualified. If the first of the proposed Schein
Certificate of Incorporation Amendments is adopted, then, under Schein's
By-laws, the Schein Board will be able to fill vacancies.
Under the WBCL, unless the articles of incorporation provide otherwise, a
vacancy occurring on the board of directors may be filled by the shareholders or
the directors remaining in office. The Sullivan Articles of Incorporation do not
provide otherwise. Sullivan's By-laws provide that a vacancy on the Sullivan
Board may be filled by shareholders, at a special meeting held for such purpose,
or by the vote of a majority of the remaining directors then in office, even
when there is less than a quorum, or by the sole remaining director.
The DGCL further provides that, if at the time of filling any vacancy or
newly created directorship, the directors then in office constitute less than a
majority of the whole board (as constituted immediately prior to such increase),
the Delaware Court of Chancery may, upon application of any stockholder(s)
holding at least 10 percent of the outstanding shares having the right to vote
for directors, order an election to fill such vacancy or newly created
directorship, or to replace the directors chosen by the directors then in
office. The WBCL contains no similar provision.
TRANSACTIONS WITH INTERESTED DIRECTORS
Generally, under the DGCL and the WBCL, no contract or transaction between
a corporation and one or more of its directors or between a corporation and
another entity in which one or more of its directors are directors or officers
or in which one or more of its directors have a material financial interest is
void or voidable because of such relationship or interest, if (i) the material
facts of the transaction and the director's interest are disclosed or known to
the board of directors or a committee of the board of directors which
authorizes, approves or ratifies the transaction by the vote of a majority of
directors who have no direct or indirect interest in the transaction; (ii) the
material facts of the transaction and the director's interest are disclosed or
known to stockholders entitled to vote and they authorize, approve or ratify the
transaction; or (iii) the transaction is fair to the corporation.
LIMITATION ON DIRECTORS' LIABILITY; INDEMNIFICATION
The DGCL provides that a corporation's certificate of incorporation may
contain a provision which eliminates or limits the personal liability of a
director to the corporation or its stockholders for monetary damages for a
breach of fiduciary duty as a director, except for (1) acts or omissions not in
good faith or which involve intentional misconduct or a knowing violation of
law, (2) any breach of the director's duty of loyalty to the corporation or its
stockholders, (3) an unlawful dividend or stock purchase or redemption, or (4)
any transaction from which the director derived an improper personal benefit.
The Schein Certificate of Incorporation includes such a provision limiting the
personal liability of its directors to the fullest extent permitted by the DGCL.
Under the DGCL, a corporation may generally indemnify its officers,
directors, employees and agents against expenses (including attorneys' fees),
judgments, fines and amounts paid in settlement of any proceedings (other than
proceedings by or in the right of the corporation), if they acted in good faith
and in a manner they reasonably believed to be in or not opposed to the best
interests of the corporation and, with respect to any criminal action or
proceeding, had no reasonable cause to believe their conduct was unlawful. A
similar standard is applicable in proceedings by or in the right of the
corporation, except that indemnification may be made only for expenses
(including attorneys' fees) and such indemnification will not be made in respect
of any matter in which the person seeking indemnification is found liable to the
corporation unless and only to the extent that a court determines that
indemnification for such expenses is fair and reasonable under all
circumstances. The DGCL provides that to the extent such persons have been
successful in the defense of any proceeding, they must be indemnified by the
corporation against expenses actually and reasonably incurred in connection
therewith. The Schein Certificate of Incorporation provides that the legal
representatives, directors, and officers of Schein will be indemnified to the
fullest extent permitted by the DGCL, which right to indemnification is not
exclusive of
89
any other right which any person may have or acquire under any statute,
provision of the Schein Certificate of Incorporation, the Schein By-laws,
agreement, vote of stockholders or disinterested directors or otherwise.
The WBCL provides that a director is not liable to the corporation, its
shareholders, or any person asserting rights on behalf of the corporation or its
shareholders for liabilities arising from a breach of, or failure to perform,
any duty resulting solely from his or her status as director, unless the person
asserting liability proves that the breach or failure to perform constitutes:
(1) wilful failure to deal fairly with the corporation or its shareholders in
connection with a matter in which the director has a material conflict of
interest; (2) a violation of criminal law, unless the director had reasonable
cause to believe that the conduct was lawful or no reasonable cause to believe
that the conduct was unlawful; (3) a transaction from which the director derived
an improper personal profit; or (4) wilful misconduct. Although the WBCL permits
a corporation to limit the statutory immunity from director liability in its
articles of incorporation, the Sullivan Articles of Incorporation contains no
such limitation. The Sullivan Articles of Incorporation provide that, to the
fullest extent authorized by the WBCL, a director of the corporation shall not
be liable to the corporation or its shareholders for monetary damages for breach
of fiduciary duty as a director.
The WBCL provides that a corporation shall indemnify a director or officer,
to the extent that he or she has been successful on the merits or otherwise in
the defense of a proceeding, for all reasonable expenses incurred in the
proceeding if the director or officer was a party because of his or her status
as a director or officer. Additionally, a corporation shall indemnify a director
or officer against liability incurred by a director or officer in a proceeding
to which the director or officer was a party because he or she is a director or
officer of the corporation, unless liability was incurred because the director
or officer breached or failed to perform a duty that he or she owes to the
corporation and the breach or failure to perform constitutes any of the conduct
enumerated above relating to liability of directors. Further, a court of law may
order that the corporation provide indemnification to a director or officer if
it finds that the director or officer is entitled thereto under the applicable
statutory provision or is fairly and reasonably entitled thereto in view of all
the relevant circumstances, whether or not such indemnification is required
under the applicable statutory provision.
The WBCL permits a corporation to provide additional rights to
indemnification under its articles of incorporation or By-laws, by written
agreement, by resolution of its board of directors or by a vote of the holders
of a majority of its outstanding shares, except that the corporation may not
indemnify a director or officer unless it is determined by or on behalf of the
corporation that the director or officer did not breach or fail to perform a
duty owed to the corporation which constitutes conduct as enumerated above
relating to liability of directors. The Sullivan Articles of Incorporation
provide that each person who is or was a director of the corporation and each
person who serves or served at the request of the corporation as a director,
officer or partner of another enterprise shall be indemnified by Sullivan to the
fullest extent authorized by the WBCL as it now exists or is hereafter amended.
Sullivan's By-laws provide for indemnification and reimbursement or advancement
of expenses to directors and officers to the fullest extent permitted by the
WBCL and for the indemnification of an employee who is not a director or officer
of the corporation, to the extent that he or she has been successful on the
merits or otherwise in defense of a proceeding, for all reasonable expenses
incurred in the proceeding if the employee was a party because he or she was an
employee of the corporation. This provision is not exclusive of any other rights
to indemnification or the advancement of expenses to which a director or officer
may be entitled to under any written agreement, resolution of directors, vote of
shareholders, by law or otherwise.
MEETINGS OF STOCKHOLDERS
Under the DGCL, special meetings of stockholders may be called by the board
of directors or by such persons as may be authorized by the certificate of
incorporation or the By-laws. Schein's By-laws provide that special meetings of
stockholders may be called by resolution of the Schein Board or the Chairman of
the Schein Board. The Schein Certificate of Incorporation provides that special
meetings may be called by resolution of the Schein Board, by the Chairman of the
Schein Board or by stockholders holding more than 10 percent of the outstanding
shares entitled to vote in the election of directors.
Under the WBCL, a corporation shall hold a special meeting of shareholders
if (1) a special meeting is called by the board of directors or any person
authorized by the articles of incorporation or By-laws to call a special
meeting, or (2) the holders of at least 10 percent of all votes entitled to be
cast on any issue proposed to be
90
considered at the proposed special meeting deliver a written demand to the
corporation describing one or more purposes for which such meeting is to be
held. Sullivan's By-laws provide that a special meeting of shareholders may be
called by the President or by the Sullivan Board.
QUORUM FOR STOCKHOLDER MEETINGS
Under the DGCL, a corporation's certificate of incorporation or By-laws may
specify the percentage of votes which constitutes a quorum at a meeting of
stockholders, but in no event may a quorum consists of less than one-third of
the shares entitled to vote. Schein's By-laws provide that a quorum exists if a
majority of the voting power entitled to vote is present in person or by proxy
at a meeting, except as otherwise provided by statute or by the Schein
Certificate of Incorporation.
The WBCL provides that a majority of the votes entitled to be cast on a
matter by a voting group constitutes a quorum, unless the articles of
incorporation, By-laws adopted under authority granted in the articles of
incorporation, or the WBCL provides otherwise. Sullivan's By-laws mirror this
statutory provision.
STOCKHOLDER VOTING REQUIREMENTS GENERALLY
Under the DGCL, unless otherwise provided by the DGCL or a Delaware
corporation's certificate of incorporation or By-laws, if a quorum exists,
directors are elected by a plurality of votes of shares represented at a meeting
and entitled to vote, and action on all other matters is approved by the
affirmative vote of a majority of the shares represented at a meeting and
entitled to vote on a particular matter. The Schein Certificate of Incorporation
requires a greater vote on matters as discussed in the section captioned
'Supermajority Provisions' below. Schein's By-laws provide that all elections
shall be decided by the vote of a majority of the stockholders present or
represented and entitled to vote at a meeting unless otherwise required by the
DGCL, the Schein Certificate of Incorporation or Schein's By-laws.
Under the WBCL, with respect to matters other than the election of
directors, unless a greater number of affirmative votes is required by the WBCL,
the articles of incorporation, or By-laws adopted under authority granted in the
articles of incorporation, if a quorum exists, action on any matter generally is
approved by the shareholders if the votes cast favoring the action exceed the
votes cast opposing the action. Unless otherwise provided in the articles of
incorporation, directors are elected by a plurality of the votes cast by the
shares entitled to vote. Sullivan's By-laws provide that, if a quorum is
present, the affirmative vote of a majority of the shares of voting stock
represented at a meeting of shareholders shall be the act of the shareholders in
all matters except for the election of directors, who shall be elected by a
plurality of the votes of the shares present in person or by proxy and entitled
to vote on the election of directors.
STOCKHOLDER ACTION BY WRITTEN CONSENT
Under the DGCL, unless otherwise provided in the certificate of
incorporation, any action required or which may be taken at any annual or
special meeting of stockholders may be taken without a meeting if written
consents are obtained from the holders of outstanding stock having not less than
the minimum number of votes that would be necessary to authorize or take such
action at a meeting at which all shares entitled to vote thereat were present
and voted. The Schein Certificate of Incorporation does not limit this statutory
provision.
The WBCL permits action otherwise required to be taken at a shareholders'
meeting to be taken without a meeting if (1) written consents are signed by all
shareholders entitled to vote on the action, or (2) if the articles of
incorporation so provide, written consents are signed by shareholders having not
less than the minimum number of votes that would be necessary to authorize the
proposed action at a meeting at which all shares entitled to vote were present
and voted. Sullivan's By-laws mirror these provisions.
SUPERMAJORITY PROVISIONS
Under the DGCL, the certificate of incorporation may provide for the vote
of a larger portion of the stock or of any class or series thereof, or of any
other securities having voting power, or a larger number of the directors, than
is required by the DGCL. The Schein Certificate of Incorporation requires the
affirmative vote of the holders of at least sixty percent of the outstanding
voting stock to approve (i) certain mergers and sales of assets and for the
amendment or repeal if any provision of the Schein Certificate of Incorporation
with respect to authorization
91
of, and (ii) adoption of any agreement with respect to such mergers and sales of
assets by, the corporation and requires the affirmative vote of eighty percent
of all outstanding shares entitled to vote in the election of directors to
repeal, alter, amend or rescind any provision of the Schein Certificate of
Incorporation regarding (x) the number, election and powers of directors and (y)
the number of votes to which each share of Schein Common Stock is entitled (the
Board of Directors also has this power).
Except as discussed below in the section captioned 'Stockholder Voting in
Certain Significant Transactions; Takeover Legislation,' the WBCL does not
impose supermajority voting requirements.
STOCKHOLDER VOTING IN CERTAIN SIGNIFICANT TRANSACTIONS; TAKEOVER LEGISLATION
The DGCL requires that a merger or consolidation or a sale, lease or
exchange of all or substantially all of the property and assets of a corporation
be approved by the holders of a majority of the outstanding stock of the
corporation entitled to vote thereon. The Schein Certificate of Incorporation
requires the affirmative vote of holders of sixty percent of the outstanding
voting stock to approve certain mergers or sales of assets.
The DGCL generally prohibits a stockholder owning 15 percent or more of a
corporation's outstanding voting stock (an 'interested stockholder') from
engaging in certain business combinations involving the corporation during the
three years after the time the person became an interested stockholder unless
(1) prior to such time, the board of directors approved either the business
combination or the transaction which resulted in the stockholder becoming an
interested stockholder, (2) upon the consummation of the transaction which
resulted in the stockholder becoming an interested stockholder, the stockholder
owned at least 85 percent of the voting stock outstanding at the time the
transaction commenced, (3) at or subsequent to such time, the transaction is
approved by the board of directors and by the stockholders by a vote of
two-thirds of the disinterested outstanding voting stock, (4) the corporation's
original certificate of incorporation provides that the corporation shall not be
governed by the statute or (5) a majority of shares entitled to vote approve an
amendment to the corporation's certificate of incorporation or By-laws expressly
electing not to be governed by the statute (but such amendment may not be
effective until one year after it was adopted and may not apply to any business
combination between the corporation and any person who became an interested
stockholder on or prior to such adoption). These business combinations include,
with certain exceptions, mergers, consolidations, sales of assets and
transactions benefitting the interested stockholder. The Schein Certificate of
Incorporation and By-laws contain no provision electing not to be governed by
this statute.
Under the WBCL, a corporation may sell, lease, exchange or otherwise
dispose of all, or substantially all, of its property, other than in the usual
and regular course of business, if such disposition is approved by a majority of
all the votes entitled to be cast thereon. A merger or share exchange plan must
be approved by each voting group entitled to vote separately on the plan by a
majority of all the votes entitled to be cast on the plan by that voting group.
The WBCL contains certain provisions that, unless a corporation elects not
to be covered by such provisions, and Sullivan has not so elected, require
approval of a supermajority of shareholders for certain 'business combinations'
involving persons who are 'significant shareholders' before the transaction or
become 'significant shareholders' after the transaction. A 'significant
shareholder' is, among others, a person who is, or an affiliate who was, within
two years of the transaction, a beneficial owner of 10% or more of the voting
power of the applicable corporation. In such a case, unless the business
combination satisfies certain 'fair price' criteria, the business combination
requires the approval of 80% of the votes entitled to be cast by the outstanding
voting shares of the corporation voting as a single class and two-thirds of all
such shares excluding the shares owned by a significant shareholder. Sullivan
has elected, in the Sullivan Articles of Incorporation, not to be covered by
this provision.
The WBCL additionally regulates a broad range of 'business combinations'
between a corporation and an 'interested shareholder.' 'Business combinations'
are defined as including a merger or a share exchange, sale of assets, issuance
of stock or rights to purchase stock and certain related party transactions. An
'interested shareholder' is a person who beneficially owns, directly or
indirectly, 10% of the outstanding voting stock of a corporation or who is an
affiliate or associate of the corporation and beneficially owned 10% of the
voting stock within the last three years. In certain cases, the WBCL prohibits a
corporation from engaging in a business combination with an interested
shareholder for a period of three years following the date on which the person
92
became an interested shareholder unless (i) the board of directors approved the
business combination or the acquisition of the stock prior to the acquisition
date, (ii) the business combination is approved by a majority of the outstanding
voting stock not owned by the interested shareholder, (iii) the consideration to
be received by shareholders meets certain requirements of the statute with
respect to form and amount or (iv) the business combination is of a type
specifically excluded from the coverage of the statute.
While a takeover offer is being made, or after a takeover offer has been
publicly announced and before it is concluded, the WBCL requires the approval of
the holders of a majority of shares entitled to vote before a public corporation
may acquire more than 5% of its voting shares at a price above market value from
a person who holds more than 3% of its voting shares and has held such shares
for less than two years, unless at least an 'equal' offer is made to acquire all
voting shares and all securities which may be converted into voting shares.
Similar approval is required before a public corporation may sell or option
assets which amount to at least 10% of its market value unless the corporation
has at least three directors who are not either officers or employees of the
corporation and a majority of the directors who are not either officers or
employees vote not to be governed by this provision. Sullivan has elected, in
the Sullivan Articles of Incorporation, not to be covered by this provision.
The WBCL provides that in particular circumstances the voting of shares of
an 'issuing public corporation' (a Wisconsin corporation which has at least 100
Wisconsin resident shareholders who have unlimited voting rights, 500 or more
shareholders of record and total assets exceeding $1 million) held by any person
in excess of 20% of the voting power is limited to 10% of the full voting power
of such excess shares. Full voting power may be restored if a majority of the
voting power of shares represented at a meeting, are voted in favor of such
restoration.
STATUTORY STOCKHOLDER LIABILITY
The WBCL provides that the shareholders of a corporation are personally
liable to up to an amount equal to the par value of shares owned by them, and to
the consideration for which shares without par value were issued, for debts
owing to employees of the corporation for services performed for such
corporation, but not exceeding six months' service in any case.
DERIVATIVE ACTIONS
Under both the DGCL and the WBCL, a stockholder may bring a derivative
action if he or she was a stockholder at the time of the alleged wrongdoing, or
acquired the shares by operation of law from a person who was a stockholder at
such time. Under the DGCL, a stockholder has no right to bring a derivative
action until he makes a demand on the corporation to institute such action or
demonstrates that demand would be futile. Under the WBCL, a shareholder may not
commence a derivative action until he makes a written demand on the corporation
to take suitable action and a period of ninety days expires, unless the
shareholder is notified that the corporation has rejected the demand or
irreparable injury to the corporation would result by waiting for the period to
expire.
DISSENTERS' RIGHTS AND APPRAISAL RIGHTS
Under the DGCL, a stockholder of a corporation who has not voted for or
consented to a merger or consolidation is entitled to an appraisal by the
Delaware Court of Chancery of the fair value of his shares of stock. Such
appraisal rights are not available to a stockholder of a Delaware corporation if
the shares are (1) listed on a national securities exchange or designated as a
national market systems security on an interdealer quotation system by the NASD,
or (2) held of record by more than 2,000 stockholders. Notwithstanding the
foregoing, a stockholder is not required by the terms of the agreement and plan
of merger or consolidation to accept anything for his shares other than (1)
shares of stock of the corporation surviving or resulting from the merger or
consolidation, or depository receipts in respect thereof, (2) shares of stock of
any other corporation, or depository receipts in respect thereof, which shares
or receipts are so listed or designated or held of record by more than 2,000
stockholders, (3) cash in lieu of fractional shares or fractional depository
receipts, or (4) any combination of the foregoing. Schein Common Stock is
currently quoted on the Nasdaq National Market.
The DGCL does not provide appraisal rights to stockholders who dissent from
the sale of all or substantially all of the corporation's assets unless the
corporation's certificate of incorporation provides otherwise. The Schein
93
Certificate of Incorporation does not provide for appraisal rights in the
context of a sale of all or substantially all of Schein's assets.
Under the WBCL, a shareholder of a corporation is generally entitled to
receive payment of the fair value of such shareholder's stock if such
shareholder dissents from a proposed merger or stock exchange or sale or
exchange of all or substantially all of the property and assets of the
corporation. However, except with respect to business combinations involving
significant shareholders (as such terms are described in the first paragraph
under 'Stockholder Voting in Certain Significant Transactions; Takeover
Legislation' above), dissenters' rights are not available to holders of shares
that are registered on a national securities exchange or quoted on NASDAQ.
Currently, Sullivan Common Stock is quoted on the Nasdaq National Market.
STOCKHOLDER INSPECTION OF BOOKS AND RECORDS
The DGCL permits any stockholder the right, during usual business hours, to
inspect and copy the corporation's stock ledger, stockholder list and other
books and records for any proper purpose upon written demand under oath stating
the purpose thereof.
The WBCL allows a shareholder, upon giving the required notice, to inspect
and copy the corporation's by-laws during regular business hours at a reasonable
location specified by the corporation. A shareholder fulfilling specified
requirements may inspect and copy, during regular business hours at a reasonable
location specified by the corporation, excerpts of any minutes or records that
the corporation is required to keep as permanent records, accounting records of
the corporation, and the record of shareholders, except that the corporation may
provide the shareholder with a list of shareholders compiled no earlier than the
date of the shareholder's demand instead of allowing the shareholder to inspect
and copy the record of shareholders.
LOANS TO DIRECTORS
Under the DGCL, a corporation may lend money to, or guaranty any obligation
of, or otherwise assist any officer or other employee of the corporation,
including any officer or employee who is a director of the corporation,
whenever, in the judgment of the directors, such loan, guaranty or assistance
may reasonably be expected to benefit the corporation. The loan, guaranty or
other assistance may be with or without interest, and may be unsecured, or
secured in such manner as the board of directors shall approve, including,
without limitation. a pledge of shares of stock of the corporation.
Under the WBCL, unless it is an advance or is made to defray expenses made
in the ordinary course of the corporation's business or an advance of expenses
with respect to indemnification, a corporation may not make loans to or guaranty
the obligation of a director unless the particular loan or guaranty is approved
by a majority of the votes represented by the voting shares of all classes,
voting as a single group, excluding votes owned or controlled by the benefitted
director, or the board of directors determines that the loan or guaranty
benefits the corporation and either approves the specific loan or guaranty or a
general plan authorizing loans or guarantees.
AMENDMENT OR REPEAL OF THE CERTIFICATES AND BY-LAWS
Under the DGCL, a corporation's certificate of incorporation generally may
be amended only if approved by a majority of the outstanding stock entitled to
vote thereon. A corporation may confer the power to adopt, amend or repeal
by-laws on the directors, without divesting or limiting the powers of the
stockholders to adopt, amend or repeal by-laws. The Schein Certificate of
Incorporation provides that (i) the Schein Board may adopt, amend or repeal any
By-law of the corporation and (ii) that any By-law made, amended or repealed by
the Schein Board may be amended or repealed, and that any by-law may be adopted
by the stockholders of the corporation and (iii) that the Schein Board may not
amend or repeal any By-law adopted by the stockholders of the corporation. Among
the proposed Schein Certificate of Incorporation Amendments is a provision which
would eliminate the prohibition set forth in clause (iii) above.
In general, the WBCL provides that a corporation's articles of
incorporation may be amended through a proposal submitted by the board of
directors to the shareholders for their approval. Unless the articles of
incorporation or by-laws provide otherwise, or unless class voting is required,
or unless the WBCL provides otherwise, the amendment may be approved by a
majority vote of the shares entitled to vote thereon. Class votes are required
in certain circumstances which, in general, affect a class of stock adversely or
uniquely. In certain
94
very limited circumstances, either specified in the corporation's articles of
incorporation or which involve certain ministerial actions which are likely to
be immaterial to the shareholders, the WBCL permits the articles of
incorporation to be amended by action of the board of directors without
shareholder approval. In general, under Wisconsin law, the by-laws of a
corporation may be amended by the board of directors, except in those instances
in which the corporation's articles of incorporation or by-laws provide
otherwise. Action by shareholders to amend or repeal amendments to the by-laws
can overrule action taken by the board of directors. The Sullivan Articles of
Incorporation provide that the Sullivan By-laws may be altered, amended or
repealed by the Sullivan Board subject to the power of the shareholders to alter
or repeal any by-law made by the Sullivan Board.
DIVIDEND DECLARATIONS
Under the DGCL, the directors may, subject to any restrictions in a
corporation's certification of incorporation, declare and pay dividends, either
(i) out of its surplus, or (ii) in case there shall be no surplus, out of the
net profits for the fiscal year. The directors may not declare a dividend out of
net profits, however, if the capital of the corporation is less than the
aggregate amount of capital represented by the issued and outstanding stock of
all classes having a preference upon the distribution of assets. The Schein
Certificate of Incorporation contains no limitations on such powers.
Under the WBCL, no distribution may be made if, after giving it effect,
either (1) the corporation would not be able to pay its debts as they become due
in the usual course of business, or (2) the corporation's total assets would be
less than the sum of its total liabilities plus, unless the articles of
incorporation permit otherwise, the amount that would be needed, if the
corporation were to be dissolved at the time of the distribution, to satisfy the
preferential rights upon dissolution of shareholders whose preferential rights
are superior to those receiving the distribution. The Sullivan Articles of
Incorporation contain no provision with respect to distributions.
EXPERTS
The consolidated financial statements and schedule included in Schein's
Annual Report on Form 10-K, Amended Annual Report on Form 10-K/A and Form 8-K
dated June 24, 1997 for the year ended December 28, 1996, which are incorporated
by reference in this Joint Proxy Statement/Prospectus, have been audited by BDO
Seidman, LLP, independent certified public accountants, to the extent and for
the periods indicated in their reports with respect thereto and are incorporated
herein in reliance upon such reports given the authority of said firm as experts
in accounting and auditing.
The financial statements and the related financial statement schedule
incorporated in this Joint Proxy Statement/Prospectus by reference from the
Sullivan Dental Products, Inc. Annual Report on Form 10-K for the year ended
December 31, 1996 have been audited by Deloitte & Touche LLP, independent
auditors, as stated in their reports, which are incorporated herein by
reference, and have been so incorporated in reliance upon the reports of such
firm given upon their authority as experts in accounting and auditing.
LEGAL MATTERS
The validity of the shares of Schein Common Stock to be issued pursuant to
this Joint Proxy Statement/Prospectus will be passed upon for Schein by
Proskauer Rose LLP, counsel to Schein. Certain U.S. tax matters will be passed
upon for Schein by Proskauer Rose LLP.
Shareholders wishing to present proposals for action by the shareholders at
the next Annual Meeting of Sullivan's Shareholders (assuming that the Merger is
not consummated prior thereto) must present such proposals at Sullivan's
principal offices not later than November 25, 1997. It is suggested that any
such proposals be submitted by certified mail, return receipt requested.
Stockholders wishing to present proposals for action by the stockholders at
the next Annual Meeting of Schein Stockholders must present such proposals at
the principal offices of Schein not later than December 24, 1997. It is
suggested that any such proposals be submitted by certified mail, return receipt
requested.
95
ANNEX I
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
HENRY SCHEIN, INC.,
HSI ACQUISITION CORP.
AND
SULLIVAN DENTAL PRODUCTS, INC.
DATED AUGUST 3, 1997
TABLE OF CONTENTS
PAGE
----
ARTICLE I
THE MERGER............................................................................................ 1
Section 1.1 The Merger............................................................................ 1
Section 1.2 Effective Time of the Merger.......................................................... 1
Section 1.3 Closing............................................................................... 1
ARTICLE II
THE SURVIVING CORPORATION............................................................................. 1
Section 2.1 Articles of Incorporation............................................................. 1
Section 2.2 By-Laws............................................................................... 1
Section 2.3 Directors and Officers of Surviving Corporation....................................... 2
ARTICLE III
CONVERSION OF SHARES.................................................................................. 2
Section 3.1 Exchange Ratio........................................................................ 2
Section 3.2 Exchange of Company Common Stock; Procedures.......................................... 2
Section 3.3 Dividends; Transfer Taxes, Escheat.................................................... 3
Section 3.4 No Fractional Securities.............................................................. 3
Section 3.5 Closing of Company Transfer Books..................................................... 3
Section 3.6 Further Assurances.................................................................... 3
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE COMPANY......................................................... 4
Section 4.1 Organization.......................................................................... 4
Section 4.2 Capitalization........................................................................ 4
Section 4.3 Company Subsidiaries.................................................................. 5
Section 4.4 Authority Relative to this Agreement.................................................. 5
Section 4.5 Consents and Approvals; No Violations................................................. 5
Section 4.6 Reports and Financial Statements...................................................... 5
Section 4.7 Absence of Certain Changes or Events; Material Contracts.............................. 6
Section 4.8 Litigation............................................................................ 6
Section 4.9 Absence of Undisclosed Liabilities.................................................... 6
Section 4.10 No Default............................................................................ 6
Section 4.11 Taxes................................................................................. 6
Section 4.12 Title to Properties; Encumbrances..................................................... 7
Section 4.13 Intellectual Property................................................................. 7
Section 4.14 Compliance with Applicable Law........................................................ 8
Section 4.15 Information in Disclosure Documents and Registration Statement........................ 8
Section 4.16 Employee Benefit Plans; ERISA......................................................... 9
Section 4.17 Environmental Laws and Regulations.................................................... 10
Section 4.18 Vote Required......................................................................... 10
Section 4.19 Opinion of Financial Advisor.......................................................... 10
Section 4.20 Accounting Matters.................................................................... 10
Section 4.21 WBCL Sections 1131, 1134 and 1141..................................................... 10
Section 4.22 Labor Matters......................................................................... 11
Section 4.23 Affiliate Transactions................................................................ 11
Section 4.24 Brokers............................................................................... 11
Section 4.25 Tax Matters........................................................................... 11
Section 4.26 Accounts Receivable................................................................... 11
Section 4.27 Inventory............................................................................. 11
i
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF PARENT.............................................................. 11
Section 5.1 Organization.......................................................................... 11
Section 5.2 Capitalization........................................................................ 12
Section 5.3 Authority Relative to this Agreement.................................................. 12
Section 5.4 Consents and Approvals No Violations.................................................. 12
Section 5.5 Reports and Financial Statements...................................................... 13
Section 5.6 Absence of Certain Changes or Events; Material Contracts.............................. 13
Section 5.7 Litigation............................................................................ 13
Section 5.8 Absence of Undisclosed Liabilities.................................................... 13
Section 5.9 No Default............................................................................ 13
Section 5.10 Compliance with Applicable Law........................................................ 13
Section 5.11 Information in Disclosure Documents and Registration Statement........................ 14
Section 5.12 Vote Required......................................................................... 14
Section 5.13 Opinion of Financial Advisor.......................................................... 14
Section 5.14 Accounting Matters.................................................................... 14
Section 5.15 Brokers............................................................................... 14
Section 5.16 Acceleration of Parent Stock Options.................................................. 15
Section 5.17 Parent Subsidiaries................................................................... 15
Section 5.18 Taxes................................................................................. 15
Section 5.19 Title to Properties; Encumbrances..................................................... 16
Section 5.20 Intellectual Property................................................................. 16
Section 5.21 Employee Benefit Plans; ERISA......................................................... 16
Section 5.22 Environmental Laws and Regulations.................................................... 17
Section 5.23 Labor Matters......................................................................... 18
Section 5.24 Affiliate Transactions................................................................ 18
Section 5.25 Tax Matters........................................................................... 18
Section 5.26 Accounts Receivable................................................................... 18
Section 5.27 Inventory............................................................................. 18
ARTICLE VI
CONDUCT OF BUSINESS PENDING THE MERGER................................................................ 18
Section 6.1 Conduct of Business by the Company Pending the Merger................................. 18
Section 6.2 Conduct of Business by Parent Pending the Merger...................................... 19
Section 6.3 Conduct of Business of Sub............................................................ 20
ARTICLE VII
ADDITIONAL AGREEMENTS................................................................................. 20
Section 7.1 Access and Information................................................................ 20
Section 7.2 No Solicitation....................................................................... 20
Section 7.3 Registration Statement................................................................ 21
Section 7.4 Proxy Statements; Stockholder Approvals............................................... 21
Section 7.5 Compliance with the Securities Act.................................................... 22
Section 7.6 Reasonable Best Efforts............................................................... 22
Section 7.7 Irrevocable Proxy and Termination Rights Agreement.................................... 23
Section 7.8 Company Stock Options................................................................. 23
Section 7.9 Public Announcements.................................................................. 23
Section 7.10 Expenses.............................................................................. 23
Section 7.11 Listing Application................................................................... 23
Section 7.12 Supplemental Disclosure............................................................... 23
Section 7.13 Letters of Accountants................................................................ 24
Section 7.14 Directors of Parent................................................................... 24
Section 7.15 Indemnification....................................................................... 24
Section 7.16 Solicitation of Employees and Representatives......................................... 24
ii
ARTICLE VIII
CONDITIONS TO CONSUMMATION OF THE MERGER.............................................................. 25
Section 8.1 Conditions to Each Party's Obligation to Effect the Merger............................ 25
Section 8.2 Conditions to Obligations of Parent and Sub to Effect the Merger...................... 25
Section 8.3 Conditions to Obligation of the Company to Effect the Merger.......................... 26
ARTICLE IX
TERMINATION........................................................................................... 27
Section 9.1 Termination........................................................................... 27
Section 9.2 Effect of Termination................................................................. 28
ARTICLE X
GENERAL PROVISIONS.................................................................................... 28
Section 10.1 Amendment and Modification............................................................ 28
Section 10.2 Waiver................................................................................ 29
Section 10.3 Survivability; Investigations......................................................... 29
Section 10.4 Notices............................................................................... 29
Section 10.5 Descriptive Headings; Interpretation.................................................. 30
Section 10.6 Entire Agreement; Assignment.......................................................... 30
Section 10.7 Governing Law......................................................................... 30
Section 10.8 Severability.......................................................................... 30
Section 10.9 Counterparts.......................................................................... 30
iii
AGREEMENT AND PLAN OF MERGER
AGREEMENT AND PLAN OF MERGER dated August 3, 1997, by and among Henry
Schein, Inc., a Delaware corporation ('Parent'), HSI Acquisition Corp., a
Wisconsin corporation and wholly-owned subsidiary of Parent ('Sub'), and
Sullivan Dental Products, Inc., a Wisconsin corporation (the 'Company').
The Boards of Directors of Parent and Sub and the Company deem it advisable
and in the best interests of their respective stockholders that Parent acquire
the Company pursuant to the terms and conditions of this Agreement, and, in
furtherance of such acquisition, such Boards of Directors have approved the
merger of Sub with and into the Company in accordance with the terms of this
Agreement, the General Corporation Law of the State of Delaware (the 'DGCL') and
the Wisconsin Business Corporation Law (the 'WBCL').
Concurrently with the execution and delivery of this Agreement and as a
condition and inducement to Parent's willingness to enter into this Agreement,
certain holders of shares of the common stock, par value $.01 per share (the
'Company Common Stock'), of the Company are entering into an agreement with
Parent and Sub in the form attached hereto as Exhibit A (the 'Irrevocable Proxy
and Termination Rights Agreement') granting Parent the right to vote such shares
of the Company Common Stock and granting Parent the right to receive a portion
of the proceeds from the sale of such shares under certain circumstances in
accordance with the terms set forth in the Irrevocable Proxy and Termination
Rights Agreement.
For federal income tax purposes, it is intended that the Merger (as defined
in Section 1.1) shall qualify as a reorganization within the meaning of Section
368(a) of the Internal Revenue Code of 1986, as amended (the 'Code').
For accounting purposes, it is intended that the Merger shall be accounted
for as a pooling of interests.
In consideration of the foregoing and the respective representations,
warranties, covenants and agreements set forth herein, the parties hereto agree
as follows:
ARTICLE I
THE MERGER
Section 1.1 The Merger. In accordance with the provisions of this
Agreement, the DGCL and the WBCL, at the Effective Time (as defined in Section
1.2), Sub shall be merged with and into the Company (the 'Merger'), the separate
existence of Sub shall thereupon cease, and the Company shall be the surviving
corporation in the Merger (sometimes hereinafter called the 'Surviving
Corporation') and shall continue its corporate existence under the laws of the
State of Wisconsin. The Merger shall have the effects set forth in Section 1106
of the WBCL.
Section 1.2 Effective Time of the Merger. The Merger shall become
effective at the time of filing of or at such later time specified in, a
properly executed Certificate of Merger, in the form required by and executed in
accordance with the WBCL, filed with the Secretary of State of the State of
Wisconsin in accordance with the provisions of Chapter 180 of the WBCL. Such
filing shall be made as soon as practicable after the Closing (as defined in
Section 1.3). When used in this Agreement, the term 'Effective Time' shall mean
the date and time at which the Merger shall become effective.
Section 1.3 Closing. The closing of the transactions contemplated by this
Agreement (the 'Closing') shall take place at the offices of Proskauer Rose LLP,
1585 Broadway, New York, New York, at 10:00 a.m., on the day on which all of the
conditions set forth in Article VIII are satisfied or waived or on such other
date and at such other time and place as Parent and the Company shall agree
(such date, the 'Closing Date').
ARTICLE II
THE SURVIVING CORPORATION
Section 2.1 Articles of Incorporation. The Articles of Incorporation of
Sub in effect at the Effective Time shall be the Certificate of Incorporation of
the Surviving Corporation until amended in accordance with applicable law,
except that the name of the Surviving Corporation shall be 'Sullivan Dental
Products, Inc.'
Section 2.2 By-Laws. The By-Laws of Sub as in effect at the Effective
Time shall be the By-Laws of the Surviving Corporation until amended in
accordance with applicable law.
Section 2.3 Directors and Officers of Surviving Corporation.
(a) The directors of Sub at the Effective Time shall be the initial
directors of the Surviving Corporation and shall hold office from the Effective
Time until their respective successors are duly elected or appointed and
qualified in the manner provided in the Certificate of Incorporation or By-Laws
of the Surviving Corporation or as otherwise provided by law.
(b) The officers of the Company at the Effective Time shall be the initial
officers of the Surviving Corporation and shall hold office from the Effective
Time until their respective successors are duly elected or appointed and
qualified in the manner provided in the Certificate of Incorporation or By-Laws
of the Surviving Corporation, or as otherwise provided by law.
ARTICLE III
CONVERSION OF SHARES
Section 3.1 Exchange Ratio. At the Effective Time, by virtue of the
Merger and without any action on the part of the holder thereof:
(a) Each share of Company Common Stock issued and outstanding immediately
prior to the Effective Time (other than shares to be cancelled in accordance
with Section 3.1(b)) shall be converted into the right to receive 0.735 (the
'Exchange Ratio') of a share of the common stock, par value $.01 per share, of
Parent (the 'Parent Common Stock'), payable upon the surrender of the
certificate formerly representing such share of Company Common Stock.
(b) All shares of Company Common Stock that are held by the Company as
treasury shares shall be cancelled and retired and cease to exist, and no
securities of Parent or other consideration shall be delivered in exchange
therefor.
(c) Each share of Common Stock, par value $.01 per share, of Sub (the 'Sub
Common Stock'), issued and outstanding immediately prior to the Effective Time
shall be converted into and become one fully paid and nonassessable share of
Common Stock, par value $.01 per share, of the Surviving Corporation.
(d) Each outstanding option to purchase Company Common Stock issued by the
Company (each, a 'Company Stock Option') shall be assumed by Parent as more
specifically provided in Section 7.8.
Section 3.2 Exchange of Company Common Stock; Procedures.
(a) Prior to the Closing Date, Parent shall designate a bank or trust
company reasonably acceptable to the Company to act as Exchange Agent hereunder
(the 'Exchange Agent'). As soon as practicable after the Effective Time, Parent
shall cause the Transfer Agent to deposit with or for the account of the
Exchange Agent stock certificates representing the number of shares of Parent
Common Stock issuable pursuant to Section 3.1 in exchange for outstanding shares
of Company Common Stock, which shares of Parent Common Stock shall be deemed to
have been issued at the Effective Time.
(b) As soon as practicable after the Effective Time, Parent shall cause the
Exchange Agent to mail to each holder of record of a certificate or certificates
which immediately prior to the Effective Time represented outstanding shares of
Company Common Stock (the 'Certificates') that were converted pursuant to
Section 3.1 into the right to receive shares of Parent Common Stock (i) a form
of letter of transmittal specifying that delivery shall be effected, and risk of
loss and title to the Certificates shall pass, only upon proper delivery of the
Certificates to the Exchange Agent and (ii) instructions for use in surrendering
such Certificates in exchange for certificates representing shares of Parent
Common Stock. Upon surrender of a Certificate for cancellation (or delivery of
such customary affidavit with respect to a lost Certificate as the Exchange
Agent may reasonably require) to the Exchange Agent, together with such letter
of transmittal, duly executed, the holder of such Certificate shall be entitled
to receive in exchange therefor (x) a certificate representing that number of
whole shares of Parent Common Stock which such holder has the right to receive
pursuant to the provisions of this Article III and (y) cash in lieu of any
fractional shares of Parent Common Stock to which such holder is entitled
pursuant to Section 3.4, after giving effect to any required tax withholdings,
and the Certificate so surrendered (or with respect to which a lost Certificate
affidavit has been delivered as provided above) shall forthwith be
2
cancelled. In the event of a transfer of ownership of Company Common Stock which
is not registered in the transfer records of the Company, a certificate
representing the proper number of shares of Parent Common Stock may be issued to
a transferee if the Certificate representing such Company Common Stock is
presented to the Exchange Agent, accompanied by all documents required to
evidence and effect such transfer, and by evidence that any applicable stock
transfer taxes have been paid. Until surrendered as contemplated by this Section
3.2(b), each Certificate shall be deemed at any time after the Effective Time to
represent only the right to receive upon such surrender a certificate
representing shares of Parent Common Stock and cash in lieu of any fractional
shares of Parent Common Stock as contemplated by this Article III.
Section 3.3 Dividends; Transfer Taxes, Escheat. No dividends or
distributions that are declared on shares of Parent Common Stock will be paid to
persons entitled to receive certificates representing shares of Parent Common
Stock until such persons surrender their Certificates. Upon such surrender,
there shall be paid to the person in whose name the certificates representing
such shares of Parent Common Stock shall be issued, any dividends or
distributions with respect to such shares of Parent Common Stock which have a
record date after the Effective Time and shall have become payable between the
Effective Time and the time of such surrender. In no event shall the person
entitled to receive such dividends or distributions be entitled to receive
interest thereon. Promptly following the date which is six months after the
Effective Time, the Exchange Agent shall deliver to the Surviving Corporation
all cash, certificates and other documents in its possession relating to the
transactions described in this Agreement, and any holders of Company Common
Stock who have not theretofore complied with this Article III shall look
thereafter only to the Surviving Corporation for the shares of Parent Common
Stock, any dividends or distributions thereon, and any cash in lieu of
fractional shares thereof to which they are entitled pursuant to this Article
III. Notwithstanding the foregoing, neither the Exchange Agent nor any party
hereto shall be liable to a holder of Company Common Stock for any shares of
Parent Common Stock, any dividends or distributions thereon or any cash in lieu
of fractional shares thereof delivered to a public official pursuant to
applicable abandoned property, escheat or similar laws.
Section 3.4 No Fractional Securities. No certificates or scrip
representing fractional shares of Parent Common Stock shall be issued upon the
surrender for exchange of Certificates, and such fractional interests shall not
entitle the owner thereof to vote or to any rights of a security holder. In lieu
of any such fractional securities, each holder of Company Common Stock who would
otherwise have been entitled to a fraction of a share of Parent Common Stock
upon surrender of such holder's Certificates will be entitled to receive, and
Parent will timely provide (or cause to be provided) to the Exchange Agent
sufficient funds to make, a cash payment (without interest) determined by
multiplying (i) the fractional interest to which such holder would otherwise be
entitled (after taking into account all shares of Company Common Stock then held
of record by such holder) and (ii) the average of the per share closing prices
for Parent Common Stock on the NASDAQ National Market ('NASDAQ') for the five
trading days immediately preceding the Effective Time. It is understood (i) that
the payment of cash in lieu of fractional shares of Parent Common Stock is
solely for the purpose of avoiding the expense and inconvenience to Parent of
issuing fractional shares and does not represent separately bargained-for
consideration and (ii) that no holder of Company Common Stock will receive cash
in lieu of fractional shares of Parent Common Stock in an amount greater than
the value of one full share of Parent Common Stock.
Section 3.5 Closing of Company Transfer Books. At the Effective Time, the
stock transfer books of the Company shall be closed and no transfer of shares of
Company Common Stock shall thereafter be made. If, after the Effective Time,
Certificates are presented to the Surviving Corporation, they shall be cancelled
and exchanged as provided in this Article III.
Section 3.6 Further Assurances. If, at any time after the Effective Time,
the Surviving Corporation shall consider or be advised that any deeds, bills of
sale, assignments, assurances or any other actions or things are necessary or
desirable to vest, perfect or confirm of record or otherwise in the Surviving
Corporation its right, title or interest in, to or under any of the rights,
properties or assets of either of Sub or the Company acquired or to be acquired
by the Surviving Corporation as a result of, or in connection with, the Merger
or otherwise to carry out this Agreement, the officers of the Surviving
Corporation shall be authorized to execute and deliver, in the name and on
behalf of each of Sub and the Company or otherwise, all such deeds, bills of
sale, assignments and assurances and to take and do, in such names and on such
behalves or otherwise, all such other actions and things as may be necessary or
desirable to vest, perfect or confirm any and all right, title and interest in,
to and under
3
such rights, properties or assets in the Surviving Corporation or otherwise to
carry out the purposes of this Agreement.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to Parent and Sub as follows:
Section 4.1 Organization. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Wisconsin
and has the corporate power to carry on its business as it is now being
conducted or presently proposed to be conducted. The Company is duly qualified
as a foreign corporation to do business, and is in good standing, in each
jurisdiction where the character of its properties owned or held under lease or
the nature of its activities makes such qualification necessary, except where
the failure to be so qualified will not have a material adverse effect,
individually or in the aggregate, on the financial condition, results of
operations, assets, liabilities or properties of the Company and its
Subsidiaries taken as a whole, or on the ability of the Company to consummate
the Merger and the other transactions contemplated by this Agreement (a 'Company
Material Adverse Effect'). As used in this Agreement, the term 'Subsidiary'
means, with respect to any party, any corporation or other organization, whether
incorporated or unincorporated, of which (x) such party or any other Subsidiary
of such party is a general partner (excluding partnerships, the general
partnership interests of which held by such party or any Subsidiary of such
party do not have a majority of the voting interest in such partnership) or (y)
at least a majority of the securities or other interests having by their terms
ordinary voting power to elect a majority of the board of directors or others
performing similar functions with respect to such corporation or other
organization is directly or indirectly owned or controlled by such party and/or
one or more of its Subsidiaries.
Section 4.2 Capitalization.
(a) The authorized capital stock of the Company consists of 30,000,000
shares of Company Common Stock and 500,000 shares of preferred stock, par value
$.01 per share of the Company (the 'Company Preferred Stock'). As of July 31,
1997, (i) approximately 10,027,951 shares of Company Common Stock were issued
and outstanding, (ii) no shares of Company Preferred Stock were issued and
outstanding, (iii) Company Stock Options to acquire approximately 1,766,775
shares of Company Common Stock were outstanding under all stock option plans of
the Company, and (iv) approximately 2,435,550 shares of Company Common Stock
were reserved for issuance pursuant to the Company Stock Options and all other
employee benefit plans of the Company. All of the issued and outstanding shares
of Company Common Stock are validly issued, fully paid and nonassessable.
(b) Except as disclosed in this Section 4.2 or as set forth on Schedule
4.2(b), (i) there is no outstanding right, subscription, warrant, call, option
or other agreement or arrangement of any kind (collectively, 'Rights') to
purchase or otherwise to receive from the Company or any of its Subsidiaries any
of the outstanding, authorized but unissued or treasury shares of the capital
stock or any other security of the Company or any of its Subsidiaries or to
require the Company or any of its Subsidiaries to purchase any such security,
(ii) there is no outstanding security of any kind convertible into or
exchangeable for such capital stock, and (iii) there is no voting trust or other
agreement or understanding to which the Company or any of its Subsidiaries is a
party or is bound with respect to the voting of the capital stock of the Company
or any of its Subsidiaries. The conversion of the Company Stock Options provided
for in Section 7.8 of this Agreement is in accordance with the respective terms
of the Company Stock Options and the plans under which they were issued.
(c) Since December 31, 1995, except as set forth on Schedule 4.2(c), the
Company has not in any manner accelerated or provided for the acceleration of
the vesting or exercisability of, or otherwise modified the terms and conditions
applicable to, any of the Company Stock Options, whether set forth in the
governing stock option plans of the Company, a stock option grant, award or
other agreement or otherwise. Except as set forth on Schedule 4.2(c), none of
the awards, grants or other agreements pursuant to which Company Stock Options
were issued have provisions which accelerate the vesting or right to exercise
such options upon the execution of this Agreement (including the documents
attached as Exhibits hereto), the consummation of the transactions contemplated
hereby (or thereby) or any other 'change of control' events.
4
Section 4.3 Company Subsidiaries. Schedule 4.3 contains a complete and
accurate list of all Subsidiaries of the Company. Each Subsidiary of the Company
that is a corporation is duly organized, validly existing and in good standing
under the laws of its jurisdiction of incorporation. Each Subsidiary of the
Company that is a partnership or limited liability company is duly formed and
validly existing under the laws of its jurisdiction of formation. Each
Subsidiary of the Company has the corporate, partnership or limited liability
company power, as the case may be, to carry on its business as it is now being
conducted or presently proposed to be conducted. Each Subsidiary of the Company
is duly qualified as a foreign corporation, foreign partnership or a foreign
limited liability company, as the case may be, authorized to do business, and is
in good standing, in each jurisdiction where the character of its properties
owned or held under lease or the nature of its activities makes such
qualification necessary, except where the failure to be so qualified will not
have a Company Material Adverse Effect. All of the outstanding shares of capital
stock of the Subsidiaries of the Company that are corporations are validly
issued, fully paid and nonassessable. Except as set forth in the Company SEC
Reports (as hereinafter defined), all of the outstanding shares of capital stock
of, or other membership or ownership interests in, each Subsidiary of the
Company are owned by the Company or a Subsidiary of the Company, in each case
free and clear of any liens, pledges, security interests, claims, charges or
other encumbrances of any kind whatsoever ('Liens').
Section 4.4 Authority Relative to this Agreement. The Company has the
requisite corporate power and authority to execute and deliver this Agreement
and to consummate the transactions contemplated hereby. The execution and
delivery of this Agreement by the Company and the consummation by the Company of
the transactions contemplated on its part hereby have been duly authorized by
the Company's Board of Directors and, except for the approval of its
stockholders to be sought at the stockholders meeting contemplated by Section
7.4(a) with respect to this Agreement, no other corporate proceedings on the
part of the Company are necessary to authorize this Agreement or for the Company
to consummate the transactions contemplated hereby. This Agreement has been duly
and validly executed and delivered by the Company and constitutes a valid and
binding agreement of the Company, enforceable against the Company in accordance
with its terms.
Section 4.5 Consents and Approvals; No Violations. Neither the execution,
delivery and performance of this Agreement by the Company, nor the consummation
by the Company of the transactions contemplated hereby, will (i) conflict with
or result in any breach of any provisions of the charter, by-laws or other
organizational documents of the Company or any of its Subsidiaries, (ii) require
a filing with, or a permit, authorization, consent or approval of, any federal,
state, local or foreign court, arbitral tribunal, administrative agency or
commission or other governmental or other regulatory authority or administrative
agency or commission (a 'Governmental Entity'), except in connection with, or in
order to comply with, the applicable provisions of the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the 'HSR Act'), the Securities
Act of 1933, as amended (the 'Securities Act'), the Securities Exchange Act of
1934, as amended (the 'Exchange Act'), state securities or 'blue sky' laws, the
By-Laws of the National Association of Securities Dealers, Inc. (the 'NASD') and
the filing and recordation of a Certificate of Merger as required by the WBCL,
(iii) except as set forth on Schedule 4.5, result in a violation or breach of,
or constitute (with or without due notice or lapse of time or both) a default
(or give rise to any right of termination, cancellation or acceleration) under,
or result in the creation of a Lien on any property or asset of the Company or
any of its Subsidiaries pursuant to, any of the terms, conditions or provisions
of any material note, bond, mortgage, indenture, license, contract, agreement or
other instrument or obligation (each, a 'Contract') to which the Company or any
of its Subsidiaries is a party or by which any of them or any of their
properties or assets may be bound or (iv) violate any material law, order, writ,
injunction, decree, statute, rule or regulation of any Governmental Entity
applicable to the Company, any of its Subsidiaries or any of their properties or
assets.
Section 4.6 Reports and Financial Statements. The Company has timely
filed all reports required to be filed with the Securities and Exchange
Commission (the 'SEC') pursuant to the Exchange Act or the Securities Act since
January 1, 1995 (collectively, the 'Company SEC Reports'), and has previously
made available to Parent true and complete copies of all such Company SEC
Reports. Such Company SEC Reports, as of their respective dates, complied in all
material respects with the applicable requirements of the Securities Act and the
Exchange Act, as the case may be, and none of such Company SEC Reports contained
any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading. The
consolidated financial
5
statements of the Company included in the Company SEC Reports have been prepared
in accordance with United States generally accepted accounting principles
('GAAP') consistently applied throughout the periods indicated (except as
otherwise noted therein) and fairly present the consolidated financial position
of the Company and its consolidated Subsidiaries as at the dates thereof and the
consolidated results of operations and cash flows of the Company and its
consolidated Subsidiaries as of the respective dates, and for the respective
periods, presented therein, except that in the case of the unaudited
consolidated financial statements included in any Form 10-Q, the presentation
and disclosures conform with the applicable rules of the Exchange Act, but
include all adjustments necessary to conform to GAAP requirements with respect
to interim financial statements. Except as set forth on Schedule 4.6, since
January 1, 1996, there has been no change in any of the significant accounting
(including tax accounting) policies, practices or procedures of the Company or
any of its consolidated Subsidiaries. References in this Agreement to the
Company's consolidated financial statements shall be deemed to include the
Company's financial statements with respect to any period or as of any date
during which or which the Company did not have any consolidated Subsidiaries.
Section 4.7 Absence of Certain Changes or Events; Material
Contracts. Except as set forth on Schedule 4.7 or the Company's SEC Reports,
since December 31, 1996 (i) neither the Company nor any of its Subsidiaries has
conducted its business and operations other than in the ordinary course of
business and consistent with past practices or taken any actions that, if it had
been in effect, would have violated or been inconsistent with the provisions of
Section 6.1 and (ii) there has not been any fact, event, circumstance or change
affecting or relating to the Company or any of its Subsidiaries which has had or
is reasonably likely to have a Company Material Adverse Effect. Except as set
forth on Schedule 4.7, the transactions contemplated by this Agreement will not
constitute a change of control under or require the consent from or the giving
of notice to a third party pursuant to the terms, conditions or provisions of
any material Contract to which Parent or any of its Subsidiaries is a party.
Section 4.8 Litigation. Except for litigation disclosed on Schedule 4.8,
in the notes to the financial statements included in the Company's Annual Report
on Form 10-K for the year ended December 31, 1996 or in the Company SEC Reports
filed subsequent thereto, there is no suit, action, proceeding or investigation
pending or, to the Actual Knowledge of the Company, threatened against the
Company or any of its Subsidiaries or any of their respective properties, the
outcome of which is reasonably likely to have a Company Material Adverse Effect;
nor is there any judgment, decree, injunction, ruling or order of any
Governmental Entity outstanding against the Company or any of its Subsidiaries
having, or which is reasonably likely to have a Company Material Adverse Effect.
The term 'Actual Knowledge of the Company' shall mean the actual knowledge of
any of Robert J. Sullivan, Robert E. Doering, Timothy J. Sullivan, Kevin J.
Ackeret, Geoffrey A. Reichardt, David A. Steck and Kenneth A. Schwing.
Section 4.9 Absence of Undisclosed Liabilities. Except for liabilities or
obligations which are accrued or reserved against in the Company's consolidated
financial statements (or disclosed in the notes thereto) included in the Company
SEC Reports or which were incurred after December 31, 1996 in the ordinary
course of business and consistent with past practice, and except as set forth on
Schedule 4.9, none of the Company and its Subsidiaries has any liabilities or
obligations (whether absolute, accrued, contingent or otherwise) of a nature
required by GAAP to be reflected in a consolidated balance sheet (or disclosed
in the notes thereto) or which may, to the Actual Knowledge of the Company, have
a Company Material Adverse Effect.
Section 4.10 No Default. Except as set forth on Schedule 4.10, neither
the Company nor any Subsidiary of the Company is in default or violation (and no
event has occurred which with notice or the lapse of time or both would
constitute a default or violation) of any term, condition or provision of (i)
its charter, by-laws or comparable organizational documents, (ii) any material
Contract to which the Company or any of its Subsidiaries is a party or by which
they or any of their properties or assets may be bound, or (iii) any material
order, writ, injunction, decree, statute, rule or regulation of any Governmental
Entity applicable to the Company or any of its Subsidiaries.
Section 4.11 Taxes.
(a) The Company has heretofore delivered or will make available to Parent
true, correct and complete copies of the consolidated federal, state, local and
foreign income, franchise sales and other Tax Returns (as hereinafter defined)
filed by the Company and its Subsidiaries for each of the Company's years ended
December 31, 1995, 1994, 1993 and 1992, inclusive. Except as set forth on
Schedule 4.11, the Company has duly filed, and
6
each Subsidiary has duly filed, all material federal, state, local and foreign
income, franchise, sales and other Tax Returns required to be filed by the
Company or any of its Subsidiaries. All such Tax Returns are true, correct and
complete, in all material respects, and the Company and its Subsidiaries have
duly paid, all Taxes (as hereinafter defined) shown on such Tax Returns and has
made adequate provision for payment of all accrued but unpaid material Taxes
anticipated in respect of all periods since the periods covered by such Tax
Returns. Except as set forth on Schedule 4.11, all material deficiencies
assessed as a result of any examination of Tax Returns of the Company or any of
its Subsidiaries by federal, state, local or foreign tax authorities have been
paid or reserved on the financial statements of the Company in accordance with
GAAP consistently applied, and true, correct and complete copies of all revenue
agent's reports, '30-day letters,' or '90-day letters' or similar written
statements proposing or asserting any Tax deficiency against the Company or any
of its Subsidiaries for any open year have been heretofore delivered to Parent.
The Company has heretofore delivered or will make available to Parent true,
correct and complete copies of all written tax-sharing agreements and written
descriptions of all such unwritten agreement or arrangements to which the
Company or any of its Subsidiaries is a party. Except as set forth in Schedule
4.11, no material issue has been raised during the past five years by any
federal, state, local or foreign taxing authority which, if raised with regard
to any other period not so examined, could reasonably be expected to result in a
proposed material deficiency for any other period not so examined. Except as
disclosed in Schedule 4.11 hereof, neither the Company nor any of its
Subsidiaries has granted any extension or waiver of the statutory period of
limitations applicable to any claim for any material Taxes. The consolidated
federal income tax returns of the Company and its Subsidiaries have been
examined by and settled with the Internal Revenue Service (the 'Service') for
all years through 1987. Except as set forth in Schedule 4.11, (i) neither the
Company nor any of the Company Subsidiaries is a party to any agreement,
contract or arrangement that would result, separately or in the aggregate, in
the payment of any 'excess parachute payments' within the meaning of Section
28OG of the Code; (ii) no consent has been filed under Section 341(f) of the
Code with respect to any of the Company or the Subsidiaries of the Company;
(iii) neither the Company nor any of the Subsidiaries of the Company has
participated in, or cooperated with, an international boycott within the meaning
of Section 999 of the Code; and (iv) neither the Company nor any of the
Subsidiaries of the Company has issued or assumed any corporate acquisition
indebtedness, as defined in Section 279(b) of the Code. The Company and each
Subsidiary of the Company have complied (and until the Effective Time will
comply) in all material respects with all applicable laws, rules and regulations
relating to the payment and withholding of Taxes (including, without limitation,
withholding of Taxes pursuant to Sections 1441 and 1442 of the Code or similar
provisions under any foreign laws) and have, within the time and in the manner
prescribed by law, withheld from employee wages and paid over to the proper
governmental authorities all amounts required to be so withheld and paid over
under all applicable laws.
(b) For purposes of this Agreement, the term 'Taxes' shall mean all taxes,
charges, fees, levies, duties, imposts or other assessments, including, without
limitation, income, gross receipts, excise, property, sales, use, transfer,
gains, license, payroll, withholding, capital stock and franchise taxes, imposed
by the United States, or any state, local or foreign government or subdivision
or agency thereof, including any interest, penalties or additions thereto. For
purposes of this Agreement, the term 'Tax Return' shall mean any report, return
or other information or document required to be supplied to a taxing authority
in connection with Taxes.
Section 4.12 Title to Properties; Encumbrances. Except as described in
the following sentence, each of the Company and its Subsidiaries has good, valid
and marketable title to, or a valid leasehold interest in, all of its material
properties and assets (real, personal and mixed, tangible and intangible),
including, without limitation, all the properties and assets reflected in the
balance sheet of the Company as of March 31, 1997 included in the Company's
Quarterly Report on Form 10-Q for the period ended on such date (except for
properties and assets disposed of in the ordinary course of business and
consistent with past practices since March 31, 1997). None of such properties or
assets are subject to any Liens (whether absolute, accrued, contingent or
otherwise), except (i) as specifically set forth in the Company SEC Reports and
(ii) minor imperfections of title and encumbrances, if any, which are not
substantial in amount, do not materially detract from the value of the property
or assets subject thereto and do not impair the operations of any of the Company
and its Subsidiaries.
Section 4.13 Intellectual Property.
(a) Except as set forth on Schedule 4.13(a), the Company and its
Subsidiaries are the sole and exclusive owners of all material patents, patent
applications, patent rights, trademarks, trademark rights, trade names, trade
7
name rights, copyrights, service marks, trade secrets, registrations for and
applications for registration of trademarks, service marks and copyrights,
technology and know-how, rights in computer software and other proprietary
rights and information and all technical and user manuals and documentation made
or used in connection with any of the foregoing, used or held for use in
connection with the businesses of the Company or any of its Subsidiaries as
currently conducted (collectively, the 'Intellectual Property'), free and clear
of all Liens except as set forth on Schedule 4.13(a) and except minor
imperfections of title and encumbrances, if any, which are not substantial in
amount, do not materially detract from the value of the Intellectual Property
subject thereto and do not impair the operations of any of the Company and its
Subsidiaries.
(b) All grants, registrations and applications for Intellectual Property
that are used in and are material to the conduct of the Business (as hereinafter
defined) (i) are valid, subsisting, in proper form and enforceable, and have
been duly maintained, including the submission of all necessary filings and fees
in accordance with the legal and administrative requirements of the appropriate
jurisdictions and (ii) have not lapsed, expired or been abandoned, and no grant,
registration or license therefor is the subject of any legal or governmental
proceeding before any registration authority in any jurisdiction.
(c) Each of the Company and its Subsidiaries owns or has the right to use
all of the material Intellectual Property used by it or held for use by it in
connection with its business. To the Actual Knowledge of the Company, there are
no conflicts with or infringements of any Intellectual Property by any third
party. The conduct of the businesses of the Company and its Subsidiaries as
currently conducted (collectively, the 'Business') does not conflict with or
infringe in any way any proprietary right of any third party, which conflict or
infringement would have a Company Material Adverse Effect, and there is no
claim, suit, action or proceeding pending or, to the Actual Knowledge of the
Company, threatened against the Company or any of its Subsidiaries (i) alleging
any such conflict or infringement with any third party's proprietary rights, or
(ii) challenging the ownership, use, validity or enforceability of the
Intellectual Property.
Section 4.14 Compliance with Applicable Law. Except as set forth on
Schedule 4.14 or as disclosed in the Company SEC Reports, (i) the Company and
its Subsidiaries hold, and are in compliance with the terms of, all material
permits, licenses, exemptions, orders and approvals of all Governmental Entities
necessary for the current and proposed conduct of their respective businesses
('Company Permits'), except for failures to hold or to comply with such permits,
licenses, exemptions, orders and approvals which would not have a Company
Material Adverse Effect, (ii) no fact exists or event has occurred, and no
action or proceeding is pending or, to the Actual Knowledge of the Company
threatened, that has a reasonable possibility of resulting in a revocation,
nonrenewal, termination, suspension or other material impairment of any material
Company Permits, (iii) the businesses of the Company and its Subsidiaries are
not being conducted in material violation of any applicable law, ordinance,
regulation, judgment, decree or order of any Governmental Entity ('Applicable
Law'), and (iv) to the Actual Knowledge of the Company (x) no investigation or
review by any Governmental Entity with respect to the Company or its
Subsidiaries is pending or threatened, and (y) no Governmental Entity has
indicated an intention to conduct the same.
Section 4.15 Information in Disclosure Documents and Registration
Statement. None of the information to be supplied by or on behalf of the
Company for inclusion in (i) the Registration Statement to be filed with the SEC
by Parent on Form S-4 under the Securities Act for the purpose of registering
the shares of Parent Common Stock to be issued in connection with the Merger
(the 'Registration Statement') or (ii) the joint proxy statement to be
distributed in connection with Parent's and the Company's meetings of
stockholders to vote upon this Agreement (the 'Proxy Statement') will, in the
case of the Registration Statement, at the time it becomes effective, at the
time of the filing of any post-effective amendment thereto and at the Effective
Time, and, in the case of the Proxy Statement or any amendments thereof or
supplements thereto, at the time of the mailing of the Proxy Statement and any
amendments or supplements thereto, and at the respective times of the meetings
of stockholders of the Company and Parent to be held in connection with the
Merger, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made, not
misleading. The Proxy Statement will comply as to form in all material respects
with the applicable provisions of the Exchange Act, and the rules and
regulations promulgated thereunder, except that no representation is made by the
Company with respect to statements made therein based on information supplied by
Parent or its representatives for inclusion in the Proxy
8
Statement or with respect to information concerning Parent or any of its
Subsidiaries incorporated by reference in the Proxy Statement.
Section 4.16 Employee Benefit Plans; ERISA.
(a) Schedule 4.16 hereto sets forth a true and complete list of each
'employee benefit plan,' within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended ('ERISA'), and any other
material employee benefit plan, arrangement or agreement, that is maintained, or
was maintained at any time during the five (5) calendar years preceding the date
of this Agreement (the 'Company Plans'), by the Company or by any trade or
business, whether or not incorporated (a 'Company ERISA Affiliate'), which
together with the Company would be deemed a 'single employer' within the meaning
of Section 4001 of ERISA or under Section 414(b), (c), (m) or (o) of the Code.
True and complete copies of each of the Company Plans and related documents have
been delivered to the Parent.
(b) Each of the Company Plans is and has been maintained and operated in
compliance with its terms and applicable law, including without limitation,
ERISA and the Code; each of the Company Plans intended to be 'qualified' within
the meaning of Section 401(a) of the Code is so qualified and has been qualified
since its inception.
(c) None of the Company, any Company ERISA Affiliate, or any of their
respective predecessors has ever contributed to, contributes to, has ever been
required to contribute to, or otherwise participated in or participates in or in
any way, directly or indirectly, has any liability with respect to any plan
subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA,
including, without limitation any, 'multiemployer plan' (within the meaning of
Sections (3)(37) or 4001(a)(3) of ERISA or Section 414(f) of the Code), or any
single employer pension plan and no Company Plan is a multiple employer plan
described in Section 413 of the Code. All contributions or other amounts payable
by the Company as of the Effective Time with respect to each Company Plan in
respect of current or prior plan years have been either paid or accrued on the
balance sheet of the Company. There are no pending, threatened or, to the Actual
Knowledge of the Company, anticipated claims, lawsuits, arbitrations or other
actions (other than non-material routine claims for benefits) by, on behalf of
or against any of the Company Plans, any trustee or fiduciaries thereof or any
trusts related thereto. No Company Plan currently is under audit or
investigation by the Internal Revenue Service, U.S. Department of Labor, or any
other governmental authority and no such completed audit, if any, has resulted
in the imposition of any tax or penalty. With respect to each Company Plan that
is funded mostly or partially through an insurance policy, neither the Company
nor any Company ERISA Affiliate has any material liability in the nature of
retroactive rate adjustment, loss sharing arrangement or other actual or
contingent material liability arising wholly or partially out of events
occurring on or before the Effective Time.
(d) Neither the Company nor any Company ERISA Affiliate, nor any Company
Plan, nor any trust created thereunder, nor any trustee or administrator thereof
has engaged in a transaction in connection with which the Company or any Company
ERISA Affiliate, any Company Plan, any such trust, or any trustee or
administrator thereof, or any party dealing with any Company Plan or any such
trust that is a 'prohibited transaction,' within the meaning of Section 4975 of
the Code and Section 406 of ERISA, other than a prohibited transaction that has
been corrected and with respect to which all taxes and penalties have been paid
prior to the date hereof. Except as set forth on Schedule 4.16, no Company Plan
provides benefits (whether or not insured), with respect to current or former
employees of the Company or any Company ERISA Affiliate beyond their retirement
or other termination of service other than benefits under any 'employee pension
plan,' as that term is defined in Section 3(2) of ERISA, qualified under Section
401(a) of the Code or under Section 4980B of the Code. Neither the Company, any
Company ERISA Affiliate, nor any officer or employee thereof, has made any
promises or commitments, whether legally binding or not, to create any
additional plan, agreement, or arrangement, or to modify or change any existing
Company Plan. The consummation of the transactions contemplated by this
Agreement will not give rise to any liability, including, without limitation,
liability for severance pay, unemployment compensation, termination pay, or
withdrawal liability, or accelerate the time of payment or vesting or increase
the amount of compensation or benefits due to any employee, director,
shareholder, or beneficiary of the Company (whether current, former, or retired)
or their beneficiaries solely by reason of such transactions. Neither the
Company nor any Company ERISA Affiliate has any material unfunded liabilities
pursuant to any Company Plan that is not intended to be qualified under Section
401(a) of the Code.
9
Section 4.17 Environmental Laws and Regulations.
(a) Except as set forth on Schedule 4.17(a), (i) the Company and its
Subsidiaries are and have been, in all material respects, in compliance with,
and there are no outstanding written allegations or, to the Actual Knowledge of
the Company, oral allegations by any person or entity that the Company or its
Subsidiaries has not been in compliance with, all material applicable laws,
rules, regulations, common law, ordinances, decrees, orders or other binding
legal requirements relating to pollution (including the treatment, storage and
disposal of hazardous wastes or materials and the remediation of releases and
threatened releases of hazardous materials or wastes), the preservation of the
environment, and the exposure to hazardous wastes or materials in the
environment or work place ('Environmental Laws') and (ii) the Company and its
Subsidiaries currently hold all material permits, licenses, registrations and
other governmental authorizations (including exemptions, waivers, and the like)
and financial assurance required under Environmental Laws for the Company and
its Subsidiaries to operate their businesses as currently conducted.
(b) Except as set forth on Schedule 4.17(b), (i) there is no friable
asbestos-containing material in or on any real property currently owned, leased
or operated by the Company or its Subsidiaries and (ii) there are and, to the
Actual Knowledge of the Company, have been no underground storage tanks (whether
or not required to be registered under any applicable law), dumps, landfills,
lagoons, surface impoundments, injection wells or other land disposal units in
or on any property currently owned, leased or operated by the Company or its
Subsidiaries.
(c) Except as set forth on Schedule 4.17(c), (i) neither the Company nor
its Subsidiaries has received (x) any written communication from any person
stating or alleging that any of them may be a potentially responsible party
under any Environmental Law (including, without limitation, the Federal
Comprehensive Environmental Response, Compensation, and Liability Act of 1980,
as amended) with respect to any actual or alleged environmental contamination or
(y) any request for information under any Environmental Law from any
Governmental Entity with respect to any actual or alleged material environmental
contamination; and (ii) neither the Company, nor its Subsidiaries nor any
Governmental Entity is conducting or has conducted (or, to the Actual Knowledge
of the Company, is threatening to conduct) any environmental remediation or
investigation.
(d) To the Actual Knowledge of the Company, all real properties formerly
owned, used, leased, occupied, managed or operated by the Company or its
Subsidiaries complied, in all material respects, with the Environmental Laws
during the Company's or its Subsidiaries' tenure thereat, and there are no
environmental liabilities associated therewith that are reasonably likely to
result in a Company Material Adverse Effect.
Section 4.18 Vote Required. The affirmative vote of the holders of a
majority of the outstanding shares of the Company Common Stock are the only
votes of the holders of any class or series of the Company's capital stock
necessary to approve the Merger. The Board of Directors of the Company (at a
meeting duly called and held) has unanimously (i) approved this Agreement and
the Irrevocable Proxy and Termination Rights Agreement, (ii) determined that the
transactions contemplated hereby and thereby are fair to and in the best
interests of the holders of Company Common Stock and (iii) determined to
recommend this Agreement, the Merger and the other transactions contemplated
hereby to such holders for approval and adoption. The resolutions of the
Company's Board of Directors taking the actions described in the preceding
sentence have not been rescinded, withdrawn, amended or otherwise modified,
remain in full force and effect, and constitute the only action of such Board of
Directors with respect to the Merger or the other transactions contemplated by
this Agreement.
Section 4.19 Opinion of Financial Advisor. The Board of Directors of the
Company has received the opinion of Cleary Gull Reiland & McDevitt, Inc.
('Cleary Gull'), dated August 1, 1997, substantially to the effect that the
consideration to be received in the Merger by the holders of Company Common
Stock is fair to such holders from a financial point of view, a copy of which
opinion has been delivered to Parent.
Section 4.20 Accounting Matters. None of the Company, any of its
Subsidiaries or, to the Actual Knowledge of the Company, any of their respective
directors, officers or stockholders, has taken any action which would prevent
the accounting for the Merger as a pooling of interests in accordance with
Accounting Principles Board Opinion No. 16, the interpretative releases pursuant
thereto and the pronouncements of the SEC.
Section 4.21 WBCL Sections 1131, 1134 and 1141. Prior to the date hereof,
the Board of Directors of the Company has approved this Agreement and the
Irrevocable Proxy and Termination Rights Agreement, and the
10
Merger and the other transactions contemplated hereby and thereby, and such
approval is sufficient to render inapplicable to the Merger and any of such
other transactions the provisions of Sections 1131, 1134 and 1141 of the WBCL.
Section 4.22 Labor Matters. Neither the Company nor any of its
Subsidiaries is a party to, or bound by, any collective bargaining agreement,
contract or other understanding with a labor union or labor organization and, to
the Actual Knowledge of the Company, there is no activity involving any
employees of the Company or its Subsidiaries seeking to certify a collective
bargaining unit or engaging in any other organizational activity.
Section 4.23 Affiliate Transactions. Except as set forth in Schedule 4.23
or as disclosed in the Company SEC Reports, there are no, and since January 1,
1996 there have not been any, material Contracts or other transactions between
the Company or any of its Subsidiaries, on the one hand, and any (i) officer or
director of the Company or any of its Subsidiaries, (ii) record or beneficial
owner of five percent or more of the voting securities of the Company or (iii)
affiliate (as such term is defined in Regulation 12b-2 promulgated under the
Exchange Act) of any such officer, director or beneficial owner, on the other
hand.
Section 4.24 Brokers. Except for its financial advisor, Cleary Gull, no
broker, finder or financial advisor is entitled to any brokerage, finder's or
other fee or commission in connection with the Merger or the transactions
contemplated by this Agreement based upon arrangements made by or on behalf of
the Company and the Company has disclosed to Parent the material terms of the
agreement pursuant to which Cleary Gull is entitled to its fee.
Section 4.25 Tax Matters. The Company knows of no fact or circumstance
which is reasonably likely to cause the Merger to be treated other than as a
tax-free reorganization under Section 368(a) of the Code.
Section 4.26 Accounts Receivable. All of the accounts and notes
receivable of the Company and its Subsidiaries set forth on the books and
records of the Company (net of the applicable reserves reflected on the books
and records of the Company and in the financial statements included in the
Company SEC Reports) (i) represent sales actually made in the ordinary course of
business for goods or services delivered or rendered to unaffiliated customers
in bona fide arm's length transactions, (ii) constitute valid claims, and (iii)
are good and collectible at the aggregate recorded amounts thereof (net of such
reserves) without right of recourse, defense, deduction, return of goods,
counterclaim, or offset and have been or will be collected in the ordinary
course of business and consistent with past experience.
Section 4.27 Inventory. All inventory of the Company and its Subsidiaries
is (net of the applicable reserves reflected on the books and records of the
Company and in the financial statements included in the Company SEC reports) of
merchantable quality, free of defects in workmanship or design and is usable and
saleable at normal profit margins and in accordance with historical sales
practices in the ordinary course of the business of the Company and its
Subsidiaries. The inventory (net of such reserves) does not include any items
which are obsolete, damaged, excessive, below standard quality or slow moving
(i.e., items that are for discontinued or expected to be discontinued product
lines, or items that have not been used or sold within 12 months prior to the
date hereof).
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF PARENT
Parent represents and warrants to the Company as follows:
Section 5.1 Organization. Parent is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has
the corporate power to carry on its business as it is now being conducted or
presently proposed to be conducted. Parent is duly qualified as a foreign
corporation to do business, and is in good standing, in each jurisdiction where
the character of its properties owned or held under lease or the nature of its
activities make such qualification necessary, except where the failure to be so
qualified will not have a material adverse effect individually or in the
aggregate, on the financial condition, results of operations, assets,
liabilities or properties of Parent and its Subsidiaries taken as a whole or on
the ability of Parent to consummate the Merger and the other transactions
contemplated by this Agreement (a 'Parent Material Adverse Effect'). Sub is a
corporation duly organized, validly existing and in good standing under the laws
of the State of
11
Wisconsin and Parent has delivered to Company a copy of (i) the Articles of
Incorporation of Sub and (ii) the By-Laws of Sub, each as in effect as of the
date of this Agreement. Sub has not engaged in any business (other than in
connection with this Agreement and the transactions contemplated hereby) since
the date of its incorporation. Schedule 5.17 contains a complete and accurate
list of all Subsidiaries of Parent (other than inactive subsidiaries the assets
of which are de minimis). The Sub has no subsidiaries.
Section 5.2 Capitalization.
(a) The authorized capital stock of Parent consists of 60,000,000 shares of
Parent Common Stock and 1,000,000 shares of Preferred Stock, par value $0.01 per
share ('Parent Preferred Stock'), of Parent. As of July 31, 1997, (i)
approximately 24,200,000 shares of Parent Common Stock were issued and
outstanding, (ii) no shares of Parent Preferred Stock were issued and
outstanding, (iii) options to acquire approximately 1,300,000 shares of Parent
Common Stock (the 'Parent Stock Options') were outstanding under all stock
option plans of Parent, and (iv) approximately 2,230,000 shares of Parent Common
Stock were reserved for issuance pursuant to the Parent Stock Options and all
other employee benefit plans of Parent. All of the outstanding shares of capital
stock of Parent are, and the shares of Parent Common Stock issuable in exchange
for shares of Company Common Stock at the Effective Time in accordance with this
Agreement will be, when so issued, duly authorized, validly issued, fully paid
and nonassessable. The numbers for outstanding shares, options and shares
reserved for issuance in connection with the exercise of options set forth in
this Section 5.2 do not reflect the shares and options issued or reserved for
issuance in connection with Parent's acquisition of Micro Bio-Medics, Inc.,
which acquisition was consummated on August 1, 1997.
(b) The authorized capital stock of Sub consists of 1,000 shares of Sub
Common Stock, all of which shares, as of the date hereof, were issued and
outstanding. All of such outstanding shares are owned by Parent, and are validly
issued, fully paid and nonassessable.
(c) Except as disclosed in this Section 5.2, (i) there are no outstanding
Rights to purchase or otherwise to receive from Parent, Sub or any of Parent's
other Subsidiaries any of the outstanding authorized but unissued or treasury
shares of the capital stock or any other security of Parent or Sub, (ii) there
is no outstanding security of any kind convertible into or exchangeable for such
capital stock, and (iii) there is no voting trust or other agreement or
understanding to which Parent or Sub is a party or is bound with respect to the
voting of the capital stock of Parent or Sub.
(d) Parent and its subsidiaries do not beneficially own any shares of the
Company's Common Stock and, to Parent's knowledge, none of its affiliates
beneficially owns any shares of the Company's Common Stock.
Section 5.3 Authority Relative to this Agreement. Each of Parent and Sub
has the requisite corporate power and authority to execute and deliver this
Agreement and to consummate the transactions contemplated hereby. The execution
and delivery of this Agreement by each of Parent and Sub and the consummation by
each of Parent and Sub of the transactions contemplated on its part hereby have
been duly authorized by their respective Boards of Directors, and by Parent as
the sole stockholder of Sub, and, except for the approval of Parent's
stockholders to be sought at the stockholders' meeting contemplated by Section
7.4(b), no other corporate proceedings on the part of Parent or Sub are
necessary to authorize this Agreement or for Parent and Sub to consummate the
transactions contemplated hereby. This Agreement has been duly and validly
executed and delivered by each of Parent and Sub and constitutes a valid and
binding agreement of each of Parent and Sub, enforceable against Parent and Sub
in accordance with its terms.
Section 5.4 Consents and Approvals No Violations. Neither the execution,
delivery and performance of this Agreement by Parent or Sub, nor the
consummation by Parent or Sub of the transactions contemplated hereby will (i)
conflict with or result in any breach of any provisions of the Amended and
Restated Certificate of Incorporation or By-Laws of Parent or the Articles of
Incorporation or By-Laws of Sub, (ii) require a filing with, or a permit,
authorization, consent or approval of, any Governmental Entity except in
connection with, or in order to comply with, the applicable provisions of the
HSR Act, the Securities Act, the Exchange Act, state securities or 'blue sky'
laws, the By-Laws of the NASD, and the filing and recordation of a Certificate
of Merger as required by the WBCL, (iii) except as set forth on Schedule 5.4
hereto, result in a violation or breach of, or constitute (with or without due
notice or lapse of time or both) a default (or give rise to any right of
termination, cancellation or acceleration) under, or result in the creation of a
Lien on any property or asset of Parent or any of
12
its Subsidiaries pursuant to, any of the terms, conditions or provisions of any
material Contract to which Parent or Sub is a party or by which either of them
or any of their properties or assets may be bound or (iv) violate any material
law, order, writ, injunction, decree, statute, rule or regulation of any
Governmental Entity applicable to Parent, Sub or any of their properties or
assets.
Section 5.5 Reports and Financial Statements. Parent has timely filed all
reports required to be filed with the SEC pursuant to the Exchange Act or the
Securities Act since January 1, 1995 (collectively, the 'Parent SEC Reports'),
and has previously made available to the Company true and complete copies of all
such Parent SEC Reports. Such Parent SEC Reports, as of their respective dates,
complied in all material respects with the applicable requirements of the
Securities Act and the Exchange Act, as the case may be, and none of such SEC
Reports contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading. The consolidated financial statements of Parent included in the
Parent SEC Reports have been prepared in accordance with GAAP consistently
applied throughout the periods indicated (except as otherwise noted therein and
fairly present the consolidated financial position of Parent and its
consolidated Subsidiaries as at the dates thereof and the consolidated results
of operations and cash flows of Parent and its consolidated Subsidiaries as of
the respective dates, and for the respective periods, presented therein except
that in the case of the unaudited consolidated financial statements included in
any Form 10-Q, the presentation and disclosures conform with the applicable
rules of the Exchange Act, but include all adjustments necessary to conform to
GAAP requirements with respect to interim financial statements. Except as set
forth in the Parent SEC Reports or on Schedule 5.5, since January 1, 1996, there
has been no change in any of the significant accounting (including tax
accounting) policies, practices or procedures of the Parent or, any of its
consolidated Subsidiaries.
Section 5.6 Absence of Certain Changes or Events; Material
Contracts. Except as set forth in the Parent SEC Reports or on Schedule 5.6,
since December 28, 1996, (i) Parent has not conducted its business and
operations other than in the ordinary course of business and consistent with
past practices or taken any of the actions set forth in Section 6.2(b) and (ii)
there has not been any fact, event, circumstance or change affecting or relating
to Parent and its Subsidiaries which has had or is reasonably likely to have a
Parent Material Adverse Effect.
Section 5.7 Litigation. Except for litigation disclosed in the notes to
the financial statements included in Parent's Annual Report to Stockholders for
the year ended December 28, 1996 or in the Parent SEC Reports filed subsequent
thereto, there is no suit, action, proceeding or investigation pending or, to
the Actual Knowledge of Parent, threatened against Parent or any of its
Subsidiaries or any of their respective properties, the outcome of which is
reasonably likely to have a Parent Material Adverse Effect; nor is there any
judgment, decree, injunction, ruling or order of any Governmental Entity
outstanding against Parent or any of its Subsidiaries having, or which is
reasonably likely to have, a Parent Material Adverse Effect. The term 'Actual
Knowledge of Parent' shall mean the actual knowledge of any of Stanley M.
Bergman, James P. Breslawski, Mark E. Mlotek, Steven Paladino and James W.
Stahly.
Section 5.8 Absence of Undisclosed Liabilities. Except for liabilities or
obligations which are accrued or reserved against in Parent's financial
statements (or disclosed in the notes thereto) included in the Parent SEC
Reports or which were incurred after June 30, 1997 in the ordinary course of
business and consistent with past practice, none of Parent and its Subsidiaries
has any liabilities or obligations (whether absolute, accrued, contingent or
otherwise) of a nature required by GAAP to be reflected in a consolidated
balance sheet (or disclosed in the notes thereto) or which may, to the Actual
Knowledge of Parent, have a Parent Material Adverse Effect.
Section 5.9 No Default. Neither Parent nor any Subsidiary of Parent is in
default or violation (and no event has occurred which with notice or the lapse
of time or both would constitute a default or violation) of any term, condition
or provision of (i) its charter, by-laws or comparable organizational documents,
(ii) any material Contracts to which Parent or any of its Subsidiaries is a
party or by which they or any of their properties or assets may be bound, or
(iii) any material order, writ, injunction, decree, statute, rule or regulation
of any Governmental Entity applicable to Parent or any of its Subsidiaries.
Section 5.10 Compliance with Applicable Law. Except as disclosed in the
Parent SEC Reports, (i) Parent and its Subsidiaries hold, and are in compliance
with the terms of, all material permits, licenses, exemptions,
13
orders and approvals of all Governmental Entities necessary for the current or
proposed conduct of their respective businesses ('Parent Permits'), (ii) no fact
exists or event has occurred, and no action or proceeding is pending or, to the
Actual Knowledge of Parent threatened, that has a reasonable possibility of
resulting in a revocation, non-renewal, termination, suspension or other
material impairment of any material Parent Permits, (iii) the businesses of
Parent and its Subsidiaries are not being conducted in material violation of any
Applicable Law, and (iv) to the Actual Knowledge of Parent (x) no investigation
or review by any Governmental Entity with respect to Parent or its Subsidiaries
is pending or threatened and (y) no Governmental Entity has indicated an
intention to conduct the same.
Section 5.11 Information in Disclosure Documents and Registration
Statement. None of the information to be supplied by or on behalf of Parent or
Sub for inclusion in (i) the Registration Statement or (ii) the Proxy Statement
will, in the case of the Registration Statement, at the time it becomes
effective, at the time of the filing of any post-effective amendment thereto,
and at the Effective Time, and, in the case of the Proxy Statement or any
amendments thereof or supplements thereto, at the time of the mailing of the
Proxy Statement and any amendments or supplements thereto, and at the respective
times of the meetings of stockholders of Parent to be held in connection with
the Merger, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made, not
misleading. The Registration Statement and the Proxy Statement will comply as to
form in all material respects with the applicable provisions of the Securities
Act and the Exchange Act, and the rules and regulations promulgated thereunder,
except that no representation is made by Parent with respect to statements made
therein based on information supplied by the Company or its representatives for
inclusion in the Registration Statement or the Proxy Statement or with respect
to information concerning the Company or any of its Subsidiaries incorporated by
reference in the Registration Statement or the Proxy Statement.
Section 5.12 Vote Required. The affirmative vote of the holders of a
majority of the shares of Parent Common Stock present in person or represented
by proxy at the stockholders meeting of Parent described in Section 7.4(b)
(provided that the shares so present or represented constitute a majority of the
outstanding shares of Parent Common Stock) is the only vote of the holders of
any class or series of Parent capital stock necessary to approve the Merger and
the issuance of shares of Parent Common Stock pursuant thereto. The affirmative
vote of Parent, as the sole stockholder of all outstanding shares of Sub Common
Stock, is the only vote of the holders of any class or series of Sub capital
stock necessary to approve the Merger. The Board of Directors of Parent (at a
meeting duly called and held) has by the unanimous vote of the directors present
(i) approved this Agreement and the Irrevocable Proxy and Termination Rights
Agreement, (ii) determined that the transactions contemplated hereby are fair to
and in the best interests of the holders of Parent Common Stock, (iii)
determined to recommend this Agreement, the Merger and the other transactions
contemplated hereby to such holders for approval and adoption and (iv) caused
Parent, as the sole stockholder of Sub, to approve and adopt this Agreement and
the Irrevocable Proxy and Termination Rights Agreement. The Board of Directors
of Sub (by unanimous written consent) has approved this Agreement and the
Irrevocable Proxy and Termination Rights Agreement.
Section 5.13 Opinion of Financial Advisor. The Board of Directors of
Parent has received the opinion of Smith Barney Inc., dated August 1, 1997,
substantially to the effect that as of such date, the Exchange Ratio is fair to
Parent from a financial point of view, the material terms of which opinion have
been disclosed to the Company.
Section 5.14 Accounting Matters. None of Parent, any of its Subsidiaries
or, to the Actual Knowledge of Parent, any of their respective directors,
officers or stockholders, has taken any action which would prevent the
accounting for the Merger as a pooling of interests in accordance with
Accounting Principles Board Opinion No. 16, the interpretative releases pursuant
thereto and the pronouncements of the SEC.
Section 5.15 Brokers. Except for Smith Barney Inc., no broker, finder or
financial advisor is entitled to any brokerage, finder's or other fee or
commission in connection with the Merger or the transactions contemplated by
this Agreement based upon arrangements made by or on behalf of Parent or Sub,
and Parent has disclosed to the Company the material terms of the agreement
pursuant to which Smith Barney Inc. is entitled to its fee.
14
Section 5.16 Acceleration of Parent Stock Options. Since December 31,
1995, except as set forth on Schedule 5.16, the Parent has not in any manner
accelerated or provided for the acceleration of the vesting or exercisability
of, or otherwise modified the terms and conditions applicable to, any
outstanding option to purchase Parent Common Stock ('Parent Stock Options'),
whether set forth in the governing stock option plans of the Parent, a stock
option grant, award or other agreement or otherwise. Except as set forth on
Schedule 5.16, none of the awards, grants or other agreements pursuant to which
Parent Stock Options were issued have provisions which accelerate the vesting or
right to exercise such options upon the execution of this Agreement (including
the documents attached as Exhibits hereto), the consummation of the transactions
contemplated hereby (or thereby) or any other 'change of control' events.
Section 5.17 Parent Subsidiaries. Schedule 5.17 contains a complete and
accurate list of all Subsidiaries of the Parent (other than inactive
subsidiaries the assets of which are de minimis). Each Subsidiary of Parent
listed on Schedule 5.17 that is a corporation is duly organized, validly
existing and in good standing under the laws of its jurisdiction of
incorporation. Each Subsidiary of Parent listed on Schedule 5.17 that is a
partnership or limited liability company is duly formed and validly existing
under the laws of its jurisdiction of formation. Each Subsidiary of Parent
listed on Schedule 5.17 has the corporate, partnership or limited liability
company power, as the case may be, to carry on its business as it is now being
conducted or presently proposed to be conducted. Each Subsidiary of Parent is
duly qualified as a foreign corporation, foreign partnership or a foreign
limited liability company, as the case may be, authorized to do business, and is
in good standing, in each jurisdiction where the character of its properties
owned or held under lease or the nature of its activities makes such
qualification necessary, except where the failure to be so qualified will not
have a Parent Material Adverse Effect. All of the outstanding shares of capital
stock of the Subsidiaries of Parent listed on Schedule 5.17 that are
corporations are validly issued, fully paid and nonassessable. Except as set
forth in the Parent SEC Reports, all of the outstanding shares of capital stock
of, or other membership or ownership interests in, each Subsidiary of Parent are
owned by the Parent or a Subsidiary of the Parent, in each case free and clear
of any Liens.
Section 5.18 Taxes. (a) Parent has heretofore delivered or will make
available to the Company true, correct and complete copies of the consolidated
federal, state, local and foreign income, franchise, sales and other Tax Returns
filed by Parent and its Subsidiaries for each of Parent's 1995, 1994, 1993 and
1992 fiscal years, inclusive. Except as set forth on Schedule 5.18, Parent has
duly filed, and each Subsidiary of Parent has duly filed, all material federal,
state, local and foreign income, franchise, sales and other Tax Returns required
to be filed by Parent or any of its Subsidiaries. All such Tax Returns are true,
correct and complete, in all material respects, and Parent and its Subsidiaries
have duly paid, all Taxes shown on such Tax Returns and has made adequate
provision for payment of all accrued but unpaid material Taxes anticipated in
respect of all periods since the periods covered by such Tax Returns. Except as
set forth on Schedule 5.18, all material deficiencies assessed as a result of
any examination of Tax Returns of Parent or any of its Subsidiaries by federal,
state, local or foreign tax authorities have been paid or reserved on the
financial statements of Parent in accordance with GAAP consistently applied, and
true, correct and complete copies of all revenue agent's reports, '30-day
letters,' or '90-day letters' or similar written statements proposing or
asserting any Tax deficiency against Parent or any of its Subsidiaries for any
open year have been heretofore delivered to the Company. Parent has heretofore
delivered or will make available to the Company true, correct and complete
copies of all written tax-sharing agreements and written descriptions of all
such unwritten agreement or arrangements to which Parent or any of its
Subsidiaries is a party. Except as set forth in Schedule 5.18, no material issue
has been raised during the past five years by any federal, state, local or
foreign taxing authority which, if raised with regard to any other period not so
examined, could reasonably be expected to result in a proposed material
deficiency for any other period not so examined. Except as disclosed in Schedule
5.18 hereof, neither Parent nor any of its Subsidiaries has granted any
extension or waiver of the statutory period of limitations applicable to any
claim for any material Taxes. The consolidated federal income tax returns of
Parent and its Subsidiaries have been examined by and settled with the Internal
Revenue Service (the 'Service') for all years through 1989. Except as set forth
in Schedule 5.18, (i) neither Parent nor any of Parent's Subsidiaries is a party
to any agreement, contract or arrangement that would result, separately or in
the aggregate, in the payment of any 'excess parachute payments' within the
meaning of Section 28OG of the Code; (ii) no consent has been filed under
Section 341(f) of the Code with respect to any of Parent or the Subsidiaries of
Parent; (iii) neither Parent nor any of the Subsidiaries of Parent has
participated in, or cooperated with, an international boycott within the meaning
of Section 999 of the Code; and (iv) neither Parent nor any of the Subsidiaries
of Parent has issued or assumed any
15
corporate acquisition indebtedness, as defined in Section 279(b) of the Code.
Parent and each Subsidiary of Parent have complied (and until the Effective Time
will comply) in all material respects with all applicable laws, rules and
regulations relating to the payment and withholding of Taxes (including, without
limitation, withholding of Taxes pursuant to Sections 1441 and 1442 of the Code
or similar provisions under any foreign laws) and have, within the time and in
the manner prescribed by law, withheld from employee wages and paid over to the
proper governmental authorities all amounts required to be so withheld and paid
over under all applicable laws.
Section 5.19 Title to Properties; Encumbrances. Except as described in
the following sentence, each of Parent and its Subsidiaries has good, valid and
marketable title to, or a valid leasehold interest in, all of its material
properties and assets (real, personal and mixed, tangible and intangible),
including, without limitation, all the properties and assets reflected in the
consolidated balance sheet of Parent and its Subsidiaries as of March 29, 1997
included in Parent's Quarterly Report on Form 10-Q for the period ended on such
date (except for properties and assets disposed of in the ordinary course of
business and consistent with past practices since March 29, 1997). None of such
properties or assets are subject to any Liens (whether absolute, accrued,
contingent or otherwise), except (i) as specifically set forth in the Parent SEC
Reports and (ii) minor imperfections of title and encumbrances, if any, which
are not substantial in amount, do not materially detract from the value of the
property or assets subject thereto and do not impair the operations of any of
Parent and its Subsidiaries.
Section 5.20 Intellectual Property.
(a) Except as set forth on Schedule 5.20(a), Parent and its Subsidiaries
are the sole and exclusive owners of all material patents, patent applications,
patent rights, trademarks, trademark rights, trade names, trade name rights,
copyrights, service marks, trade secrets, registrations for and applications for
registration of trademarks, service marks and copyrights, technology and
know-how, rights in computer software and other proprietary rights and
information and all technical and user manuals and documentation made or used in
connection with any of the foregoing used or held for use in connection with the
businesses of Parent or any of its Subsidiaries as currently conducted
(collectively, the 'Parent Intellectual Property'), free and clear of all Liens
except as set forth on Schedule 5.20 and except minor imperfections of title and
encumbrances, if any, which are not substantial in amount, do not materially
detract from the value of the Parent Intellectual Property subject thereto and
do not impair the operations of any of Parent and its Subsidiaries.
(b) All grants, registrations and applications for Parent Intellectual
Property that are used in and are material to the conduct of the business of
Parent and its Subsidiaries (i) are valid, subsisting, in proper form and
enforceable, and have been duly maintained, including the submission of all
necessary filings and fees in accordance with the legal and administrative
requirements of the appropriate jurisdictions and (ii) have not lapsed, expired
or been abandoned, and no grant, registration or license therefor is the subject
of any legal or governmental proceeding before any registration authority in any
jurisdiction.
(c) Each of Parent and its Subsidiaries owns or has the right to use all of
the material Parent Intellectual Property used by it or held for use by it in
connection with its business. To the Actual Knowledge of Parent, there are no
conflicts with or infringements of any Parent Intellectual Property by any third
party. The conduct of the business of Parent and its Subsidiaries does not
conflict with or infringe in any way any proprietary right of any third party,
which conflict or infringement would have a Parent Material Adverse Effect, and
there is no claim, suit, action or proceeding pending or, to the Actual
Knowledge of Parent, threatened against Parent or any of its Subsidiaries (i)
alleging any such conflict or infringement with any third party's proprietary
rights, or (ii) challenging the ownership, use, validity or enforceability of
the Parent Intellectual Property.
Section 5.21 Employee Benefit Plans; ERISA.
(a) Each 'employee benefit plan,' within the meaning of Section 3(3) of
ERISA, and any other material employee benefit plan, arrangement or agreement,
that is maintained, or was maintained at any time during the five (5) calendar
years preceding the date of this Agreement (the 'Parent Plans'), by the Parent
or by any trade or business, whether or not incorporated (a 'Parent ERISA
Affiliate'), which together with the Parent would be deemed a 'single employer'
within the meaning of Section 4001 of ERISA or under Section 414(b), (c), (m) or
(o) of the Code is and has been maintained and operated in compliance with its
terms and applicable law,
16
including without limitation, ERISA and the Code; each of the Parent Plans
intended to be 'qualified' within the meaning of Section 401(a) of the Code is
so qualified and has been qualified since its inception.
(b) None of the Parent, any Parent ERISA Affiliate, or any of their
respective predecessors has ever contributed to, contributes to, has ever been
required to contribute to, or otherwise participated in or participates in or in
any way, directly or indirectly, has any liability with respect to any plan
subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA,
including, without limitation any, 'multiemployer plan' (within the meaning of
Sections (3)(37) or 4001(a)(3) of ERISA or Section 414(f) of the Code), or any
single employer pension plan and no Parent Plan is a multiple employer plan
described in Section 413 of the Code. All contributions or other amounts payable
by the Parent as of the Effective Time with respect to each Parent Plan in
respect of current or prior plan years have been either paid or accrued on the
balance sheet of the Parent. There are no pending, threatened or, to the Actual
Knowledge of the Parent, anticipated claims, lawsuits, arbitrations or other
actions (other than non-material routine claims for benefits) by, on behalf of
or against any of the Parent Plans, any trustee or fiduciaries thereof or any
trusts related thereto. No Parent Plan currently is under audit or investigation
by the Internal Revenue Service, U.S. Department of Labor, or any other
governmental authority and no such completed audit, if any, has resulted in the
imposition of any tax or penalty. With respect to each Parent Plan that is
funded mostly or partially through an insurance policy, neither the Parent nor
any Parent ERISA Affiliate has any material liability in the nature of
retroactive rate adjustment, loss sharing arrangement or other actual or
contingent material liability arising wholly or partially out of events
occurring on or before the Effective Time.
(c) Neither the Parent nor any Parent ERISA Affiliate, nor any Parent Plan,
nor any trust created thereunder, nor any trustee or administrator thereof has
engaged in a transaction in connection with which the Parent or any Parent ERISA
Affiliate, any Parent Plan, any such trust, or any trustee or administrator
thereof, or any party dealing with any Parent Plan or any such trust that is a
'prohibited transaction,' within the meaning of Section 4975 of the Code and
Section 406 of ERISA, other than a prohibited transaction that has been
corrected and with respect to which all taxes and penalties have been paid prior
to the date hereof. No Parent Plan provides benefits (whether or not insured),
with respect to current or former employees of the Parent or any Parent ERISA
Affiliate beyond their retirement or other termination of service other than
benefits under any 'employee pension plan,' as that term is defined in Section
3(2) of ERISA, qualified under Section 401(a) of the Code or under Section 4980B
of the Code. The consummation of the transactions contemplated by this Agreement
will not give rise to any liability, including, without limitation, liability
for severance pay, unemployment compensation, termination pay, or withdrawal
liability, or accelerate the time of payment or vesting or increase the amount
of compensation or benefits due to any employee, director, shareholder, or
beneficiary of the Parent (whether current, former, or retired) or their
beneficiaries solely by reason of such transactions.
Section 5.22 Environmental Laws and Regulations. Except as would not
reasonably be likely to have a Parent Material Adverse Effect, or except as set
forth on Schedule 5.22:
(a) (i) Parent and its Subsidiaries are and have been, in all material
respects, in compliance with, and there are no outstanding written allegations
or, to the Actual Knowledge of Parent, oral allegations, by any person or entity
that Parent or its Subsidiaries has not been in compliance with, all
Environmental Laws and (ii) Parent and its Subsidiaries currently hold all
material permits, licenses, registrations and other governmental authorizations
(including exemptions, waivers, and the like) and financial assurance required
under Environmental Laws for Parent and its Subsidiaries to operate their
businesses as currently conducted.
(b) (i) There is no friable asbestos-containing material in or on any real
property currently owned, leased or operated by Parent or its Subsidiaries and
(ii) there are and, to the Actual Knowledge of Parent, have been no underground
storage tanks (whether or not required to be registered under any applicable
law), dumps, landfills, lagoons, surface impoundments, injection wells or other
land disposal units in or on any property currently owned, leased or operated by
Parent or its Subsidiaries.
(c) (i) Neither Parent nor its Subsidiaries has received (x) any written
communication from any person stating or alleging that any of them may be a
potentially responsible party under any Environmental Law (including, without
limitation, the Federal Comprehensive Environmental Response, Compensation, and
Liability Act of 1980, as amended) with respect to any actual or alleged
environmental contamination or (y) any request for information under any
Environmental Law from any Governmental Entity with respect to any actual or
17
alleged material environmental contamination; and (ii) neither of Parent, nor
its Subsidiaries nor any Governmental Entity is conducting or has conducted (or,
to the Actual Knowledge of the Parent, is threatening to conduct) any
environmental remediation or investigation.
(d) To the Actual Knowledge of Parent, all real properties formerly owned,
used, leased, occupied, managed or operated by Parent or its Subsidiaries
complied, in all material respects, with the Environmental Laws during Parent's
or its Subsidiaries' tenure thereat and, to the Actual Knowledge of Parent there
are no environmental liabilities associated therewith that are reasonably likely
to result in a Parent Material Adverse Effect.
Section 5.23 Labor Matters. Neither Parent nor any of its Subsidiaries is
a party to, or bound by, any collective bargaining agreement, contract or other
understanding with a labor union or labor organization and, to the Actual
Knowledge of Parent, there is no activity involving any employees of Parent or
its Subsidiaries seeking to certify a collective bargaining unit or engaging in
any other organizational activity.
Section 5.24 Affiliate Transactions. Except as set forth in Schedule 5.24
or as disclosed in Parent SEC Reports, there are no, and since January 1, 1996
there have not been any, material Contracts or other transactions between the
Parent or any of its Subsidiaries, on the one hand, and any (i) officer or
director of the Parent or any of its Subsidiaries, (ii) record or beneficial
owner of five percent or more of the voting securities of the Parent or (iii)
affiliate (as such term is defined in Regulation 12b-2 promulgated under the
Exchange Act) of any such officer, director or beneficial owner, on the other
hand.
Section 5.25 Tax Matters. Parent knows of no fact or circumstance which
is reasonably likely to cause the Merger to be treated other than as a tax-free
reorganization under Section 368(a) of the Code.
Section 5.26 Accounts Receivable. All of the accounts and notes
receivable of the Parent and its Subsidiaries set forth on the books and records
of the Parent net of the applicable reserves reflected on the books and records
of the Parent and in the financial statements included in the Parent SEC
Reports): (i) represent sales actually made in the ordinary course of business
for goods or service delivered or rendered to unaffiliated customers in bona
fide arm's length transactions, (ii) constitute valid claims, and (iii) are good
and collectible, at the aggregate recorded amounts thereof (net of such
reserves) without right of recourse, defense, deduction, return of goods,
counterclaim, or offset and have been or will be collected in the ordinary
course of business and consistent with past experience.
Section 5.27 Inventory. All inventory of the Parent and its Subsidiaries
is (net of the applicable reserves reflected on the books and records of the
Parent and in the financial statements included in the Parent SEC Reports) of
merchantable quality, free of defects in workmanship or design and is usable and
salable at normal profit margins and in accordance with historical sales
practices in the ordinary course of the business of the Parent and its
Subsidiaries. The inventory (net of such reserves) does not include any items
which are obsolete, damaged, excessive, below standard quality or slow moving
(i.e., items that are for discontinued or expected to be discontinued product
lines, or items that have not been used or sold within 12 months prior to the
date hereof).
ARTICLE VI
CONDUCT OF BUSINESS PENDING THE MERGER
Section 6.1 Conduct of Business by the Company Pending the Merger. Prior
to the Effective Time, unless Parent shall otherwise agree in writing, or as
otherwise expressly contemplated by this Agreement:
(a) the Company shall conduct, and cause each of its Subsidiaries to
conduct, its business only in the ordinary and usual course consistent with
past practice, and the Company shall use, and cause each of its
Subsidiaries to use, its reasonable efforts to preserve intact the present
business organization, keep available the services of its present officers
and key employees, and preserve the goodwill of those having business
relationships with it;
(b) the Company shall not, nor shall it permit any of its Subsidiaries
to, (i) amend its charter, bylaws or other organizational documents, (ii)
split, combine or reclassify any shares of its outstanding capital stock,
(iii) declare, set aside or pay any dividend or other distribution payable
in cash, stock or property, or
18
(iv) directly or indirectly redeem or otherwise acquire any shares of its
capital stock or shares of the capital stock of any of its Subsidiaries;
(c) except as provided in Schedule 6.1(c), the Company shall not, nor
shall it permit any of its Subsidiaries to, (i) authorize for issuance,
issue or sell or agree to issue or sell any shares of, or Rights to acquire
or which are convertible into any shares of, its capital stock or shares of
the capital stock of any of its Subsidiaries (whether through the issuance
or granting of options, warrants, commitments, subscriptions, rights to
purchase or otherwise), except for the issuance of shares of Company Common
Stock upon the exercise of Company Stock Options outstanding on the date of
this Agreement and the issuance of options in connection with the hiring of
sales representatives consistent with past practices; (ii) merge or
consolidate with another entity; (iii) acquire or purchase an equity
interest in or a substantial portion of the assets of another corporation,
partnership or other business organization or otherwise acquire any assets
outside the ordinary and usual course of business and consistent with past
practice or otherwise enter into any material contract, commitment or
transaction outside the ordinary and usual course of business consistent
with past practice; (iv) sell, lease, license, waive, release, transfer,
encumber or otherwise dispose of any of its assets outside the ordinary and
usual course of business and consistent with past practice; (v) incur,
assume or prepay any material indebtedness or any other material
liabilities other than in the ordinary course of business and consistent
with past practice; (vi) assume, guarantee, endorse or otherwise become
liable or responsible (whether directly, contingently or otherwise) for the
obligations of any other person other than a Subsidiary of the Company, in
each case in the ordinary course of business and consistent with past
practice; (vii) make any loans, advances or capital contributions to, or
investments in, any other person, other than to Subsidiaries of the
Company; (viii) authorize or make capital expenditures in excess of the
amounts currently budgeted therefor; (ix) permit any insurance policy
naming the Company or any Subsidiary of the Company as a beneficiary or a
loss payee to be cancelled or terminated other than in the ordinary course
of business; or (x) enter into any contract, agreement, commitment or
arrangement with respect to any of the foregoing;
(d) the Company shall not, nor shall it permit its Subsidiaries to,
(i) adopt, enter into, terminate or amend (except as may be required by
Applicable Law) any Company Plan or other arrangement for the current or
future benefit or welfare of any director, officer or current or former
employee, (ii) increase in any manner the compensation or fringe benefits
of, or pay any bonus to, any director, officer or employee (except for
normal increases in salaried compensation in the ordinary course of
business consistent with past practice, or (iii) take any action to fund or
in any other way secure, or to accelerate or otherwise remove restrictions
with respect to, the payment of compensation or benefits under any employee
plan, agreement, contract, arrangement or other Company Plan (including the
Company Stock Options);
(e) the Company shall not, nor shall it permit its Subsidiaries to,
take any action with respect to, or make any material change in, its
accounting or tax policies or procedures, except as required by law or to
comply with GAAP;
(f) the Company shall not (i) take or allow to be taken any action
which would jeopardize the treatment of Parent's acquisition of the Company
as a pooling of interests for accounting purposes; or (ii) take any action
which would jeopardize qualification of the Merger as a reorganization
within the meaning of Section 368(a) of the Code.
Section 6.2 Conduct of Business by Parent Pending the Merger. Prior to
the Effective Time, unless the Company shall otherwise agree in writing, and
except as otherwise expressly contemplated by this Agreement:
(a) Parent shall conduct its business and the business of its
Subsidiaries in a manner designed, in the good faith judgment of its Board
of Directors, to enhance the long-term value of the Parent Common Stock and
the business prospects of Parent and Subsidiaries;
(b) Parent shall not (i) split, combine or reclassify any shares of
its outstanding capital stock; or (ii) declare, set aside or pay any
dividend or other distribution payable in cash, stock or property;
(c) Parent shall not authorize for issuance, issue or sell or agree to
issue or sell any shares of, or Rights to acquire or which are convertible
into any shares of, its capital stock, except for (i) the issuance of
shares of Parent Common Stock (x) upon the exercise of stock options or
other Rights outstanding on the date of
19
this Agreement, or (y) upon the exercise of Rights described in the
immediately following clause (ii) or (z) upon the conversion of the Parent
Preferred Stock in accordance with its present terms, (ii) the issuance of
Rights or shares of Parent Common Stock pursuant to existing employee
benefit plans or arrangements in a manner consistent with past practice,
and (iii) the issuance of shares of Parent Common Stock or Rights in
connection with arm's length transactions with non-affiliates;
(d) neither Parent nor Sub shall (i) take or allow to be taken any
action which would jeopardize the treatment of Parent's acquisition of the
Company as a pooling of interests for accounting purposes; or (ii) take any
action which would jeopardize qualification of the Merger as a
reorganization within the meaning of Section 368(a) of the Code.
Section 6.3 Conduct of Business of Sub. During the period from the date
of this Agreement to the Effective Time, Sub shall not engage in any activities
of any nature except as provided in or contemplated by this Agreement. It is
understood that Sub was formed by Parent solely for the purpose of effecting the
Merger, and that Sub will have no material assets and no material liabilities
prior to the Merger.
ARTICLE VII
ADDITIONAL AGREEMENTS
Section 7.1 Access and Information. Each of the Company and Parent shall
(and shall cause its Subsidiaries and its and those of their respective
officers, directors and employees whose names appear on Schedule 7.1, auditors
and agents to) afford to the other and to the other's officers, employees,
financial advisors, legal counsel, accountants, consultants and other
representatives reasonable access during normal business hours throughout the
period prior to the Effective Time to all of its books and records and its
properties, plants and personnel and, during such period, each shall furnish
promptly to the other a copy of each report, schedule and other document filed
or received by it pursuant to the requirements of federal securities laws,
provided that no investigation pursuant to this Section 7.1 shall affect any
representations or warranties made herein or the conditions to the obligations
of the respective parties to consummate the Merger. Unless otherwise required by
law, each party agrees that it (and its Subsidiaries and its and their
respective representatives) shall hold in confidence all non-public information
so acquired in accordance with the terms of the confidentiality agreement, dated
July 1, 1997, between Parent and the Company (the 'Confidentiality Agreement').
Section 7.2 No Solicitation.
(a) Prior to the Effective Time, the Company agrees that neither it, any of
its Subsidiaries or its affiliates, nor any of the respective directors,
officers, employees, agents or representatives of the foregoing will, directly
or indirectly, solicit, initiate, facilitate or encourage (including by way of
furnishing or disclosing non-public information) any inquiries or the making of
any proposal with respect to any merger, consolidation or other business
combination involving the Company or any material Subsidiary of the Company or
the acquisition of any securities of the Company or all or any material assets
(including stock of a subsidiary) of the Company and the Subsidiaries of the
Company taken as a whole (an 'Acquisition Transaction') or negotiate, explore or
otherwise engage in discussions with any person (other than Parent and its
representatives) with respect to any Acquisition Transaction or enter into any
agreement, arrangement or understanding with respect to any such Acquisition
Transaction or which would require it to abandon, terminate or fail to
consummate the Merger or any other transaction contemplated by this Agreement;
provided, however, that the Company may, in response to an unsolicited written
proposal from a third party with respect to an Acquisition Transaction, furnish
information to and engage in discussions with such third party, in each case
only if the Board of Directors of the Company determines in good faith by a
majority vote, after consultation with its financial advisors and based upon the
advice of outside counsel to the Company, that failing to take such action would
result in a breach of the fiduciary duties of the Board of Directors and, prior
to taking such action, the Company (i) provides reasonable notice to Parent to
the effect that it is taking such action and (ii) receives from such
corporation, partnership, person or other entity or group (and delivers to
Parent) an executed confidentiality agreement in reasonably customary form. The
Company agrees that as of the date hereof, it, its Subsidiaries and affiliates,
and the respective directors, officers, employees, agents and representatives of
the foregoing, shall immediately cease and cause to be terminated any existing
activities, discussions or negotiations with any person (other than Parent and
its representatives) conducted heretofore with respect to any Acquisition
Transaction. The Company agrees to
20
immediately advise Parent in writing of any inquiries or proposals (or desire to
make a proposal) received by any such information requested from, or any such
negotiations or discussions sought to be initiated or continued with, any of it,
its Subsidiaries or affiliates, or any of the respective directors, officers,
employees, agents or representatives of the foregoing, in each case from a
person (other than Parent and its representatives) with respect to an
Acquisition Transaction, and the terms thereof, including the identity of such
third party, and to update on an ongoing basis or upon Parent's request, the
status thereof, as well as any actions taken or other developments pursuant to
this Section 7.2(a). Notwithstanding anything in the foregoing provisions of
this Section 7.2(a) to the contrary: (i) the Company shall not disclose any
information received by it or any of its directors, officers, employees, agents
or representatives pursuant to the Confidentiality Agreement or any other
confidentiality or other similar agreement between the Company and Parent to any
person in violation of such agreement and (ii) the Company shall not be
obligated to disclose to Parent any confidential information provided to the
Company by any third party in violation of any law or any confidentiality
agreement between the Company and such third party provided for in this Section
7.2.
(b) Except as set forth in this Section 7.2(b), the Board of Directors of
the Company shall not (i) withdraw or modify, or propose to withdraw or modify,
in a manner adverse to the Parent or the Sub, the approval or recommendation by
the Board of Directors of this Agreement or the Merger, (ii) approve or
recommend, or propose to approve or recommend, any Acquisition Transaction or
(iii) cause the Company to enter into any agreement with respect to any
Acquisition Transaction. Notwithstanding the foregoing, in the event that prior
to the Effective Time the Board of Directors of the Company determines in its
good faith reasonable judgment, by a majority vote, after consultation with its
financial advisors, that the Acquisition Transaction is more favorable to the
stockholders of the Company than the Merger and, based upon the advice of
outside counsel to the Company, that such action is required by the fiduciary
duties of the Board of Directors, the Board of Directors of the Company may
withdraw or modify its approval or recommendation of this Agreement and the
Merger, approve or recommend such Acquisition Transaction or (subject to Section
9.2(b)) cause the Company to enter into an agreement with respect to such
Acquisition Transaction, but only if the Company gives Parent at least five
business days' prior written notice thereof, during which time Parent may make,
and, in such event, the Company shall in good faith consider, a counter proposal
to such Acquisition Transaction.
Section 7.3 Registration Statement. As promptly as practicable, Parent
and the Company shall in consultation with each other prepare and file with the
SEC the Proxy Statement and Parent in consultation with the Company shall
prepare and file with the SEC the Registration Statement. Each of Parent and the
Company shall use its reasonable best efforts to have the Registration Statement
declared effective as soon as practicable. Parent shall also use its reasonable
best efforts to take any action required to be taken under state securities or
'blue sky' laws in connection with the issuance of the shares of Parent Common
Stock pursuant to this Agreement in the Merger. The Company shall furnish Parent
with all information concerning the Company and the holders of its capital stock
and shall take such other action as Parent may reasonably request in connection
with the Registration Statement and the issuance of shares of Parent Common
Stock. If at any time prior to the Effective Time any event or circumstance
relating to Parent, any Subsidiary of Parent, the Company, any Subsidiary of the
Company, or their respective officers or directors, should be discovered by such
party which should be set forth in an amendment or a supplement to the
Registration Statement or Proxy Statement, such party shall promptly inform the
other thereof and take appropriate action in respect thereof. Neither Parent nor
Company shall distribute any written material that would constitute a
'prospectus' relating to the Merger other than in compliance with the Securities
Act or any applicable state's securities laws.
Section 7.4 Proxy Statements; Stockholder Approvals.
(a) The Company, acting through its Board of Directors, shall, subject to
and in accordance with applicable law and its Certificate of Incorporation and
By-Laws, promptly and duly call, give notice of, convene and hold as soon as
practicable following the date upon which the Registration Statement becomes
effective a meeting of the holders of Company Common Stock for the purpose of
voting to approve and adopt this Agreement and the transactions contemplated
hereby, and, subject to the fiduciary duties of the Board of Directors of the
Company under applicable law as advised by outside legal counsel, (i) recommend
approval and adoption of this Agreement and the transactions contemplated hereby
by the stockholders of the Company and include in the Proxy Statement such
recommendation and (ii) take all reasonable and lawful action to solicit and
obtain such approval.
21
(b) Parent, acting through its Board of Directors, shall, subject to and in
accordance with applicable law and its Certificate of Incorporation and By-Laws,
promptly and duly call, give notice of, convene and hold as soon as practicable
following the date upon which the Registration Statement becomes effective a
meeting of the holders of Parent Common Stock for the purpose of voting to
approve and adopt this Agreement and the transactions contemplated hereby, and,
subject to the fiduciary duties of the Board of Directors of Parent under
applicable law as advised by outside counsel, (i) recommend approval and
adoption of this Agreement and the transactions contemplated hereby by the
stockholders of Parent and include in the Proxy Statement such recommendation,
and (ii) take all reasonable and lawful action to solicit and obtain such
approval.
(c) Parent and the Company, as promptly as practicable (or with such other
timing as they mutually agree), shall cause the definitive Proxy Statement to be
mailed to their stockholders.
(d) At or prior to the Closing, each of Parent and the Company shall
deliver to the other a certificate of its Secretary setting forth the voting
results from its stockholder meeting.
Section 7.5 Compliance with the Securities Act.
(a) At least 45 days prior to the Effective Time, each of Parent and the
Company shall cause to be delivered to the other a list identifying all persons
who were, in its reasonable judgment, at the record date for its stockholders'
meeting convened in accordance with Section 7.4 hereof, 'affiliates' of such
party as that term is used in paragraphs (c) and (d) of Rule 145 under the
Securities Act (the 'Affiliates').
(b) Each of Parent and the Company shall use its reasonable best efforts to
cause each person who is identified as one of its Affiliates in its list
referred to in, Section 7.5(a) above to deliver to Parent (with a copy to the
Company), at least 30 days prior to the Effective Time, a written agreement, in
the form attached hereto as Exhibit B-1, in the case of Affiliates of Parent,
and in the form attached hereto as Exhibit B-2, in the case of Affiliates of the
Company (the 'Affiliate Agreement').
(c) If any Affiliate of the Company refuses to provide an Affiliate
Agreement, Parent may place appropriate legends on the certificates evidencing
the shares of Parent Common Stock to be received by such Affiliate pursuant to
the terms of this Agreement and to issue appropriate stop transfer instructions
to the transfer agent for shares of Parent Common Stock to the effect that the
shares of Parent Common Stock received by such Affiliate pursuant to this
Agreement may be sold, transferred or otherwise conveyed only (i) pursuant to an
effective registration statement under the Securities Act, (ii) in compliance
with Rule 145 promulgated under the Securities Act, or (iii) pursuant to another
exemption under the Securities Act.
Section 7.6 Reasonable Best Efforts. Subject to the terms and conditions
herein provided, each of the parties hereto agrees to use its reasonable best
efforts to take, or cause to be taken, all action and to do, or cause to be
done, all things necessary, proper or advisable under applicable laws and
regulations to consummate and make effective the transactions contemplated by
this Agreement, including, without limitation, the obtaining of all necessary
waivers, consents and approvals and the effecting of all necessary registrations
and filings. Without limiting the generality of the foregoing, as promptly as
practicable, the Company, Parent and Sub shall make all filings and submissions
under the HSR Act as may be reasonably required to be made in connection with
this Agreement and the transactions contemplated hereby and the Company shall
use its reasonable best efforts to cause any affiliate of the Company who is
required to make a filing or submission under the HSR Act in connection with
this Agreement and the transactions contemplated hereby to do so promptly.
Subject to the Confidentiality Agreement, the Company will furnish to Parent and
Sub, and Parent and Sub will furnish to the Company, such information and
assistance as the other may reasonably request in connection with the
preparation of any such filings or submissions. Subject to the Confidentiality
Agreement, the Company will provide Parent and Sub, and Parent and Sub will
provide the Company, with copies of all material written correspondence, filings
and communications (or memoranda setting forth the substance thereof) between
such party or any of its representatives and any Governmental Entity, with
respect to the obtaining of any waivers, consent or approvals and the making of
any registrations or filings, in each case that is necessary to consummate the
Merger and the other transactions contemplated hereby. In case at any time after
the Effective Time any further action is necessary or desirable to carry out the
purposes of this Agreement, the proper officers or directors of Parent and the
Surviving Corporation shall take all such necessary action.
22
Section 7.7 Irrevocable Proxy and Termination Rights Agreement.
Concurrently herewith, and as an essential inducement for Parent's entering into
this Agreement, Parent and Sub are entering into the Irrevocable Proxy and
Termination Rights Agreement with certain holders of the Company Common Stock
with respect to all such shares of Company Common Stock held by such holders.
Section 7.8 Company Stock Options. To the extent permitted by the
respective terms of the Company Stock Options and the plans under which they
were issued, at the Effective Time, each of the Company Stock Options (and,
solely with respect to such options, the applicable option plans pursuant to
which such options were issued) which is outstanding immediately prior to the
Effective Time shall be assumed by Parent and converted automatically into an
option to purchase shares of Parent Common Stock (a 'New Option') in an amount
and at an exercise price determined as provided below:
(a) The number of shares of Parent Common Stock to be subject to the
New Option shall be equal to the product of the number of shares of Company
Common Stock remaining subject (as of immediately prior to the Effective
Time) to the original option and the Exchange Ratio, provided that any
fractional shares of Parent Common Stock resulting from such multiplication
shall be rounded down to the nearest share; and
(b) The exercise price per share of Parent Common Stock under the New
Option shall be equal to the exercise price per share of Company Common
Stock under the original option divided by the Exchange Ratio, provided
that such exercise price shall be rounded down to the nearest cent.
The adjustment provided herein with respect to any options which are
'incentive stock options' (as defined in Section 422 of the Code) shall be
modified to the extent required to comply with Section 424(a) of the Code and
the applicable Treasury regulations. After the Effective Time, each New Option
shall be exercisable and shall vest upon the same terms and conditions as were
applicable to the related Company Stock Option immediately prior to the
Effective Time, except that all references to the Company shall be deemed to be
references to Parent. Parent shall file with the SEC a registration statement on
Form S-8 (or other appropriate form) or a post-effective amendment to the
Registration Statement and shall take any action required to be taken under
state securities 'blue sky' laws for purposes of registering all shares of
Parent Common Stock issuable after the Effective Time upon exercise of the New
Options, and shall use all reasonable efforts to have such registration
statement or post-effective amendment (or a successor or replacement
registration statement) become effective with respect thereto as promptly as
practicable after the Effective Time.
Section 7.9 Public Announcements. Each of Parent, Sub, and the Company
agrees that it will not issue any press release or otherwise make any public
statement with respect to this Agreement (including the Exhibits hereto) or the
transactions contemplated hereby (or thereby) without the prior consent of the
other party, which consent shall not be unreasonably withheld or delayed;
provided, however, that such disclosure can be made without obtaining such prior
consent if (i) the disclosure is required by law or by obligations imposed
pursuant to any listing agreement with any national securities exchange and (ii)
the party making such disclosure has first used its reasonable best efforts to
consult with (but not obtain the consent of) the other party about the form and
substance of such disclosure.
Section 7.10 Expenses. Except as otherwise set forth in Section 9.2(b),
whether or not the Merger is consummated, all costs and expenses incurred in
connection with this Agreement (including the Exhibits hereto) and the
transactions contemplated hereby (and thereby) shall be paid by the party
incurring such expenses, except that (i) the expenses incurred in connection
with printing the Registration Statement and the Proxy Statement and (ii) the
filing fee with the SEC relating to the Registration Statement or the Proxy
Statement will be shared equally by Parent and the Company and the filing fee in
connection with filings under the HSR Act by Parent or the Company (but not any
Affiliate of the Company) shall be the expense solely of Parent.
Section 7.11 Listing Application. Parent will use its reasonable best
efforts to cause the shares of Parent Common Stock to be issued pursuant to this
Agreement in the Merger (as well as the shares of Parent Common Stock issuable
after the Effective Time upon exercise of the New Options) to be listed for
quotation and trading on the NASDAQ National Market.
Section 7.12 Supplemental Disclosure. The Company shall give prompt
notice to Parent, and Parent shall give prompt notice to the Company, of (i) the
occurrence, or non-occurrence, of any event the occurrence, or non-occurrence,
of which would be likely to cause (x) any representation or warranty contained
in this
23
Agreement to be untrue or inaccurate or (y) any covenant, condition or agreement
contained in this Agreement not to be complied with or satisfied and (ii) any
failure of the Company or Parent, as the case may be, to comply with or satisfy
any covenant, condition or agreement to be complied with or satisfied by it
hereunder; provided, however, that the delivery of any notice pursuant to this
Section 7.12 shall not have any effect for the purpose of determining the
satisfaction of the conditions set forth in Article VIII of this Agreement or
otherwise limit or affect the remedies available hereunder to any party.
Section 7.13 Letters of Accountants.
(a) Parent shall use all reasonable efforts to cause to be delivered to the
Company (i) a letter of BDO Seidman LLP, Parent's independent auditors, dated a
date within two business days before the date on which the Registration
Statement shall become effective and addressed to the Company, in form and
substance reasonably satisfactory to the Company and customary in scope and
substance for letters delivered by independent public accountants in connection
with registration statements similar to the Registration Statement, which letter
shall be brought down to the Effective Time, and (ii) the letter referred to in
8.2(d).
(b) The Company shall use all reasonable best efforts to cause to be
delivered to Parent a letter of Deloitte & Touche LLP, the Company's independent
auditors, dated a date within two business days before the date on which the
Registration Statement shall become effective and addressed to Parent, in form
and substance reasonably satisfactory to Parent and customary in scope and
substance for letters delivered by independent public accountants in connection
with registration statements similar to the Registration Statement, which letter
shall be brought down to the Effective Time.
Section 7.14 Directors of Parent. Parent agrees that, promptly after the
Effective Time, Parent shall take such action as may be necessary to cause
either Robert J. Sullivan or Timothy J. Sullivan (or if both Robert J. Sullivan
and Timothy J. Sullivan are unwilling or unable to serve, then Timothy J.
Sullivan's designee, which designee shall be reasonably acceptable to Parent),
to be nominated for election to Parent's Board of Directors, and to use its
reasonable best efforts to cause such individual to be elected to Parent's Board
of Directors.
Section 7.15 Indemnification.
(a) Parent agrees that all rights to indemnification existing as of
the date of this Agreement in favor of the employees, agents, directors or
officers ('Indemnified Persons') of the Company, as provided in the
Company's articles of incorporation, as amended, and bylaws, as amended
('Organic Documents') of the Company or in any written agreement between
the Company and an Indemnified Person ('Indemnification Agreements') listed
on Schedule 7.15 (true and complete copies of which have been delivered to
Parent), shall survive the Effective Date and shall continue in full force
and effect as obligations of the Parent for a period not less than six
years from the Effective Date. Parent shall cause Surviving Corporation on
the Effective Date not to cause or permit the amendment of such provisions
of the Organic Documents for a period of not less than six years from the
Effective Date.
(b) Parent shall use its reasonable best efforts to maintain in effect
(for at least six years from the Effective Time in the case of claims made
policies) directors' and officers' liability insurance policies providing
coverage in an aggregate amount of at least $4,000,000 and with a
carrier(s) having a Best's rating of at least 'A' covering directors and
officers of the Company serving as of or after December 1, 1990 with
respect to claims arising from occurrences prior to or at the Effective
Time (including the transactions contemplated by or related to this
Agreement).
Section 7.16 Solicitation of Employees and Representatives. Each of
Parent and the Company agrees that, subject to the last sentence of this Section
7.16, (i) for a period beginning on the Termination Date, if any, and ending on
the 6 month anniversary of such date, it will not hire any individual who at any
time during the three month period preceding the date of this Agreement was, or
who at any time on or after the date of this Agreement is, an employee or
independent sales representative of the other party and (ii) for a period
beginning on the Termination Date, if any, and ending on the 12-month
anniversary of such date, it will not directly or indirectly solicit any such
individual of the other party. Notwithstanding the foregoing, each party may
place advertisements in publications of general circulation to recruit
personnel, provided such publications containing such advertisements are
distributed solely through the customary and public distribution channels of the
24
publication. The covenants provided for in this Section 7.16 shall not apply to
any party from and after the time that such party becomes entitled to receive a
fee pursuant to Section 9.2(b), (c) or (d).
ARTICLE VIII
CONDITIONS TO CONSUMMATION OF THE MERGER
Section 8.1 Conditions to Each Party's Obligation to Effect the
Merger. The respective obligations of each party to effect the Merger shall be
subject to the satisfaction at or prior to the Effective Time of the following
conditions:
(a) HSR Approval. Any waiting period applicable to the consummation
of the Merger under the HSR Act shall have expired or been terminated, and
no action shall have been instituted by the U.S. Department of Justice or
Federal Trade Commission challenging or seeking to enjoin the consummation
of this transaction, which action shall have not been withdrawn or
terminated.
(b) Stockholder Approval. This Agreement and the transactions
contemplated hereby shall have been approved and adopted by (i) the
requisite vote (as described in Section 4.18) of the stockholders of the
Company and (ii) by the requisite vote (as described in Section 5.12) of
the stockholders of Parent, in each case, in accordance with applicable
law.
(c) NASDAQ Listing. The shares of Parent Common Stock issuable to
the holders of Company Common Stock pursuant to this Agreement in the
Merger shall have been authorized for listing on the NASDAQ National
Market, upon official notice of issuance.
(d) Registration Statement. The Registration Statement shall have
become effective under the Securities Act and shall not be the subject of
any stop order or proceeding by the SEC seeking a stop order.
(e) No Order. No Governmental Entity (including a federal or state
court) of competent jurisdiction shall have enacted, issued, promulgated,
enforced or entered any statute, rule, regulation, executive order, decree,
injunction or other order (whether temporary, preliminary or permanent)
which is in effect and which materially restricts, prevents or prohibits
consummation of the Merger or any transaction contemplated by this
Agreement; provided, however, that the parties shall use their reasonable
best efforts to cause any such decree, judgment, injunction or other order
to be vacated or lifted.
(f) Approvals. Other than the filing of Merger documents in
accordance with the WBCL, all authorizations, consents, waivers, orders or
approvals of, or declarations or filings with, or expirations of waiting
periods imposed by, any Governmental Entity the failure of which to obtain,
make or occur would individually or in the aggregate have a material
adverse effect at or after the Effective Time on (i) Parent and its
Subsidiaries or (ii) the Surviving Corporation and its Subsidiaries shall
have been obtained, been filed or have occurred. Parent shall have received
all state securities or 'blue sky' permits and other authorizations
necessary to issue the shares of Parent Common Stock pursuant to this
Agreement in the Merger.
(g) Litigation. No preliminary or permanent injunction or other
order shall have been issued by any court or by any governmental or
regulatory agency, body or authority which enjoins, restrains or prohibits
the transactions contemplated hereby, including the consummation of the
Merger or has the effect of making the Merger illegal and which is in
effect at the Effective Time (each party agreeing to use its best efforts
to have any such injunction or order lifted).
(h) Statutes. No statute, rule, regulation, executive order, decree
or order of any kind shall have been enacted, entered, promulgated or
enforced by any court or governmental authority which prohibits the
consummation of the Merger or has the effect of making the Merger illegal.
(i) Market Events. There shall not have occurred and be continuing
any general suspension or limitation of trading in Parent Common Stock
(exclusive, however, of any temporary suspension pending an ensuing public
announcement) or in securities generally on the NASDAQ National Market.
Section 8.2 Conditions to Obligations of Parent and Sub to Effect the
Merger. The obligations of Parent and Sub to effect the Merger shall be subject
to the satisfaction at or prior to the Effective Time of the following
additional conditions, unless waived in writing by Parent:
25
(a) Representations and Warranties. The representations and warranties
of the Company set forth in this Agreement shall be true and correct in all
material respects as of the date hereof and, except to the extent such
representations and warranties speak as of an earlier date, as of the Effective
Time as though made at and as of the Effective Time, except, in each case, to
the extent that the aggregate effect of all such breaches or misrepresentations
does not and would not reasonably be expected to have a Company Material Adverse
Effect, and Parent shall have received a certificate signed on behalf of the
Company by the chief executive officer or the chief financial officer of the
Company to such effect.
(b) Performance of Obligations of the Company. Each of the Company and
its Subsidiaries shall have performed in all material respects all obligations
required to be performed by it under this Agreement at or prior to the Effective
Time, and Parent shall have received a certificate signed on behalf of the
Company by the chief executive officer or the chief financial officer of the
Company to such effect.
(c) Affiliate Agreements. Parent shall have received the Affiliate
Agreements from each of the Affiliates of the Company, as contemplated in
Section 7.5.
(d) 'Pooling Letter'. Parent shall have received from BDO Seidman LLP a
letter, dated the Closing Date and addressed to Parent, to the effect that,
subject to customary qualifications, the Merger qualifies for pooling of
interests treatment for financial reporting purposes in accordance with GAAP,
and Parent shall have received from the Company, with the consent of Deloitte &
Touche LLP, a copy of a letter, dated the Closing Date, of Deloitte & Touche LLP
addressed to the Company to the effect that, subject to customary
qualifications, the Merger qualifies for pooling of interests for financial
reporting purposes in accordance with GAAP.
(e) Tax Opinion of Counsel. Parent shall have received an opinion of
Proskauer Rose LLP, tax counsel to Parent, in form and substance reasonably
satisfactory to Parent, dated as of the Effective Time, substantially to the
effect that no gain or loss will be recognized by the Company, Parent or Sub as
a result of the Merger.
(f) Letters of Resignation. Parent and Sub shall have received letters
of resignation addressed to the Company from the members of the Company's board
of directors, which resignations shall be effective as of the Effective Time.
(g) Legal Opinion. Parent shall have received an opinion, dated the
Closing Date, of Wolfe, Wolfe & Ryd, counsel to the Company, substantially to
the effect set forth in Exhibit C hereto, subject to assumptions, qualifications
and limitations reasonably satisfactory to Parent. In such opinion Wolfe, Wolfe
& Ryd may rely on an opinion of local counsel as to matters of Wisconsin law,
provided that such local counsel and its opinion are reasonably satisfactory to
Parent and a copy of such counsel's opinion is attached to Wolfe, Wolfe & Ryd's
opinion.
Section 8.3 Conditions to Obligation of the Company to Effect the
Merger. The obligation of the Company to effect the Merger shall be subject to
the satisfaction at or prior to the Effective Time of the following additional
conditions:
(a) Representations and Warranties. The representations and warranties
of Parent set forth in this Agreement shall be true and correct in all material
respects as of the date hereof and, except to the extent such representations
and warranties speak as of an earlier date, as of the Effective Time as though
made on and as of the Effective Time, except, in each case, to the extent that
the aggregate effect of all such breaches or misrepresentations does not and
would not reasonably be expected to have a Parent Material Adverse Effect, and
the Company shall have received a certificate signed on behalf of Parent by the
chief executive officer or the chief financial officer of Parent to such effect.
(b) Performance of Obligations of Parent and Sub. Each of Parent and Sub
shall have performed in all material respects all obligations required to be
performed by it under this Agreement at or prior to the Effective Time, and the
Company shall have received a certificate signed on behalf of Parent by the
chief executive officer or the chief financial officer of Parent to such effect.
(c) Legal Opinion. The Company shall have received the opinion, dated as
of the Effective Time, of Proskauer Rose LLP, counsel to Parent, substantially
to the effect set forth in Exhibit D hereto, subject to assumptions,
qualifications and limitations reasonably satisfactory to the Company. In such
opinion Proskauer Rose LLP may rely on an opinion of local counsel as to matters
of Wisconsin law, provided that such local
26
counsel and its opinion are reasonably satisfactory to the Company and a copy of
such counsel's opinion is attached to Proskauer Rose LLP's opinion.
ARTICLE IX
TERMINATION
Section 9.1 Termination. This Agreement may be terminated at any time
prior to the Effective Time, whether before or after approval by the
stockholders of Parent or the Company:
(a) by mutual consent of Parent and the Company;
(b) by either Parent or the Company, if (i) the Merger shall not have been
consummated before January 31, 1998 or (ii) the approval of the stockholders of
each of Parent and the Company required by Sections 5.12 and 4.18, respectively,
shall not have been obtained at a meeting duly convened therefor or any
adjournment thereof (unless, in the case of any such termination pursuant to
this Section 9.1(b), the failure to so consummate the Merger by such date or to
obtain such stockholder approval shall have been caused by the action or failure
to act of the party (or its Subsidiaries) seeking to terminate this Agreement,
which action or failure to act constitutes a breach of this Agreement);
provided, however, that this Agreement may be extended not more than 90 days by
Parent or the Company by written notice to the other party if the Merger shall
not have been consummated solely as a result of the failure of any of the
conditions set forth in Section 8.1(a) or Section 8.1(f) to be satisfied, but
only if no permanent injunction or other order described in Section 9.1(c) shall
have been issued and the failure of such conditions to be satisfied shall not
have been caused by the action or failure to act of the party seeking to extend
this Agreement, which action or failure to act constitutes a breach of this
Agreement;
(c) by either Parent or the Company, if any permanent injunction or action
by any Governmental Entity of competent jurisdiction preventing the consummation
of the Merger shall have become final and nonappealable; provided, however, that
the party seeking to terminate this Agreement pursuant to this Section 9.1(c)
shall have used all reasonable efforts to remove such injunction or overturn
such action;
(d) by Parent, if (i) there has been a breach of any representations or
warranties of the Company set forth herein the effect of which individually or
together with all other such breaches, is a Company Material Adverse Effect,
(ii) there has been a material breach of any covenant or agreement set forth in
this Agreement on the part of the Company, which breach is not cured within 30
days after written notice of such breach is given by Parent to the Company,
(iii) the Board of Directors of the Company (x) withdraws or amends or modifies
in a manner adverse to Parent or Sub its recommendation or approval in respect
of this Agreement or the Merger, (y) makes any recommendation with respect to an
Acquisition Transaction (including making no recommendation or stating an
inability to make a recommendation), other than a recommendation to reject such
Acquisition Transaction, or (z) takes any action that would be prohibited by
Section 7.2, (iv) any corporation, partnership, person or other entity or group
(as defined in Section 13(d)(3) of the Exchange Act) ('Acquiring Person') other
than Parent, or any affiliate or Subsidiary of Parent, shall have become the
beneficial owner of more than 20% of the outstanding voting equity of the
Company (either on a primary or a fully diluted basis); provided, however that
'Acquiring Person' shall not include any corporation, partnership, person, other
entity or group which beneficially owns as of the date hereof (either on a
primary or a fully diluted basis) more than 20% of the outstanding voting equity
of the Company (either on a primary or a fully diluted basis) and which has not
after the date hereof increased such ownership percentage by more than an
additional 1% of the outstanding voting equity of the Company (either on a
primary or a fully diluted basis), or (v) any other Acquisition Transaction
shall have occurred with any Acquiring Person other than Parent, or any
affiliate or Subsidiary of Parent;
(e) by the Company, if (i) there has been a breach of any representations
or warranties of Parent set forth herein the effect of which individually or
together with all other such breaches is a Parent Material Adverse Effect, (ii)
there has been a material breach of any covenant or agreement set forth in this
Agreement on the part of Parent, which breach is not cured within 30 days after
written notice of such breach is given by the Company to Parent or (iii) such
termination is necessary to allow the Company to enter into an Acquisition
Transaction in accordance with the last sentence of Section 7.2(b) (provided
that the termination described in this clause (iii) shall not be effective
unless and until the Company shall have paid to Parent in full the fee described
in Section 9.2(b);
27
(f) by Parent, if the meeting of stockholders of the Company to vote upon
this Agreement is canceled or is otherwise not held prior to January 31, 1998
(or such later date to which the date for termination of this Agreement pursuant
to Section 9.1(b) has been extended in accordance with the terms thereof) except
as a result of a judgment, injunction, order or decree of any competent
authority or events or circumstances beyond the reasonable control of the
Company;
(g) by the Company, if the meeting of stockholders of the Parent to vote
upon this Agreement is canceled or is otherwise not held prior to January 31,
1998 (or such later date to which the date for termination of this Agreement
pursuant to Section 9.2(b) has been extended in accordance with the terms
thereof) except as a result of a judgment, injunction, order or decree of any
competent authority or events or circumstances beyond the reasonable control of
the Parent; and
(h) by the Company, if the average of the closing sale prices of a share of
Parent Common Stock during the twenty (20) trading days preceding the third
business day prior to the date of the mailing of the Proxy Statement is less
than $25.00 per share.
Section 9.2 Effect of Termination.
(a) In the event of termination of this Agreement pursuant to this Article
IX, the Merger shall be deemed abandoned and this Agreement shall forthwith
become void, without liability on the part of any party hereto, except as
provided in this Section 9.2, Section 7.1 (solely with respect to
confidentiality), Section 7.10 and Section 7.16, and except that nothing herein
shall relieve any party from liability for any breach of this Agreement.
(b) If (x) Parent shall have terminated this Agreement pursuant to Sections
9.1(d)(iii), 9.1(d)(iv) or 9.1(d)(v) or (y) either (1) the Company shall have
terminated this Agreement pursuant to Section 9.1(b) or (2) Parent shall have
terminated this Agreement pursuant to Section 9.1(d)(i), 9.1(d)(ii) or 9.1(f)
and, prior to or within six (6) months after any termination described in this
clause (y), the Company (or any of its Subsidiaries) shall have directly or
indirectly entered into a definitive agreement for, or shall have consummated,
an Acquisition Transaction, or (z) the Company shall have terminated this
Agreement pursuant to Section 9.1(e)(iii), then, in any of such cases, the
Company shall pay Parent a termination fee of twelve million dollars
($12,000,000); provided, however, that any liquidated damage amounts previously
paid by the Company to Parent pursuant to Section 9.2(c) shall be credited
against the termination fee payable under this Section 9.2(b). Any fees payable
under this Section 9.2(b) shall be paid in same day funds no later than: (i)
five business days after a termination described in clause (x) of this Section
9.2(b); (ii) concurrently with or prior to the entering into of the definitive
agreement for, or the consummation of, such Acquisition Transaction, in the case
of a termination described in clause (y) of this Section 9.2(b); or (iii)
concurrently with or prior to a termination described in clause (z) of this
Section 9.2(b). For the sake of clarity, the parties hereto expressly
acknowledge that Parent shall not be entitled to a fee pursuant to this Section
9.2(b) if, prior to the time that Parent would otherwise be entitled to such
fee, the Company shall have properly terminated this agreement pursuant to
Sections 9.1(e)(i), 9.1(e)(ii) or 9.1(g).
(c) If Parent shall have terminated this Agreement pursuant to Sections
9.1(d)(i), 9.1(d)(ii) or 9.1(f), then, in any of such cases, the Company shall
pay to Parent, as liquidated damages and not as a penalty, seven million dollars
($7,000,000). Such liquidated damage amount shall be payable no later than five
business days after such termination.
(d) If the Company shall have terminated this Agreement pursuant to
Sections 9.1(e)(i), 9.1(e)(ii) or 9.1(g), then, in either such case, Parent
shall pay to the Company as liquidated damages and not as a penalty, seven
million dollars ($7,000,000). Such liquidated damage amount shall be payable no
later than five business days after such termination.
ARTICLE X
GENERAL PROVISIONS
Section 10.1 Amendment and Modification. At any time prior to the
Effective Time, this Agreement may be amended, modified or supplemented only by
written agreement (referring specifically to this Agreement) of Parent, Sub and
the Company with respect to any of the terms contained herein; provided,
however, that after
28
any approval and adoption of this Agreement by the stockholders of Parent or the
Company, no such amendment, modification or supplementation shall be made which
under applicable law requires the approval of such stockholders, without the
further approval of such stockholders.
Section 10.2 Waiver. At any time prior to the Effective Time, Parent and
Sub, on the one hand, and the Company, on the other hand, may (i) extend the
time for the performance of any of the obligations or other acts of the other,
(ii) waive any inaccuracies in the representations and warranties of the other
contained herein or in any documents delivered pursuant hereto and (iii) waive
compliance by the other with any of the agreements or conditions contained
herein which may legally be waived. Any such extension or waiver shall be valid
only if set forth in an instrument in writing specifically referring to this
Agreement and signed on behalf of such party.
Section 10.3 Survivability; Investigations. The respective
representations and warranties of Parent and the Company contained herein or in
any certificates or other documents delivered prior to or as of the Effective
Time (i) shall not be deemed waived or otherwise affected by any investigation
made by any party hereto and (ii) shall not survive beyond the Effective Time.
The covenants and agreements of the parties hereto (including the Surviving
Corporation after the Merger) shall survive the Effective Time without
limitation (except for those which, by their terms, contemplate a shorter
survival period).
Section 10.4 Notices. All notices and other communications hereunder
shall be in writing and shall be delivered personally or by next-day courier or
telecopied with confirmation of receipt, to the parties at the addresses
specified below (or at such other address for a party as shall be specified by
like notice; provided that notices of a change of address shall be effective
only upon receipt thereof. Any such notice shall be effective upon receipt, if
personally delivered or telecopied, or one day after delivery to a courier for
next-day delivery.
(a) If to Parent or Sub, to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek
with a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
(b) if to the Company, to:
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
Attention: Timothy J. Sullivan
with a copy to:
Wolfe, Wolfe & Ryd
20 N. Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry B. Wolfe, Esq.
If Parent, on the one hand, or the Company, on the other, has or gains knowledge
prior to the Effective Date of any breach of any representation, warranty or
covenant of the other set forth in this Agreement, Parent or the Company, as the
case may be, shall promptly notify the other of such breach, but any failure to
give such notice shall not affect such party's rights or remedies hereunder in
respect thereof.
29
Section 10.5 Descriptive Headings; Interpretation. The headings
contained in this Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement. References in this
Agreement to Sections, Schedules, Exhibits or Articles mean a Section, Schedule,
Exhibit or Article of this Agreement unless otherwise indicated. References to
this Agreement shall be deemed to include the Exhibits and Schedules hereto,
unless the context otherwise requires. The term 'person' shall mean and include
an individual, a partnership, a joint venture, a corporation, a trust, a
Governmental Entity or an unincorporated organization.
Section 10.6 Entire Agreement; Assignment. This Agreement (including the
Schedules and other documents and instruments referred to herein), together with
the Irrevocable Proxy and Termination Rights Agreement and the Confidentiality
Agreement, constitute the entire agreement and supersede all other prior
agreements and understandings, both written and oral, among the parties or any
of them, with respect to the subject matter hereof. This Agreement is not
intended to confer upon any person not a party hereto any rights or remedies
hereunder. This Agreement shall not be assigned by operation of law or
otherwise; provided that Parent or Sub may assign its rights and obligations
hereunder to a direct or indirect subsidiary of Parent, but no such assignment
shall relieve Parent or Sub, as the case may be, of its obligations hereunder.
Section 10.7 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York without giving
effect to the provisions thereof relating to conflicts of law, except to the
extent relating to matters governed by the General Corporation Law of the State
of Delaware or the WBCL.
Section 10.8 Severability. In case any one or more of the provisions
contained in this Agreement should be invalid, illegal or unenforceable in any
respect against a party hereto, the validity, legality and enforceability of the
remaining provisions contained herein shall not in any way be affected or
impaired thereby and such invalidity, illegality or unenforceability shall only
apply as to such party in the specific jurisdiction where such judgment shall be
made.
Section 10.9 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original but all of which
shall constitute one and the same agreement.
IN WITNESS WHEREFORE, each of Parent, Sub and the Company has caused this
Agreement to be executed on its behalf by its officers thereunto duly
authorized, all as of the date first above written.
HENRY SCHEIN, INC.
By: /S/ Mark E. Mlotek
----------------------------------
Mark E. Mlotek
Vice President
HSI ACQUISITION CORP.
By: /S/ Mark E. Mlotek
-----------------------------------
Mark E. Mlotek
Vice President
SULLIVAN DENTAL PRODUCTS, INC.
By: /S/ Timothy J. Sullivan
-----------------------------------
Timothy J. Sullivan
30
ANNEX II
OPINION OF CLEARY GULL REILAND & MCDEVITT INC.
August 3, 1997
Board of Directors
SULLIVAN DENTAL PRODUCTS, INC.
10920 West Lincoln Avenue
West Allis, WI 53227
Gentlemen:
You have requested our opinion as to the fairness, from a financial point
of view, to the holders (the 'Shareholders') of shares of common stock, par
value $0.01 per share ('Sullivan Common Stock'), of Sullivan Dental Products,
Inc. ('Sullivan') of the consideration to be received by the Stockholders
pursuant to the terms of the Merger Agreement dated as of August 3, 1997 (the
'Merger Agreement') by and among Henry Schein, Inc. ('Schein'), HSI Acquisition
Corp., a wholly owned subsidiary of Schein ('Subsidiary'), and Sullivan,
pursuant to which Subsidiary will be merged (the 'Merger') with and into
Sullivan and Sullivan will become a wholly owned subsidiary of Schein.
Under the Merger Agreement, each issued and outstanding share of Sullivan
Common Stock, other than shares of Sullivan Common Stock to be canceled pursuant
to Section 3.1(b) of the Merger Agreement, will be converted into the right to
receive 0.735 shares (the 'Exchange Ratio') of the $0.01 par value common stock
of Schein ('Schein Common Stock'). Notwithstanding the foregoing, if the Schein
Average Trading Price is less than $25.00 per share, the Sullivan Board of
Directors has the right to terminate the Merger Agreement without liability in
any respect whatsoever. The 'Schein Average Trading Price' shall mean the
average of the closing sales prices of a share of Schein Common Stock, as
reported on the NASDAQ National Market during the 20 trading day period
preceding the third business day prior to the date of the mailing of the Proxy
Statement. The terms and conditions of the Merger are more fully set forth in
the Merger Agreement.
In arriving at our opinion, we have reviewed, among other things, the
Merger Agreement and certain business and financial information relating to
Sullivan, including certain financial projections, estimates and analyses
provided to us by Sullivan. We have also reviewed and discussed the business and
prospects of Sullivan and its subsidiaries with representatives of Sullivan's
management. We have considered certain financial and stock market data relating
to Sullivan and in certain cases have compared that information to similar data
for other publicly held companies in businesses considered to be generally
comparable to Sullivan.
We have also reviewed certain publicly available business and financial
information relating to Schein, including certain information concerning the
estimates of future operating and financial performance prepared by industry
experts unaffiliated with Schein, and have had discussions with representatives
of Schein's management. In addition, we have reviewed financial plans prepared
by Schein's management. We have considered certain financial and stock market
data relating to Schein and in certain cases have compared that information to
similar data for other publicly held companies in businesses considered to be
generally comparable to Schein.
In arriving at our opinion, we have also considered the financial impact of
the Merger on Schein's future earnings per share, an unleveraged after-tax
discounted cash flow analysis of both Sullivan and Schein, an analysis of
Sullivan's percentage contribution to the pro forma operating results for the
combined entity resulting from the Merger compared to the implied percentage
ownership interest of holders of Sullivan Common Stock in Schein after giving
effect to the Merger, a comparison of the purchase price premium to be paid for
the Sullivan Common Stock based on the Exchange Ratio to certain other similar
mergers, publicly available information concerning the nature and terms of
certain other transactions that Cleary Gull believed to be relevant on a
comparative basis, a historical comparison of Sullivan's and Schein's stock
market prices and such other
II-1
information, financial studies and analyses and financial, economic and market
criteria as we deemed relevant and appropriate.
In connection with our review, we have not assumed any responsibility for
independent verification of any of the foregoing information and have relied on
its being complete and accurate in all material respects. We have not made an
independent evaluation or appraisal of any assets or liabilities (contingent or
otherwise) of Sullivan or Schein or any of their respective subsidiaries, nor
have we been furnished with any such evaluation or appraisal that has not been
publicly disclosed. With respect to the financial plans, estimates and analyses
provided to us by Sullivan, we have assumed, with your permission, that all such
information was reasonably prepared on bases reflecting the best currently
available estimates and judgments of management of Sullivan as to future
financial performance and was based upon the historical performance of Sullivan
and certain estimates and assumptions which were reasonable at the time made.
Upon advice of Sullivan and its legal and accounting advisors, we have assumed
the Merger will be treated as a pooling of interests transaction in accordance
with generally accepted accounting principles and as a tax-free reorganization
for federal income tax purposes. Our opinion is based on economic, monetary and
market conditions existing on the date hereof.
Based upon and subject to the foregoing, it is our opinion that, as of the
date hereof, the consideration to be received by the Shareholders pursuant to
the Merger Agreement is fair, from a financial point of view, to the
Shareholders.
We are acting as financial advisor to the Board of Directors of Sullivan in
this transaction and will receive a fee for our services, a portion of which was
payable as a result of the delivery of this letter and a portion of which is
contingent upon the approval and consummation of the Merger. In addition,
Sullivan has agreed to indemnify us for certain liabilities that may arise out
of the rendering of this opinion. On March 31, 1992, we were the co-manager for
a public offering of 700,000 shares of Sullivan Common Stock for which we
received customary compensation. In the ordinary course of business, we actively
trade securities of Sullivan and Schein for our own account and for the accounts
of our customers and, accordingly, may at any time hold a long or short position
in such securities. We currently make a market in Sullivan Common Stock and
Schein Common Stock.
This opinion is for the use and benefit of the Board of Directors of
Sullivan and is rendered to the Board of Directors of Sullivan in connection
with its consideration of the Merger. We are not making any recommendation
regarding whether or not it is advisable for Shareholders to vote in favor of
the Merger. We have not been requested to opine as to, and our opinion does not
in any manner address, Sullivan's underlying business decision to proceed with
or effect the Merger. We are not rendering any opinion as to the value of Schein
or making any recommendation to the Shareholders in respect of the advisability
of disposing of or retaining Schein Common Stock received pursuant to the
Merger.
Very truly yours,
CLEARY GULL REILAND & MCDEVITT INC.
II-2
ANNEX III
OPINION OF SMITH BARNEY INC.
August 3, 1997
The Board of Directors
HENRY SCHEIN, INC.
135 Duryea Road
Melville, New York 11747
Members of the Board:
You have requested our opinion as to the fairness, from a financial point
of view, to Henry Schein, Inc. ('Schein') of the consideration to be paid by
Schein pursuant to the terms and subject to the conditions set forth in the
Agreement and Plan of Merger, dated as of August 3, 1997 (the 'Merger
Agreement'), by and among Schein, HSI Acquisition Corp., a wholly owned
subsidiary of Schein ('Sub'), and Sullivan Dental Products, Inc. ('Sullivan').
As more fully described in the Merger Agreement, (i) Sub will be merged with and
into Sullivan (the 'Merger') and (ii) each outstanding share of the common
stock, par value $0.01 per share, of Sullivan (the 'Sullivan Common Stock') will
be converted into the right to receive 0.735 (the 'Exchange Ratio') of a share
of the common stock, par value $0.01 per share, of Schein (the 'Schein Common
Stock').
In arriving at our opinion, we reviewed the Merger Agreement and held
discussions with certain senior officers, directors and other representatives
and advisors of Schein and certain senior officers and other representatives and
advisors of Sullivan concerning the businesses, operations and prospects of
Schein and Sullivan. We examined certain publicly available business and
financial information relating to Schein and Sullivan as well as certain
financial forecasts and other information and data for Schein and Sullivan which
were provided to or otherwise discussed with us by the respective managements of
Schein and Sullivan, including information relating to certain strategic
implications and operational benefits anticipated to result from the Merger. We
reviewed the financial terms of the Merger as set forth in the Merger Agreement
in relation to, among other things: current and historical market prices and
trading volumes of Schein Common Stock and Sullivan Common Stock; the historical
and projected earnings and other operating data of Schein and Sullivan; and the
capitalization and financial condition of Schein and Sullivan. We considered, to
the extent publicly available, the financial terms of certain other similar
transactions recently effected which we considered relevant in evaluating the
Merger and analyzed certain financial, stock market and other publicly available
information relating to the businesses of other companies whose operations we
considered relevant in evaluating those of Schein and Sullivan. We also
evaluated the potential pro forma financial impact of the Merger on Schein. In
addition to the foregoing, we conducted such other analyses and examinations and
considered such other financial, economic and market criteria as we deemed
appropriate in arriving at our opinion.
In rendering our opinion, we have assumed and relied, without independent
verification, upon the accuracy and completeness of all financial and other
information and data publicly available or furnished to or otherwise reviewed by
or discussed with us. With respect to financial forecasts and other information
and data provided to or otherwise reviewed by or discussed with us, we have been
advised by the managements of Schein and Sullivan that such forecasts and other
information and data were reasonably prepared on bases reflecting the best
currently available estimates and judgments of the respective managements of
Schein and Sullivan as to the future financial performance of Schein and
Sullivan and the strategic implications and operational benefits anticipated to
result from the Merger. We have assumed, with your consent, that the Merger will
be treated as a pooling of interests in accordance with generally accepted
accounting principles and as a tax-free reorganization for federal income tax
purposes. Our opinion, as set forth herein, relates to the relative values of
Schein and Sullivan. We are not expressing any opinion as to what the value of
the Schein Common Stock actually will be when issued to Sullivan stockholders
pursuant to the Merger or the price at which the Schein Common Stock will trade
subsequent to the Merger. We have not made or been provided with an independent
evaluation or appraisal of the
III-1
assets or liabilities (contingent or otherwise) of Schein or Sullivan nor have
we made any physical inspection of the properties or assets of Schein or
Sullivan. We were not requested to consider, and our opinion does not address,
the relative merits of the Merger as compared to any alternative business
strategies that might exist for Schein or the effect of any other transaction in
which Schein might engage. Our opinion is necessarily based upon information
available to us, and financial, stock market and other conditions and
circumstances existing and disclosed to us, as of the date hereof.
Smith Barney has been engaged to render financial advisory services to
Schein in connection with the Merger and will receive a fee for such services, a
significant portion of which is contingent upon the consummation of the Merger.
We also will receive a fee upon the delivery of this opinion. In the ordinary
course of our business, we and our affiliates may actively trade or hold the
securities of Schein and Sullivan for our own account or for the account of our
customers and, accordingly, may at any time hold a long or short position in
such securities. We have in the past provided investment banking services to
Schein unrelated to the proposed Merger, for which services we have received
compensation. In addition, we and our affiliates (including Travelers Group Inc.
and its affiliates) may maintain relationships with Schein and Sullivan.
Our advisory services and the opinion expressed herein are provided for the
information of the Board of Directors of Schein in its evaluation of the
proposed Merger, and our opinion is not intended to and does not constitute a
recommendation to any stockholder as to how such stockholder should vote on any
matter relating to the proposed Merger. Our opinion may not be published or
otherwise used or referred to, nor shall any public reference to Smith Barney be
made, without our prior written consent.
Based upon and subject to the foregoing, our experience as investment
bankers, our work as described above and other factors we deemed relevant, we
are of the opinion that, as of the date hereof, the Exchange Ratio is fair, from
a financial point of view, to Schein.
Very truly yours,
SMITH BARNEY INC.
III-2
ANNEX IV
ARTICLE FIFTH OF SCHEIN CERTIFICATE OF INCORPORATION
PRIOR TO THE PROPOSED SCHEIN CERTIFICATE OF INCORPORATION AMENDMENTS
FIFTH:
A. The business and affairs of the Corporation shall be managed by its
Board of Directors whose members need not be residents of the State of Delaware
nor stockholders of the Corporation. The number of directors which shall
constitute the entire Board of Directors shall be no less than five and no more
than 11 through December 31, 1998; thereafter the number of directors which
shall constitute the entire Board of Directors shall be nine.
B. In furtherance and not in limitation of the powers conferred by statute,
the Board of Directors is expressly authorized:
1. To adopt, amend or repeal any By-Law (provided, however, that (a)
any By-Law made, amended or repealed by the Board of Directors may be
amended or repealed, and that any by-laws may be adopted, by the
stockholders of the Corporation and (b) the Board of Directors may not
amend or repeal any By-Law adopted by the stockholders of the Corporation);
2. To authorize and cause to be executed mortgages and liens upon the
real and personal property of the Corporation;
3. To set apart out of any of the funds of the Corporation available
for dividends a reserve or reserves for any proper purpose and to abolish
any such reserve in the manner in which it was created; and
4. By resolution passed by a majority of the whole Board, to designate
one or more committees, each committee to consist of two or more of the
directors of the Corporation, which, to the extent provided in such
resolution or in the By-laws of the Corporation, shall have and may
exercise all the powers and the authority of the Board of Directors in the
management of the business and affairs of the Corporation, and may
authorize the seal of the Corporation to be affixed to all papers which may
require it. Such committee or committees shall have such name or names as
may be stated in the By-laws of the Corporation or as may be determined
from time to time by resolution adopted by the Board of Directors.
C. The affirmative vote of the holders of 80% or more of the shares
entitled to vote in the election of directors shall be required to amend or
repeal, or adopt any provisions inconsistent with, this Article FIFTH.
IV-1
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 20. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Article TENTH of the Company's Amended and Restated Certificate of
Incorporation provides that the Company shall indemnify and hold harmless, to
the fullest extent authorized by the Delaware General Corporation Law, its
officers and directors against all expenses, liability and loss actually and
reasonably incurred in connection with any civil, criminal, administrative or
investigative action, suit or proceeding. The Amended and Restated Certificate
of Incorporation also extends indemnification to those serving at the request of
the Company as directors, officers, employees or agents of other enterprises.
In addition, Article NINTH of the Company's Amended and Restated
Certificate of Incorporation provides that no director shall be personally
liable for any breach of fiduciary duty. Article NINTH does not eliminate a
director's liability (i) for a breach of his or her duty of loyalty to the
Company or its stockholders, (ii) for acts or omissions of intentional
misconduct, (iii) under Section 174 of the Delaware General Corporation Law for
unlawful declarations of dividends or unlawful stock purchases or redemptions,
or (iv) for any transactions from which the director derived an improper
personal benefit.
Section 145 of the Delaware General Corporation Law permits a corporation
to indemnify its directors and officers against expenses (including attorney's
fees), judgments, fines and amounts paid in settlements actually and reasonably
incurred by them in connection with any action, suit or proceeding brought by
third parties, if such directors or officers acted in good faith and in a manner
they reasonably believed to be in or not opposed to the best interests of the
corporation and, with respect to any criminal action or proceeding, had no
reason to believe their conduct was unlawful. In a derivative action, i.e., one
by or in the right of the corporation, indemnification may be made only for
expenses actually and reasonably incurred by directors and officers in
connection with the defense or settlement of an action or suit, and only with
respect to a matter as to which they shall have acted in good faith and in a
manner they reasonably believed to be in or not opposed to the best interests of
the corporation, except that no indemnification shall be made if such person
shall have been adjudged liable to the corporation, unless and only to the
extent that the court in which the action or suit was brought shall determine
upon application that the defendant officers or directors are reasonably
entitled to indemnity for such expenses despite such adjudication of liability.
Section 102(b)(7) of the Delaware General Corporation Law provides that a
corporation may eliminate or limit the personal liability of a director to the
corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director, provided that such provision shall not eliminate or limit
the liability of a director (i) for any breach of the director's duty of loyalty
to the corporation or its stockholders, (ii) for acts or omissions not in good
faith or which involve intentional misconduct or a knowing violation of law,
(iii) for liabilities arising under Section 174 of the Delaware General
Corporation Law, or (iv) for any transaction from which the director derived an
improper personal benefit. No such provision shall eliminate or limit the
liability of a director for any act or omission occurring prior to the date when
such provision becomes effective.
ITEM 21. EXHIBITS AND FINANCIAL STATEMENTS
(a) Exhibits
The exhibits required by Item 601 of Regulation S-K and filed herewith are
listed in the Exhibit Index immediately preceding the exhibits.
(b) Financial Statement Schedules
All schedules are omitted as the required information is presented in the
financial statements or related notes incorporated by reference in the Joint
Proxy Statement/Prospectus or are not applicable.
(c) Reports, Opinions or Appraisals
Opinion of Cleary Gull Reiland & McDevitt Inc. and Opinion of Smith Barney
Inc. (filed as Annexes II and III, respectively, to the Joint Proxy
Statement/Prospectus constituting part of this Registration Statement and
incorporated herein by reference).
II-i
ITEM 22. UNDERTAKINGS
(1) The undersigned registrant hereby undertakes that, for the purpose of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(2) Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons of
the undersigned registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.
(3) The undersigned registrant hereby undertakes to respond to requests for
information that is incorporated by reference into the prospectus pursuant to
Item 4, 10(b), 11 or 13 of this form, within one business day of receipt of such
request, and to send the incorporated documents by first class mail or other
equally prompt means. This includes information contained in documents filed
subsequent to the effective date of the registration statement through the date
of responding to the request.
(4) The undersigned registrant hereby undertakes to supply by means of a
post-effective amendment all information concerning a transaction, and the
company being acquired involved therein, that was not the subject of and
included in the registration statement when it became effective.
II-ii
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT, THE REGISTRANT HAS DULY
CAUSED THIS REGISTRATION STATEMENT TO BE SIGNED ON ITS BEHALF BY THE
UNDERSIGNED, THEREUNTO DULY AUTHORIZED, IN THE CITY OF MELVILLE, STATE OF NEW
YORK ON SEPTEMBER 22, 1997.
HENRY SCHEIN, INC.
By: /s/ STANLEY M. BERGMAN
---------------------------------
Stanley M. Bergman
Chairman, Chief Executive Officer
and President
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Stanley M. Bergman and Steven Paladino, and each
of them, such person's true and lawful attorney-in-fact and agent, with full
power of substitution and resubstitution, for such persons and in such person's
name, place and stead, in any and all capacities, to sign any and all Amendments
(including pre-effective and post-effective amendments) to this Registration
Statement, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the United States Securities and Exchange
Commission, granting unto said attorney-in-fact and agent, and both of them,
full power and authority to do and perform each and every act and thing
requisite and necessary to be done in and about the premises, as fully to all
intents and purposes as such person might or could do in person, hereby
ratifying and confirming all that said attorney-in-fact and agents, or either of
them, or his substitute or substitutes, may lawfully do or cause to be done by
virtue thereof.
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS
REGISTRATION STATEMENT HAS BEEN SIGNED BY THE FOLLOWING PERSONS IN THE
CAPACITIES AND ON THE DATES INDICATED.
SIGNATURE CAPACITY DATE
- ------------------------------------------ ------------------------------------------- -------------------
/s/ STANLEY M. BERGMAN Chairman, Chief Executive Officer, September 22, 1997
- ------------------------------------------ President and Director (principal executive
Stanley M. Bergman officer)
/s/ STEVEN PALADINO Senior Vice President, Chief Financial September 22, 1997
- ------------------------------------------ Officer and Director (principal financial
Steven Paladino and accounting officer)
/s/ JAMES P. BRESLAWSKI Director September 22, 1997
- ------------------------------------------
James P. Breslawski
/s/ GERALD S. BENJAMIN Director September 22, 1997
- ------------------------------------------
Gerald A. Benjamin
/s/ LEONARD A. DAVID Director September 22, 1997
- ------------------------------------------
Leonard A. David
/s/ MARK E. MLOTEK Director September 22, 1997
- ------------------------------------------
Mark E. Mlotek
/s/ PAMELA JOSEPH Director September 22, 1997
- ------------------------------------------
Pamela Joseph
/s/ MARVIN H. SCHEIN Director September 22, 1997
- ------------------------------------------
Marvin H. Schein
/s/ IRVING SHAFRAN Director September 22, 1997
- ------------------------------------------
Irving Shafran
/s/ BARRY J. ALPERIN Director September 22, 1997
- ------------------------------------------
Barry J. Alperin
/s/ DONALD J. ALPERIN Director September 22, 1997
- ------------------------------------------
Donald J. Alperin
II-iii
EXHIBIT INDEX
Unless otherwise indicated, exhibits are incorporated by reference to the
correspondingly numbered exhibits in the Henry Schein, Inc.'s Registration
Statement on Form S-1 (Registration No. 33-96528)
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
2.1 -- Agreement and Plan of Merger, dated as of August 3, 1997 by and among Henry Schein, Inc.,
HSI Acquisition Corp and Sullivan Dental Products, Inc. (filed as Annex I to the Joint
Proxy Statement/Prospectus included in this Registration Statement).
3.1 -- Form of Amended and Restated Articles of Incorporation.
3.2 -- Form of Amended and Restated Bylaws.
3.3 -- Amendments to Amended and Restated By-laws adopted July 15, 1997 (filed herewith).
5.1 -- Opinion of Proskauer Rose LLP regarding legality (filed herewith).
5.2 -- Opinion of Proskauer Rose LLP regarding certain tax matters (filed herewith).
9.1 -- Voting Trust Agreement dated September 30, 1994, as amended, among Henry Schein, Inc., the
Estate of Jacob M. Schein, the Trusts under Articles Third and Fourth of the Will of Jacob
M. Schein, the Trust established by Pamela Joseph under Trust Agreement dated February 9,
1994, the Trust established by Martin Sperber under Trust Agreement dated September 19,
1994, management stockholders and Stanley M. Bergman, as voting trustee.
9.2 -- Agreements dated December 27, 1994 among Henry Schein, Inc., various executive officers
and Stanley M. Bergman, as voting trustee.
9.3 -- Agreements dated as of May 1, 1995 among Henry Schein, Inc., various executive officers
and Stanley M. Bergman, as voting trustee.
10.1 -- Amended and Restated Schein Agreement (the 'Schein Agreement'), effective as of February
16, 1994, among Henry Schein, Inc., Marvin H. Schein, the Trust established by Marvin H.
Schein under Trust Agreement dated September 9, 1994, the Charitable Trust established by
Marvin H. Schein under Trust Agreement dated September 12, 1994, the Estate of Jacob M.
Schein, the Trusts established by Articles Third and Fourth of the Will of Jacob M.
Schein, the Trust established by Pamela Joseph under Trust Agreement dated February 9,
1994, the Trust established by Martin Sperber under Trust Agreement dated September 19,
1994, the Trust established by Stanley M. Bergman under Trust Agreement dated September
15, 1994, Pamela Schein, Pamela Joseph, Martin Sperber, Stanley M. Bergman, Steven
Paladino and James P. Breslawski (collectively, the 'Schein Parties').
10.2 -- Schein Registration Rights Agreement dated September 30, 1994, among Henry Schein, Inc.,
Pamela Schein, the Trust established by Pamela Joseph under Trust Agreement dated February
9, 1994, Marvin H. Schein, the Trust established by Marvin H. Schein under Trust Agreement
dated December 31, 1993, the Trust established by Marvin H. Schein under Trust Agreement
dated September 19, 1994, the Charitable Trust established by Marvin H. Schein under Trust
Agreement dated September 12, 1994, Martin Sperber, the Trust established by Martin
Sperber under Trust Agreement dated September 19, 1994, Stanley M. Bergman and the Trust
established by Stanley M. Bergman under Trust Agreement dated September 15, 1994.
10.3 -- Letter Agreement dated September 30, 1994 to Henry Schein, Inc. from Marvin H. Schein,
Pamela Joseph and Pamela Schein.
10.4 -- Release to the Schein Agreement dated September 30, 1994.
10.5 -- Separation Agreement dated as of September 30, 1994 by and between Henry Schein, Inc.,
Schein Pharmaceutical, Inc. and Schein, Schein Holdings.
II-iv
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
10.6 -- Restructuring Agreement dated September 30, 1994 among Schein, Schein Holdings, Henry
Schein, Inc., the Estate of Jacob M. Schein, Marvin H. Schein, the Trust established by
Marvin H. Schein under Trust Agreement dated December 31, 1993, the Trust established by
Marvin H. Schein under Trust Agreement dated September 9, 1994, the Charitable Trust
established by Marvin H. Schein under Trust Agreement dated September 12, 1994, Pamela
Schein, Pamela Joseph, the Trust established by Pamela Joseph under Trust Agreement dated
February 9, 1994; the Trusts under Articles Third and Fourth of the Will of Jacob M.
Schein; Stanley M. Bergman, the Trust established by Stanley M. Bergman under Trust
Agreement dated September 15, 1994, Martin Sperber, the Trust established by Martin
Sperber under Trust Agreement dated December 31, 1993, and the Trust established by Martin
Sperber under Trust Agreement dated September 19, 1994.
10.7 -- Agreement and Plan of Corporate Separation and Reorganization dated as of September 30,
1994 among Schein, Schein Holdings, Henry Schein, Inc., the Estate of Jacob M. Schein,
Marvin H. Schein, the Trust established by Marvin H. Schein under Trust Agreement dated
December 31, 1993, the Trust established by Marvin H. Schein under Trust Agreement dated
September 9, 1994, the Charitable Trust established by Marvin H. Schein under Trust
Agreement dated September 12, 1994, Pamela Schein, the Trust established by Article Fourth
of the Will of Jacob M. Schein for the benefit of Pamela Schein and her issue under Trust
Agreement dated September 29, 1994, Pamela Joseph, the Trust established by Pamela Joseph
under Trust Agreement dated February 9, 1994, the Trust established by Pamela Joseph under
Trust Agreement dated September 28, 1994 and the Trusts under Articles Third and Fourth of
the Will of Jacob M. Schein.
10.8 -- Henry Schein, Inc. 1994 Stock Option Plan, as amended and restated effective as of July 1,
1995**.
10.9 -- Henry Schein, Inc. Amendment and Restatement of the Supplemental Executive Retirement Plan
**.
10.10 -- Henry Schein, Inc. Summary Executive Incentive Plan**.
10.11 -- Consulting Agreement dated September 30, 1994 between Henry Schein, Inc. and Marvin H.
Schein**.
10.12 -- Employment Agreement dated as of January 1, 1992 between Henry Schein, Inc. and Stanley M.
Bergman**.
10.13 -- Amended and Restated Stock Issuance Agreement dated as of December 24, 1992 between Henry
Schein, Inc. and Stanley M. Bergman**.
10.14 -- Stock Issuance Agreements dated December 27, 1994 between Henry Schein, Inc. and various
executive officers**.
10.15 -- Agreement and Plan of Merger dated as of September 1, 1995, among Henry Schein, Inc.,
Schein Dental Equipment Corp., Marvin Schein and others.
10.16 -- Stock Purchase Agreement dated August 25, 1995, by Henry Schein, Inc., PRN Medical, Inc.
and its shareholders, and Florida Doctor Supply, Inc. and its shareholders.
10.17 -- Restated Standard Indemnity Agreement dated February 8, 1993, as amended January 25, 1993,
by and between Showa Denko America, Inc. and Henry Schein, Inc.
10.18 -- Guaranty Agreement by and between Showa Denko K.K. and Henry Schein, Inc., relating to the
Restated Standard Indemnity Agreement dated February 8, 1993, as amended January 25, 1993,
by and between Showa Denko America, Inc. and Henry Schein, Inc.
II-v
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
10.19 -- Stock Issuance Agreements dated as of May 1, 1995 between Henry Schein, Inc. and executive
officers.
10.20 -- Agreement of Purchase and Sale of Assets dated February 28, 1996 by and among Henry
Schein, Inc., Benton Dental, Inc. and Modern Dental Concepts, Inc. (incorporated by
reference to Exhibit 10.20 of the registrant's Form 10-K for the fiscal year ended
December 28, 1996).
10.21 -- Credit Agreement dated as of December 8, 1994 between Henry Schein, Inc. and The Chase
Manhattan Bank, N.A.
10.22 -- Loan Agreement dated May 5, 1995 by and between Henry Schein, Inc. and New York State
Urban Development Corporation.
10.23 -- Term Loan Agreement dated as of November 15, 1993 between Henry Schein Europe, Inc. and
Cooperatieve Centrale Raiffeisen-Boerenleenbank B.A.
10.24 -- Corporate Guarantee dated November 15, 1993 by Henry Schein, Inc., Zahn Dental Co., Inc.
Zahn Dental (Florida), Inc., Zahn Dental (Mass), Inc., Tri-State Medical Supply, Inc. and
Zahn Schein Holdings with respect to the Term Loan dated as of November 15, 1993 between
Henry Schein Europe, Inc. and Cooperatieve Centrale Raiffeisen-Boerenleenbank, B.A.
10.25 -- Joint and Several Guarantee dated February 7, 1995 by Henry Schein, Inc. in favor of
Banque Nationale de Paris.
10.26 -- Joint and Several Guarantee dated February 7, 1995 by Henry Schein, Inc. in favor of
Banque Francaise du Commerce Exterieur.
10.27 -- Guarantee dated March 1, 1996 by Henry Schein, Inc. in favor of Deutsche Bank AG
(incorporated by reference to Exhibit 10.27 of the registrant's Form 10-K for the fiscal
year ended December 28, 1996).
10.28 -- Lease Agreement dated December 22, 1995 by and between Dugan Realty, L.L.C. and Henry
Schein, Inc. (incorporated by reference to Exhibit 10.28 of the registrant's Form 10-K for
the fiscal year ended December 28, 1996).
10.29 -- Commercial Guaranty dated August 1, 1994 by Henry Schein, Inc. in favor of the Mid-City
National Bank.
10.30 -- Discretionary Line of Credit dated August 18, 1995 between PNC Bank, Delaware and one of
Henry Schein, Inc.'s 50% owned companies.
10.31 -- Discretionary Line of Credit Demand Note dated August 18, 1995 in favor of one of Henry
Schein, Inc.'s 50% owned companies.
10.32 -- Loan Agreement dated March 30, 1992 between the Royal Bank of Scotland plc, Henry Schein
U.K. Schein Holdings Limited and BDG U.K. Schein Holdings Limited.
10.33 -- Loan Agreement dated January 28, 1994 between the Royal Bank of Scotland plc, Henry Schein
U.K. Schein Holdings Limited and Dental Express (Supplies) Limited.
10.34 -- Credit Agreement dated June 5, 1995 among Canadian Imperial Bank of Commerce and one of
Henry Schein, Inc.'s 50% owned companies.
10.35 -- Master Lease Agreement dated as of February 28, 1991 between General Electric Capital
Corporation and Henry Schein, Inc.
10.36 -- Master Lease Agreement dated December 2, 1994 between Chase Equipment Leasing, Inc. and
Henry Schein, Inc.
10.37 -- Software License Agreement dated as of June 20, 1995 between Henry Schein, Inc. and
XcelleNet, Inc.
10.38 -- Software License Agreement dated as of October 31, 1994, as amended, between J.D. Edwards
& Henry Schein, Inc.
II-vi
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
10.39 -- Software Update Agreement dated as of October 31, 1994, as amended, between J.D. Edwards &
Company and Henry Schein, Inc.
10.40 -- Software Services Agreement dated as of October 31, 1994, as amended, between J.D. Edwards
& Company and Henry Schein, Inc.
10.41 -- Lease dated December 3, 1990 between WRC Properties, Inc. and Henry Schein, Inc.
10.42 -- Lease dated March 2, 1992 between Vista Distribution Center, Inc. and Henry Schein, Inc.
10.43 -- Lease dated as of September 30, 1993, as amended October 14, 1993 and May 23, 1995, by and
between Broad Hollow Realty Co. and Henry Schein, Inc.
10.44 -- Lease dated April 27, 1995 by Lyndean Investments Limited to Kent Dental Limited and Henry
Schein U.K. Schein Holdings Limited.
10.45 -- Lease dated October 23, 1994 between Georg and Pia Netzhammer and Henry-Schein Dentina
GmbH (English translation and original version).
10.46 -- Lease dated January 11, 1995 between Lyndean Investments Limited, Kent Dental Limited and
Henry Schein U.K. Schein Holdings Limited.
10.47 -- Stock Purchase Agreement dated as of August 18, 1995 among Henry Schein, Inc., the Mark
Family Partnership and others.
10.48 -- Group Purchasing Program Agreement dated March 31, 1994, as amended June 26, 1995, by and
between AMA Resources, Inc. and Henry Schein, Inc.
10.49 -- Hospital Supply Purchase Agreement dated as of November 10, 1994 between Veterinary
Centers of America, Inc. and Henry Schein, Inc.
10.50 -- Award of Contract to Henry Schein, Inc. dated April 14, 1995 by Department of the Army.
10.51 -- Sales Agent Agreement dated March 1, 1995 by and between Merck & Co., Inc. and Henry
Schein, Inc.
10.52 -- Supply Agreement dated March 20, 1991.
10.53 -- Shareholders' Agreement dated March 20, 1991.
10.54 -- Non-Negotiable Promissory Note dated March 20, 1991 from Henry Schein, Inc. to N-Tech.
10.55 -- Guaranty dated March 20, 1991 by Henry Schein, Inc. and others in favor of N-Tech, Inc.
10.56 -- Demand Debenture dated December 20, 1988 from one of Henry Schein, Inc.'s 50% owned
companies to Canadian Imperial Bank of Commerce.
10.57 -- Pledge Agreement dated December 20, 1988 of one of Henry Schein, Inc.'s 50% owned
companies to Canadian Imperial Bank of Commerce.
10.58 -- Shareholders' Agreement dated as of December 1, 1990 by and among the shareholders of
Henry Schein Espana, S.A.
10.59 -- Shareholders' Agreement dated as of April 1, 1991 between the shareholders of
Schein-Dentina, B.V. (English translation).
10.60 -- Put and Call Option Agreement dated August 29, 1991 between Schein International (Europe)
Inc. and the shareholders of Henry Schein U.K. Schein Holdings Limited.
10.61 -- Deed of Guarantee dated August 29, 1991 between Henry Schein, Inc. and the shareholders of
Henry Schein U.K. Schein Holdings Limited.
10.62 -- Stock Purchase Agreement dated November 1, 1992 among SSN Healthcare Supply, Inc., Henry
Schein, Inc., Tri-State Medical Supply, Inc. and a shareholder.
10.63 -- Stock Purchase and Shareholders' Agreement dated March 19, 1993 by and among S.A.
Hospithera N.V. and Henry Schein Europe, Inc.
II-vii
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
10.64 -- Agreement dated March 19, 1993 by and among S.A. Hospithera N.V., Henry Schein Europe,
Inc. and S.A. Henry Schein Hospithera N.V.
10.65 -- Supply Agreement dated as of March 15, 1993 between Henry Schein B.V. and S.A. Henry
Schein Hospithera N.V.
10.66 -- Put and Call Option Agreement dated July 1, 1993 between P.W. White Schein Holdings
Limited and Henry Schein Europe Inc.
10.67 -- Shareholders' Agreement dated July 1, 1993 between the shareholders of Henry Schein UK
Schein Holdings Ltd.
10.68 -- Consortium Agreement dated July 1, 1993 between the shareholders of Henry Schein UK Schein
Holdings Ltd.
10.69 -- Guarantee dated July 1, 1993 between Henry Schein, Inc. and P.W. White Schein Holdings
Limited.
10.70 -- Restructuring Agreement dated July 30, 1993 by and among Henry Schein, Inc., Dental Plan,
Inc., and certain of its employees.
10.71 -- Share Purchase Agreement dated as of November 17, 1993 by and among Henry Schein B.V. and
Johannes Cornelis van den Braak.
10.72 -- Asset Purchase and Business Development Agreement dated May 23, 1994 among Henry Schein,
Inc., Chicago Medical Equipment Company, and its principal stockholder, Universal Footcare
Schein Holdings Corp., Universal Footcare Products, Inc. and Universal Footcare Sales Co.,
L.L.C.
10.73 -- Sales Service Agreement dated as of August 1, 1994 between Universal Footcare Products,
Inc. and Universal Footcare Sales Co., L.L.C.
10.74 -- Unanimous Shareholders Agreement dated August 4, 1994 among Henry Schein Canada Inc.,
Henry Schein, Inc., 972704 Ontario Inc. and its shareholders, and Consolidated Dental Ltd.
10.75 -- Share Purchase Agreement dated June 27, 1994 by and between the shareholders of Henry
Schein France S.A.
10.76 -- Shareholders Agreement dated January 1, 1995 among SSN Healthcare Supply, Inc., South
Jersey Medical Supply Co., Inc., South Jersey Surgical Supply Co., Inc., and its
shareholders.
10.77 -- Shareholders Agreement dated as of January 24, 1995 by and among the shareholders of
Dentisoft, Inc.
10.78 -- Purchase Agreement dated as of June 14, 1995 among The Veratex Corporation, Henry Schein,
Inc. and Schein Michigan Corp.
10.79 -- Form of Henry Schein, Inc. Non-Employee Director Stock Option Plan (incorporated by
reference to Exhibit 10.79 of the registrant's Form 10-K for the fiscal year ended
December 28, 1996)**.
10.80 -- Supply Agreement made as of July 7, 1995 between Tidi Products, Inc. and Henry Schein,
Inc.
10.81 -- Agreement Subject to Conditions Precedent dated July 21, 1995 between Henry Schein Europe
Inc., Henry Schein France S.A., Gerard Ifker, Didier Cochet, Frederic Ladet, Jean-Hugues
Lelievre and Christophe Morales (English Translation).
10.82 -- Put and Call Option Agreement dated June 9, 1995 between William Roger Killiner and Henry
Schein U.K. Schein Holdings Limited.
10.83 -- Put and Call Option Agreement dated June 9, 1995 between Anthony Alan Anderson and Henry
Schein U.K. Schein Holdings Limited.
II-viii
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
10.84 -- Agreement of Purchase and Sale of Assets dated as of July 1, 1995 by and among Precision
Dental Specialties, Inc. and its shareholders, PDS Acquisition Corp., and Henry Schein,
Inc.
10.85 -- Shareholders Agreement dated as of July 1, 1995 by and among Precision Dental Specialties,
Inc. and its shareholders, PDS Acquisition Corp., and Henry Schein, Inc.
10.86 -- Agreement dated January 1, 1995 between Henry Schein (UK) Holdings Ltd. and The Royal Bank
of Scotland plc.
10.87 -- Agreement dated March 4, 1993 between Henry Schein (UK) Holdings Ltd. and The Royal Bank
of Scotland plc.
10.88 -- Loan Agreement dated November 16, 1993 between Henry Schein B.V. and others and
Crediet-en-Effectenbank N.V. (English translation and original version).
10.89 -- Multicurrency Credit Policy between Henry Schein Espana, S.A. and others and Banco Popular
Espanol, S.A. (English translation and original version).
10.90 -- Revolving Credit Agreement (the 'Credit Agreement') dated as of January 31, 1997 among
Henry Schein, Inc., The Chase Manhattan Bank, Fleet Bank, N.A., Cooperatieve Centrale
Raiffeisen Boerenleenbank, B.A. 'Rabobank Nederland', New York Branch and European
American Bank (previously Exhibit 10.20 to Henry Schein, Inc.'s Registration Statement on
Form S-1 (Commission File No. 33-96528)).
10.91 -- Option and Proxy Agreement, dated as of March 7, 1997, as revised, by and among Henry
Schein, Inc. and the persons listed on Schedule A thereto, each a shareholder of Micro
Bio-Medics, Inc. (Incorporated by reference to Henry Schein, Inc.'s Registration Statement
on Form S-4 (Registration No. 333-30615))
10.92 -- Employment Agreement, dated March 7, 1997, between Bruce J. Haber and Henry Schein, Inc.
(Incorporated by reference to Henry Schein, Inc.'s Registration Statement on Form S-4
(Registration No. 333-30615))**
10.93 -- Termination of Employment Agreement, dated March 7, 1997, as revised, between Bruce J.
Haber and Henry Schein, Inc. (Incorporated by reference to Henry Schein, Inc.'s
Registration Statement on Form S-4 (Registration No. 333-30615))**
10.94 -- Agreement and Plan of Merger among Henry Schein, Inc., HS Acquisition, Inc., Roane-Barker,
Inc. and Ralph L. Falls, Jr. dated as of May 23, 1997, as amended by letters dated June
24, 1997 and June 25, 1997 (Incorporated by reference to Henry Schein, Inc.'s Registration
Statement on Form S-4 (Registration No. 333-30615))
10.95 -- Irrevocable Proxy and Termination Rights Agreement, dated as of August 3, 1997, as
revised, by and among Henry Schein, Inc. and the persons listed on Schedule A thereto,
each a shareholder of Sullivan Dental Products, Inc. (filed as Exhibit 10.95 to Henry
Schein, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended June 28, 1997).
10.96 -- Employment Agreement, dated as of August 3, 1997, by and between Robert J. Sullivan and
the registrant (filed herewith).**
10.97 -- Employment Agreement, dated as of August 3, 1997, by and between Robert E. Doering and the
registrant (filed herewith).**
10.98 -- Employment Agreement, dated as of August 3, 1997, by and between Timothy J. Sullivan and
the registrant (filed herewith).**
10.99 -- Employment Agreement, dated as of August 3, 1997, by and between Kevin J. Ackeret and the
registrant (filed herewith).**
10.100 -- Employment Agreement, dated as of August 3, 1997, by and between Geoffrey A. Reichardt and
the registrant (filed herewith).**
10.101 -- Employment Agreement, dated as of August 3, 1997, by and between David A. Steck and the
registrant (filed herewith).**
II-ix
EXHIBIT
NO. DESCRIPTION PAGE NO.
- ------ ------------------------------------------------------------------------------------------------ ---------
10.102 -- Employment Agreement, dated as of August 3, 1997, by and between Kenneth A. Schwing and
the registrant (filed herewith).**
10.103 -- Amendment dated as of June 30, 1997 to Credit Agreement (filed herewith).
10.104 -- Amendment No. 2 and Supplement dated as of August 15, 1997 to Credit Agreement (filed
herewith).
11.1 -- Statements regarding computation of per share income (filed as part of Henry Schein,
Inc.'s Current Report on Form 8-K dated June 24, 1997 and incorporated by reference in the
Proxy Statement/Prospectus included in this Registration Statement)
23.1 -- Consent of BDO Seidman, LLP* (filed herewith).
23.2 -- Consent of Deloitte & Touche LLP (filed herewith).
23.3 -- Consent of Proskauer Rose LLP (included in exhibit 5.1).
24.1 -- Powers of Attorney (included in Part II of the Registration Statement).
- ------------------
** Indicates management contract or compensatory plan or arrangement.
II-x
EXHIBIT 3.3
AMENDMENTS TO THE AMENDED AND RESTATED BY-LAWS
At the July 15, 1997 Annual Meeting, Schein's Stockholders adopted the
following amendments to Article VI and Article III of the Company's Amended and
Restated By-Laws as proposed by the Board of Directors.
Article VI of the By-Laws was amended to read in its entirety as
follows:
These By-Laws may be amended or repealed and any By-Laws may
be adopted at any annual meeting of the stockholders or at any
special meeting thereof if notice of the proposed amendment or
repeal, or By-Law or By-Laws to be adopted, be contained in
that notice of such special meeting, by the affirmative vote
of holders of two-thirds of the shares of the stock issued and
outstanding and entitled to vote thereat (unless a greater
percentage is provided herein), or at any regular meeting of
the Board of Directors, or at any special meeting of the Board
of Directors, if notice of the proposed amendment or repeal,
or By-Law or By-Laws to be adopted, be contained in the notice
of such special meeting, by the affirmative vote of two-thirds
of the Board of Directors.
Article III, Section 3 of the By-Laws was amended to read in its
entirety as follows:
Section 3. Vacancies. Newly created directorships resulting
from any increase in the number of directors and any other
vacancies on the Board of Directors, whether resulting from
death, disability, resignation, disqualification, removal or
any other circumstances, shall be filled by the affirmative
vote of a majority of the directors then in office, although
less than a quorum of the Board of Directors. Any director
elected in accordance with the preceding sentence shall hold
office until such director's successor shall have been elected
and qualified. Without limiting the generality of the
foregoing, a vacancy shall also be deemed to exist if the
stockholders fail at any annual meeting of the stockholders at
which any director or directors are required to be elected, to
elect the full authorized number of directors to be voted for
at that meeting.
EXHIBIT 5.1
Proskauer Rose LLP
1585 Broadway
New York, N.Y. 10036-8299
September 22, 1997
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Re: Registration Statement on Form S-4 covering a Maximum of 8,029,000 Shares of
Common Stock
Ladies and Gentlemen:
We are delivering this opinion in connection with the Registration Statement on
Form S-4 (the "Registration Statement") filed by Henry Schein, Inc. (the
"Company") on September 22, 1997 with the Securities and Exchange Commission
under the Securities Act of 1933, as amended, with respect to up to 8,029,000
shares (the "Shares") of common stock, par value $.01, of the Company (the
"Common Stock") to be issued in connection with the merger of Sullivan Dental
Products, Inc. ("Sullivan") with and into a wholly-owned subsidiary of the
Company ("Merger Sub") pursuant to the Agreement and Plan of Merger, dated
August 3, 1997, among the Company, Sullivan and Merger Sub (the "Merger
Agreement").
As counsel for the Company, we have reviewed the Amended and Restated
Certificate of Incorporation of the Company, resolutions adopted by the
Company's board of directors, the Registration Statement and such corporate
records and documents as we have deemed relevant and necessary as the basis for
this opinion, and have made such investigations of law as we deemed necessary in
order to render the opinion hereinafter set forth.
Based upon the foregoing, it is our opinion that the Shares, upon their
issuance and sale in accordance with the Merger Agreement, will be duly
authorized and validly issued, fully paid and non-assessable.
Henry Schein, Inc.
September 22, 1997
Page 2
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the reference to our Firm under the heading "Legal
Matters" in the Joint Proxy Statement/ Prospectus included in the Registration
Statement. In giving this consent, we do not hereby admit that we come within
the category of persons whose consent is required under Section 7 of the
Securities Act or the rules and regulations of the Securities and Exchange
Commission thereunder.
Very truly yours,
PROSKAUER ROSE LLP
EXHIBIT 5.2
PROSKAUER ROSE LLP
1585 BROADWAY
NEW YORK, NY 10036-8299
September 22, 1997
Henry Schein, Inc.
135 Duryea Road
Melville, NY 11747
Ladies and Gentlemen:
You have requested our opinion as to certain federal income tax consequences to
Henry Schein, Inc., a Delaware corporation ("Schein"), Sullivan Dental Products,
Inc., a Wisconsin corporation ("Sullivan"), and the shareholders of Sullivan,
resulting from the acquisition by Schein of all of the stock of Sullivan in
exchange for voting common stock of Schein, which will be accomplished by the
merger (the "Merger") of HSI Acquisition Corp., a Wisconsin corporation and a
wholly-owned subsidiary of Schein that was organized and will be used solely for
purposes of the Merger ("Sub"), with and into Sullivan pursuant to the Agreement
and Plan of Merger dated August 3, 1997 (the "Merger Agreement") among Schein,
Sub and Sullivan.
Except as otherwise provided, capitalized terms not defined herein have the
meanings set forth in the Merger Agreement. All section references, unless
otherwise indicated, are to the Internal Revenue Code of 1986, as amended (the
"Code").
Pursuant to the Merger Agreement, (i) Sub will be merged with and into Sullivan,
with Sullivan as the surviving corporation, (ii) all shares of Sub common stock
outstanding immediately prior to the effective time of the Merger will be
converted into shares of Sullivan common stock, (iii) each share of Sullivan
common stock outstanding immediately prior to the effective time of the Merger
(not including shares of such stock held in the treasury of Sullivan) will be
converted into the right to receive 0.735 shares of Schein common stock and (iv)
the shareholders of Sullivan will receive cash in lieu of fractional share
interests in the Schein common stock to which they would otherwise be entitled.
The description of the transaction set forth above, and our opinion as stated
herein, are based upon and subject to (i) the Merger and related transactions
being effected in the manner
described in the Joint Proxy Statement / Prospectus forming part of Schein's
Registration Statement on Form S-4 dated September 22, 1997 (the "Joint Proxy
Statement / Prospectus") and in accordance with the provisions of the Merger
Agreement, (ii) the accuracy of the representations made to us by Schein and
Sullivan in their respective officer's certificates dated the date of this
opinion (the "Officer's Certificates"), (iii) the accuracy of the
representations, and compliance with the covenants, contained in the Merger
Agreement, insofar as they relate to or affect the tax treatment of the Merger,
(iv) the holders of Sullivan common stock receiving and retaining a meaningful
continuing equity ownership in Schein that is sufficient to satisfy the
continuity of interest requirement set forth in Treasury Regulations section
1.368-1(b), (v) Schein and Sullivan satisfying the continuity of business
enterprise requirement set forth in Regs. section 1.368-1(d), (vi) Sullivan
holding after the Merger "substantially all" of its properties and the
properties of Sub within the meaning of Section 368(a)(2)(E) of the Code and the
regulations promulgated thereunder, and (vii) none of the consideration being
received by any holder of Sullivan common stock for that stock being other than
Schein common stock (except for cash paid for fractional share interests).
In rendering our opinion, we have considered the applicable provisions of the
Code, Treasury Regulations, pertinent judicial authorities, rulings of the
Internal Revenue Service and such other authorities as we have considered
relevant. Any subsequent change therein may adversely affect the conclusions
reached in this opinion.
Subject to the limitations set forth herein, we are of the opinion that for
federal income tax purposes:
1. The Merger of Sub with and into Sullivan, with Sullivan surviving,
will qualify as a reorganization under section 368(a). Sullivan, Sub and Schein
will each be a party to the reorganization within the meaning of section 368(b).
2. No gain or loss will be recognizable by Schein or Sullivan with
respect to the Merger. Section 1032.
3. No gain or loss will be recognized by a shareholder of Sullivan upon
the exchange of his or her Sullivan common stock for Schein common stock.
Section 354.
4. Cash received by a shareholder of Sullivan in lieu of a fractional
share of Schein common stock will be treated as if the cash were received in
exchange for such fractional share. Any gain or loss recognized as a result of
the receipt of such cash will be capital gain or loss if the Sullivan common
stock was held by that shareholder as a capital asset at the time of the
exchange, in an amount equal to the difference between the amount of cash
received and the shareholder's tax basis in the Sullivan common stock to which
such fractional share interest relates. Rev. Rul. 66-365, 1966-2 C.B. 116.
5. The aggregate tax basis of the Schein common stock received by a
shareholder of Sullivan in the exchange (including any fractional shares which
the Sullivan shareholder
otherwise would be entitled to receive) will be the same as the basis of the
Sullivan common stock exchanged therefor. Section 358.
6. The holding period of the Schein common stock received by a Sullivan
shareholder will include the holding period of the Sullivan common stock
surrendered by the shareholder in the exchange, provided the Sullivan common
stock was held as a capital asset on the date of the exchange. Section 1223(1).
This opinion does not extend to the tax consequences of the Merger under the
laws of any state or any political subdivision of any state or any other
jurisdiction. This opinion is being furnished only to Schein and Sullivan, on
its own behalf and on behalf of its shareholders, in connection with the Merger,
in accordance with Section 8.2(e) of the Merger Agreement, and may not be used
or relied upon for any other purpose. This opinion may be included as an exhibit
to Schein's Registration Statement on Form S-4 dated September 22, 1997, and, in
that connection, we hereby consent to the references to our firm in the Joint
Proxy Statement/Prospectus included in the Registration Statement. In giving
this consent, we do not admit that we come within the category of persons whose
consent is required under Section 7 of the Securities Act or the rules and
regulations of the Securities and Exchange Commission thereunder.
Very truly yours,
PROSKAUER ROSE LLP
EXHIBIT 10.95
IRREVOCABLE PROXY AND TERMINATION RIGHTS AGREEMENT
IRREVOCABLE PROXY AND TERMINATION RIGHTS AGREEMENT dated as of
August 3, 1997, by and among Henry Schein, Inc., a Delaware corporation
("Parent"), and the persons listed on Schedule A hereto (collectively, the
"Shareholders" and each a "Shareholder"), each a shareholder of Sullivan Dental
Products, Inc., a Wisconsin corporation (the "Company"), as revised.
Contemporaneously with the execution of this Agreement, the
Company, Parent and HSI Acquisition Corp., a Wisconsin corporation and
wholly-owned subsidiary of Parent ("Sub"), are entering into an Agreement and
Plan of Merger (the "Merger Agreement") pursuant to which it is contemplated
that Sub will be merged with and into the Company (the "Merger") and the holders
of the Company's common stock, par value $.01 per share (the "Company Common
Stock"), will be entitled to receive shares of Parent's common stock, par value
$.01 per share ("Parent Common Stock"), for such shares of Company Common Stock.
Parent, as a condition to its willingness to enter into the
Merger Agreement, has required the Shareholders to pay Parent certain amounts in
respect of the sale of their shares of Company Common Stock following
termination of the Merger Agreement in certain circumstances and to grant Parent
an irrevocable proxy with respect to all of the shares of Company Common Stock
owned by the Shareholders, together with any additional shares of Company Common
Stock hereafter acquired by the Shareholders (pursuant to Section 8, by exercise
of options or otherwise (such specified number of shares, and any additional
shares when and if acquired, being referred to as the "Shares") on the terms and
conditions hereinafter set forth.
The parties hereto agree as follows:
1. Termination Rights.
(a) If (i) the Merger Agreement is terminated by
Parent pursuant to Sections 9.1(d)(i), 9.1(d)(ii), 9.1(d)(iii), 9.1(d)(iv),
9.1(d)(v) or 9.1(f) of the Merger Agreement, or by the Company pursuant to
Section 9.1(e)(iii) of the Merger Agreement, or by the Company pursuant to
Section 9.1(b) of the Merger Agreement, and (ii) any Shareholder shall have
sold, exchanged or otherwise disposed of any of his, her or its Shares pursuant
to an Acquisition Transaction (such term as defined in the Merger Agreement),
then, such Shareholder shall pay, or cause to be paid, in same day funds (to the
extent of cash received and otherwise payable in kind) to Parent upon demand an
amount equal to (x) such Shareholder's Profit per Share multiplied by (y) the
aggregate number of Shares sold, exchanged or otherwise disposed of by such
Shareholder. As used herein, "Profit per Share" in connection with a sale,
exchange or other disposition of Shares by a Shareholder shall mean, on a per
Share basis, thirty-five percent (35%) of the amount by which (A) the sum of (1)
if such sale, exchange or other disposition is for or made in cash, the cash
received by the Shareholder in respect of each Share, (2) if such sale, exchange
or other disposition is for or made in marketable securities, the fair market
value at the time such securities are received by the Shareholder of the
securities received in respect of each Share, (3) if such sale, exchange or
other disposition is for or made in property other than cash or marketable
securities, the fair market value at the time such property is received by the
Shareholder of the property received in respect of each Share (or any
combination of the consideration referred to in clauses (1), (2) and (3)), and
(4) without duplication, any dividends or interest received by the Shareholder
in respect of each Share, exceeds (B) the fair market value of 0.735 shares of
Parent Common Stock on the date of termination of the Merger Agreement. As used
herein, the term "fair market value" shall mean, in the case of marketable
securities, the average of the closing sales prices of such securities, for the
five immediately preceding trading days, on the principal securities exchange on
which such security is listed, if such security is listed on any such exchange,
or on the NASDAQ National Market, if such security is listed thereon, or the
closing bid quotation with respect to the security on NASDAQ or any similar
system then in general use, if such quotations are available, and, in the case
of other property, the fair market value thereof as agreed to by the parties,
or, if they are unable to agree, as determined by a third party appraiser
selected by the parties.
(b) Notwithstanding anything in this Agreement to
the contrary, if (x) any Shares listed on Schedule A as being beneficially owned
by Robert J. Sullivan ("Sullivan") or the Timothy J. Sullivan Irrevocable Trust
dated December 22, 1989 (the "Trust") are acquired (the "Acquired Shares") by
any other person pursuant to any lien, option or other right listed thereon, and
(y) Sullivan and/or the Trust, as applicable, sells or disposes of any Shares
pursuant to an Acquisition Transaction, Sullivan and/or the Trust, as the case
may be, shall be deemed to have sold or disposed of the Acquired Shares in the
Acquisition Transaction and shall be responsible for paying the Profit per Share
with respect thereto in accordance with Section 1(a).
2. Irrevocable Proxy. Each Shareholder hereby
irrevocably constitutes and appoints Parent or any designee of Parent the lawful
agent, attorney and proxy of such Shareholder during the term of this Agreement,
to vote all of his, her or its Shares at any meeting or in connection with any
written consent of the Company's shareholders (a) in favor of the Merger, (b) in
favor of the Merger Agreement, as such may be modified or amended from time to
time, (c) against any Acquisition Transaction (other than the Merger) or other
merger, sale, or other business combination between the Company and any other
person or entity or any other action which would make it impractical for Parent
to effect a merger or other business combination of the Company with Parent or
Sub, and (d) against any other action or agreement that would result in a breach
of any covenant, representation or warranty or any other obligation or agreement
of the Company under the Merger Agreement or which would result in any of the
Company's obligations under the Merger Agreement not being fulfilled. This proxy
shall not authorize Parent to vote the Shares on any matters other than those
specified above which may be presented to the Company's shareholders at any
meeting or in connection with any written
-2-
consent of the Company's shareholders. This power of attorney is irrevocable, is
granted in consideration of Parent entering into the Merger Agreement and is
coupled with an interest sufficient in law to support an irrevocable power. This
appointment shall revoke all prior attorneys and proxies appointed by any
Shareholder at any time with respect to the Shares and the matters set forth in
clauses (a) through (d) above and no subsequent attorneys or proxies will be
appointed by such Shareholder, or be effective, with respect thereto.
3. Representations and Warranties of the Shareholders.
Each Shareholder represents and warrants to Parent as follows:
(a) Ownership of Shares. Except as set forth on
Schedule A hereto, that Shareholder is the sole beneficial owner of the number
of Shares set forth as being owned by that Shareholder on Schedule A hereto. The
Shares set forth opposite that Shareholder's name on Schedule A constitute all
the Shares owned beneficially or of record by that Shareholder. The Shares owned
by that Shareholder are validly issued, fully paid and nonassessable and such
Shares set forth opposite that Shareholder's name on Schedule A are held by that
Shareholder, or by a nominee or custodian for the benefit of that Shareholder,
free and clear of all liens, claims, security interests, agreements and other
encumbrances, except for encumbrances arising under this Agreement or as set
forth on Schedule A.
(b) Power; Binding Agreement. That Shareholder
has the legal capacity to enter into and perform all of that Shareholder's
obligations under this Agreement. The execution, delivery and performance of
this Agreement by that Shareholder will not violate any other agreement to which
that Shareholder is a party, including, without limitation, any voting
agreement, shareholders agreement or voting trust or, if applicable, that
shareholder's trust agreement. This Agreement has been duly and validly executed
and delivered by that Shareholder and constitutes a valid and binding obligation
of that Shareholder, enforceable against that Shareholder in accordance with its
terms, except as enforceability may be limited by applicable bankruptcy,
insolvency and similar laws affecting creditors' rights generally and subject to
general principles of equity. If that Shareholder is married and that
Shareholder's Shares constitute community property, this Agreement has been duly
authorized, executed and delivered by, and constitutes a valid and binding
obligation of, that Shareholder's spouse, enforceable against that spouse in
accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency and similar laws affecting creditors' rights generally
and subject to general principles of equity. (Robert J. Sullivan (and no other
Shareholder) make the representations and warranties set forth in this Section
3(b) with respect to each Shareholder.)
(c) Consents and Approvals; No Violation.
Neither the execution and delivery of this Agreement by that Shareholder nor the
consummation of the transactions contemplated by this Agreement will: (i)
require any consent, approval, authorization or permit of, or filing with or
notification to, any person or entity or any governmental or regulatory
authority, except in connection with the HSR Act or pursuant to the Securities
Exchange Act of 1934; (ii) conflict with, result in a breach of, or result in a
default (or give rise to a right of
-3-
termination, cancellation or acceleration) under any of the terms, conditions or
provisions of any note, license, agreement or other instrument or obligation to
which that Shareholder is a party or by which that Shareholder or any of that
Shareholder's assets may be bound; or (iii) violate any order, writ, injunction,
decree, statute, rule or regulation applicable to that Shareholder or by which
any of that Shareholder's assets are bound.
(d) Brokers. No broker, finder or other
investment banker is entitled to any broker's, finder's or other similar fee or
commission in connection with this Agreement or the transactions contemplated by
this Agreement based upon agreements made by or on behalf of that Shareholder.
4. Representations and Warranties of Parent. Parent
represents and warrants to each Shareholder that:
(a) Power; Binding Agreement. Parent has the
corporate power and authority to enter into and perform all its obligations
under this Agreement. The execution, delivery and performance of this Agreement
by Parent will not violate any other agreement to which Parent is a party. This
Agreement has been duly and validly authorized, executed and delivered by Parent
and constitutes a valid and binding obligation of Parent, enforceable against
Parent in accordance with its terms, except as enforceability may be limited by
applicable bankruptcy, insolvency and similar laws affecting creditors' rights
generally and subject to general principles of equity.
(b) Consents and Approvals; No Violation.
Neither the execution and delivery of this Agreement by Parent nor the
consummation by Parent of the transactions contemplated by this Agreement will:
(i) require any consent, approval, authorization or permit of, or filing with or
notification to, any person or entity or any governmental or regulatory
authority, except in connection with the HSR Act or pursuant to the Securities
Exchange Act of 1934; (ii) conflict with, result in a breach of, or result in a
default (or give rise to a right of termination, cancellation or acceleration)
under any of the terms, conditions or provisions of any note, license, agreement
or other instrument or obligation to which Parent is a party or by which Parent
or any of its assets may be bound; or (iii) violate any order, writ, injunction,
decree, statute, rule or regulation applicable to Parent or by which any of its
assets are bound.
(c) Brokers. No broker, finder or other
investment banker is entitled to any broker's, finder's or other similar fee or
commission in connection with this Agreement or the transactions contemplated by
this Agreement based upon agreements made by or on behalf of Parent.
5. Additional Covenants of the Shareholders. Each
Shareholder hereby covenants and agrees that:
(a) that Shareholder will not enter into any
transaction, take any action, or by inaction permit any event to occur that
would (i) result in any of the representations
-4-
or warranties of such Shareholder herein contained not being true and correct at
and as of the time immediately after the occurrence of such transaction, action
or event; or (ii) have the effect of preventing or disabling that Shareholder
from performing that Shareholder's obligations under this Agreement;
(b) until the termination of the proxies granted
under Section 2 hereof, that Shareholder will not grant any proxies or powers of
attorney with respect to any Shares, deposit any Shares into a voting trust or
enter into a voting agreement with respect to such Shares;
(c) until the termination of the proxies granted
under Section 2 hereof, that Shareholder will at all times use his, her or its
best efforts in his, her or its capacity as a shareholder of the Company to
prevent the Company from taking any action in violation of the Merger Agreement;
(d) from and after the date hereof until the
termination of this Agreement, other than under the circumstances contemplated
by Section 1 hereof, the Shares will not be sold, transferred, pledged,
hypothecated, transferred by gift, or otherwise disposed of in any manner
whatsoever without notifying Parent in advance and obtaining and delivering to
Parent any evidence that Parent may reasonably request to evidence the
transferee's agreement to be bound by this Agreement; provided, however, that in
the event of that Shareholder's death during the term of this Agreement, the
Shares may be transferred in accordance with the Shareholder's last will and
testament, or if none, in accordance with the applicable laws of intestate
succession, in either of which cases, the Shares shall remain subject in all
respects to the terms of this Agreement; and
(e) the Shareholder will execute and deliver any
additional documents reasonably necessary or desirable, in the opinion of
Parent's or the Company's counsel, to evidence the irrevocable proxy granted in
Section 2 with respect to the Shares or otherwise implement and effect the
provisions of this Agreement.
6. No Solicitation. No Shareholder shall, in that
Shareholder's capacity as such, directly or indirectly, (a) solicit, initiate,
facilitate or encourage (including by way of furnishing or disclosing non-public
information) any inquiries or the making of any proposal with respect to any
Acquisition Transaction, (b) negotiate, explore or otherwise engage in
discussion with any person (other than Parent and its representatives) with
respect to any Acquisition Transaction, (c) agree to or endorse an Acquisition
Transaction with any person (other than Parent or Sub) or enter into any
agreement, arrangement or understanding with respect to any such Acquisition
Transaction or which would require the Company to abandon, terminate or fail to
consummate the Merger or any other transaction contemplated by the Merger
Agreement, or (d) authorize or permit any person or entity acting on behalf of
that Shareholder to do any of the foregoing. If any Shareholder receives any
inquiry or proposal regarding any Acquisition Transaction, that Shareholder
shall promptly inform Parent of that inquiry or proposal.
-5-
7. Legending of Certificates; Nominee Shares. Each
Shareholder agrees to submit to Parent contemporaneously with or promptly
following execution of this Agreement (or promptly following receipt of any
additional certificates representing any additional Shares) all certificates
representing the Shares so that Parent may note thereon a legend referring to
the rights to certain payments and proxy granted to it by this Agreement. If any
of the Shares beneficially owned by a Shareholder are held of record by a
brokerage firm in "street name" or in the name of any other nominee (a
"Nominee," and, as to such Shares, "Nominee Shares"), the Shareholder agrees
that, upon written notice by Parent requesting it, such Shareholder will within
five days of the giving of such notice execute and deliver to Parent a limited
power of attorney in such form as shall be reasonably satisfactory to Parent
enabling Parent to require the Nominee to grant to Parent the rights to certain
payments and an irrevocable proxy to the same effect as Sections 1 and 2 hereof
with respect to the Nominee Shares held by such Nominee and to submit to Parent
the certificates representing such Nominee Shares for notation of the
above-referenced legend thereon.
8. Adjustments to Prevent Dilution, Etc. In the event
of a stock dividend or distribution, or any change in Company Common Stock by
reason of any stock dividend, split-up, recapitalization, combination, exchange
of shares or the like, the term "Shares" shall be deemed to refer to and include
the Shares as well as all such stock dividends and distributions and any shares
into which or for which any or all of the Shares may be changed or exchanged.
9. Shareholder Capacity. No person executing this
Agreement who is or becomes during the term of this Agreement a director of the
Company makes any agreement hereunder in his or her capacity as a director. Each
Shareholder is executing and delivering this Agreement solely in that
Shareholder's capacity as the record and beneficial owner of that Shareholder's
Shares. Notwithstanding anything to the contrary in this Agreement, no action or
inaction by a Shareholder in his capacity as a director, officer, or employee of
the Company shall be deemed to contravene Section 6, as long as the action or
inaction does not contravene Section 7.2 of the Merger Agreement.
10. Termination. This Agreement shall terminate on the
earlier of (i) the Effective Time of the Merger and (ii) 12 months following the
date of termination of the Merger Agreement; provided, however, that the
appointment of Parent or any designee of Parent as agent, attorney and proxy
pursuant to Section 2 hereof, and any proxy or other instrument executed
pursuant thereto, shall in any event automatically terminate upon the
termination of the Merger Agreement.
11. Miscellaneous.
(a) No Waiver. The failure of any party to
exercise any right, power or remedy under this Agreement or otherwise available
in respect of this Agreement at law or in equity, or to insist upon compliance
by any other party with that party's obligations under this Agreement, shall not
constitute a waiver of any right to exercise any such or other right, power or
remedy or to demand such compliance.
-6-
(b) Notices. All notices and other
communications hereunder shall be in writing and shall be delivered personally
or by next-day courier or telecopied with confirmation of receipt, to the
parties at the addresses specified below (or at such other address for a party
as shall be specified by like notice; provided that notices of a change of
address shall be effective only upon receipt thereof). Any such notice shall be
effective upon receipt, if personally delivered or telecopied, or one day after
delivery to a courier for next-day delivery.
(i) If to Parent, to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attn: Mark E. Mlotek, Esq.
with a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
(ii) if to a Shareholder, to the address set forth opposite
such Shareholder's name on Schedule A
with a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attn: Kerry B. Wolfe, Esq.
(c) Descriptive Headings; Interpretation. The
headings contained in this Agreement are for reference purposes only and shall
not affect in any way the meaning or interpretation of this Agreement.
References in this Agreement to Sections and Schedules mean a Section or
Schedule of this Agreement unless otherwise indicated. The terms "beneficially
own" and "beneficial owner" with respect to any securities shall have the same
meaning as in,
-7-
and shall be determined in accordance with, Rule 13d-3 under the Securities
Exchange Act of 1934.
(d) Entire Agreement; Assignment. This
Agreement (including the schedule and other documents and instruments referred
to herein), together with the Merger Agreement, constitute the entire agreement
and supersede all other prior agreements and understandings, both written and
oral, among the parties or any of them, with respect to the subject matter
hereof. Except as otherwise expressly provided herein, this Agreement is not
intended to confer upon any person not a party hereto any rights or remedies
hereunder. Except as otherwise expressly provided herein, this Agreement shall
not be assigned by operation of law or otherwise; provided that Parent or Sub
may assign its rights and obligations hereunder to a direct or indirect
subsidiary of Parent, but no such assignment shall relieve Parent or Sub, as the
case may be, of its obligations hereunder.
(e) Liability After Transfer. Each Shareholder
agrees that, notwithstanding any transfer of that Shareholder's Shares in
accordance with Section 5(d), that Shareholder shall remain liable for his or
her performance of all obligations under this Agreement.
(f) Injunctive Relief; Remedies Cumulative.
(i) Parent, on the one hand, and the
Shareholders, on the other hand, acknowledge that the other party will be
irreparably harmed and that there will be no adequate remedy at law for a
violation of any of the covenants or agreements of such party that are contained
in this Agreement. It is accordingly agreed that, in addition to any other
remedies that may be available to the non-breaching party upon the breach by any
other party of such covenants and agreements, the non-breaching party shall have
the right to obtain injunctive relief to restrain any breach or threatened
breach of such covenants or agreements or otherwise to obtain specific
performance of any of such covenants or agreements.
(ii) No remedy conferred upon or reserved
to any party herein is intended to be exclusive of any other remedy and every
remedy shall be cumulative and in addition to every other remedy herein or now
or hereafter existing at law, in equity or by statute.
(g) Governing Law. This Agreement shall be
governed by and construed in accordance with the laws of the State of New York
without giving effect to the provisions thereof relating to conflicts of laws.
(h) Effect of Partial Invalidity. Whenever
possible, each provision of this Agreement shall be construed in such a manner
as to be effective and valid under applicable law. If any provision of this
Agreement or the application thereof to any party or circumstance shall be
prohibited by or invalid under applicable law, such provisions shall be
ineffective to the extent of such prohibition without invalidating the remainder
of such provision or any other
-8-
provisions of this Agreement or the application of such provision to the other
party or other circumstances.
(i) Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed to be an
original but all of which shall constitute one and the same agreement.
-9-
IN WITNESS WHEREOF, this Agreement has been executed by the
parties as of the date first above written.
THE SHAREHOLDERS:
THE TIMOTHY SULLIVAN IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ TIMOTHY J. SULLIVAN
------------------------------------
Timothy J. Sullivan, as Co-Trustee
By: /S/ KAY M. SULLIVAN
------------------------------------
Kay M. Sullivan, as Co-Trustee
THE KATHERINE BLACK IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ KATHERINE BLACK
------------------------------------
Katherine Black, as Co-Trustee
By: /S/ HOWARD O. WOLFE
------------------------------------
Howard O. Wolfe, as Co-Trustee
-10-
THE MARY SCHWANKE IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ MARY SCHWANKE
------------------------------------
Mary Schwanke, as Co-Trustee
By: /S/ HOWARD O. WOLFE
------------------------------------
Howard O. Wolfe, as Co-Trustee
THE DONALD SCHWANKE IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ MARY SCHWANKE
------------------------------------
Mary Schwanke, as Co-Trustee
By: /S/ HOWARD O. WOLFE
------------------------------------
Howard O. Wolfe, as Co-Trustee
THE ROBERT SULLIVAN, JR. IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ ROBERT SULLIVAN, JR.
------------------------------------
Robert Sullivan, Jr., as Co-Trustee
By: /S/ HOWARD O. WOLFE
------------------------------------
Howard O. Wolfe, as Co-Trustee
-11-
THE JANINE SULLIVAN IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ ROBERT SULLIVAN, JR.
------------------------------------
Robert Sullivan, Jr., as Co-Trustee
By: /S/ HOWARD O. WOLFE
------------------------------------
Howard O. Wolfe, as Co-Trustee
THE ELIZABETH SULLIVAN IRREVOCABLE
TRUST DATED DECEMBER 22, 1989
By: /S/ ELIZABETH CIMLER
------------------------------------
Elizabeth Cimler, as Co-Trustee
By: /S/ HOWARD O. WOLFE
------------------------------------
Howard O. Wolfe, as Co-Trustee
/S/ ROBERT J. SULLIVAN, SR.
------------------------------------
Robert J. Sullivan, Sr.
/S/ TIMOTHY J. SULLIVAN
------------------------------------
Timothy J. Sullivan
/S/ KATHERINE BLACK
------------------------------------
Katherine Black
/S/ MARY SCHWANKE
------------------------------------
Mary Schwanke
-12-
/S/ ROBERT SULLIVAN, JR.
------------------------------------
Robert Sullivan, Jr.
/S/ ELIZABETH CIMLER
------------------------------------
Elizabeth Cimler
/S/ ROBERT E. DOERING
------------------------------------
Robert E. Doering
/S/ WAYNE G. HOLT
------------------------------------
Wayne G. Holt
/S/ KEVIN J. ACKERET
------------------------------------
Kevin J. Ackeret
HENRY SCHEIN, INC.
By: /S/ MARK E. MLOTEK
------------------------------------
Name: Mark E. Mlotek
Title: Vice President
-13-
EXHIBIT 10.96
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between Robert J.
Sullivan (the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the Chairman of Sullivan Dental
Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to secure the continued services of the
Executive, and the Executive desires to continue to provide services to the
Company at and after the Effective Time, as that term is defined in the Merger
Agreement. Accordingly, the parties hereto are entering into this Agreement to
set forth and confirm their respective rights and obligations with respect to
the Executive's retention by the Company commencing as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall retain the Executive, as of
the Effective Time, and the Executive shall provide services to the Company,
subject to and upon the terms and conditions set forth in this Agreement;
provided, however, that this Agreement shall terminate and be of no further
force or effect if the Executive shall have died or, in the reasonable judgment
of the Company, become disabled (as defined in Section 7(a)(i)), or if he is
terminated by Sullivan for cause (as hereinafter defined), in any such case,
prior to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company, the
Executive shall, subject to the direction and control of the Board of Directors
of the Company and the Chairman of the Company, provide such executive services
of an advisory and consultative nature and perform such functions as he may be
called upon by such Board or Chairman to perform, consistent with his prior
duties as Chairman of Sullivan.
(b) The Executive shall devote his full time and reasonable
best efforts to the performance of his duties hereunder; and, to the extent
requested by the Board of Directors of the Company or the Chairman of the
Company, render such executive services for any other subsidiary or affiliated
business of the Company. Notwithstanding the foregoing, the Executive
1
may devote time and effort to charitable activities and (subject to the
provisions of Section 8) to his activities in connection with Dash Medical
Gloves, Inc. and Dash Medical Gloves Sdn Bhd, provided that such activities do
not interfere with the Executive fulfilling his obligations under this
Agreement.
(c) The Company shall not require the Executive to maintain
his principal office anywhere other than within a 50 mile radius of Sullivan's
principal executive offices in West Allis, Wisconsin, provided that the
Executive shall travel on the Company's behalf within and outside such area to
the extent reasonably necessary to perform his duties hereunder.
3. Compensation.
(a) The Company shall pay to the Executive for all services to
be rendered by him pursuant to this Agreement a salary at the annual rate of Two
Hundred Fifty Thousand Dollars ($250,000), payable in accordance with the
Company's practices with respect to its senior executives as in effect from time
to time ("Company's Practices"). Such salary rate shall be increased each year
beginning in 1999 by an amount determined by the Company in accordance with the
Company's Practices, but in any event such amount shall be no less than the
percentage increase in the cost of living over the preceding year.
(b) At the Effective Time, the Executive shall be granted
options to purchase shares of common stock, par value $.01 per share ("Common
Stock"), of the Company in accordance with the stock option agreement attached
hereto as Exhibit A (the "Option Agreement").
(c) At the Effective Time, the Executive shall be paid the sum
of Five Hundred Fifty Thousand Dollars ($550,000) as an inducement to enter into
this Agreement.
4. Working Conditions and Benefits. While employed by the
Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of paid
vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
(b) The Executive shall be authorized to incur reasonable and
necessary expenses for promoting the business of the Company, including expenses
for entertainment, travel and similar items, all in accordance with the
Company's Practices. The Company shall reimburse the Executive for all such
expenses, upon presentation by the Executive of an itemized account of such
authorized expenditures in accordance with the Company's Practices with respect
to expense reimbursement.
2
(c) The Company in accordance with Sullivan's prior practices
(x) shall provide the Executive an automobile for business use and (y) shall pay
for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the full
extent provided for under the laws of the Company's state of incorporation and
the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligation
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While providing services to the Company
hereunder the Executive shall be entitled to participate in all benefit, welfare
and perquisite plans, policies and programs, in accordance with the terms
thereof and in accordance with the Company's Practices (the "Benefit Programs").
6. Term. The Executive's employment hereunder shall commence
at the Effective Time and shall continue until the earlier of (a) the third
anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof.
7. Termination.
(a) Notwithstanding anything herein contained, if on or after
the Effective Time and prior to the third anniversary of the Effective Time, (i)
the Executive shall have been determined by the Board of Directors of the
Company to have become "Permanently Disabled" or (ii) the Executive shall have
furnished the Company with Cause for his discharge then, and in any such case,
the Company shall have the right, by notice given to the Executive to terminate
the Executive's employment as of a date to be specified in such notice. Cause
shall be defined as: (A) the Executive shall be convicted of a felony involving
fraud, dishonesty or moral turpitude (other than ordinary traffic infractions),
(B) action by the Executive involving willful malfeasance having a material
adverse effect on the Company, or (C) any other willful action by the Executive
constituting a material breach of this Agreement which causes or is reasonably
likely to cause material economic or reputational injury to the Company or its
affiliates. For purposes hereof, the term "Permanently Disabled" shall mean a
condition (certified by two licensed physicians, one selected by the Company and
one by the Executive and each reasonably satisfactory to the other party)
rendering the Executive unable to perform his responsibilities under this
Agreement for a period of 180 days, whether or not continuous, in any period of
12 months.
(b) Upon the Executive's death, termination of the Executive's
employment pursuant to Section 7(a) or the voluntary termination of his
employment hereunder, the Executive (or his estate, as the case may be) shall be
entitled to receive only his salary at the rate provided in Section 3(a) to the
date of termination.
3
(c) Upon termination of the Executive's employment hereunder
by the Company without Cause the Executive shall be entitled to receive (i) his
annual compensation at the rate provided in Section 3(a) to the date of
termination, (ii) continuation of the Executive's annual compensation for a
period after the date of such termination equal to the unexpired term of this
Agreement but in no event less than twelve months at the rate in effect at such
date of termination and (iii) for a period following such termination equal to
the unexpired term of this Agreement, continuation of the participation of the
Executive and his spouse and dependent children, if any, in all health and
medical benefit plans, policies and programs in effect from time to time with
respect to the most senior executive officers of the Company and their families
generally (at the same levels and at the same cost, if any, as provided to such
officers generally).
8. Confidentiality and Non-Competition. In view of the unique
and valuable services it is expected the Executive will render to the Company,
the Executive's knowledge of the customers, trade secrets, and other proprietary
information relating to the business of the Company and its customers and
suppliers and in consideration of (i) Five Hundred Fifty Thousand Dollars
($550,000) payable within 60 days of the third anniversary of the date of this
Agreement and (ii) the compensation to be received hereunder, the Executive
agrees that he will not, during his employment with the Company and for five
years thereafter except on behalf of the Company: (a) directly or indirectly
engage or have an interest (whether as owner, partner, lender, consultant,
employee, agent, supplier, distributor or otherwise) in any business, activity
or enterprise which competes with any material businesses or operations of the
Company or any of the Company's affiliates (including Sullivan) at any time
during his employment with the Company; provided, however, that Executive may be
employed by or otherwise interested in the businesses listed on Schedule 1; (b)
directly or indirectly employ or otherwise engage, or offer to employ or
otherwise engage, any person who is then (or was at anytime within three months
prior to the time of such employment, engagement or offer thereof) an employee,
sales representative or agent of the Company or any of the Company's affiliates
(including Sullivan); or (c) solicit any business from any person or entity that
during his employment with the Company has been a customer of the Company or any
of the Company's affiliates (including Sullivan) or directly or indirectly
induce or influence any customer, supplier or other person that has a business
relationship with the Company or any of the Company's affiliates (including
Sullivan) to discontinue or reduce the extent of such relationship with the
Company or any of the Company's affiliates (including Sullivan). In addition,
the Executive shall never use or divulge (unless available in the public domain
not due to the Executive's disclosure in violation of this Agreement) any trade
secrets, customer or supplier lists, pricing information, marketing arrangements
or strategies, business plans, internal performance statistics, training manuals
or other information concerning the Company or its affiliates that is
confidential, except on behalf of the Company, and shall not knowingly make
false or misleading or negative statements, either orally or in writing, about
the Company or its affiliates (including Sullivan), or their respective
directors, officers or employees. Because the breach or attempted breach of this
Section 8 will result in immediate and irreparable injury to the Company for
which the Company will not have an adequate remedy at law, the Company shall be
entitled, in addition to all other remedies, to a decree of specific performance
of this covenant and to a temporary and permanent injunction enjoining such
breach, without posting bond or furnishing similar security. The provisions of
this Section 8 are in addition to and
4
independent of any agreements or covenants contained in any other agreement
between the Company and the Executive. If any restriction contained in this
Section 8 shall be deemed to be invalid, illegal, or unenforceable by reason of
the extent, duration, or geographical scope thereof, or otherwise, then the
court making such determination shall have the right to reduce such extent,
duration, geographical scope, or other provisions hereof, and in its reduced
form such restriction shall then be enforceable in the manner contemplated
hereby. Notwithstanding the foregoing the Executive (i) may have an interest
(whether as owner, partner, lender, consultant, employee or agent, but not as a
distributor or supplier) in any manufacturer that sells its products exclusively
and directly to health care practitioners rather than through distributors or
(ii) hold up to 2% of the outstanding shares of any class of stock of a publicly
traded entity.
9. Amendment and Modification; Waiver. This Agreement may be
amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by either party of
any breach or violation of any provision of this agreement shall not operate or
be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the terms
of this Agreement shall be in writing and shall be deemed to have been duly
given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
If to the Executive, addressed to:
Robert J. Sullivan, Vice Chairman
Henry Schein, Inc.
c/o Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
5
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts paid or
payable to the Executive pursuant to this Agreement shall adversely affect the
qualification of the Merger (as defined in the Merger Agreement) as a pooling of
interests, then the Company and the Executive shall endeavor in good faith to
modify such payments so that they will not adversely affect the Merger as a
pooling of interests for financial reporting purposes; provided, however, that
the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement constitutes the
entire agreement and supersede all other prior agreements and understandings,
both written and oral, between the parties with respect to the subject matter
hereof and all prior employment or other compensation or compensation
continuation agreements and arrangements between the Executive and Sullivan.
This Agreement shall inure to and shall be binding upon the parties hereto, the
successors and assigns of the Company and the heirs and personal representatives
of the Executive.
14. Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York without giving
effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two or
more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
6
IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the day and year first above written.
------------------------------------
Robert J. Sullivan
HENRY SCHEIN, INC.
By:_________________________________
Authorized Officer
7
Schedule 1
1. Dash Medical Gloves, Inc.
2. Dash Medical Gloves Sdn Bhd
In each case only to the extent that, except for their current principal
business activities, the above companies do not engage in any activities that
would otherwise be prohibited by Section 8.
EXHIBIT 10.97
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between Robert E.
Doering (the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the Chief Executive Officer of
Sullivan Dental Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to secure the continued services of the
Executive, and the Executive desires to continue to provide services to the
Company at and after the Effective Time, as that term is defined in the Merger
Agreement. Accordingly, the parties hereto are entering into this Agreement to
set forth and confirm their respective rights and obligations with respect to
the Executive's retention by the Company commencing as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall retain the Executive,
as of the Effective Time, and the Executive shall provide services to the
Company, subject to and upon the terms and conditions set forth in this
Agreement; provided, however, that this Agreement shall terminate and be of no
further force or effect if the Executive shall have died or, in the reasonable
judgment of the Company, become disabled (as defined in Section 7(a)(i)), or if
he is terminated by Sullivan for cause (as hereinafter defined), in any such
case, prior to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company,
the Executive shall, subject to the direction and control of the Boards of
Directors of the Company and Sullivan and the President of the U.S. Dental
Division of the Company (the "Dental Division"), provide such executive services
of an advisory and consultative nature and perform such functions as he may be
called upon by such Boards to perform, consistent with his prior duties as Chief
Executive Officer of Sullivan.
(b) The Executive shall devote his full time and
reasonable best efforts to the performance of his duties hereunder; and, to the
extent requested by the Chairman of the Company or the President of the Dental
Division, render such executive services for any other
subsidiary or affiliated business of the Company. Notwithstanding the foregoing,
the Executive may devote time and effort to charitable activities (subject to
the provisions of Section 8), provided that such activities do not interfere
with the Executive fulfilling his obligations under this Agreement.
(c) The Company shall not require the Executive to
maintain his principal office anywhere other than within a 50 mile radius of
Sullivan's principal executive offices in West Allis, Wisconsin, provided that
the Executive shall travel on the Company's behalf within and outside such area
to the extent reasonably necessary to perform his duties hereunder.
3. Compensation.
(a) The Company shall pay to the Executive for all
services to be rendered by him pursuant to this Agreement a salary at the annual
rate of One Hundred Fifty Thousand Dollars ($150,000), payable in accordance
with the Company's practices with respect to its senior executives as in effect
from time to time ("Company's Practices"). Such salary rate shall be increased
each year (beginning in 1999) by an amount determined by the Company in
accordance with the Company's Practices, but in any event such amount shall be
no less than the percentage increase in the cost of living over the preceding
year.
(b) At the Effective Time, the Executive shall be granted
options to purchase shares of common stock, par value $.01 per share ("Common
Stock"), of the Company in accordance with the stock option agreement attached
hereto as Exhibit A (the "Option Agreement").
(c) At the Effective Time, the Executive shall be paid
the sum of One Hundred Sixty Thousand Dollars ($160,000) as an inducement to
enter into this Agreement.
4. Working Conditions and Benefits. While employed by
the Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of
paid vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
(b) The Executive shall be authorized to incur reasonable
and necessary expenses for promoting the business of the Company, including
expenses for entertainment, travel and similar items, all in accordance with the
Company's Practices. The Company shall reimburse the Executive for all such
expenses, upon presentation by the Executive of an itemized account of such
authorized expenditures in accordance with the Company's Practices with respect
to expense reimbursement.
2
(c) The Company in accordance with Sullivan's prior
practices (x) shall provide the Executive an automobile for business use and (y)
shall pay for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the
full extent provided for under the laws of the Company's state of incorporation
and the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligation
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While providing services to the
Company hereunder the Executive shall be entitled to participate in all benefit,
welfare and perquisite plans, policies and programs, in accordance with the
terms thereof and in accordance with the Company's Practices (the "Benefit
Programs").
6. Term. The Executive's employment hereunder shall
commence at the Effective Time and shall continue until the earlier of (a) the
third anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof.
7. Termination.
(a) Notwithstanding anything herein contained, if on or
after the Effective Time and prior to the third anniversary of the Effective
Time, (i) the Executive shall have been determined by the Board of Directors of
the Company to have become "Permanently Disabled" or (ii) the Executive shall
have furnished the Company with Cause for his discharge then, and in any such
case, the Company shall have the right, by notice given to the Executive to
terminate the Executive's employment as of a date to be specified in such
notice. Cause shall be defined as: (A) the Executive shall be convicted of a
felony involving fraud, dishonesty or moral turpitude (other than ordinary
traffic infractions), (B) action by the Executive involving willful malfeasance
having a material adverse effect on the Company, or (C) any other willful action
by the Executive constituting a material breach of this Agreement which causes
or is reasonably likely to cause material economic or reputational injury to the
Company or its affiliates. For purposes hereof, the term "Permanently Disabled"
shall mean a condition (certified by two licensed physicians, one selected by
the Company and one by the Executive and each reasonably satisfactory to the
other party) rendering the Executive unable to perform his responsibilities
under this Agreement for a period of 180 days, whether or not continuous, in any
period of 12 months.
(b) Upon the Executive's death, termination of the
Executive's employment pursuant to Section 7(a) or the voluntary termination of
his employment hereunder, the Executive (or his estate, as the case may be)
shall be entitled to receive only his salary at the rate provided in Section
3(a) to the date of termination.
3
(c) Upon termination of the Executive's employment
hereunder by the Company without Cause the Executive shall be entitled to
receive (i) his annual compensation at the rate provided in Section 3(a) to the
date of termination, (ii) continuation of the Executive's annual compensation
for a period after the date of such termination equal to the unexpired term of
this Agreement but in no event less than twelve months at the rate in effect at
such date of termination and (iii) for a period following such termination equal
to the unexpired term of this Agreement, continuation of the participation of
the Executive and his spouse and dependent children, if any, in all health and
medical benefit plans, policies and programs in effect from time to time with
respect to the most senior executive officers of the Company and their families
generally (at the same levels and at the same cost, if any, as provided to such
officers generally).
8. Confidentiality and Non-Competition. In view of the
unique and valuable services it is expected the Executive will render to the
Company, the Executive's knowledge of the customers, trade secrets, and other
proprietary information relating to the business of the Company and its
customers and suppliers and in consideration of (i) Five Hundred Fifty Thousand
Dollars ($550,000) payable within 60 days of the third anniversary of the date
of this Agreement and (ii) the compensation to be received hereunder, the
Executive agrees that he will not, during his employment with the Company and
for five years thereafter except on behalf of the Company: (a) directly or
indirectly engage or have an interest (whether as owner, partner, lender,
consultant, employee, agent, supplier, distributor or otherwise) in any
business, activity or enterprise which competes with any material businesses or
operations of the Company or any of the Company's affiliates (including
Sullivan) at any time during his employment with the Company; (b) directly or
indirectly employ or otherwise engage, or offer to employ or otherwise engage,
any person who is then (or was at anytime within three months prior to the time
of such employment, engagement or offer thereof) an employee, sales
representative or agent of the Company or any of the Company's affiliates
(including Sullivan); or (c) solicit any business from any person or entity that
during his employment with the Company has been a customer of the Company or any
of the Company's affiliates (including Sullivan) or directly or indirectly
induce or influence any customer, supplier or other person that has a business
relationship with the Company or any of the Company's affiliates (including
Sullivan) to discontinue or reduce the extent of such relationship with the
Company or any of the Company's affiliates (including Sullivan). In addition,
the Executive shall never use or divulge (unless available in the public domain
not due to the Executive's disclosure in violation of this Agreement) any trade
secrets, customer or supplier lists, pricing information, marketing arrangements
or strategies, business plans, internal performance statistics, training manuals
or other information concerning the Company or its affiliates that is
confidential, except on behalf of the Company, and shall not knowingly make
false or misleading or negative statements, either orally or in writing, about
the Company or its affiliates (including Sullivan), or their respective
directors, officers or employees. Because the breach or attempted breach of this
Section 8 will result in immediate and irreparable injury to the Company for
which the Company will not have an adequate remedy at law, the Company shall be
entitled, in addition to all other remedies, to a decree of specific performance
of this covenant and to a temporary and permanent injunction enjoining such
breach, without posting bond or furnishing similar security. The provisions of
this Section 8 are in addition to and independent of any agreements or covenants
contained in any other agreement between the Company and the
4
Executive. If any restriction contained in this Section 8 shall be deemed to be
invalid, illegal, or unenforceable by reason of the extent, duration, or
geographical scope thereof, or otherwise, then the court making such
determination shall have the right to reduce such extent, duration, geographical
scope, or other provisions hereof, and in its reduced form such restriction
shall then be enforceable in the manner contemplated hereby. Notwithstanding the
foregoing the Executive (i) may have an interest (whether as owner, partner,
lender, consultant, employee or agent, but not as a distributor or supplier) in
any manufacturer that sells its products exclusively and directly to health care
practitioners rather than through distributors or (ii) hold up to 2% of the
outstanding shares of any class of stock of a publicly traded entity.
9. Amendment and Modification; Waiver. This Agreement
may be amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by either party of
any breach or violation of any provision of this agreement shall not operate or
be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the
terms of this Agreement shall be in writing and shall be deemed to have been
duly given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
If to the Executive, addressed to:
Robert E. Doering, President Emeritus
U.S. Dental Division
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
5
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts paid
or payable to the Executive pursuant to this Agreement shall adversely affect
the qualification of the Merger (as defined in the Merger Agreement) as a
pooling of interests, then the Company and the Executive shall endeavor in good
faith to modify such payments so that they will not adversely affect the Merger
as a pooling of interests for financial reporting purposes; provided, however,
that the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement constitutes
the entire agreement and supersede all other prior agreements and
understandings, both written and oral, between the parties with respect to the
subject matter hereof and all prior employment or other compensation or
compensation continuation agreements and arrangements between the Executive and
Sullivan. This Agreement shall inure to and shall be binding upon the parties
hereto, the successors and assigns of the Company and the heirs and personal
representatives of the Executive.
14. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York without
giving effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
6
IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the day and year first above written.
------------------------------------
Robert E. Doering
HENRY SCHEIN, INC.
By:
---------------------------------
Authorized Officer
7
EXHIBIT 10.98
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between Timothy J.
Sullivan (the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the President of Sullivan Dental
Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to employ the Executive, and the Executive
desires to be employed by the Company, at the Effective Time, as that term is
defined in the Merger Agreement. Accordingly, the parties hereto are entering
into this Agreement to set forth and confirm their respective rights and
obligations with respect to the Executive's employment by the Company commencing
as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall employ the Executive, as of
the Effective Time, as President of the U.S. Dental Division of the Company and
President of Sullivan, and the Executive shall accept such employment and serve
as such, subject to and upon the terms and conditions set forth in this
Agreement; provided, however, that this Agreement shall terminate and be of no
further force or effect if the Executive shall have died or, in the reasonable
judgment of the Company, become disabled (as defined in Section 7(a)(i)), or his
employment by Sullivan shall have been terminated for Cause (as hereinafter
defined), in any such case, prior to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company, the
Executive shall, subject to the direction and control of the Boards of Directors
of the Company and Sullivan and the President of the North American Dental
Division of the Company, perform such executive duties and functions as he may
be called upon by such Boards or such President of the North American Dental
Division to perform, consistent with his employment hereunder as President of
the U.S. Dental Division of the Company and President of Sullivan. As President
of the Company's U.S. Dental Division and Sullivan, the Executive shall have the
authority customarily vested in the President of a significant division of the
Company, including day to day authority
with respect to field sales, equipment service centers and the hiring,
compensation and discharge of all employees who are part of such groups.
(b) The Executive shall devote his full time and reasonable
best efforts to the performance of his duties hereunder; and, to the extent
requested by the Board of Directors of the Company or Sullivan or the President
of the North American Dental Division of the Company, render such executive
services for any other subsidiary or affiliated business of the Company.
Notwithstanding the foregoing, the Executive may devote time and effort to
charitable activities (subject to the provisions of Section 8) and to Wild
Promotions, Inc., provided that neither of the aforementioned activities
interfere with the Executive's fulfilling his obligations under this Agreement.
3. Compensation.
(a) The Company shall pay to the Executive for all services to
be rendered by him pursuant to this Agreement a base salary at the annual rate
of Two Hundred Ten Thousand Dollars ($210,000), payable in accordance with the
Company's practices with respect to its senior executives as in effect from time
to time, ("Company's Practices"). Such salary rate shall be increased each year
(beginning in 1999) by an amount determined by the Company in accordance with
the Company's Practices, but in any event such amount shall be no less than the
percentage increase in the cost of living over the preceding year.
(b) The Executive shall be entitled to a bonus in respect of
each fiscal year of the Company during which he is employed hereunder, payable
no later than 90 days after the end of each year for which such bonus is
payable, the thresholds and amounts of which shall be determined in accordance
with the Company's Practices.
(c) At the Effective Time, the Executive shall be granted
options to purchase shares of common stock, par value $.01 per share ("Common
Stock"), of the Company in accordance with the stock option agreement attached
hereto as Exhibit A (the "Option Agreement").
(d) At the Effective Time, the Executive shall be granted
shares of Common Stock of the Company in accordance with the restricted stock
agreement attached hereto as Exhibit B (the "Restricted Stock Agreement").
(e) At the Effective Time, the Executive shall be paid the sum
of Three Hundred Thirty Thousand Dollars ($330,000) as an inducement to enter
into this Agreement.
2
4. Working Conditions and Benefits. While employed by the
Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of paid
vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
(b) The Executive shall be authorized to incur reasonable and
necessary expenses for promoting the business of the Company, including expenses
for entertainment, travel and similar items, all in accordance with the
Company's Practices. The Company shall reimburse the Executive for all such
expenses, upon presentation by the Executive of an itemized account of such
authorized expenditures in accordance with the Company's Practices with respect
to expense reimbursement.
(c) The Company in accordance with Sullivan's prior practices
(x) shall provide to the Executive an automobile for business use and (y) shall
pay for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the full
extent provided for under the laws of the Company's state of incorporation and
the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligations
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While employed by the Company hereunder the
Executive shall be entitled to participate in all benefit, welfare and
perquisite plans, policies and programs, in accordance with the terms thereof
and in accordance with the Company's Practices (the "Benefit Programs"). Without
limiting the generality of the foregoing, at the Effective Time the Company and
the Executive shall enter into the change in control agreement attached hereto
as Exhibit C (the "Change In Control Agreement").
6. Term. The Executive's employment hereunder shall commence
at the Effective Time and shall continue until the earlier of (a) the fifth
anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof. Notwithstanding clause (a) of the
preceding sentence (and subject to clauses (b) and (c) of such sentence), the
term of this Agreement shall automatically be extended for successive one year
periods, commencing on the fifth anniversary of the Effective Time, unless
either party gives written notice of termination at least six months prior to
the commencement of the initial or next successive one year renewal period, as
applicable.
7. Termination.
(a) Notwithstanding anything herein contained, if on or after
the Effective Time and prior to the fifth anniversary of the Effective Time (or
the expiration of the then current renewal period, as applicable), (i) the
Executive shall have been determined by the Board of
3
Directors of the Company to have become "Permanently Disabled", or (ii) the
Executive shall have furnished the Company with Cause for his discharge then,
and in any such case, the Company shall have the right, by notice given to the
Executive, to terminate the Executive's employment as of a date to be specified
in such notice. Cause shall be defined as: (A) the Executive shall be convicted
of a felony involving fraud, dishonesty or moral turpitude (other than ordinary
traffic infractions), (B) the Board of Directors of the Company shall have
determined in good faith that the Executive has committed any act, or omitted to
take any action, in bad faith or has materially neglected the Company's
business, which, in any case, shall have had, or reasonably would be expected to
have, a material adverse effect on the Company or Sullivan, or (C) the Board of
Directors of the Company shall have determined in good faith that the Executive
has materially breached any term of this Agreement and failed to correct such
breach, if such breach is curable, within 30 days after receipt of written
notice thereof. For purposes hereof, the term "Permanently Disabled" shall mean
a condition (certified by two licensed physicians, one selected by the Company
and one by the Executive and each reasonably satisfactory to the other party)
rendering the Executive unable to perform his responsibilities under this
Agreement for a period of 180 days, whether or not continuous, in any period of
12 months.
(b) Notwithstanding anything herein contained, on or after the
Effective Time and prior to the fifth anniversary of the Effective Time (or the
expiration of the then current renewal period, as applicable), the Executive
shall have the right to terminate this Agreement for good reason. For purposes
of this Agreement, "good reason" shall mean (i) a material breach by the Company
of this Agreement, which breach is not cured within 30 days after notice from
the Executive thereof or (ii) the Company's requiring Executive to maintain his
principal office anywhere other than within a 50 mile radius of Sullivan's
principal executive offices in West Allis, Wisconsin, provided that the
Executive shall travel on the Company's behalf within and outside such area to
the extent necessary to perform his duties hereunder.
(c) Upon the Executive's death, or termination of the
Executive's employment pursuant to Section 7(a)(i), the Executive (or his
estate, as the case may be) shall be entitled to receive only (i) his salary at
the rate provided in Section 3(a) to the date of termination (ii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs and (iii) an amount
equal to such bonus in respect of such prior fiscal year multiplied by a
fraction the numerator of which shall be the number of days that shall have
elapsed from the first day of the fiscal year in which such termination occurs
to the date of such termination and the denominator of which shall be 365.
(d) Upon termination of the Executive's employment hereunder
pursuant to Section 7(a)(ii) or the Executive's voluntary termination of his
employment hereunder other than pursuant to Section 7(b), the Executive shall be
entitled to receive only (i) his salary at the rate provided in Section 3(a) to
the date of termination and (ii) any unpaid bonus pursuant to Section 3(b) in
respect of the fiscal year of the Company ended prior to the year in which such
termination occurs. In either event, the Executive shall not be entitled to
receive any bonuses pursuant to Section 3(b) in respect of the year in which
such termination occurs or any year thereafter.
4
(e) Upon termination of the Executive's employment by the
Company without Cause or by the Executive hereunder pursuant to Section 7(b),
the Executive shall be entitled to receive (i) his salary at the rate provided
in Section 3(a) to the date of termination, (ii) continuation of the Executive's
base salary for a period after the date of such termination equal to the
unexpired term of this Agreement but in no event less than twelve months at the
rate in effect at such date of termination (iii) any unpaid bonus pursuant to
Section 3(b) in respect of the fiscal year of the Company ended prior to the
year in which such termination occurs, (iv) for a period following such
termination equal to the unexpired term of this Agreement, continuation of the
participation of the Executive and his spouse and dependent children, if any, in
all health and medical benefit plans, policies and programs in effect from time
to time with respect to the most senior executive officers of the Company and
their families generally (at the same levels and at the same cost, if any, as
provided to such officers generally) and (v) an amount equal to such bonus in
respect of such prior fiscal year multiplied by a fraction the numerator of
which shall be the number of days left in the unexpired term of this Agreement
and the denominator of which shall be 365.
8. Confidentiality and Non-Competition. In view of the unique
and valuable services it is expected the Executive will render to the Company,
the Executive's knowledge of the customers, trade secrets, and other proprietary
information relating to the business of the Company and its customers and
suppliers, and in consideration of (i) Nine Hundred Fifty Thousand Dollars
($950,000), payable to the Executive within 60 days of the third anniversary of
the date of this Agreement and (ii) the compensation to be received hereunder,
the Executive agrees that he will not, during his employment with the Company
and for three years thereafter except on behalf of the Company: (a) directly or
indirectly engage or have an interest (whether as owner, partner, lender,
consultant, employee, agent, supplier distributor or otherwise) in any business,
activity or enterprise which competes with any material businesses or operations
of the Company or any of the Company's affiliates (including Sullivan) at any
time during his employment with the Company provided, however, that Executive
may be employed by or otherwise interested in the businesses listed on Schedule
1; (b) directly or indirectly employ or otherwise engage, or offer to employ or
otherwise engage, any person who is then (or was at any time within three months
prior to the time of such employment, engagement or offer thereof) an employee,
sales representative or agent of the Company or any of the Company's affiliates
(including Sullivan); or (c) solicit any business from any person or entity that
during his employment with the Company has been a customer of the Company or any
of the Company's affiliates (including Sullivan) or directly or indirectly
induce or influence any customer, supplier or other person that has a business
relationship with the Company or any of the Company's affiliates (including
Sullivan) to discontinue or reduce the extent of such relationship with the
Company or any of the Company's affiliates (including Sullivan). In addition,
the Executive shall never use or divulge (unless available in the public domain
not due to Executive's disclosure in violation of this Agreement) any trade
secrets, customer or supplier lists, pricing information, marketing arrangements
or strategies, business plans, internal performance statistics, training manuals
or other information concerning the Company or its affiliates that is
confidential, except on behalf of the Company, and shall not knowingly make
false or misleading or negative statements, either orally or in writing, about
the Company or its affiliates (including Sullivan), or their respective
directors, officers or employees. Because the breach or attempted breach of this
Section 8 will result in immediate and
5
irreparable injury to the Company for which the Company will not have an
adequate remedy at law, the Company shall be entitled, in addition to all other
remedies, to a decree of specific performance of this covenant and to a
temporary and permanent injunction enjoining such breach, without posting bond
or furnishing similar security. The provisions of this Section 8 are in addition
to and independent of any agreements or covenants contained in any other
agreement between the Company and the Executive. If any restriction contained in
this Section 8 shall be deemed to be invalid, illegal, or unenforceable by
reason of the extent, duration, or geographical scope thereof, or otherwise,
then the court making such determination shall have the right to reduce such
extent, duration, geographical scope, or other provisions hereof, and in its
reduced form such restriction shall then be enforceable in the manner
contemplated hereby. Notwithstanding any of the forgoing the Executive (i) may
have an interest (as owner, partner, lender, consultant, employee or agent but
not as a distributor or supplier) in any manufacturer that sells its products
exclusively and directly to health care practitioners rather than through
distributors or (ii) hold up to 2% of the outstanding shares of any class of
stock of a publicly traded entity.
9. Amendment and Modification; Waiver. This Agreement may be
amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by either party of
any breach or violation of any provision of this agreement shall not operate or
be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the terms
of this agreement shall be in writing and shall be deemed to have been duly
given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
6
If to the Executive, addressed to:
Timothy J. Sullivan, President
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts paid or
payable to the Executive pursuant to this Agreement shall adversely affect the
qualification of the Merger (as defined in the Merger Agreement) as a pooling of
interests, then the Company and the Executive shall endeavor in good faith to
modify such payments so that they will not adversely affect the Merger as a
pooling of interests for financial reporting purposes; provided, however, that
the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement constitutes the
entire agreement and supersede all other prior agreements and understandings,
both written and oral, between the parties with respect to the subject matter
hereof and all prior employment or other compensation or compensation
continuation agreements and arrangements between the Executive and Sullivan.
This agreement shall inure to and shall be binding upon the parties hereto, the
successors and assigns of the Company and the heirs and personal representatives
of the Executive.
14. Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York without giving
effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two or
more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
7
IN WITNESS WHEREOF, the parties hereto have executed this
agreement as of the day and year first above written.
------------------------------------
Timothy J. Sullivan
HENRY SCHEIN, INC.
By:
---------------------------------
Authorized Officer
8
Schedule 1
1. Dash Medical Gloves, Inc.
2. Dash Medical Gloves Sdn Bhd
In each case only to the extent that, except for their current principal
business activities, the above companies do not engage in any activities that
would otherwise be prohibited by Section 8.
EXHIBIT 10.99
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between Kevin J. Ackeret
(the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the Executive Vice President of
Sullivan Dental Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to employ the Executive, and the Executive
desires to be employed by the Company, at the Effective Time, as that term is
defined in the Merger Agreement. Accordingly, the parties hereto are entering
into this Agreement to set forth and confirm their respective rights and
obligations with respect to the Executive's employment by the Company commencing
as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall employ the Executive,
as of the Effective Time, as Executive Vice President of the U.S. Dental
Division of the Company and Executive Vice President of Sullivan, and the
Executive shall accept such employment and serve as such, subject to and upon
the terms and conditions set forth in this Agreement; provided, however, that
this Agreement shall terminate and be of no further force or effect if the
Executive shall have died or, in the reasonable judgment of the Company, become
disabled (as defined in Section 7(a)(i)), or his employment by Sullivan shall
have been terminated for Cause (as hereinafter defined), in any such case, prior
to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company,
the Executive shall, subject to the direction and control of the Boards of
Directors of the Company and Sullivan and the President of the North American
Dental Division of the Company, perform such executive duties and functions as
he may be called upon by such Boards or such President of the North American
Dental Division to perform, consistent with his employment hereunder as
Executive Vice President of the U.S. Dental Division of the Company and
Executive Vice President of Sullivan.
1
(b) The Executive shall devote his full time and
reasonable best efforts to the performance of his duties hereunder; and, to the
extent requested by the Board of Directors of the Company or Sullivan or the
President of the North American Dental Division of the Company, render such
executive services for any other subsidiary or affiliated business of the
Company. Notwithstanding the foregoing, the Executive may devote time and effort
to charitable activities and, provided that such activities do not interfere
with the Executive's fulfilling his obligations under this Agreement.
3. Compensation.
(a) The Company shall pay to the Executive for all
services to be rendered by him pursuant to this Agreement a base salary at the
annual rate of Two Hundred Ten Thousand Dollars ($210,000), payable in
accordance with the Company's practices with respect to its senior executives as
in effect from time to time, ("Company's Practices"). Such salary shall be
increased each year (beginning in 1999) by an amount determined by the Company
in accordance with the Company's Practices, but in any event such amount shall
be no less than the percentage increase in the cost of living over the preceding
year.
(b) The Executive shall be entitled to a bonus in respect
of each fiscal year of the Company during which he is employed hereunder,
payable no later than 90 days after the end of each year for which such bonus is
payable, the thresholds and amounts of which shall be determined in accordance
with the Company's Practices.
(c) At the Effective Time, the Executive shall be granted
options to purchase shares of common stock, par value $.01 per share ("Common
Stock"), of the Company in accordance with the stock option agreement attached
hereto as Exhibit A (the "Option Agreement").
(d) At the Effective Time, the Executive shall be granted
shares of Common Stock of the Company in accordance with the restricted stock
agreement attached hereto as Exhibit B (the "Restricted Stock Agreement").
(e) At the Effective Time, the Executive shall be paid
the sum of Three Hundred Ten Thousand Dollars ($310,000) as an inducement to
enter into this Agreement.
4. Working Conditions and Benefits. While employed by
the Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of
paid vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
(b) The Executive shall be authorized to incur reasonable
and necessary expenses for promoting the business of the Company, including
expenses for entertainment, travel
2
and similar items, all in accordance with the Company's Practices. The Company
shall reimburse the Executive for all such expenses, upon presentation by the
Executive of an itemized account of such authorized expenditures in accordance
with the Company's Practices with respect to expense reimbursement.
(c) The Company in accordance with Sullivan's prior
practices (x) shall provide to the Executive an automobile for business use and
(y) shall pay for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the
full extent provided for under the laws of the Company's state of incorporation
and the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligations
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While employed by the Company
hereunder the Executive shall be entitled to participate in all benefit, welfare
and perquisite plans, policies and programs, in accordance with the terms
thereof and in accordance with the Company's Practices (the "Benefit Programs").
Without limiting the generality of the foregoing, at the Effective Time the
Company and the Executive shall enter into the change in control agreement
attached hereto as Exhibit C (the "Change In Control Agreement").
6. Term. The Executive's employment hereunder shall
commence at the Effective Time and shall continue until the earlier of (a) the
fifth anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof. Notwithstanding clause (a) of the
preceding sentence (and subject to clauses (b) and (c) of such sentence), the
term of this Agreement shall automatically be extended for successive one year
periods, commencing on the fifth anniversary of the Effective Time, unless
either party gives written notice of termination at least six months prior to
the commencement of the initial or next successive one year renewal period, as
applicable.
7. Termination.
(a) Notwithstanding anything herein contained, if on or
after the Effective Time and prior to the fifth anniversary of the Effective
Time (or the expiration of the then current renewal period, as applicable), (i)
the Executive shall have been determined by the Board of Directors of the
Company to have become "Permanently Disabled", or (ii) the Executive shall have
furnished the Company with Cause for his discharge then, and in any such case,
the Company shall have the right, by notice given to the Executive, to terminate
the Executive's employment as of a date to be specified in such notice. Cause
shall be defined as: (A) the Executive shall be convicted of a felony involving
fraud, dishonesty or moral turpitude (other than ordinary traffic infractions),
(B) the Board of Directors of the Company shall have determined in good faith
that the Executive has committed any act, or omitted to take any action, in bad
faith or has materially neglected the Company's business, which, in any case,
shall have had, or reasonably would be expected to have, a material adverse
effect on the Company or Sullivan, or (C) the Board of
3
Directors of the Company shall have determined in good faith that the Executive
has materially breached any term of this Agreement and failed to correct such
breach, if such breach is curable, within 30 days after receipt of written
notice thereof. For purposes hereof, the term "Permanently Disabled" shall mean
a condition (certified by two licensed physicians, one selected by the Company
and one by the Executive and each reasonably satisfactory to the other party)
rendering the Executive unable to perform his responsibilities under this
Agreement for a period of 180 days, whether or not continuous, in any period of
12 months.
(b) Notwithstanding anything herein contained, on or
after the Effective Time and prior to the fifth anniversary of the Effective
Time (or the expiration of the then current renewal period, as applicable), the
Executive shall have the right to terminate this Agreement for good reason. For
purposes of this Agreement, "good reason" shall mean (i) a material breach by
the Company of this Agreement, which breach is not cured within 30 days after
notice from the Executive thereof or (ii) the Company's requiring Executive to
maintain his principal office anywhere other than within a 50 mile radius of
Sullivan's principal executive offices in West Allis, Wisconsin, provided that
the Executive shall travel on the Company's behalf within and outside such area
to the extent necessary to perform his duties hereunder.
(c) Upon the Executive's death, or termination of the
Executive's employment pursuant to Section 7(a)(i), the Executive (or his
estate, as the case may be) shall be entitled to receive only (i) his salary at
the rate provided in Section 3(a) to the date of termination (ii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs and (iii) an amount
equal to such bonus in respect of such prior fiscal year multiplied by a
fraction the numerator of which shall be the number of days that shall have
elapsed from the first day of the fiscal year in which such termination occurs
to the date of such termination and the denominator of which shall be 365.
(d) Upon termination of the Executive's employment
hereunder pursuant to Section 7(a)(ii) or the Executive's voluntary termination
of his employment hereunder other than pursuant to Section 7(b), the Executive
shall be entitled to receive only (i) his salary at the rate provided in Section
3(a) to the date of termination and (ii) any unpaid bonus pursuant to Section
3(b) in respect of the fiscal year of the Company ended prior to the year in
which such termination occurs. In either event, the Executive shall not be
entitled to receive any bonuses pursuant to Section 3(b) in respect of the year
in which such termination occurs or any year thereafter.
(e) Upon termination of the Executive's employment by the
Company without Cause or by the Executive hereunder pursuant to Section 7(b),
the Executive shall be entitled to receive (i) his salary at the rate provided
in Section 3(a) to the date of termination, (ii) continuation of the Executive's
base salary for a period after the date of such termination equal to the
unexpired term of this Agreement but in no event less than twelve months at the
rate in effect at such date of termination (iii) any unpaid bonus pursuant to
Section 3(b) in respect of the fiscal year of the Company ended prior to the
year in which such termination occurs, (iv) for a period following such
termination equal to the unexpired term of this Agreement, continuation of the
participation of the Executive and his spouse and dependent children, if any, in
all health and medical benefit plans, policies and programs in effect from time
to time with respect to the most senior executive officers of the Company and
their families generally (at the same levels and at
4
the same cost, if any, as provided to such officers generally) and (v) an amount
equal to such bonus in respect of such prior fiscal year multiplied by a
fraction the numerator of which shall be the number of days left in the
unexpired term of this Agreement and the denominator of which shall be 365.
8. Confidentiality and Non-Competition. In view of the
unique and valuable services it is expected the Executive will render to the
Company, the Executive's knowledge of the customers, trade secrets, and other
proprietary information relating to the business of the Company and its
customers and suppliers, and in consideration of (i) an aggregate sum of Two
Hundred Fifty-Five Thousand Dollars ($255,000) payable to the Executive in three
(3) equal annual installments of Eighty-Five Thousand Dollars ($85,000)
commencing on the first anniversary of the date of this Agreement and (ii) the
compensation to be received hereunder, the Executive agrees that he will not,
during his employment with the Company and for three years thereafter (the
"Noncompete Period") except on behalf of the Company: (a) directly or indirectly
engage or have an interest (whether as owner, partner, lender, consultant,
employee, agent, supplier distributor or otherwise) in any business, activity or
enterprise which competes with any material businesses or operations of the
Company or any of the Company's affiliates (including Sullivan) at any time
during his employment with the Company; (b) directly or indirectly employ or
otherwise engage, or offer to employ or otherwise engage, any person who is then
(or was at any time within three months prior to the time of such employment,
engagement or offer thereof) an employee, sales representative or agent of the
Company or any of the Company's affiliates (including Sullivan); or (c) solicit
any business from any person or entity that during his employment with the
Company has been a customer of the Company or any of the Company's affiliates
(including Sullivan) or directly or indirectly induce or influence any customer,
supplier or other person that has a business relationship with the Company or
any of the Company's affiliates (including Sullivan) to discontinue or reduce
the extent of such relationship with the Company or any of the Company's
affiliates (including Sullivan). Notwithstanding the foregoing, however, if the
Executive's employment hereunder continues until the fifth anniversary of the
Effective Time (or the end of the then applicable renewal period pursuant to
Section 6 hereof), then (subject to the immediately following sentence), the
Executive shall not upon termination of his employment be subject to the
restrictions and limitations set forth in clause (a) above, subject to the right
of the Company to enforce clause (a) for a period beginning on the date of
termination of the Executive's employment and ending not more than eighteen (18)
months after such date (the "Optional Period") upon payment to the Executive of
an amount equal to the Executive's then current rate of salary for the Optional
Period. Notwithstanding immediately preceding sentence, if prior to the fifth
anniversary of the Effective Time (or the end of the then applicable renewal
period pursuant to Section 6 hereof), the Executive gives notice of termination
pursuant to Section 6, then the Executive shall remain subject to the
restrictions and limitations set forth in clauses (a), (b) and (c) above for the
full Noncompete Period. In addition, the Executive shall never use or divulge
(unless available in the public domain not due to Executive's disclosure in
violation of this Agreement) any trade secrets, customer or supplier lists,
pricing information, marketing arrangements or strategies, business plans,
internal performance statistics, training manuals or other information
concerning the Company or its affiliates that is confidential, except on behalf
of the Company, and shall not knowingly make false or misleading or negative
statements, either orally or in writing, about the Company or its affiliates
(including Sullivan), or their respective directors, officers or employees.
Because the breach or attempted breach of this Section 8 will
5
result in immediate and irreparable injury to the Company for which the Company
will not have an adequate remedy at law, the Company shall be entitled, in
addition to all other remedies, to a decree of specific performance of this
covenant and to a temporary and permanent injunction enjoining such breach,
without posting bond or furnishing similar security. The provisions of this
Section 8 are in addition to and independent of any agreements or covenants
contained in any other agreement between the Company and the Executive. If any
restriction contained in this Section 8 shall be deemed to be invalid, illegal,
or unenforceable by reason of the extent, duration, or geographical scope
thereof, or otherwise, then the court making such determination shall have the
right to reduce such extent, duration, geographical scope, or other provisions
hereof, and in its reduced form such restriction shall then be enforceable in
the manner contemplated hereby. Notwithstanding any of the forgoing the
Executive (i) may have an interest (as owner, partner, lender, consultant,
employee or agent but not as a distributor or supplier) in any manufacturer that
sells its products exclusively and directly to health care practitioners rather
than through distributors or (ii) hold up to 2% of the outstanding shares of any
class of stock of a publicly traded entity.
9. Amendment and Modification; Waiver. This Agreement
may be amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by either party of
any breach or violation of any provision of this agreement shall not operate or
be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the
terms of this agreement shall be in writing and shall be deemed to have been
duly given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
If to the Executive, addressed to:
Kevin J. Ackeret, Executive Vice President
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
6
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts paid
or payable to the Executive pursuant to this Agreement shall adversely affect
the qualification of the Merger (as defined in the Merger Agreement) as a
pooling of interests, then the Company and the Executive shall endeavor in good
faith to modify such payments so that they will not adversely affect the Merger
as a pooling of interests for financial reporting purposes; provided, however,
that the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement constitutes
the entire agreement and supersede all other prior agreements and
understandings, both written and oral, between the parties with respect to the
subject matter hereof and all prior employment or other compensation or
compensation continuation agreements and arrangements between the Executive and
Sullivan. This agreement shall inure to and shall be binding upon the parties
hereto, the successors and assigns of the Company and the heirs and personal
representatives of the Executive.
14. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York without
giving effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
7
IN WITNESS WHEREOF, the parties hereto have executed this
agreement as of the day and year first above written.
------------------------------------
Kevin J. Ackeret
HENRY SCHEIN, INC.
By:
---------------------------------
Authorized Officer
8
EXHIBIT 10.100
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between Geoffrey A.
Reichardt (the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the Senior Vice President of
Sullivan Dental Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to employ the Executive, and the Executive
desires to be employed by the Company, at the Effective Time, as that term is
defined in the Merger Agreement. Accordingly, the parties hereto are entering
into this Agreement to set forth and confirm their respective rights and
obligations with respect to the Executive's employment by the Company commencing
as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall employ the Executive,
as of the Effective Time, as Vice President, Sales of the U.S. Dental Division
of the Company (the "Dental Division") and Vice President, Sales of Sullivan,
and the Executive shall accept such employment and serve as such, subject to and
upon the terms and conditions set forth in this Agreement; provided, however,
that this Agreement shall terminate and be of no further force or effect if the
Executive shall have died or, in the reasonable judgment of the Company, become
disabled (as defined in Section 7(a)(i)), or his employment by Sullivan shall
have been terminated for Cause (as hereinafter defined), in any such case, prior
to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company,
the Executive shall, subject to the direction and control of the President and
the Executive Vice President of the Dental Division, perform such executive
duties and functions as he may be called upon by such persons to perform,
consistent with his employment hereunder as Vice President, Sales of the Dental
Division and Vice President, Sales of Sullivan.
(b) The Executive shall devote his full time and
reasonable best efforts to the performance of his duties hereunder; and, to the
extent requested by the President or the
1
Executive Vice President of the Dental Division, render such executive services
for any other subsidiary or affiliated business of the Company. Notwithstanding
the foregoing, Executive may devote time and effort to charitable activities
(subject to the provision of Section 8), provided that such activities do not
interfere with the Executive fulfilling his obligations under this Agreement.
(c) The Company shall not require the Executive to
maintain his principal office anywhere other than within a 50 mile radius of
Sullivan's principal executive offices in West Allis, Wisconsin provided that
the Executive shall travel on the Company's behalf within and outside such area
to the extent reasonably necessary to perform his duties hereunder.
3. Compensation.
(a) The Company shall pay to the Executive for all
services to be rendered by him pursuant to this Agreement a base salary at the
annual rate of One Hundred Eighty-Five Thousand Dollars ($185,000), payable in
accordance with the Company's practices with respect to its senior executives as
in effect from time to time) ("Company's Practices"). Such salary shall be
increased each year (beginning in 1999) by an amount determined by the Company
in accordance with the Company's Practices, but in any event such amount shall
be no less than the percentage increase in the cost of living over the preceding
year.
(b) The Executive shall be entitled to a bonus in respect
of each fiscal year of the Company during which he is employed hereunder,
payable no later than 90 days after the end of each year for which such bonus is
payable, the thresholds and amounts of which shall be determined in accordance
with the Company's Practices.
(c) At the Effective Time, the Executive shall be granted
options to purchase shares of common stock, par value $.01 per share ("Common
Stock"), of the Company in accordance with the stock option agreement attached
hereto as Exhibit A (the "Option Agreement").
(d) At the Effective Time, the Executive shall be granted
shares of Common Stock of the Company in accordance with the restricted stock
agreement attached hereto as Exhibit B (the "Restricted Stock Agreement").
(e) At the Effective Time, the Executive shall be paid
the sum of Two Hundred Thousand Dollars ($200,000) as an inducement to enter
into this Agreement.
4. Working Conditions and Benefits. While employed by
the Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of
paid vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
2
(b) The Executive shall be authorized to incur reasonable
and necessary expenses for promoting the business of the Company, including
expenses for entertainment, travel and similar items, all in accordance with the
Company's Practices. The Company shall reimburse the Executive for all such
expenses, upon presentation by the Executive of an itemized account of such
authorized expenditures in accordance with the Company's Practices with respect
to expense reimbursement.
(c) The Company in accordance with Sullivan's prior
practices (x) shall provide to the Executive an automobile for business use and
(y) shall pay for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the
full extent provided for under the laws of the Company's state of incorporation
and the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligations
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While employed by the Company
hereunder:
The Executive shall be entitled to participate in all benefit,
welfare and perquisite plans, policies and programs, in accordance with the
terms thereof and in accordance with the Company's Practices ("Benefit
Programs").
6. Term. The Executive's employment hereunder shall
commence at the Effective Time and shall continue until the earlier of (a) the
fifth anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof.
7. Termination.
(a) Notwithstanding anything herein contained, if on or
after the Effective Time and prior to the fifth anniversary of the Effective
Time, (i) Executive shall have been determined by the Board of Directors of the
Company to have become "Permanently Disabled," or (ii) the Executive shall have
furnished the Company with Cause for his discharge then, and in any such case,
the Company shall have the right, by notice given to the Executive, to terminate
the Executive's employment as of a date to be specified in such notice. Cause
shall be defined as: (A) the Executive shall be convicted of a felony involving
fraud, dishonesty or moral turpitude (other than ordinary traffic infractions),
(B) the Board of Directors of the Company shall have determined that the
Executive has committed any act, or omitted to take any action, in bad faith or
has materially neglected the Company's business, which, in any case, shall have
had, or reasonably would be expected to have, a material adverse effect on the
Company or Sullivan, or (C) the Board of Directors of the Company shall have
determined in good faith that the Executive has materially breached any term of
this Agreement and failed to correct such breach, if such breach is curable,
within 30 days after receipt of written notice thereof. For purposes hereof, the
3
term "Permanently Disabled" shall mean a condition (certified by two licensed
physicians, one selected by the Company and one by the Executive and each
reasonably satisfactory to the other party) rendering the Executive unable to
perform his responsibilities under this Agreement for a period of 180 days
whether or not continuous, in any period of 12 months.
(b) Upon the Executive's death, or termination of the
Executive's employment pursuant to Section 7(a)(i), the Executive (or his
estate, as the case may be) shall be entitled to receive only (i) his salary at
the rate provided in Section 3(a) to the date of termination and (ii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs and (iii) an amount
equal to such bonus in respect of such prior fiscal year multiplied by a
fraction the numerator of which shall be the number of days that shall have
elapsed from the first day of the fiscal year in which such termination occurs
to the date of such termination and the denominator of which shall be 365.
(c) Upon termination of the Executive's employment
hereunder pursuant to Section 7(a)(ii) or the Executive's voluntary termination
of his employment hereunder, the Executive shall be entitled to receive only (i)
his salary at the rate provided in Section 3(a) to the date of termination and
(ii) any unpaid bonus pursuant to Section 3(b) in respect of the fiscal year of
the Company ended prior to the year in which such termination occurs. In either
of such events, the Executive shall not be entitled to receive any bonuses
pursuant to Section 3(b) in respect of the year in which such termination occurs
or any year thereafter.
(d) Upon termination of the Executive's employment
hereunder by the Company other than for cause the Executive shall be entitled to
receive (i) his salary at the rate provided in Section 3(a) to the date of
termination, (ii) continuation of the Executive's base salary for a period of
one year (subject to extension pursuant to Section 8(b)) after the date of such
termination at the rate in effect at such date of termination, (iii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs, and (iv) an amount
equal to the bonus paid to the Executive in respect of the prior fiscal year
multiplied by a fraction the numerator of which shall be the number of days that
shall have elapsed from the first day of the fiscal year in which such
termination occurs and the denominator of which shall be 365.
8. Confidentiality and Non-Competition.
(a) In view of the unique and valuable services it is
expected the Executive will render to the Company, the Executive's knowledge of
the customers, trade secrets, and other proprietary information relating to the
business of the Company and its customers and suppliers, and in consideration of
the compensation to be received hereunder, the Executive agrees that he will
not, during his employment with the Company and for a period of (i) three years
thereafter if the Executive is terminated for Cause pursuant to Section 7(a)
hereof or if Executive voluntarily terminates this Agreement or (ii) twelve (12)
months thereafter if the Executive is terminated other than for Cause or
for Permanent Disability (each of (i) and (ii), a "Noncompete Period") except on
behalf of the Company: (a) directly or indirectly engage or have an interest
(whether
4
as owner, partner, lender, consultant, employee, agent, supplier, distributor or
otherwise) in any business, activity or enterprise which competes with any
material businesses or operations of the Company or any of the Company's
affiliates (including Sullivan) at any time during his employment with the
Company; (b) directly or indirectly employ or otherwise engage, or offer to
employ or otherwise engage, any person who is then (or was at any time within
three months prior to the time of such employment, engagement or offer thereof)
an employee, sales representative or agent of the Company or any of the
Company's affiliates (including Sullivan); or (c) solicit any business from any
person or entity that during his employment with the Company has been a customer
of the Company or any of the Company's affiliates (including Sullivan) or
directly or indirectly induce or influence any customer, supplier or other
person that has a business relationship with the Company or any of the Company's
affiliates (including Sullivan) to discontinue or reduce the extent of such
relationship with the Company or any of the Company's affiliates (including
Sullivan). Notwithstanding the foregoing, however, if the Executive's employment
hereunder continues until the fifth anniversary of the Effective Time, then
(subject to the immediately following sentence), the Executive shall not, upon
termination of the Executive's employment hereunder, be subject to the
restrictions and limitations set forth in clause (a) above, subject to the right
of the Company to enforce clause (a) above for a period beginning on the date of
termination of the Executive's employment hereunder and ending no more than
eighteen (18) months after such date (the "Optional Period") upon payment to the
Executive of an amount equal to the Executive's then current rate of salary for
the Optional Period. Notwithstanding the immediately preceding sentence, if
prior to the fifth anniversary of the Effective Time, the Company offers the
Executive continued employment at his then current rate of salary and otherwise
on terms (excluding the employment term) not substantially less favorable to the
Executive as those provided for in this Agreement (as modified or amended from
time to time) and the Executive rejects said offer, then the Noncompete Period
referred to in clause (ii) above shall remain in effect with respect to all of
clauses (a), (b) and (c) above for eighteen (18) months from the date the
Executive's employment is terminated. In addition, the Executive shall never use
or divulge (unless available in the public domain not due to Executive's
disclosure in violation of this Agreement) any trade secrets, customer or
supplier lists, pricing information, marketing arrangements or strategies,
business plans, internal performance statistics, training manuals or other
information concerning the Company or its affiliates that is confidential,
except on behalf of the Company, and shall not knowingly make false or
misleading or negative statements, either orally or in writing, about the
Company or its affiliates (including Sullivan), or their respective directors,
officers or employees. Because the breach or attempted breach of this Section 8
will result in immediate and irreparable injury to the Company for which the
Company will not have an adequate remedy at law, the Company shall be entitled,
in addition to all other remedies, to a decree of specific performance of this
covenant and to a temporary and permanent injunction enjoining such breach,
without posting bond or furnishing similar security. The provisions of this
Section 8 are in addition to and independent of any agreements or covenants
contained in any other agreement between the Company and the Executive. If any
restriction contained in this Section 8 shall be deemed to be invalid, illegal,
or unenforceable by reason of the extent, duration, or geographical scope
thereof, or otherwise, then the court making such determination shall have the
right to reduce such extent, duration, geographical scope, or other
5
provisions hereof, and in its reduced form such restriction shall then be
enforceable in the manner contemplated hereby. Notwithstanding any of the
foregoing, the Executive (i) may have an interest (whether as owner, partner,
lender, consultant, employee or agent but not as distributor or supplier) in any
manufacturer that sells products exclusively and directly to health care
practitioners rather than through distributors or (ii) hold up to 2% of the
outstanding shares of any class of stock of a publicly traded entity.
(b) Notwithstanding anything to the contrary in the
foregoing paragraph, the Company shall have the option, at any time prior to its
expiration, to extend the Noncompete Period provided for in clause (ii) of the
preceding paragraph for additional periods by written notice to the Executive,
provided, however, that under no circumstance shall the Noncompete Period
pursuant to such clause (ii) (including all extensions thereof) exceed two years
in the aggregate. Any such extension shall be conditioned upon the payment by
the Company to the Executive of salary in accordance with Sections 3(a) and 3(b)
for such extended period.
9. Amendment and Modification; Waiver. This Agreement
may be amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by either party of
any breach or violation of any provision of this agreement shall not operate or
be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the
terms of this Agreement shall be in writing and shall be deemed to have been
duly given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
If to the Executive, addressed to:
Geoffrey A. Reichardt, Vice President, Sales
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
6
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts paid
or payable to the Executive pursuant to this Agreement shall adversely affect
the qualification of the Merger (as defined in the Merger Agreement) as a
pooling of interests, then the Company and the Executive shall endeavor in good
faith to modify such payments so that they will not adversely affect the Merger
as a pooling of interests for financial reporting purposes; provided, however,
that the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement constitutes
the entire agreement and supersede all other prior agreements and
understandings, both written and oral, between the parties with respect to the
subject matter hereof and all prior employment or other compensation or
compensation continuation agreements and arrangements between the Executive and
Sullivan. This agreement shall inure to and shall be binding upon the parties
hereto, the successors and assigns of the Company and the heirs and personal
representatives of the Executive.
14. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York without
giving effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
7
IN WITNESS WHEREOF, the parties hereto have executed this
agreement as of the day and year first above written.
------------------------------------
Geoffrey A. Reichardt
HENRY SCHEIN, INC.
By:
---------------------------------
Authorized Officer
8
EXHIBIT 10.101
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between David A. Steck
(the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the Vice-President, Product
Division of Sullivan Dental Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to employ the Executive, and the Executive
desires to be employed by the Company, at the Effective Time, as that term is
defined in the Merger Agreement. Accordingly, the parties hereto are entering
into this Agreement to set forth and confirm their respective rights and
obligations with respect to the Executive's employment by the Company commencing
as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall employ the Executive,
as of the Effective Time, as Vice-President, Product Division of the U.S. Dental
Division of the Company (the "Dental Division") and Vice-President, Product
Division of Sullivan, and the Executive shall accept such employment and serve
as such, subject to and upon the terms and conditions set forth in this
Agreement; provided, however, that this Agreement shall terminate and be of no
further force or effect if the Executive shall have died or, in the reasonable
judgment of the Company, become disabled (as defined in Section 7(a)(i)), or his
employment by Sullivan shall have been terminated for Cause (as hereinafter
defined), in any such case, prior to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company,
the Executive shall, subject to the direction and control of the President and
the Executive Vice President of the Dental Division, perform such executive
duties and functions as he may be called upon by such persons to perform,
consistent with his employment hereunder as Vice-President, Product Division of
the Dental Division and Vice-President, Product Division of Sullivan.
(b) The Executive shall devote his full time and
reasonable best efforts to the performance of his duties hereunder; and, to the
extent requested by the President or the
1
Executive Vice President of the Dental Division, render such executive services
for any other subsidiary or affiliated business of the Company. Notwithstanding
the foregoing, Executive may devote time and effort to charitable activities
(subject to the provision of Section 8), provided that such activities do not
interfere with the Executive fulfilling his obligations under this Agreement.
(c) The Company shall not require the Executive to
maintain his principal office anywhere other than within a 50 mile radius of
Sullivan's principal executive offices in West Allis, Wisconsin provided that
the Executive shall travel on the Company's behalf within and outside such area
to the extent reasonably necessary to perform his duties hereunder.
3. Compensation.
(a) The Company shall pay to the Executive for all
services to be rendered by him pursuant to this Agreement a base salary at the
annual rate of One Hundred Seventy-Five Thousand Dollars ($175,000), payable in
accordance with the Company's practices with respect to its senior executives as
in effect from time to time) ("Company's Practices"). Such salary shall be
increased each year (beginning in 1999) by an amount determined by the Company
in accordance with the Company's Practices, but in any event such amount shall
be no less than the percentage increase in the cost of living over the preceding
year.
(b) The Executive shall be entitled to a bonus in
respect of each fiscal year of the Company during which he is employed
hereunder, payable no later than 90 days after the end of each year for which
such bonus is payable, the thresholds and amounts of which shall be determined
in accordance with the Company's Practices.
(c) At the Effective Time, the Executive shall be
granted options to purchase shares of common stock, par value $.01 per share
("Common Stock"), of the Company in accordance with the stock option agreement
attached hereto as Exhibit A (the "Option Agreement").
(d) At the Effective Time, the Executive shall be
granted shares of Common Stock of the Company in accordance with the restricted
stock agreement attached hereto as Exhibit B (the "Restricted Stock Agreement").
(e) At the Effective Time, the Executive shall be paid
the sum of One Hundred Nine-Five Thousand Dollars ($195,000) as an inducement to
enter into this Agreement.
4. Working Conditions and Benefits. While employed by
the Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of
paid vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
2
(b) The Executive shall be authorized to incur
reasonable and necessary expenses for promoting the business of the Company,
including expenses for entertainment, travel and similar items, all in
accordance with the Company's Practices. The Company shall reimburse the
Executive for all such expenses, upon presentation by the Executive of an
itemized account of such authorized expenditures in accordance with the
Company's Practices with respect to expense reimbursement.
(c) The Company in accordance with Sullivan's prior
practices (x) shall provide to the Executive an automobile for business use and
(y) shall pay for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the
full extent provided for under the laws of the Company's state of incorporation
and the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligations
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While employed by the Company
hereunder:
The Executive shall be entitled to participate in all benefit,
welfare and perquisite plans, policies and programs, in accordance with the
terms thereof and in accordance with the Company's Practices ("Benefit
Programs").
6. Term. The Executive's employment hereunder shall
commence at the Effective Time and shall continue until the earlier of (a) the
fifth anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof.
7. Termination.
(a) Notwithstanding anything herein contained, if on or
after the Effective Time and prior to the fifth anniversary of the Effective
Time, (i) Executive shall have been determined by the Board of Directors of the
Company to have become "Permanently Disabled," or (ii) the Executive shall have
furnished the Company with Cause for his discharge then, and in any such case,
the Company shall have the right, by notice given to the Executive, to terminate
the Executive's employment as of a date to be specified in such notice. Cause
shall be defined as: (A) the Executive shall be convicted of a felony involving
fraud, dishonesty or moral turpitude (other than ordinary traffic infractions),
(B) the Board of Directors of the Company shall have determined that the
Executive has committed any act, or omitted to take any action, in bad faith or
has materially neglected the Company's business, which, in any case, shall have
had, or reasonably would be expected to have, a material adverse effect on the
Company or Sullivan, or (C) the Board of Directors of the Company shall have
determined in good faith that the Executive has materially breached any term of
this Agreement and failed to correct such breach, if such breach is curable,
within 30 days after receipt of written notice thereof. For purposes hereof, the
3
term "Permanently Disabled" shall mean a condition (certified by two licensed
physicians, one selected by the Company and one by the Executive and each
reasonably satisfactory to the other party) rendering the Executive unable to
perform his responsibilities under this Agreement for a period of 180 days
whether or not continuous, in any period of 12 months.
(b) Upon the Executive's death, or the termination of the
Executive's employment pursuant to Section 7(a)(i), the Executive (or his
estate, as the case may be) shall be entitled to receive only (i) his salary at
the rate provided in Section 3(a) to the date of termination and (ii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs and (iii) an amount
equal to such bonus in respect of such prior fiscal year multiplied by a
fraction the numerator of which shall be the number of days that shall have
elapsed from the first day of the fiscal year in which such termination occurs
to the date of such termination and the denominator of which shall be 365.
(c) Upon termination of the Executive's employment
hereunder pursuant to Section 7(a)(ii) or the Executive's voluntary termination
of his employment hereunder, the Executive shall be entitled to receive only (i)
his salary at the rate provided in Section 3(a) to the date of termination and
(ii) any unpaid bonus pursuant to Section 3(b) in respect of the fiscal year of
the Company ended prior to the year in which such termination occurs. In either
of such events, the Executive shall not be entitled to receive any bonuses
pursuant to Section 3(b) in respect of the year in which such termination occurs
or any year thereafter.
(d) Upon termination of the Executive's employment
hereunder by the Company other than for cause the Executive shall be entitled to
receive (i) his salary at the rate provided in Section 3(a) to the date of
termination, (ii) continuation of the Executive's base salary for a period of
one year (subject to extension pursuant to Section 8(b)) after the date of such
termination at the rate in effect at such date of termination, (iii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs, and (iv) an amount
equal to the bonus paid to the Executive in respect of the prior fiscal year
multiplied by a fraction the numerator of which shall be the number of days that
shall have elapsed from the first day of the fiscal year in which such
termination occurs and the denominator of which shall be 365.
8. Confidentiality and Non-Competition.
(a) In view of the unique and valuable services it is
expected the Executive will render to the Company, the Executive's knowledge of
the customers, trade secrets, and other proprietary information relating to the
business of the Company and its customers and suppliers, and in consideration of
the compensation to be received hereunder, the Executive agrees that he will
not, during his employment with the Company and for a period of (i) three years
thereafter if the Executive is terminated for Cause pursuant to Section 7(a)
hereof or if Executive voluntarily terminates this Agreement or (ii) twelve (12)
months thereafter if the Executive is terminated other than for Cause or
for Permanent Disability (each of (i) and (ii), a "Noncompete Period") except on
behalf of the Company: (a) directly or indirectly engage or have an interest
(whether
4
as owner, partner, lender, consultant, employee, agent, supplier, distributor or
otherwise) in any business, activity or enterprise which competes with any
material businesses or operations of the Company or any of the Company's
affiliates (including Sullivan) at any time during his employment with the
Company; (b) directly or indirectly employ or otherwise engage, or offer to
employ or otherwise engage, any person who is then (or was at any time within
three months prior to the time of such employment, engagement or offer thereof)
an employee, sales representative or agent of the Company or any of the
Company's affiliates (including Sullivan); or (c) solicit any business from any
person or entity that during his employment with the Company has been a customer
of the Company or any of the Company's affiliates (including Sullivan) or
directly or indirectly induce or influence any customer, supplier or other
person that has a business relationship with the Company or any of the Company's
affiliates (including Sullivan) to discontinue or reduce the extent of such
relationship with the Company or any of the Company's affiliates (including
Sullivan). Notwithstanding the foregoing, however, if the Executive's employment
hereunder continues until the fifth anniversary of the Effective Time, then
(subject to the immediately following sentence), the Executive shall not, upon
termination of the Executive's employment hereunder, be subject to the
restrictions and limitations set forth in clause (a) above, subject to the right
of the Company to enforce clause (a) above for a period beginning on the date of
termination of the Executive's employment hereunder and ending no more than
eighteen (18) months after such date (the "Optional Period") upon payment to the
Executive of an amount equal to the Executive's then current rate of salary for
the Optional Period. Notwithstanding the immediately preceding sentence, if
prior to the fifth anniversary of the Effective Time, the Company offers the
Executive continued employment at his then current rate of salary and otherwise
on terms (excluding the employment term) not substantially less favorable to the
Executive as those provided for in this Agreement (as modified or amended from
time to time) and the Executive rejects said offer, then the Noncompete Period
referred to in clause (ii) above shall remain in effect with respect to all of
clauses (a), (b) and (c) above for eighteen (18) months from the date the
Executive's employment is terminated. In addition, the Executive shall never use
or divulge (unless available in the public domain not due to
Executive's disclosure in violation of this Agreement) any trade secrets,
customer or supplier lists, pricing information, marketing arrangements or
strategies, business plans, internal performance statistics, training manuals or
other information concerning the Company or its affiliates that is confidential,
except on behalf of the Company, and shall not knowingly make false or
misleading or negative statements, either orally or in writing, about the
Company or its affiliates (including Sullivan), or their respective directors,
officers or employees. Because the breach or attempted breach of this Section 8
will result in immediate and irreparable injury to the Company for which the
Company will not have an adequate remedy at law, the Company shall be entitled,
in addition to all other remedies, to a decree of specific performance of this
covenant and to a temporary and permanent injunction enjoining such breach,
without posting bond or furnishing similar security. The provisions of this
Section 8 are in addition to and independent of any agreements or covenants
contained in any other agreement between the Company and the Executive. If any
restriction contained in this Section 8 shall be deemed to be invalid, illegal,
or unenforceable by reason of the extent, duration, or geographical scope
thereof, or otherwise, then the court making such determination shall have the
right to reduce such extent, duration, geographical scope, or other
5
provisions hereof, and in its reduced form such restriction shall then be
enforceable in the manner contemplated hereby. Notwithstanding any of the
foregoing, the Executive (i) may have an interest (whether as owner, partner,
lender, consultant, employee or agent but not as distributor or supplier) in any
manufacturer that sells products exclusively and directly to health care
practitioners rather than through distributors or (ii) hold up to 2% of the
outstanding shares of any class of stock of a publicly traded entity.
(b) Notwithstanding anything to the contrary in the
foregoing paragraph, the Company shall have the option, at any time prior to its
expiration, to extend the Noncompete Period provided for in clause (ii) of the
preceding paragraph for additional periods by written notice to the Executive,
provided, however, that under no circumstance shall the Noncompete Period
pursuant to such clause (ii) (including all extensions thereof) exceed two years
in the aggregate. Any such extension shall be conditioned upon the payment by
the Company to the Executive of salary in accordance with Sections 3(a) and 3(b)
for such extended period.
9. Amendment and Modification; Waiver. This Agreement
may be amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by
either party of any breach or violation of any provision of this agreement shall
not operate or be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the
terms of this Agreement shall be in writing and shall be deemed to have been
duly given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
If to the Executive, addressed to:
David A. Steck, Vice President, Products Division
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
6
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts
paid or payable to the Executive pursuant to this Agreement shall adversely
affect the qualification of the Merger (as defined in the Merger Agreement) as a
pooling of interests, then the Company and the Executive shall endeavor in good
faith to modify such payments so that they will not adversely affect the Merger
as a pooling of interests for financial reporting purposes; provided, however,
that the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement
constitutes the entire agreement and supersede all other prior agreements and
understandings, both written and oral, between the parties with respect to the
subject matter hereof and all prior employment or other compensation or
compensation continuation agreements and arrangements between the Executive and
Sullivan. This agreement shall inure to and shall be binding upon the parties
hereto, the successors and assigns of the Company and the heirs and personal
representatives of the Executive.
14. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York without
giving effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
7
IN WITNESS WHEREOF, the parties hereto have executed this
agreement as of the day and year first above written.
------------------------------------
David A. Steck
HENRY SCHEIN, INC.
By:
------------------------------------
Authorized Officer
8
EXHIBIT 10.102
EMPLOYMENT AGREEMENT
AGREEMENT dated as of August 3, 1997, between Kenneth A.
Schwing (the "Executive") and HENRY SCHEIN, INC., a Delaware corporation (the
"Company").
The Executive is presently the Vice-President, Equipment
Division of Sullivan Dental Products, Inc. ("Sullivan").
The Company and Sullivan are parties to an Agreement and Plan
of Merger dated August 3, 1997 (the "Merger Agreement"), pursuant to which it is
contemplated that HSI Acquisition Corp., a wholly-owned subsidiary of the
Company, will be merged with and into Sullivan.
The Company desires to employ the Executive, and the Executive
desires to be employed by the Company, at the Effective Time, as that term is
defined in the Merger Agreement. Accordingly, the parties hereto are entering
into this Agreement to set forth and confirm their respective rights and
obligations with respect to the Executive's employment by the Company commencing
as of the Effective Time.
The parties agree as follows:
1. Employment. The Company shall employ the Executive,
as of the Effective Time, as Vice-President, Equipment Division of the U.S.
Dental Division of the Company (the "Dental Division") and Vice-President,
Equipment Division of Sullivan, and the Executive shall accept such employment
and serve as such, subject to and upon the terms and conditions set forth in
this Agreement; provided, however, that this Agreement shall terminate and be of
no further force or effect if the Executive shall have died or, in the
reasonable judgment of the Company, become disabled (as defined in Section
7(a)(i)), or his employment by Sullivan shall have been terminated for Cause (as
hereinafter defined), in any such case, prior to the Effective Time.
2. Duties.
(a) At all times during his employment with the Company,
the Executive shall, subject to the direction and control of the President and
the Executive Vice President of the Dental Division, perform such executive
duties and functions as he may be called upon by such persons to perform,
consistent with his employment hereunder as Vice-President, Equipment Division
of the Dental Division and Vice-President, Equipment Division of Sullivan.
(b) The Executive shall devote his full time and
reasonable best efforts to the performance of his duties hereunder; and, to the
extent requested by the President and the
1
Executive Vice President of the Dental Division, render such executive services
for any other subsidiary or affiliated business of the Company. Notwithstanding
the foregoing, Executive may devote time and effort to charitable activities
(subject to the provision of Section 8), provided that such activities do not
interfere with the Executive fulfilling his obligations under this Agreement.
(c) The Company shall not require the Executive to
maintain his principal office anywhere other than within a 50 mile radius of
Sullivan's principal executive offices in West Allis, Wisconsin provided that
the Executive shall travel on the Company's behalf within and outside such area
to the extent reasonably necessary to perform his duties hereunder.
3. Compensation.
(a) The Company shall pay to the Executive for all
services to be rendered by him pursuant to this Agreement a base salary at the
annual rate of One Hundred Seventy-Five Thousand Dollars ($175,000), payable in
accordance with the Company's practices with respect to its senior executives as
in effect from time to time) ("Company's Practices"). Such salary shall be
increased each year (beginning in 1999) by an amount determined by the Company
in accordance with the Company's Practices, but in any event such amount shall
be no less than the percentage increase in the cost of living over the preceding
year.
(b) The Executive shall be entitled to a bonus in respect
of each fiscal year of the Company during which he is employed hereunder,
payable no later than 90 days after the end of each year for which such bonus is
payable, the thresholds and amounts of which shall be determined in accordance
with the Company's Practices.
(c) At the Effective Time, the Executive shall be granted
options to purchase shares of common stock, par value $.01 per share ("Common
Stock"), of the Company in accordance with the stock option agreement attached
hereto as Exhibit A (the "Option Agreement").
(d) At the Effective Time, the Executive shall be granted
shares of Common Stock of the Company in accordance with the restricted stock
agreement attached hereto as Exhibit B (the "Restricted Stock Agreement").
(e) At the Effective Time, the Executive shall be paid
the sum of One Hundred Ninety-Five Thousand Dollars ($195,000) as an inducement
to enter into this Agreement.
4. Working Conditions and Benefits. While employed by
the Company hereunder:
(a) The Executive shall be entitled to four (4) weeks of
paid vacation per year, in accordance with the Company's Practices and shall be
entitled to sick leave and personal time in accordance with the Company's
policies for its senior executives.
2
(b) The Executive shall be authorized to incur reasonable
and necessary expenses for promoting the business of the Company, including
expenses for entertainment, travel and similar items, all in accordance with the
Company's Practices. The Company shall reimburse the Executive for all such
expenses, upon presentation by the Executive of an itemized account of such
authorized expenditures in accordance with the Company's Practices with respect
to expense reimbursement.
(c) The Company in accordance with Sullivan's prior
practices (x) shall provide to the Executive an automobile for business use and
(y) shall pay for certain expenses incurred in connection with such use.
(d) The Company shall provide to the Executive to the
full extent provided for under the laws of the Company's state of incorporation
and the Company's By-Laws, indemnification for any claim or lawsuit which may be
asserted against the Executive with respect to his capacity as an officer or
employee of the Company, provided that said indemnification is not in violation
of any Federal or state law, rule or regulation. The indemnification obligations
of the Company shall survive the termination of this Agreement.
5. Other Benefits. While employed by the Company
hereunder:
The Executive shall be entitled to participate in all benefit,
welfare and perquisite plans, policies and programs, in accordance with the
terms thereof and in accordance with the Company's Practices ("Benefit
Programs").
6. Term. The Executive's employment hereunder shall
commence at the Effective Time and shall continue until the earlier of (a) the
fifth anniversary of the Effective Time, (b) his death, or (c) termination of
employment pursuant to Section 7 hereof.
7. Termination.
(a) Notwithstanding anything herein contained, if on or
after the Effective Time and prior to the fifth anniversary of the Effective
Time, (i) Executive shall have been determined by the Board of Directors of the
Company to have become "Permanently Disabled," or (ii) the Executive shall have
furnished the Company with Cause for his discharge then, and in any such case,
the Company shall have the right, by notice given to the Executive, to terminate
the Executive's employment as of a date to be specified in such notice. Cause
shall be defined as: (A) the Executive shall be convicted of a felony involving
fraud, dishonesty or moral turpitude (other than ordinary traffic infractions),
(B) the Board of Directors of the Company shall have determined that the
Executive has committed any act, or omitted to take any action, in bad faith or
has materially neglected the Company's business, which, in any case, shall have
had, or reasonably would be expected to have, a material adverse effect on the
Company or Sullivan, or (C) the Board of Directors of the Company shall have
determined in good faith that the Executive has materially breached any term of
this Agreement and failed to correct such breach, if such breach is curable,
within 30 days after receipt of written notice thereof. For purposes hereof, the
3
term "Permanently Disabled" shall mean a condition (certified by two licensed
physicians, one selected by the Company and one by the Executive and each
reasonably satisfactory to the other party) rendering the Executive unable to
perform his responsibilities under this Agreement for a period of 180 days
whether or not continuous, in any period of 12 months.
(b) Upon the Executive's death, or termination of the
Executive's employment pursuant to Section 7(a)(i), the Executive (or his
estate, as the case may be) shall be entitled to receive only (i) his salary at
the rate provided in Section 3(a) to the date of termination and (ii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs and (iii) an amount
equal to such bonus in respect of such prior fiscal year multiplied by a
fraction the numerator of which shall be the number of days that shall have
elapsed from the first day of the fiscal year in which such termination occurs
to the date of such termination and the denominator of which shall be 365.
(c) Upon termination of the Executive's employment
hereunder pursuant to Section 7(a)(ii) or the Executive's voluntary termination
of his employment hereunder, the Executive shall be entitled to receive only (i)
his salary at the rate provided in Section 3(a) to the date of termination and
(ii) any unpaid bonus pursuant to Section 3(b) in respect of the fiscal year of
the Company ended prior to the year in which such termination occurs. In either
of such events, the Executive shall not be entitled to receive any bonuses
pursuant to Section 3(b) in respect of the year in which such termination occurs
or any year thereafter.
(d) Upon termination of the Executive's employment
hereunder by the Company other than for cause the Executive shall be entitled to
receive (i) his salary at the rate provided in Section 3(a) to the date of
termination, (ii) continuation of the Executive's base salary for a period of
one year (subject to extension pursuant to Section 8(b)) after the date of such
termination at the rate in effect at such date of termination, (iii) any unpaid
bonus pursuant to Section 3(b) in respect of the fiscal year of the Company
ended prior to the year in which such termination occurs, and (iv) an amount
equal to the bonus paid to the Executive in respect of the prior fiscal year
multiplied by a fraction the numerator of which shall be the number of days that
shall have elapsed from the first day of the fiscal year in which such
termination occurs and the denominator of which shall be 365.
8. Confidentiality and Non-Competition.
(a) In view of the unique and valuable services it is
expected the Executive will render to the Company, the Executive's knowledge of
the customers, trade secrets, and other proprietary information relating to the
business of the Company and its customers and suppliers, and in consideration of
the compensation to be received hereunder, the Executive agrees that he will
not, during his employment with the Company and for a period of (i) three years
thereafter if the Executive is terminated for Cause pursuant to Section 7(a)
hereof or if Executive voluntarily terminates this Agreement or (ii) twelve
(12) months thereafter if the Executive is terminated other than for Cause or
for Permanent Disability (each of (i) and (ii), a "Noncompete Period") except on
behalf of the Company: (a) directly or indirectly engage or have an interest
(whether
4
as owner, partner, lender, consultant, employee, agent, supplier, distributor or
otherwise) in any business, activity or enterprise which competes with any
material businesses or operations of the Company or any of the Company's
affiliates (including Sullivan) at any time during his employment with the
Company; (b) directly or indirectly employ or otherwise engage, or offer to
employ or otherwise engage, any person who is then (or was at any time within
three months prior to the time of such employment, engagement or offer thereof)
an employee, sales representative or agent of the Company or any of the
Company's affiliates (including Sullivan); or (c) solicit any business from any
person or entity that during his employment with the Company has been a customer
of the Company or any of the Company's affiliates (including Sullivan) or
directly or indirectly induce or influence any customer, supplier or other
person that has a business relationship with the Company or any of the Company's
affiliates (including Sullivan) to discontinue or reduce the extent of such
relationship with the Company or any of the Company's affiliates (including
Sullivan). Notwithstanding the foregoing, however, if the Executive's employment
hereunder continues until the fifth anniversary of the Effective Time, then
(subject to the immediately following sentence), the Executive shall not, upon
termination of the Executive's employment hereunder, be subject to the
restrictions and limitations set forth in clause (a) above, subject to the right
of the Company to enforce clause (a) above for a period beginning on the date of
termination of the Executive's employment hereunder and ending no more than
eighteen (18) months after such date (the "Optional Period") upon payment to the
Executive of an amount equal to the Executive's then current rate of salary for
the Optional Period. Notwithstanding the immediately preceding sentence, if
prior to the fifth anniversary of the Effective Time, the Company offers the
Executive continued employment at his then current rate of salary and otherwise
on terms (excluding the employment term) not substantially less favorable to the
Executive as those provided for in this Agreement (as modified or amended from
time to time) and the Executive rejects said offer, then the Noncompete Period
referred to in clause (ii) above shall remain in effect with respect to all of
clauses (a), (b) and (c) above for eighteen (18) months from the date the
Executive's employment is terminated. In addition, the Executive shall never use
or divulge (unless available in the public domain not due to Executive's
disclosure in violation of this Agreement) any trade secrets, customer or
supplier lists, pricing information, marketing arrangements or strategies,
business plans, internal performance statistics, training manuals or other
information concerning the Company or its affiliates that is confidential,
except on behalf of the Company, and shall not knowingly make false or
misleading or negative statements, either orally or in writing, about the
Company or its affiliates (including Sullivan), or their respective directors,
officers or employees. Because the breach or attempted breach of this Section 8
will result in immediate and irreparable injury to the Company for which the
Company will not have an adequate remedy at law, the Company shall be entitled,
in addition to all other remedies, to a decree of specific performance of this
covenant and to a temporary and permanent injunction enjoining such breach,
without posting bond or furnishing similar security. The provisions of this
Section 8 are in addition to and independent of any agreements or covenants
contained in any other agreement between the Company and the Executive. If any
restriction contained in this Section 8 shall be deemed to be invalid, illegal,
or unenforceable by reason of the extent, duration, or geographical scope
thereof, or otherwise, then the court making such determination shall have the
right to reduce such extent, duration, geographical scope, or other
5
provisions hereof, and in its reduced form such restriction shall then be
enforceable in the manner contemplated hereby. Notwithstanding any of the
foregoing, the Executive (i) may have an interest (whether as owner, partner,
lender, consultant, employee or agent but not as distributor or supplier) in any
manufacturer that sells products exclusively and directly to health care
practitioners rather than through distributors or (ii) hold up to 2% of the
outstanding shares of any class of stock of a publicly traded entity.
(b) Notwithstanding anything to the contrary in the
foregoing paragraph, the Company shall have the option, at any time prior to its
expiration, to extend the Noncompete Period provided for in clause (ii) of the
preceding paragraph for additional periods by written notice to the Executive,
provided, however, that under no circumstance shall the Noncompete Period
pursuant to such clause (ii) (including all extensions thereof) exceed two years
in the aggregate. Any such extension shall be conditioned upon the payment by
the Company to the Executive of salary in accordance with Sections 3(a) and 3(b)
for such extended period.
9. Amendment and Modification; Waiver. This Agreement
may be amended, modified or supplemented only by written agreement (referring
specifically to this Agreement) of the parties. The waiver by either party of
any breach or violation of any provision of this agreement shall not operate or
be construed as a waiver of any subsequent breach.
10. Notice. All notices required to be given under the
terms of this Agreement shall be in writing and shall be deemed to have been
duly given if delivered to the addressee in person or mailed by certified mail,
return receipt requested, as follows:
If to the Company, addressed to:
Henry Schein, Inc.
135 Duryea Road
Melville, New York 11747
Attention: Mark E. Mlotek, Esq.
With a copy to:
Proskauer Rose LLP
1585 Broadway
New York, New York 10036
Attention: Robert A. Cantone, Esq.
If to the Executive, addressed to:
Kenneth A. Schwing, Vice-President, Equipment Division
Sullivan Dental Products, Inc.
10920 West Lincoln Avenue
West Allis, Wisconsin 53227
6
With a copy to:
Wolfe, Wolfe & Ryd
20 North Wacker Drive, Suite 3550
Chicago, IL 60606
Attention: Kerry Wolfe, Esq.
or to any such other address as the party to receive the notice shall advise by
due notice given in accordance with this paragraph.
11. Further Agreement. In the event that any amounts paid
or payable to the Executive pursuant to this Agreement shall adversely affect
the qualification of the Merger (as defined in the Merger Agreement) as a
pooling of interests, then the Company and the Executive shall endeavor in good
faith to modify such payments so that they will not adversely affect the Merger
as a pooling of interests for financial reporting purposes; provided, however,
that the parties shall, in any event, carry out the intent of this Agreement.
12. Headings. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
13. Entire Agreement; Benefit. This Agreement constitutes
the entire agreement and supersede all other prior agreements and
understandings, both written and oral, between the parties with respect to the
subject matter hereof and all prior employment or other compensation or
compensation continuation agreements and arrangements between the Executive and
Sullivan. This agreement shall inure to and shall be binding upon the parties
hereto, the successors and assigns of the Company and the heirs and personal
representatives of the Executive.
14. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York without
giving effect to the provisions thereof relating to conflicts of law.
15. Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed to be an original but all of
which shall constitute one and the same agreement.
7
IN WITNESS WHEREOF, the parties hereto have executed this
agreement as of the day and year first above written.
------------------------------------
Kenneth A. Schwing
HENRY SCHEIN, INC.
By:
---------------------------------
Authorized Officer
8
AMENDMENT TO REVOLVING CREDIT AGREEMENT, dated as of June __,
1997, among HENRY SCHEIN, INC., a corporation organized under the laws of the
State of Delaware (the "Borrower") and THE CHASE MANHATTAN BANK, a New York
banking corporation ("Chase"), FLEET BANK, NATIONAL ASSOCIATION, a national
banking association organized under the laws of the United States of America
("Fleet"), COOPERATIEVE CENTRALE RAIFFEISEN-BOEREN LEENBANK, B.A. "RABOBANK
NEDERLAND", New York Branch, a corporation organized under the laws of the
Netherlands ("Rabobank Nederland") and EUROPEAN AMERICAN BANK, a New York
banking corporation ("EAB"; collectively with Chase, Fleet and Rabobank
Nederland, the "Banks") and Chase, as Agent for the Banks.
RECITALS:
---------
A. The parties hereto entered in to that Revolving Credit
Agreement, dated as of January 31, 1997 (the "Credit Agreement").
B. The parties hereto desire to amend the Credit Agreement on
the terms and conditions hereinafter set forth.
NOW, THEREFORE, the parties hereto agree as follows:
ARTICLE 1. AMENDMENTS TO REVOLVING CREDIT AGREEMENT.
This Amendment shall be deemed to be an amendment to the
Credit Agreement and shall not be construed in any way as a replacement or
substitution therefor. All of the terms and provisions of this Agreement are
hereby incorporated by reference into the Credit Agreement as if such terms were
set forth in full therein.
Section 1.1. Section 8.4, clause (ix) of the Credit Agreement
is hereby amended by deleting the reference to "$1,000,000" therefrom and
substituting "$2,000,000" in its place.
Article 2. Additional Terms.
Section 2.1. The Borrower hereby represents and warrants to
the Banks that (a) the execution, delivery and performance by the Borrower of
this Amendment, and the consummation of the transactions contemplated hereby,
have been duly authorized by all necessary corporate action, (b) the resolutions
and corporate documents delivered to the Agent pursuant to Section 5.1(a)(ii) of
the Credit Agreement on the date thereof have not been amended, revoked or
rescinded at any time on or subsequent to the date thereof and are in effect at
the date hereof, and (c) after giving effect to the transactions contemplated
hereby or referenced herein, the representations and warranties in Article 6 of
the Credit Agreement are true and correct on the date hereof as though made on
and as of such date, and no event has occurred and is continuing, which
constitutes or will constitute a Default or Event of Default.
Section 2.2. The parties hereto agree that all terms and
conditions of the Credit Agreement and the Facility Documents not amended
hereunder or pursuant hereto shall remain in full force and effect.
Section 2.3. All capitalized terms used herein and not defined
herein shall have the meanings given to them in the Credit Agreement.
Section 2.4. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same
instrument, and any party hereto may execute this Amendment by signing any such
counterpart.
Section 2.5. This Amendment shall be governed by, and
interpreted and construed in accordance with, the laws of the State of New York.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to
be duly executed as of the day and year first above written.
HENRY SCHEIN, INC.
By: /s/ H. BRADLEY SEIDENSTICKER
-----------------------------
Name: H. BRADLEY SEIDENSTICKER
Title: TREASURER
THE CASE MANHATTAN BANK, as
Agent and a Bank
By: /s/ Evelin K. Teryo
-----------------------------
Name: Evelin K. Teryo
Title: Vice President
2
FLEET BANK, NATIONAL ASSOCIATION
By: /s/ Thomas Dionian
-----------------------------
Name: Thomas Dionian
Title: Vice President
COOPERATIVE CENTRALE RAIFFEISSEN-
BOERENLEENBANK, B.A. - "RABOBANK
NEDERLAND", NEW YORK BRANCH
By: /s/ M. Christina Debler
-----------------------------
Name: M. Christina Debler
Title: Vice President
By: /s/ IAN REECE
-----------------------------
Name: IAN REECE
Title: Senior Credit Officer
EUROPEAN AMERICAN BANK
By: /s/ Gerald F. Baccagline
-----------------------------
Name: Gerald F. Baccagline
Title: Vice President
AMENDMENT NO. 2 AND SUPPLEMENT TO
REVOLVING CREDIT AGREEMENT
AMENDMENT NUMBER 2 AND SUPPLEMENT TO REVOLVING CREDIT
AGREEMENT, dated as of August 15, 1997, among HENRY SCHEIN, INC., a corporation
organized under the laws of the State of Delaware (the "Borrower"), and THE
CHASE MANHATTAN BANK, a New York banking corporation ("Chase"), FLEET BANK,
NATIONAL ASSOCIATION, a national banking association organized under the laws of
the United States of America "("Fleet"), COOPERATIEVE CENTRALE
RAIFFEISEN-BOERENLEENBANK B.A. "RABOBANK NEDERLAND", New York Branch, a
corporation organized under the laws of the Netherlands ("Rabobank Nederland"),
and EUROPEAN AMERICAN BANK, a New York banking corporation ("EAB"; collectively
with Chase, Fleet and Rabobank Nederland, the "Banks") and Chase, as Agent for
the Banks.
RECITALS:
A. The parties hereto entered in to that Revolving Credit
Agreement, dated as of January 31, 1997 as amended by any Amendment to Revolving
Credit Agreement dated as of June 30, 1997 (the Revolving Credit Agreement, as
so amended, being hereinafter referred to as the "Credit Agreement").
B. The parties hereto desire to amend and supplement the
Credit Agreement on the terms and conditions hereinafter set forth.
C. Any capitalized terms used herein and not defined herein
shall have the meanings given to them in the Credit Agreement.
NOW, THEREFORE, the parties hereto agree as follows:
ARTICLE 1.
AMENDMENTS TO REVOLVING CREDIT AGREEMENT.
This Amendment shall be deemed to be an amendment to the
Credit Agreement and shall not be construed in any way as a replacement or
substitution therefor. All of the terms and provisions of this Agreement are
hereby incorporated by reference into the Credit Agreement as if such terms were
set forth in full therein.
Section 1.1. Section 1.1 of the Credit Agreement is hereby
amended by deleting the definition of the term "Revolving Credit Commitment" and
substituting the following in its place:
"Revolving Credit Commitment" means, with respect to each
Bank, the obligation of such Bank to extend credit to the
Borrower hereunder, subject to the terms hereof, in the
following aggregate amounts:
Chase $52,500,000
Fleet 37,500,000
Rabobank Nederland 37,500,000
EAB 22,500,000
Section 1.2. Section 1.1 of the Credit Agreement is hereby
further amended by deleting the definition of the term "Revolving Credit Note"
and substituting the following in its place:
"Revolving Credit Note" means a promissory note of the
Borrower in the form of Exhibit A annexed hereto evidencing
Revolving Credit Loans made by a Bank hereunder, together with
any promissory note issued in substitution or replacement
therefor.
Section 1.3. Section 1.1 of the Credit Agreement is hereby
further amended by deleting the phrase "January 30, 2002" therefrom and
substituting the following in its place: "August 14, 2002".
Section 1.4. Section 2.1 of the Credit Agreement is hereby
amended by deleting the last sentence therefrom and substituting the following
in its place:
"Notwithstanding the foregoing, in no event shall the Dollar
Equivalent of the aggregate principal balance (determined at
the Relevant Exchange Rate) of Revolving Credit Loans
denominated in Approved Currencies other than Dollars exceed
$25,000,000 at any one time."
Section 1.5. Section 2.7(a) of the Credit Agreement is hereby
amended by deleting the second sentence thereof and substituting the following
in its place:
"Notwithstanding the foregoing, at no time shall the sum of
Aggregate Letters of Credit Outstandings plus Aggregate
Banker's Acceptance Outstandings exceed $15,000,000 and no
Letter of Credit or Documentary Banker's Acceptance shall be
issued or created if after giving effect thereto the Aggregate
Outstandings would exceed the Total Revolving Credit
Commitments in effect on such date."
Section 1.6. Section 2.7(a) of the Credit Agreement is hereby
amended by deleting the following phrase from the penultimate sentence thereof:
2
"and no Standby Letter of Credit shall expire more than one
year after its issuance".
Section 1.7. Section 8.2 of the Credit Agreement is hereby
amended by inserting immediately after the reference to "Schedule 6.10 hereto"
the following: ", as such Schedule may be amended from time to time." The Credit
Agreement is hereby further amended by deleting Schedule 6.10 therefrom and by
substituting in its place Schedule 6.10 to this Amendment.
Section 1.8. Section 8.8(b) of the Credit Agreement is hereby
amended by deleting the reference to "$15,000,000" therefrom and by substituting
the following in its place: "$25,000,000."
Section 1.9. Section 8.8(c) of the Credit Agreement is hereby
amended by deleting the reference to "$25,000,000" therefrom and by substituting
the following in its place: "$40,000,000".
Section 1.10. Section 9.1 of the Credit Agreement is hereby
amended to add the following sentence at the end thereof: "For purposes of
calculating compliance with this covenant, Consolidated Net Worth and Net Income
shall each be adjusted to add back non-recurring merger and acquisition costs;
provided, that the cumulative adjustment made pursuant to this Section 9.1
during the term of this Agreement shall not exceed $35,000,000.
Section 1.11. Section 9.2 of the Credit Agreement is hereby
amended by deleting the phrase "in excess of $15,000,000 in any fiscal year or
$55,000,000 during the term of the Revolving Credit Facility" and substituting
the following in its place: "in excess of $20,000,000 in any fiscal year."
Section 1.12. Section 9.3 of the Credit Agreement is hereby
amended by inserting the following sentence at the end thereof: "For purposes of
calculating compliance with this covenant, Consolidated Net Profit shall be
adjusted to add back non-recurring merger and acquisition costs; provided, that
the cumulative adjustment made pursuant to this Section 9.3 during the term of
this Agreement shall not exceed $35,000,000."
Section 1.13. Section 9.4 of the Credit Agreement is hereby
amended by inserting the following sentence at the end thereof: "For purposes of
calculating compliance with this covenant, Consolidating Operating Income shall
be adjusted to add back non-recurring merger and acquisition costs; provided,
that the cumulative adjustment made pursuant to this Section 9.4 during the term
of this Agreement shall not exceed $35,000,000."
Section 1.14. Section 9.5 of the Credit Agreement is hereby
amended by inserting the following sentence at the end thereof: "For purposes of
calculating compliance with this covenant provided, that the cumulative
adjustment made pursuant to this Section 9.5 during the term of this Agreement
shall not exceed $35,000,000."
3
ARTICLE 2.
SUPPLEMENT TO THE CREDIT AGREEMENT
The Credit Agreement is hereby supplemented as follows:
Section 2.1. Simultaneously with the execution and delivery of
this Amendment, the Borrower shall execute and deliver to each of the Banks a
substituted note (the "Substituted Notes") in the form annexed hereto as Exhibit
A. Upon the execution and delivery of the Substituted Notes, each Bank shall
mark its Note "canceled and replaced by Substituted Note" and shall return it to
the Borrower. The unpaid principal balance of Revolving Credit Loans then
outstanding and evidenced by the Note shall be endorsed by each Bank on the
Schedule attached to its Substituted Note as outstanding thereunder.
Section 2.2. All references in the Credit Agreement and in the
Facility Documents to the "Agreement" shall be deemed to refer to the Agreement
as amended and supplemented hereby; and unless the context otherwise requires
all references in such documents to the Notes shall be deemed to refer to the
Substituted Notes.
Section 2.3. The Credit Agreement and the Facility Documents
shall each be deemed amended, to the extent necessary, to give effect to the
provisions of this Amendment.
ARTICLE 3.
REPRESENTATIONS AND WARRANTIES
The Borrower hereby represents and warrants to the Banks that:
Section 3.1. Each and every of the representations and
warranties set forth in Article 6 of the Credit Agreement is true in all
material respects as of the date hereof with respect to the Borrower and, to the
extent applicable, the Guarantors and each of their Subsidiaries and with the
same effect as though made on the date hereof (except when such representation
or warranty by its terms relates to the date hereof or to another specific
date), and is hereby incorporated herein in full by reference as if fully
restated herein in its entirety. In addition, in order to induce the Banks to
enter into this Amendment, the Borrower hereby covenants, represents and
warrants to the Banks that since March 29, 1997, there has been no material
adverse change in the business, operations, assets or financial or other
condition of the Borrower or of the Borrower, the Guarantors and their
Subsidiaries, taken as a whole.
Section 3.2. No Default or Event of Default, as defined in the
Agreement now exists except as specifically waived hereby.
Section 3.3. The Borrower has the requisite corporate power
and authority to enter into, perform and deliver this Amendment and the
Substituted Notes, and any other documents, instruments, agreements or other
writings to be delivered in connection herewith. This Amendment and the
Substituted Notes, and all documents contemplated hereby or delivered in
connection
4
herewith, have each been duly authorized, executed and delivered and the
transactions contemplated herein have been duly authorized by all necessary
corporate or partnership action.
Section 3.4. This Amendment and the Substituted Notes and any
other documents, agreements or instruments now or hereafter executed and
delivered to the Banks by the Borrower in connection herewith constitute (or
shall, when delivered, constitute) valid and legally binding obligations of
Borrower, each of which is and shall be enforceable against Borrower in
accordance with their respective terms except to the extent that such
enforcement may be limited by applicable bankruptcy, insolvency or other similar
laws affecting creditors rights generally or by the effect of general principles
of equity which may limit the enforceability of equitable remedies (whether in a
proceeding at law or in equity).
Section 3.5. No representation, warranty or statement by the
Borrower contained herein or in any other document to be furnished by the
Borrower in connection herewith contains, or at the time of delivery shall
contain, any untrue statement of material fact, or omits or at the time of
delivery shall omit to state a material fact necessary to make such
representation, warranty or statement not misleading.
Section 3.6. No consent, waiver or approval of any entity is
or will be required in connection with the execution, delivery, performance,
validity or enforcement or priority of this Amendment and the Substituted Notes,
or any other agreements, instruments or documents to be executed and/or
delivered in connection herewith or pursuant hereto.
Section 3.7. Except as previously disclosed to the Banks,
there is no claim, litigation, investigation or proceeding pending or threatened
against or otherwise materially affecting the Borrower's business. The
Borrower's performance of its obligations hereunder and/or the validity or
enforceability of this Amendment and the Substituted Notes are not the subject
of any suit, investigation or proceeding, and the Borrower has no knowledge of
any circumstances indicating that any such suit, investigation or proceeding is
likely or imminent.
ARTICLE 4.
CONDITIONS
This Amendment shall become effective only upon satisfaction
of the following conditions precedent:
(a) Each Bank shall have received each of the following
documents, in form and substance reasonably satisfactory to such Bank and its
counsel:
(i) this Amendment and the Substituted Notes duly
executed by the Borrower;
(ii) a certificate of the Secretary of the Borrower
and each of the Guarantors, dated the date of this Amendment, attesting to all
corporate action taken by such entity, including resolutions of its Board of
Directors authorizing the execution, delivery and performance
5
of this Amendment and each other document to be delivered pursuant to this
Amendment, together with a certification that the certificate, articles of
incorporation and the by-laws of the Borrower and each of the Guarantors have
not been amended, modified, revoked or rescinded since the Closing Date;
(iii) a certificate of the Secretary of the Borrower
and each of the Guarantors, dated the date of this Amendment, certifying the
names and true signatures of the officers of such entity authorized to sign this
Amendment and the other documents to be delivered by such entity under this
Amendment;
(iv) a certificate of a duly authorized officer of
the Borrower, dated the date of this Amendment, stating that the representations
and warranties in Article 6 are true and correct in all material respects on
such date as though made on and as of such date (except to the extent such
representation or warranty by its terms relates to the date hereof or another
specific date) and that no event has occurred and is continuing which
constitutes a Default or Event of Default;
(v) Guarantee Ratifications, duly executed by each
Guarantor;
(vi) an opinion of counsel for the Borrower and
Guarantors, dated the date of this Amendment, in the form annexed hereto as
Exhibit B;
(vii) satisfactory evidence that the Borrower and
the Guarantors are duly organized, validly existing and in good standing under
the laws of their respective jurisdictions of incorporation and each other
jurisdiction where qualification is necessary;
(viii) such other documents, instruments, approvals,
opinions and evidence as the Banks may reasonably require;
(b) the Borrower shall have paid or caused to be paid to the
Agent for the benefit of the Banks an amendment fee of $35,000 and all other
fees required to be paid hereunder or in connection herewith, and to the Agent
in full all accrued fees and expenses of the Agent in connection with the
preparation, execution and delivery of this Amendment, and the other Facility
Documents and the consummation of the transactions contemplated thereby;
(c) the Borrower and the Guarantors shall have obtained all
consents, permits and approvals (if any) required in connection with the
execution, delivery and performance by the Borrower and the Guarantors of their
obligations hereunder and such consents, permits and approvals shall continue in
full force and effect; and
(d) all legal matters in connection with this financing shall
be reasonably satisfactory to the Banks and their counsel.
6
ARTICLE 5.
MISCELLANEOUS
Section 5.1. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same
instrument, and any party hereto may execute this Amendment by signing any such
counterpart.
Section 5.2. This Amendment shall be governed by, and
interpreted and construed in accordance with, the laws of the State of New York.
Section 5.3. Except as specifically amended hereby, the Credit
Agreement shall remain in full force and effect in accordance with its terms.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed as of the day and year first above written.
HENRY SCHEIN, INC.
By:
--------------------------------
Name: Steven Paladino
Title: Senior Vice President
Chief Financial Officer
THE CHASE MANHATTAN BANK, as
Agent and a Bank
By:
--------------------------------
Name: Emelia K. Teige
Title: Vice President
FLEET BANK, NATIONAL ASSOCIATION
By:
--------------------------------
Name:
Title:
7
COOPERATIEVE CENTRALE RAIFFEISEN-
BOERENLEENBANK B.A. "RABOBANK
NEDERLAND", NEW YORK BRANCH
By:
--------------------------------
Name:
Title:
EUROPEAN AMERICAN BANK
By:
--------------------------------
Name:
Title:
8
EXHIBIT A
SUBSTITUTE REVOLVING CREDIT
PROMISSORY NOTE
$_____________ August 15, 1997
(or the Applicable Currency Equivalent thereof)
Henry Schein, Inc. (the "Borrower"), for value received,
hereby promises to pay to the order of _______________________ (the "Bank"), or
its permitted successors or assigns, at the office of The Chase Manhattan Bank,
at 395 North Service Road, Melville, New York 11747, or its permitted successors
or assigns (the "Agent"), or at the applicable Payment Office of the Agent for
the account of the appropriate Lending Office of the Bank, in lawful money of
the United States (or the Applicable Currency Equivalent thereof as provided in
the Credit Agreement) and in immediately available funds, on the Revolving
Credit Termination Date, the principal sum of _______________________ Dollars
($_________) or the Applicable Currency Equivalent thereof, or the aggregate
unpaid principal amount of all Loans made by the Bank, whichever is less. The
Borrower further promises to pay interest on the unpaid principal balance
hereof, for the period such balance is outstanding, to the Agent for the account
of the Lending Office of the Bank, in like money, at the rates of interest as
provided in the Credit Agreement described below, on the dates and in the manner
provided in such Credit Agreement.
The date and amount of each Loan, the date and amount of each payment
of principal thereof, the principal amount subject thereto, interest rate with
respect thereto and the Applicable Currency thereof shall be recorded by the
Bank on its books and, prior to any transfer of this Note (or, at the discretion
of the Bank, at any other time), endorsed by the Bank on the schedule attached
hereto or any continuation thereof, provided that the failure of the Bank to
make any such recordation shall not in any way effect the Borrower's obligations
to repay the Loans.
This is one of the Substitute Notes referred to in that certain
Revolving Credit Agreement, dated as of January 31, 1997 among the Borrower, the
Banks named therein (including the Bank) and the Agent (as amended, modified or
supplemented from time to time, the "Credit Agreement"), and is subject to all
of the terms and conditions contained therein. All terms not defined herein
shall have the meanings given to them in the Credit Agreement.
The Credit Agreement provides for the acceleration of the maturity of
principal and interest upon the occurrence of certain Events of Default, for
mandatory and voluntary prepayments on the terms and conditions specified
therein and for accrual of interest at the Default Rate in the circumstances
provided in the Credit Agreement.
The Borrower waives presentment, notice of dishonor, protest and any
other notice or formality with respect to this Note.
This Note shall be governed by and interpreted and construed in
accordance with the laws of the State of New York, without giving effect to the
principles of conflicts of law thereof.
HENRY SCHEIN, INC.
By:
--------------------------------
Name: Steven Paladino
Title: Senior Vice President
2
Amount of Loan
(Expressed in
Approved Amount of Balance
Date Currency) Payment Outstanding Notation By
3
Schedule 6.10
Guarantees
4
EXHIBIT 23.1
CONSENT OF INDEPENDENT
CERTIFIED PUBLIC ACCOUNTANTS
Henry Schein, Inc.
Melville, New York
We hereby consent to the incorporation by reference in this Joint Proxy
Statement/Prospectus constituting a part of this Registration Statement of our
reports dated March 7, 1997 relating to the consolidated financial statements
and schedule of Henry Schein, Inc. (the 'Company') and of our report dated
February 5, 1997 relating to the financial statements of HS Pharmaceutical, Inc.
appearing in the Company's Annual Report on Form 10-K and 10-K/A for the year
ended December 28, 1996 and Form 8-K dated June 24, 1997.
We also consent to the reference to us under the caption 'Experts' in the
Joint Proxy Statement/Prospectus.
New York, New York /s/ BDO Seidman, LLP
September 22, 1997
II-xi
EXHIBIT 23.2
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in this Registration Statement
of Henry Schein, Inc. on Form S-4 of our reports dated February 18, 1997,
appearing in the Annual Report on Form 10-K of Sullivan Dental Products, Inc.
for the year ended December 31, 1996 and to the reference to us under the
heading 'Experts' in the Prospectus, which is part of this Registration
Statement.
/s/ Deloitte & Touche LLP
DELOITTE & TOUCHE LLP
Milwaukee, Wisconsin
September 19, 1997
II-xii
